

```

Oy 173 ----QLELDQSG-----TWTCTVLNOKKVEBKDIYCPAPEBKSC 210
      ||| |||
Db 170 VHTFPRAVLQSSGLYSLSSVVTYVPSSSLGTYITICNV--NKKPSTNKVD---KKEVEKSC 223
      ||| |||
Oy 211 DKTHTC----PELLGSPSVFLPEPPKPKDTLMISTRPEVTCVVDVSHEDBEVKFNYYVD 265
      ||| |||
Db 224 DKHTHCPCPCAPPELLGSPSVFLPEPPKPKDTLMISTRPEVTCVVDVSHEDBEVKFNYYVD 283
      ||| |||
Oy 266 GVEVHNANKTKPREEOYNSTYRVVSVYLTVLHQDMLGKGYCKVCVSKALPAIETKTSKAK 325
      ||| |||
Db 284 GVEVHNANKTKPREEOYNSTYRVVSVYLTVLHQDMLGKGYCKVCVSKALPAIETKTSKAK 343
      ||| |||
Oy 326 GQPREPOVYTLPPSRDELTKNQVSLTCLGVGFPSDIAVEMESNQGPENNYKTTTPVLIDS 385
      ||| |||
Db 344 GQPREPQVYTLPPSRDELTKNQVSLTCLGVGFPSDIAVEMESNQGPENNYKTTTPVLIDS 403
      ||| |||
Oy 386 DGSFPLYSKLTVDKSRMOQGNFSSGVMEALAHNHYTKSLSLSPG 431
      ||| |||
Db 404 DGSFPLYSKLTVDKSRMOQGNFSSGVMEALAHNHYTKSLSLSPG 449
      ||| |||

```

RESULT 38  
AAR42066  
ID AAR42066 standard; protein; 459 AA.

AC AAR42066;

DT	25-MAR-2003	(revised)
DT	29-APR-1994	(first entry)

DE Human anti-HBs heavy chain.

KW Antibody; Ab; light; heavy; chain; hepatitis B; HB; surface antigen.

OS Homo sapiens.

FH	Key	Location/Qualifiers
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

```
FT /label= big_peptide
```

```
FT /label= mat_protein
```

PN W09320205-A1.

PD 14-OCT-1993

PF 30-MAR-1993; 93WO-JP000396.

PR 30-MAR-1992; 92JP-00074678.

PA (SUNR ) SUNTORY LTD.

PI Kurihara T, Matsukura S, Tsuruoka N, Arima K, Nishihara T;

DR WPI; 1993-336913/42.

XX

PT produce L and H chains of the antibody in large quantity.

PS Disclosure; Fig 6-8; 46pp; Japanese.

CC Polynucleotides encoding the L and H chains of human anti-HBs Ab are

quantities for therapeutic use. (Updated on 25-MAR-2003 to correct PN

XXXX

Query Match	53.2%	Score 1284.5	DB 2	Length 459
Similarity	59.4%	Pred. No. 1.1e-64		
Beet Local	30	Mismatches 68	Indels 93	Gaps 17
Matches 280				

QY	25	GNNVVLAKGGKDPVTELTCTAS--QKKSIOGFH-----KNSQJQILT---GNQSGFL--TK	71
Dd	17	GGGVV--QPEKSRILSCASAGFTFSSNSMHWROAPGKGLEWVAVILLYDGHKHFYADSVK	74
QY	72	GPSEKLDNRADSRKSLMDQGNPELLIKNLKIEDSDPTICEVEDEQKAEVOLVFGILTANSDT	131
Dd	75	GRFTIS-RDMSKNITLY-----LEKSLQTEDTDGVVYC-INDQ-----TYGV-----	113
QY	132	HLIQ--GQSLTLLTLESPPGSSPSVQCRRPRGNIOG-----KITLSVS---1722	
Dd	114	HRPDSWGQGLTVLVSSASTKGPSVEPLAPSSKTSISGGTAALGCLVKQYFPBPVTVSNWG	173
QY	173	-----QLEIDDSG-----TWCTVLQONQKVEFKFIDIVPCAP	205
Dd	174	ALMSGHTPFAVLQSSGLXSLSSVTVTVSSSLGTYOTYICNV--NHKSNKTVD---KXV	227
QY	206	EPKSCDKTHTC---PELLGGPSVFLPPPKKDTLMISRTPEVTCVAVDVSHEDPEVK	266
Dd	228	EPKSCDKTHTCPKCPAPELLGGPSVFLPPPKKDTLMISRTPEVTCVAVDVSHEDPEVK	287
QY	261	NMYVDVGVEVHNAAKTKREBOYNSTRVAVSVLTVLHODLNKEKVCXVSNKALPAPLEKT	320
Dd	288	NMYVDVGVEVHNAAKTKREBOYNSTRVAVSVLTVLHODLNKEKVCXVSNKALPAPLEKT	347
QY	321	ISRAKQOPREPQVYTLTPESRDELTKNOVSLTCLVKGFPSPDIAEWESNQGPENNYKTP	380
Dd	348	ISRAKQOPREPQVYTLTPESRDELTKNOVSLTCLVKGFPSPDIAEWESNQGPENNYKTP	407
QY	381	PVLDSSGSPFLYSKLTVDKSRWQOQNVSCSVMEHALNHTYQKSLSLSPG	431
Dd	408	PVLDSSGSPFLYSKLTVDKSRWQOQNVSCSVMEHALNHTYQKSLSLSPG	458

RESULT 39  
AAW05829  
ID AAW05829 standard; protein; 446 AA

AC AAW05829;

DT 16-OCT-2003 (revised)

XX

XX

KM leukaemia; hybridoma; monoclonal antibody.

OS Homo; sapiens

OS chimeric.

FH	Key	Location/Qualifiers
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

```
FT /label= variable_domain
```

ET

ET

ET

ET

ET

ET

ET

PN WO9626964-A1.

PD 06-SEP-1996.

XX 29-FEB-1996; 96WO-US002754.  
 PF  
 XX 01-MAR-1995; 95US-00397411.  
 PR  
 XX (PROT-) PROTEIN DESIGN LABS INC.  
 PA (IOWA-) IOWA IMMUNOTHERAPY INVESTIGATORS.  
 XX  
 PI Weiner G, Gingrich R, Link BK, Tso JY;  
 DR WPI, 1996-412742/41.  
 XX  
 XX New bi-specific antibody reactive with both T or NK cells and malignant B  
 PT cells - also their humanised forms and hybridomas producing them, useful  
 PT for treating or preventing leukaemia, lymphoma and myeloma.  
 XX  
 PS Example 4; Fig 4e; 85pp; English.  
 CC  
 CC The humanised 1D10 antibody heavy chain (AAW05829) includes a variable  
 CC region (see also AAW05823) consisting of human R3.5HG heavy chain  
 CC variable region framework and complementarity determining regions from  
 CC the murine 1D10 antibody specific for a 28/32 kDa antigen found on the  
 CC surface of malignant B-cells. It can be coexpressed with humanised 1D10  
 CC light chain (see also AAW05828) in mammalian host cells. Bispecific  
 CC antibodies can be constructed that include a first binding fragment  
 CC comprising humanised M291 heavy and light chain variable regions (see  
 CC also AAW05826, AAW05830), and a second binding fragment comprising  
 CC humanised 1D10 heavy and light chain variable regions. Such antibodies  
 CC are reactive with both T or NK cells and malignant B cells, and have  
 CC therapeutic and diagnostic applns. (Updated on 16-OCT-2003 to standardise  
 CC OS field)  
 CC  
 XX Sequence 446 AA;  
 SQ

Query Match 53.1%; Score 1282.5; DB 2; Length 446;  
 Best Local Similarity 59.8%; Pred. No. 1.4e-64;  
 Matches 274; Conservative 25; Mismatches 80; Indels 79; Gaps 10;

QY 30 LGKKDDELCTCTASQKSIQF--HMKNNOIKILGNGSFLTKGPKSLNDRAASRL- 86  
 DB 11 LKPSRFTSLCTCTVSGLTNYGVHNVQSPKGLKLEMGVMSGGSTYNAFISRLTIS 70  
 QY 87 --WDQGNPLIIKMLKIEDSDTYICEVEDQKEVQLVFGLTANSDFHLQ--QGSLLT 142  
 DB 71 KDTSKNQVSLKLNSTLTADTAIVYC-----ARRDRYAMDYWGQGLVT 113  
 QY 143 LESPFGSSPVQCSFRKNIQGG-----KTLSSV-----QLEL 176  
 DB 114 VSSASTKGPVFPPLAPSSKSTSGGTAALGLVKDVFPEPVTVMNSGALTGVHFTPAVL 173  
 QY 177 QDSG-----TWTCVLONQKVEFIDIVPCPAPPKSCDKTHTC-- 216  
 DB 174 QSSGLYSLSVVTWSSSLGTQTYICNV--NHKPSNTKVD---KVEPKSCDKTHTCPP 227  
 QY 217 ---PELLGSPVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAK 273  
 DB 228 CPAPRLGSPVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAK 287  
 QY 274 TKPREEQVNSTYRVVSVLTVLHODMLNGEKYCKKSNKALPAPLEKITSKAKGPREPOV 333  
 DB 288 TKPREEQVNSTYRVVSVLTVLHODMLNGEKYCKKSNKALPAPLEKITSKAKGPREPOV 347  
 QY 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYS 393  
 DB 348 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYS 407  
 QY 394 KLTVDKSRWQOGNVPFSCVMHEALHNHYTQKSLSLSPG 431  
 DB 408 KLTVDKSRWQOGNVPFSCVMHEALHNHYTQKSLSLSPG 445

RESULT 40  
 ABJ37106

ID ABJ37106 standard; protein; 617 AA.  
 XX  
 AC ABJ37106;  
 XX  
 DT 08-MAY-2003 (first entry)  
 XX  
 DE Concatameric immunoadhesion human protein sequence SEQ ID No 18.  
 XX  
 XX Antiinflammatory; antibacterial; immunosuppressive; antirheumatic;  
 KM antiarthritic; immunomodulator; concatameric protein; soluble domain;  
 KM dimeric protein; inflammation; septicemia; cytotoxicity;  
 KM rheumatoid arthritis; cachexia; inflammation; human.  
 OS  
 XX Homo sapiens.  
 XX  
 PN WO2003010202-A1.  
 XX  
 XX 06-FEB-2003.  
 PD  
 XX 26-JUL-2002; 2002WO-KR001427.  
 PF  
 XX 26-JUL-2001; 2001KR-00045028.  
 PR  
 XX (MEDF-) MEDEXGEN CO LTD.  
 PA  
 PI Chung Y, Han J, Lee H, Choi E, Kim J;  
 XX WPI; 2003-229639/22.  
 DR N-PSDB; ABT32049.  
 DR  
 XX  
 XX New concatameric protein having two soluble domains, useful for  
 PT diagnosing and treating disorders associated with the dimeric protein or  
 PT its glycosylated form, such as inflammation, septicemia, rheumatoid  
 PT arthritis and cachexia.  
 XX  
 XX Claim 6; Page 171-174; 211pp; English.  
 PS  
 XX  
 XX The invention relates to a novel concatameric protein comprising two  
 CC soluble domains, in which an N-terminus of a soluble domain of a  
 CC biologically active protein is linked to a C-terminus of an identical  
 CC soluble domain or a different soluble domain of a biologically active  
 CC protein. The methods and compositions of the present invention are useful  
 CC for the diagnosis and treatment of disorders associated with dimeric  
 CC protein or its glycosylated form, such as inflammation, septicemia,  
 CC cytotoxicity, rheumatoid arthritis, cachexia and other inflammation-  
 CC related diseases. This sequence represents the human concatameric protein  
 CC of the invention  
 CC  
 XX Sequence 617 AA;  
 SQ

Query Match 53.1%; Score 1282.5; DB 6; Length 617;  
 Best Local Similarity 64.5%; Pred. No. 2e-64;  
 Matches 272; Conservative 22; Mismatches 63; Indels 65; Gaps 11;

QY 35 DTVELCTASQKSIQFHMKNNOIKILGNGSFLTKGPKSLNDRAASRLSDQGNFPL 94  
 DB 235 DDIKEMKTSQKKLIAQGRKEK-----TFKEDTYKLK-----NGTL 272  
 QY 95 IIRKLKIEDSDTYICEVEDQK--EEVQLVFGLTANSDFHLQO-----SITLT 142  
 DB 273 KIRHLKTDODDIIKVSITYDKGNVLEKIFDLK-----IQBRVSKPKISMTCTINTLT 325  
 QY 143 LESPFGSSPVQCSFRKNIQGGKTLVSQLELDPSGWT-----CTVQONQKVE 194  
 DB 326 CEVWNGTDEPLN-----YQDGKILKLSQRYI--THKTTLSLAKFKCTA--GNKYSKE 375  
 QY 195 FKIDIVPCPAPPKSCDKTHTC-----PELLGSPVFLFPPPKDITLMISRTPEVTCVV 249  
 DB 376 SVSEVPVSCPA--EPKSCDKTHTCPPCPAPRLGSPVFLFPPPKDITLMISRTPEVTCVV 434  
 QY 250 DVSHEDPEVKFNMYVDGVEVNAKTKPREEQVNSTYRVVSVLTVLHODMLNGEKYCKKVS 309  
 DB 435 DVSHEDPEVKFNMYVDGVEVNAKTKPREEQVNSTYRVVSVLTVLHODMLNGEKYCKKVS 494

```
QY 310 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESN 369
DB 495 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESN 554
QY 370 GQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTKSLSL 429
DB 555 GQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTKSLSL 614
QY 430 PG 431
DB 615 PG 616

RESULT 41
ABJ37108
ID ABJ37108 standard; protein; 617 AA.
AC ABJ37108;
XX
XX
DT 08-MAY-2003 (first entry)
DE Concatameric immunoadhesion human protein sequence SEQ ID NO 22.
XX
XX
KW Antinflammatory; antibacterial; immunosuppressive; antirheumatic;
XX antiarthritic; immunomodulator; concatameric protein; soluble domain;
XX dimeric protein; inflammation; septicemia; cytotoxicity;
XX rheumatoid arthritis; cachexia; inflammation; human.
XX
XX Homo sapiens.
XX
XX WO2003010202-A1.
XX
XX 06-FEB-2003.
XX
XX 26-JUL-2002; 2002WO-KR001427.
XX
XX 26-JUL-2001; 2001KR-00045028.
XX
XX (MEDE-) MEDEXGEN CO LTD.
XX
XX Chung Y, Han J, Lee H, Choi E, Kim J;
XX
XX MPI: 2003-229639/22.
XX
XX N-PSDB; ABT32051.
XX
XX
XX New concatameric protein having two soluble domains, useful for
XX diagnosing and treating disorders associated with the dimeric protein or
XX its glycosylated form, such as inflammation, septicemia, rheumatoid
XX arthritis and cachexia.
XX
XX Claim 27; Page 188-191; 21pp; English.
XX
XX The invention relates to a novel concatameric protein comprising two
XX soluble domains, in which an N-terminus of a soluble domain of a
XX biologically active protein is linked to a C-terminus of an identical
XX soluble domain or a different soluble domain of a biologically active
XX protein. The methods and compositions of the present invention are useful
XX for the diagnosis and treatment of disorders associated with dimeric
XX protein or its glycosylated form, such as inflammation, septicemia,
XX cytotoxicity, rheumatoid arthritis, cachexia and other inflammatory-
XX related diseases. This sequence represents the human concatameric protein
XX of the invention
XX
XX SQ Sequence 617 AA;

Query Match 53.1%; Score 1282.5; DB 6; Length 617;
Best Local Similarity 64.5%; Pred. No. 2e-64;
Matches 272; Conservative 22; Mismatches 63; Indels 65; Gaps 11;
QY 35 DTVELTCTASQKKS1QFHWKNSNQIKLGNQGSFLTGKPSKLNDRADSRSLMDQGNPFL 94
DB 235 DDIKWEKTSDDKKIAQFRKEKE-----TFKEDVYKLFK-----NGTL 272
```

```
QY 95 IIKNLKIEDSPYICGEVEDOK-EEVQLLVFGLTANSPTHLLQGO-----SLFLT 142
DB 273 KIKHLKTDQDIYKVISITDGKNVLEKIFDK-----IQRVSKERISWTCTINTTLT 325
QY 143 LESPPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSGTWT-----CTVLQNKQVE 194
DB 326 CEVWNGTDPLENL-----YQDGKHLKLSGRVI--THKWTLSLSAKRCKTA-GNKVSE 375
QY 195 FKIDIVPCPAPBPSCDKTHTC-----PELLGSPVFLPPEPKDTLMIISRTPEVTCVV 249
DB 376 SSVEPVSCPA-EPKSCDKHTHCPCPAPBLGLGSPVFLPPEPKDTLMIISRTPEVTCVV 434
QY 250 DVSHEDPEKFMWYDVGVENNAKTPREEOYNSYRVVSLTVLHOMLNGKEKCVS 309
DB 435 DVSHEDPEKFMWYDVGVENNAKTPREEOYNSYRVVSLTVLHOMLNGKEKCVS 494
QY 310 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESN 369
DB 495 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESN 554
QY 370 GQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTKSLSL 429
DB 555 GQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTKSLSL 614
QY 430 PG 431
DB 615 PG 616

RESULT 42
AAB81991
ID AAB81991 standard; protein; 582 AA.
XX
XX AAB81991;
XX
XX 03-JUL-2001 (first entry)
XX
XX Ganglioside GD3 specific antibody related protein SEQ ID NO: 57.
XX
XX Ganglioside; GD3; complementarity determining region; CDR; antibody;
XX cancer.
XX
XX Synthetic.
XX
XX WO200123432-A1.
XX
XX 05-APR-2001.
XX
XX 29-SEP-2000; 2000WO-JP006774.
XX
XX 30-SEP-1999; 99JP-00278291.
XX
XX 06-APR-2000; 2000JP-00105088.
XX
XX (KYOW) KYOWA HAKKO KOGYO KK.
XX
XX Hanai N, Shitara K, Nakamura K, Niwa R;
XX
XX MPI: 2001-266143/27.
XX
XX New human type complementation-determining region-transplanted antibody
XX and derivatives against ganglioside GD3, useful in diagnosis and therapy
XX of e.g. tumors, with low antigenicity, little side effects but potent
XX activity in cancer.
XX
XX Claim 39; Page 175-179; 183pp; Japanese.
XX
XX The present invention describes a monoclonal antibody which can react
XX specifically with ganglioside GD3. The antibody and its derivatives are
XX useful in the diagnosis and therapy of tumors, particularly cancer
XX diagnosis. The present sequence is a protein used in the exemplification
XX of the invention
XX
```

Seq	Sequence	582 AA;
Query Match	53.1%; Score 1282; DB 4; Length 582;	
Beat Local Similarity	57.5%; Pred. No. 26-64;	
Matches	279; Conservative 32; Mismatches 74; Indels 100; Gaps 14;	
QY	KKGDIVELTCTAS--QKSIQIFHMKNNSNQIKL-----GNQSFLLT--KGPSKAND 78	
DB	13 KPGSLKVCSCAASGAFSHYANSWRQTPAKKLEWVAIYSSGSGSTYYSDSVKGFRTS 71	
QY	79 RADSRSLMDQGNFPLIIKNIKIEDSDTYICEVEDQKEEVQLVLTGLTANSDTHLQGS 138	
DB	72 RDNACNTLY-----LQMRSLRSEDSANVFC-----TRVKGITYFPS-----WQGG 112	
QY	139 LTLTLESPGSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172	
DB	113 TTLTVSSASTKGPVSFPLAPSSKTSGGTAALGCLVKDYFPEPPTVSMNSGALTSGVHTF 172	
QY	173 QLELDDSG-----TWTCYVLQNQKVEFKIDLVPCPAPRPSCDKTH 214	
DB	173 PAVLQSSGLYSLSSVVTVPSSSLGTYIYICNV--NHKPSNTKVD---KQVEPKSCDKTH 226	
QY	215 TC-----PELALGSPVFLFPKPKDITLMISRTPEYTCVVDVSHDEPEYKFMVYDGEV 269	
DB	227 TCPPCPAPELLGGEVFLFPKPKDITLMISRTPEYTCVVDVSHDEPEYKFMVYDGEV 286	
QY	270 HNAKTKPREEOYNSTYRVVSVLTVLADHDLNGKEYKCKVSNKALPAPLEKTISSAKGQPR 329	
DB	287 HNAKTKPREEQNSTYRVVSVLTVLADHDLNGKEYKCKVSNKALPAPLEKTISSAKGQPR 346	
QY	330 EPQVYTLPPSRDELTKNOVSLTCLVKGFPPSIAIENWESNGCPENNRYKTPPVLDSDGSF 389	
DB	347 EPQVYTLPPSRDELTKNOVSLTCLVKGFPPSIAIENWESNGCPENNRYKTPPVLDSDGSF 406	
QY	390 FLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTKQSLSLSPG-----LQLEDT 437	
DB	407 FLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTKQSLSLSPGAKPTSSSTKKTQQLQLEHL 466	
QY	438 CAEAQ 442	
DB	467 LLDLQ 471	
RESULT 43		
AAU07745		
ID	AAU07745 standard; protein; 461 AA.	
XX	AAU07745;	
AC		
XX		
DT	04-DEC-2001 (first entry)	
XX		
DE	Humanised monoclonal antibody Hu266, heavy chain.	
XX		
KM	Monoclonal antibody; Hu266; neutrotropic; neuroprotective; Abeta peptide;	
KW	Alzheimer's disease; Down's syndrome; cerebral amyloid angiopathy;	
gene therapy.		
XX		
OS	Mus sp.	
OS	Homo sapiens.	
OS	Synthetic.	
XX		
Key		
FT	Peptide	Location/Qualifiers
FT	Protein	1..19
FT		/label= signal_peptide
FT		20..461
FT		/label= Mature_Hu266_heavy_chain
FT		/note= "This sequence is specifically claimed in claim 17"
XX		
XX	WO200162801-A2.	
XX		
PD	30-AUG-2001.	

PF		26-EEB--2001; 2001WO-US0006191.	
XX			
PR	24-EEB--2000; 2000US-0184601P.		
PR	08-DEC--2000; 2000US-0254465P.		
PR	08-DEC--2000; 2000US-0254498P.		
XX			
XX	(UNIW ) UNIV WASHINGTON.		
PA	(ELIL ) LILLY & CO ELI.		
PI	Holtzman DM, Dematos R, Bales KR, Paul SM, Tsurushita N;		
PI	Vasquez M;		
XX			
DR	WPI, 2001--550087/61.		
PT			
PT	New humanized antibody for the treatment of Alzheimer's comprises the		
PT	inhibition and reduction of the formation of amyloid plaques.		
XX			
PS	Example 13; Fig 5; 63pp; English.		
XX			
CC	The invention relates a humanised antibody that specifically binds an		
CC	epitope contained within positions 13-28 of amyloid beta peptide, Abeta.		
CC	The antibody is useful to inhibit and reduce the formation of amyloid		
CC	plaques or the effects of toxic soluble Abeta species in humans their		
CC	fragments are used for the manufacture of a medicant. This includes the		
CC	prolonged expression of recombinant sequences of them in human tissues		
CC	for the treatment of clinical/pre-clinical Alzheimer's disease, Down's		
CC	syndrome or pre clinical cerebral amyloid angiopathy. Specifically, the		
CC	antibody is used to sequester Abeta into plasma, brain or cerebrospinal		
CC	fluid to prevent/reverse accumulation of the Abeta peptide within the		
CC	brain thereby improving cognition. The present sequence is the heavy		
CC	chain of a humanised monoclonal antibody, Hu266, based on the mouse		
CC	antibody 266		
XX			
SQ	Sequence 461 AA;		
Query Match	53.0%; Score 1280.5; DB 4; Length 461;		
Best Local Similarity	57.2%; Fred. No. 1.9e-64;		
Matches	282; Conservative 30; Mismatches 86; Indels 95; Gaps 13		
OY	1 MNRGVFFHLLVLQLALLPATGONKRVLGKKGDVTLETCNAS--QKKSIGFHWKNS--	56	
Db	1 MNRGLSLFLVLVLVKGVLCSEVQVLSGGGLVQPGSGLSLSCAASFTSRYSMSVRAAP	60	
OY	57 -----NQIKLGNQGSF--LTRGPSKLNDRADSRSLMDQGNFPLIIKNLIKEDSDTY	107	
Db	61 GKGLSELVAQINSVGSTYYPDTVKGRAFTRIS-RDNAKNTLVYLQM-----SLRAEDTAVY	113	
OY	108 ICEVEDQKEEVQLVFGILTANSDTHLOGSGLLTLLESPPSSSPVOCRSPRGKIIOG-	166	
Db	114 YC-----ASGD---YWGQGTLVTVSSASTKGPVFPLAPSSKSTSGGT	153	
OY	167 -----KITLSVS-----QLELDQSG-----TWIT	183	
Db	154 AALGCLVKDYREPEFYTSWMNSGALTSGVHTPRPAVLQSSGLYSLSVTPVPSSLSCTQTITI	213	
OY	184 CTVLONQKVEFKIDIVCPARPESCDKTHTC-----PELLGGSVFLFPKPXDITMI	238	
Db	214 CNV--NHRNSTKYD----KVERKSCDKHTCTCPCAPPELLGGSVFLFPKPXDITMI	267	
OY	239 SRTPPVTCVVVDVSHEDPEVKFMNYVDGVEVHNAAKTKRPREQYNSTRYVSVLTVLADDM	298	
Db	268 SRTEPVTCVVVDVSHEDPEVKFMNYVDGVEVHNAAKTKPREQYNSTRYVSVLTVLADDM	327	
OY	299 LNGEYKCKVSNKMLPAPIETTKISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFY	358	
Db	328 LNGEYKCKVSNKMLPAPIETTKISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFY	387	
OY	359 PSDIAVENESNGOEPENNYKTTIPVLDSGSEFLYSKLTVDSSRMQGVNFSCSVNHAEALH	418	
Db	388 PSDDIAVENESNGOEPENNYKTTIPVLDSGSEFLYSKLTVDSSRMQGVNFSCSVNHAEALH	447	
OY	419 NHYTQKSLISLSPG 431		



Db 448 NHYQKSLSPG 460

RESULT 44

AAW1639 standard; protein; 475 AA.

AC AAW1639;

DT 13-MAY-1997 (first entry)

XX Human anti-RSV monoclonal antibody RF-1 heavy chain.

DE Monoclonal antibody; Mab; RF-1; RF-2; respiratory syncytial virus; RSV;

KM fusion protein; F-protein; vaccine; immunotherapy; therapy;

KW Epstein Barr virus; immortalisation; recombinant antibody.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..19

FT /label= Leader\_peptide

FT Region 20..49

FT /label= FR1

FT /note= "framework region 1"

FT Region 50..56

FT /label= CDR1

FT /note= "complementarily determining region 1"

FT Region 57..70

FT /label= FR2

FT /note= "framework region 2"

FT Region 71..86

FT /label= CDR2

FT /note= "complementarily determining region 2"

FT Region 87..118

FT /label= FR3

FT /note= "framework region 3"

FT Region 119..134

FT /label= CDR3

FT /note= "complementarily determining region 3"

FT Region 135..145

FT /label= FR4

FT /note= "framework region 4"

FT Region 146..475

FT /label= Kappa

FT /note= "human gamma 1 constant region"

PN WO9640252-A1.

PD 19-DEC-1996.

XX 06-JUN-1996; 96WO-US010070.

XX 07-JUN-1995; 95US-00488376.

PR (IDEC-) IDEC PHARM CORP.

XX Brans P, Chamat SS, Pan L, Walsh EE, Heard CJ, Newman RA;

DR MPI: 1997-099892/09.

DR N-PSDB; AAT61241.

XX Human monoclonal antibody specific for respiratory syncytial virus fusion

PT protein - used for the prevention and treatment of RSV infection.

XX Example 6; Fig 9b-c; 85pp; English.

XX A polypeptide (AAW1639) comprises a leader sequence, RF-1 heavy chain

CC variable region (see also AAW1639), and human gamma 1 constant region.

CC RFI is a human monoclonal antibody (hMab) specific for the fusion protein

CC of respiratory syncytial virus (RSV). The polypeptide can be produced in

CC eukaryotic host (e.g. CHO) cells transfected with vector NEOSPLA

CC incorporating a DNA construct (AAT61241) including the RF-1 VH sequence.

CC RF-1 and RF-2 heavy and light chains (see also AAW1638, AAW1640-41) are

CC similarly produced. The transfected host cells provide a constant, stable

CC supply of anti-RSV F-protein hMabs for use in the treatment or prevention

CC of RSV infection

XX SQ Sequence 475 AA;

Query Match 53.0%; Score 1280.5; DB 2; Length 475;

Best Local Similarity 57.3%; Pred. No. 2e-64; Indels 97; Gaps 12;

Matches 282; Conservative 26; Mismatches 87;

QY 10 LILVQLALIPAATGNKVLGKKGDTVELICTAS-----QKKSQFMK 54

DB 10 LVAVATRLVLSQVQDESPPVVKPTETILTCTVSGFSLSPRMGVTWIRQPGKALM- 68

QY 55 NSNQIKLGN-----QGSFLLTKGPKSLNDRADSRSLMDQGNFLLIKLIEDSYIC 109

DB 69 -----LGNIFSSDEKSFSPSLKSLRTTSQDTSRS-----QVVLSTNVPVDTATYYC 116

QY 110 EVEDQKEVQLVPLTANSDTHL-LOGOSLTLTLESPPSSPSVQCSPKGNIQG-- 166

DB 117 -----ARVGLVDINAYLYLIDYWGQTLVTVSSASTGSPVFLPASPSSKSTSGTA 168

QY 167 -----KTLVS-----QLELDQSG-----TWTC 184

DB 169 ALGCLVKDYFPEPVVSNMGSALTSGVHTFPAVLQSSGLYSLSSVTVPPSSSLGTQYIC 228

QY 185 TVLQNKQKVEFKIDIVCPAPAPKSCDKTHTC-----DELLGSPVFLPPPKKDTLMIS 239

DB 229 NV--NHRKPSNTKVD---KKAEPKSCDKTHTCPCPAPDELIGSPVFLPPPKKDTLMIS 282

QY 240 RTPETVTVVNDVSHEDPEVKFMVYDGVENNAKTKPREEOYNSTYRVSVLTVLHOML 299

DB 283 RTPETVTVVNDVSHEDPEVKFMVYDGVENNAKTKPREEOYNSTYRVSVLTVLHOML 342

QY 300 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLTPSRDELTKNQVSLTCLVKGYFP 359

DB 343 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLTPSRDELTKNQVSLTCLVKGYFP 402

QY 360 SDIAVWESNQGPENNYKTPPVLDSDGSFPLYSKLTVDKSRMQQGNFSCSVMEALHN 419

DB 403 SDIAVWESNQGPENNYKTPPVLDSDGSFPLYSKLTVDKSRMQQGNFSCSVMEALHN 462

QY 420 HYTKSLSLSPG 431

DB 463 HYTKSLSLSPG 474

RESULT 45

ABG70743

ID ABG70743 standard; protein; 473 AA.

AC ABG70743;

XX 02-DEC-2002 (first entry)

DT Mouse/human chimeric anti-MAG antibody heavy chain protein.

DE Stroke; neurological disease; neurodegeneration; brain injury;

XX spinal cord injury; chronic disease; Alzheimer's disease; tauopathy;

KW fronto-temporal dementia; peripheral neuropathy; Parkinson's disease;

KW Huntington's disease; multiple sclerosis; mouse; human; anti-MAG;

KW antibody; heavy chain.

XX Mus sp.

OS Homo sapiens.

OS Synthetic.

OS Chimeric.

XX WO200262383-A2.

XX 15-AUG-2002.



```

QY      11 LVLVLGLALLPAATQGNKVLG-----KKGPVTELTASQKKSIOFH----- 52
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      7 VLFLVAAATASASQVULVVGSAEYKPKPGASVSKVSCASGYTTSPFLMNVRAQPGGLEW 66
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      53 --WKSNSQIKILGNQGSFLTKGSPKLNDRADSRSLMDQGNPPLIIXKLIEDSDPTYICE 110
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      67 MGNMNPNSGK-----TGVAQKFGQGVMTTRMNTSIRTAI-MELISGLRSDDTAVYFCA 116
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      111 VDDQKEEVL--VGLTANSDTHLQGGSLTLTLESPPGSSPSVDCRSPPKGNKIQG-- 166
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      117 RNADVEMAAIYHYGMD-----VMGGITVTVSSASTKGSVPFLAPSSKSTSGGTA 169
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      167 -----KTLISV-----QLELDQSG-----TWNC 184
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      170 ALGCLVKYFPEPEVTSNNSGALTSGVHPPRAVLQSSGLYSLSVVTTPSSSLGTQTYIC 229
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      185 TVLQNKQKVEFKIDIVPCPAPEPKSCDKHTTC-----PELGGPSVFLPPEPKDTLMTS 239
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      230 NV--NHKPSNTKYD-----KKVEPKSCDKHTHTCPCPAPFLLGSPSVFLPPKDTLMTS 283
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      240 RPEPVTCVVVDVSHEDPEVKFNKYVDGVVNAKTKRBEQYNSTYRVVLTVLHQMVL 299
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      284 RPEPVTCVVVDVSHEDPEVKFNKYVDGVVNAKTKRBEQYNSTYRVVLTVLHQMVL 343
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      300 NKEKYCKVSNKALPAPIEKTSKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPV 359
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      344 NKEKYCKVSNKALPAPIEKTSKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPV 403
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      360 SDIAVESNNGOPENNYKTPPVLDSDGSFFLYSKLTVDSKWSMOQGNVSCVMHEALHN 419
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      404 SDIAVESNNGOPENNYKTPPVLDSDGSFFLYSKLTVDSKWSMOQGNVSCVMHEALHN 463
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      420 HHTQKSLSLSPG 431
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      464 HHTQKSLSLSPG 475
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 47
AAM49203
ID      AAM49203 standard; protein; 448 AA.
AC      AAM49203;
XX
DT      29-AUG-2003 (revised)
DT      28-JUN-2002 (first entry)
XX
DE      Humanised monoclonal antibody 5c8 (hu5c8) heavy chain.
XX
KW      Monoclonal antibody; mAb; humanised; murine; mouse; 5c8; hu5c8;
KW      heavy chain; anti-CD145; CD145-antibody complex; 3d structure;
KW      three dimensional structure; drug design; drug discovery;
KW      activated T cell; CD40 interaction; T cell dependent immune response;
KW      agonist; antagonist; immune response; inflammatory response;
KW      autoimmune disease; allergy; inhibitor response; organ graft rejection;
KW      B cell cancer; Alzheimer's disease; multiple sclerosis; anti-inflammatory;
KW      immunosuppressive; antiallergic; cytostatic; dermatological;
KW      antileukemic; nocotropic; neuroprotective; antiarteriosclerotic;
KW      antiviral; antidiabetic; cardiatic; antischismatic; vasodilator;
KW      antithematic; antiarthritic; antipsoriatic; immunomodulator; antibody;
KW      complementarity determining region; CDR; protein co-ordinate data.
XX
OS      Mus sp.
OS      Homo sapiens.
OS      Chimeric.
XX
FH      Key
FH      Region
FT      1..219 "Forms part of the crystal of the invention"
FT      31..35
FT      /label= CDR1
FT      /note= "Complementarity determining region 1"
FT      Binding-site
FT      31..33

```

```

FT      /note= "Binds to CD145 (AAM49202)"
FT      Region
FT      50..66
FT      /label= CDR2
FT      /note= "Complementarity determining region 2"
FT      Binding-site
FT      52
FT      /note= "Binds to CD145 (AAM49202)"
FT      Binding-site
FT      54
FT      /note= "Binds to CD145 (AAM49202)"
FT      Binding-site
FT      57
FT      /note= "Binds to CD145 (AAM49202)"
FT      Binding-site
FT      59
FT      /note= "Binds to CD145 (AAM49202)"
FT      Region
FT      99..106
FT      /label= CDR3
FT      /note= "Complementarity determining region 3"
FT      Binding-site
FT      102..103
FT      /note= "Binds to CD145 (AAM49202)"

WO200218445-A2.
07-MAR-2002.
31-AUG-2001; 2001WO-US027352.
PF
PR      01-SEP-2000; 2000US-0229933P.
PR      16-MAR-2001; 2001US-0276452P.
PA      (BIOJ ) BIOGEN INC.
XX
PI      Karpusas M, Hsu Y, Taylor FR, Zheng Z;
XX      WPI; 2002-329760/36.
XX
DR      The invention relates to a crystal comprising a CD145 polypeptide in
XX      complex with an anti-CD145 antibody or its antigen-binding fragment, and
XX      the structure coordinates of such a crystal. In particular, the crystal
XX      comprises human CD145 (AAM49202) and a humanised version of the murine
XX      monoclonal antibody 5c8 (hu5c8; AAM49203; AAM49204). CD145, also known as
XX      CD140L, gp39, T-BAM, 5c8 antigen, CD40CR and TRAP) is a 32 kD type II
XX      membrane glycoprotein which is transiently expressed on activated T
XX      cells. It interacts with CD40 which is expressed on mature B cells,
XX      macrophages, dendritic cells, fibroblasts and activated endothelial
XX      cells. This CD40/CD145 interaction is required for T cell-dependent
XX      antibody responses, type I T-helper cell responses, and nitric oxide (NO)
XX      production by macrophages. NO mediates many of the pro-inflammatory
XX      activities of macrophages, and disruption of the CD40:CD145 interaction
XX      via the use of an anti-CD145 antibody has been shown to reduce the
XX      symptoms of autoimmune and inflammatory conditions. The crystal structure
XX      of the CD145:anti-CD145 antibody complex, and thereby provide information
XX      about this interaction which may be of use in designing non-antibody
XX      CD145 agonists and antagonists which modulate the CD40:CD145 interaction.
XX      Such compounds may be used in the treatment of an unwanted immune
XX      response, an unwanted inflammatory response, an autoimmune disease, an
XX      allergy, an inhibitor response to a therapeutic agent, rejection of a
XX      donor organ, or a B cell cancer. They may be specifically be used to
XX      treat systemic lupus erythematosus, lupus nephritis, lupus neuritis,
XX      asthma, chronic obstructive pulmonary disease (COPD), bronchitis,
XX      emphysema, multiple sclerosis, uveitis, Alzheimer's disease, traumatic
XX      spinal cord injury, stroke, atherosclerosis, coronary restenosis,
XX      ischaemic congestive heart failure, cirrhosis, hepatitis C, diabetic
XX      nephropathy, glomerulonephritis, osteoarthritis, rheumatoid arthritis,
XX      psoriasis, atopic dermatitis, systemic sclerosis, radiation-induced
XX      fibrosis, Crohn's disease, ulcerative colitis, multiple myeloma and
XX      cachexia. Sequences AAM49203 and AAM49204 represent, respectively, the
XX      heavy and light chains of the humanised version of the murine monoclonal

```

CC antibody 5c8 (hu5c8). (Updated on 29-AUG-2003 to standardise OS field)  
XX  
SQ Sequence 448 AA;

Query Match 53.0%; Score 1279.5; DB 5; Length 448;  
Beet Local Similarity 58.9%; Pred. No. 2.1e-64;  
Matches 275; Conservative 31; Mismatches 74; Indels 87; Gaps 13;

QY 25 GNKVLGKGDVETCTASQK--KSIQFMKNSQIKLGNQ--SFL-----TKGPSKL 76  
DB 8 GAEV--KPGASVKLSCKASGYIFTSYMW-----VQAPQGLGEMGEINPSGDTNF 60  
QY 77 NDRADSRSLW---DQGNFPLIINKLKIEDSDTYICEVEDQKEVQLLVFGILTANSDTHL 133  
DB 61 NEKFKSKATLTVDKASASTAYMELSLRSEDTAVYCTRSDDGRNDMD----- 106  
QY 134 LGGSLTLTLSPSSPSVQCRPRGNIOG-----KTLSSV----- 172  
DB 107 SWGGTLVTVSSASTKGPSVFPPLAPSSKTSGGTAALGCLVKDYFPEPVTVSMNSGALT 166  
QY 173 -----QLELDQSG-----TWCTVLQONKQVEFKIDIVPCPAPPEPS 209  
DB 167 GVHTFPAVLQSSGLXSLSSVTVPSSSSLGTQTYICNV--NHKPSNTKYD-----KVEPKS 220  
QY 210 CDKTHTC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN 264  
DB 221 CDKTHTCPPCPAPPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN 280  
QY 265 DGVENHNKKTREBOYNSTYRVVSVLTVLHODMNLGKEYCKVSNKALPAPIETISK 324  
DB 261 DGVENHNKKTREBOYNSTYRVVSVLTVLHODMNLGKEYCKVSNKALPAPIETISK 340  
QY 345 KQGPPEPVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 384  
DB 341 KQGPPEPVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 400  
QY 385 SDGSEFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSPG 431  
DB 401 SDGSEFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSPG 447

## RESULT 48

AAV30201 standard; protein; 452 AA.

AAV30201;

DT 17-OCT-2003 (revised)  
DT 01-NOV-1999 (first entry)

Heavy chain sequence of chimeric anti-CD40 antibody ch1220.

Heavy chain variable region: chimeric antibody; anti-CD40 antibody;  
ch1220; humoral immune response; T cell dependent antigen;  
collagen induced arthritis; transplant induced rejection;  
T cell mediated disorder; autoimmune disease; inflammatory disease;  
transplantation.

OS Mus sp.  
OS Homo sapiens.  
OS Chimeric.

MO9942075-A2.

26-AUG-1999.

10-FEB-1999; 99WO-US002949.

19-FEB-1998; 98US-00026291.

(BRIM ) BRISTOL-MYERS SQUIBB CO.

Aruffo AA, Hollenbaugh D, Siadak AW, Berry KK, Harris LJ;

PI Thorne BA, Bajorath J, Wu H, Huse WD, Watkins JD;  
XX  
DR WPI, 1999-527408/44.

XX Antibody that binds human CD40, for treating T cell mediated disorders.  
XX  
PS Claim 6; Page 20; 77pp; English.

CC The present sequence represents the heavy chain of a chimeric anti-CD40  
CC antibody designated ch1220. The antibodies are effective in modulating  
CC humoral immune response against T cell dependent antigens, collagen  
CC induced arthritis and transplant induced rejection. They are also useful  
CC for their anti-inflammatory properties. The antibodies have wide  
CC therapeutic applications, including autoimmune and inflammatory diseases  
CC and transplantation. The antibody can be used in a pharmaceutical  
CC composition for treating a patient suffering from a T cell mediated  
CC disorder. They can also be used to treat autoimmune diseases,  
CC inflammatory diseases, and transplantation. (Updated on 17-OCT-2003 to  
CC standardise OS field)

XX Sequence 452 AA;

Query Match 53.0%; Score 1279.5; DB 2; Length 452;  
Beet Local Similarity 59.8%; Pred. No. 2.1e-64;  
Matches 277; Conservative 23; Mismatches 80; Indels 83; Gaps 12;

QY 30 LGGKGDVETCTASQKSIQFMKNSQIKLGNQSFLLTKGPSKLNDRADSRSLWD- 88  
DB 11 LKRGELTVRISCKAS---GVAFTTGMQVQENRQK---LKTGMINTSGVKKYEDF 64  
QY 89 QGNFP-----LIINKLKIEDSDTYICEVEDQKEVQLLVFGILTANSDTHL 137  
DB 65 KGRFAPSLKTSANTAYLQINLKNEDPATYFC--VRSGNGVYDLAYFA-----YMQQ 114  
QY 138 SLTLTSPSSSPSSVQCRPRGNIOG-----KTLSSV----- 172  
DB 115 GTLVTSAASTKGPSVFPPLAPSSKTSGGTAALGCLVKDYFPEPVTVSMNSGALT 174  
QY 173 -QLELDQSG-----TWCTVLQONKQVEFKIDIVPCPAPPEPS 213  
DB 175 FPAVLQSSGLXSLSSVTVPSSSSLGTQTYICNV--NHKPSNTKYD-----KVEPKS 228  
QY 214 HTC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN 268  
DB 229 HTPCPAPPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN 288  
QY 269 VHNKKTREBOYNSTYRVVSVLTVLHODMNLGKEYCKVSNKALPAPIETISK 328  
DB 289 VHNKKTREBOYNSTYRVVSVLTVLHODMNLGKEYCKVSNKALPAPIETISK 348  
QY 329 REPQVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 388  
DB 349 REPQVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 408  
QY 389 FFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSPG 431  
DB 409 FFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSPG 451

## RESULT 49

AAV44721 standard; protein; 470 AA.

AAV44721;

DT 25-APR-2000 (first entry)

Human immune system molecule, ISMO-2.

Human immune system molecule, ISMO-2; Inocyte clone 2849752; diagnosis;  
treatment; prevention; cell proliferation; immune system disorder.

OS Homo sapiens.

XX	Key	Location/Qualifiers
FT	Peptide	1..19
FT	Protein	/label= Signal_peptide
FT	Protein	20..470
FT	Domain	/label= Mature_ISMO-2
FT	Domain	31..116
FT	Domain	/note= "shows similarity to Ig superfamily protein domain"
FT	Modified-site	47
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Modified-site	69
FT	Modified-site	/note= "Tyrosine kinase phosphorylation site"
FT	Modified-site	81
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Modified-site	92
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Modified-site	98
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Modified-site	105
FT	Modified-site	/note= "Casein kinase II phosphorylation site"
FT	Modified-site	120
FT	Modified-site	/note= "N-glycosylated"
FT	Modified-site	142
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Modified-site	154
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Domain	160..225
FT	Domain	/note= "shows similarity to Ig superfamily protein domain"
FT	Modified-site	232
FT	Modified-site	/note= "Casein kinase II phosphorylation site"
FT	Modified-site	290
FT	Modified-site	/note= "Casein kinase II phosphorylation site"
FT	Modified-site	319
FT	Modified-site	/note= "Tyrosine kinase phosphorylation site"
FT	Modified-site	320
FT	Modified-site	/note= "N-glycosylated"
FT	Modified-site	332
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Modified-site	347
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
FT	Modified-site	377
FT	Modified-site	/note= "Casein kinase II phosphorylation site"
FT	Domain	383..450
FT	Domain	/note= "shows similarity to Ig superfamily protein domain"
FT	Region	387..409
FT	Region	/note= "conserved Ig/MHC protein block"
FT	Region	446..463
FT	Region	/note= "conserved Ig/MHC protein block"
FT	Modified-site	460
FT	Modified-site	/note= "Protein kinase C phosphorylation site"
XX	WO200000608-A2.	
XX	06-JAN-2000.	
XX	PD	
XX	21-JUN-1999.	99WO-US013995.
XX	PR	30-JUN-1998.
XX	PR	98US-00107223.
XX	PA	(INCY-) INCYTE PHARM INC.
XX	PI	Lal P, Tang YT, Corley NC, Gorgone G, Guegler KJ, Patterson C,
XX	PI	Baughn MR,
XX	DR	WPI; 2000-170916/15.
XX	DR	N-PSDB; AA250012.
XX	PT	Immune system molecules used in the diagnosis, treatment and prevention
XX	XX	of disorders associated with the immune system and cell proliferation.

PS	Claim 1; Page 60-61; 69pp; English.
XX	CC The present sequence is an immune system molecule, ISMO-2 from an Incyte
XX	CC clone 2849752 isolated from the human breast tumour cDNA library
XX	CC (BRST113). This sequence is expressed in several libraries, generally
XX	CC those associated with cancer, cell proliferation, immune response or
XX	CC trauma. It shows homology to vertebrate immunoglobulin gamma heavy-chain.
XX	CC The present sequence is useful in the diagnosis, treatment and prevention
XX	CC of disorders associated with the immune system and cell proliferation
XX	XX
SQ	Sequence 470 AA;
XX	
XX	Query Match 53.0%; Score 1279; DB 3; Length 470;
XX	Best Local Similarity 57.0%; Pred. No. 2,4e-64;
XX	Matches 278; Conservative 28; Mismatches 96; Indels 84; Gaps 12;
QY	8 RHLLVLQALALP-----AATGKVVVIGKKGDTVELCTASQKKSIQFHKNSNOIXI 61
DB	2 KHLWFFLLVAPRNVLSQVQLQESGPGIIVKPSFTLSLCTVSGGSIIRSYW--NWIRL 58
QY	62 LGNQ-----GSFLTKGPKLNDRADSRSL--WQGNPPLIKNLKIEDSDTYICEVD 113
DB	59 PPGKLEWIGYITSGSTNVNPSLKSRYTVSDTSKQPSLKLSSVTADTAVVYCARPP 118
QY	114 QKEEVQLVFGITANSDFHLQG-OSLTLTLESPPGSSPSVQCRSPRGKNIQGG----- 166
DB	119 P-----NATTTTWISGAKGALVTVSSAATKGPSVPLAPSSKSTGTAALGC 167
QY	167 -----KTLVS-----QLELDQSG-----TWCTYLIQ 188
DB	168 LVKDYFPEPVTVMNSGALTSQVHTFPAPVLQSSGLYSVTVVPSSTIGTQYICNV-- 225
QY	189 NOKKVEFKIDIVPCAPRPSKCDKHTC-----PELIGPSVFLPPPKOTMLSRPE 243
DB	226 NHKPSNTKVD---KVERPKSCDKHTCPCPAPRLGGPSVFLPPPKOTMLSRPE 281
QY	244 VTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREQYNSTYRVVSVLTVLIHQDMLNGKE 303
DB	282 VTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREQYNSTYRVVSVLTVLIHQDMLNGKE 341
QY	304 YKCKVSNKALPAPIEKTIISKAKQPREPOVYTLPPSRDELTKNQVSLTCLVKGYFSPDIA 363
DB	342 YKCKVSNKALPAPIEKTIISKAKQPREPOVYTLPPSRDELTKNQVSLTCLVKGYFSPDIA 401
QY	364 VEWESNGQPENNYKTTTPVLDSDGSFLYSLKLTVDKSNQGNVSCSVMEHALNNHTQ 423
DB	402 VEWESNGQPENNYKTTTPVLDSDGSFLYSLKLTVDKSNQGNVSCSVMEHGLNNHTQ 461
QY	424 KSLSLSPG 431
DB	462 KSLSLSPG 469
XX	RESULT 50
XX	ADD25783
XX	ADD25783 standard; protein; 492 AA.
XX	AC ADD25783;
XX	DT 15-JAN-2004 (first entry)
XX	DE Binding domain-immunoglobulin fusion protein-associated protein #157.
XX	XX Binding domain; immunoglobulin, fusion protein; cytostatic;
XX	XX antiarthritic; immunosuppressive; antidiabetic; antichryoid;
XX	XX neuroprotective; hinge region; immunoglobulin heavy chain;
XX	XX CH2 constant region; CH3 constant region; IgG1;
XX	XX antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
XX	XX malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;
XX	XX rheumatoid arthritis; myasthenia gravis; Grave's disease;
XX	XX type I diabetes mellitus; multiple sclerosis; autoimmune disease.
XX	XX Unidentified.

US0003118592-A1.

26-JUN-2003.

25-JUL-2002; 2002US-00207655.

17-JAN-2001; 2001US-0367358P.

17-JAN-2002; 2002US-0005353P.

03-JUN-2002; 2002US-0385691P.

(GENE-) GENE-CRAFT INC.

Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;  
WPI: 2003-801317/75.

New binding domain-immunoglobulin fusion protein, useful for treating a subject having or suspected of having a malignant condition or a B-cell disorder, e.g. melanoma, Grave's disease or autoimmune disease.

Disclosure: SEQ ID NO 34; 157bp; English.

The invention relates to a binding domain-immunoglobulin fusion protein comprising a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, and an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide. The hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains 2 cysteine residues, where the first cysteine is not mutated; a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues, where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no more than one cysteine residue; and a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no cysteine residues. The binding domain-immunoglobulin fusion protein is capable of at least one immunological activity comprising antibody dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The binding domain polypeptide is capable of specifically binding to an antigen. Also included are an isolated polynucleotide encoding the binding domain-immunoglobulin fusion protein, a recombinant expression construct comprising the polynucleotide (operably linked to a promoter), a host cell transformed or transfected with a recombinant expression construct, producing the binding domain-immunoglobulin fusion protein, a pharmaceutical composition comprising the binding domain-immunoglobulin fusion protein or polynucleotide and a carrier, and treating a subject having or suspected of having a malignant condition or a B-cell disorder. The binding domain-immunoglobulin fusion protein is useful for treating a subject having or suspected of having a malignant condition or a B-cell disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis or autoimmune disease. The present sequence is a binding domain-immunoglobulin fusion protein-associated protein sequence. Note: The sequence data for this patent formed part of the printed specification and is also available in electronic format directly from USPTO at [seqdata.uspto.gov/sequence.html?DocID=20030118592](http://seqdata.uspto.gov/sequence.html?DocID=20030118592). The authors have not identified the sequences in the printed specification by their SEQ ID number therefore none of the sequences can be explicitly identified.

Sequence 492 AA;

Query March 53.0%; Score 1279; DB 7; Length 492;  
Best Local Similarity 55.8%; Pident. No. 2,56-64;  
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13

```

OY      61 ILNQGSLFKTPGSKJNBRADSRSLMDQG-NFPLIINKLIEPDSYICE----- 11.0
Db      63 --GASRKLMIYDTSIKLASGVNKRFGSGSGSTSYSLAINTMETEDATATYYCOQMSPTLTF 120
OY      111 ----VEDOK-----BEVOLVFGJLANSPTDHLLOGSLJTLTLESPPGSSP 151
           : : : : :
Db      121 GSGTGLKIRKGGGGSGGGGGGGGQVQLKEAGPOLVQPTQL---SLTCTVSGSFLSLTD 177
OY      152 SVQ-CSSPPGKRNQ-----GGKT-----LSVSQLELDQSGT 181
           : : : : :
Db      178 GVMWIRQPPGKGLGEMWGIIYYDGGDYNASAIKSLSLSRDTSKSQVFLKINSLQTDJDTJAM 237
OY      182 WTTCTVLAQNKQKVEFK-----IDIVCPAPBEPKSCDKHTTC-----PELLGGPSVFLPRK 231
           : : : : :
Db      238 YYCA-----RIHFIDWGQGVWVYVTSSDQEPKSCDKHTHCPCPAPFELGGPSVFLPRK 231
OY      232 PKOTLMISTRPEVTCYVDVSHEDBEVKFNNYVDGVEYHNAKTYRBEQONSTRYVSVL 230
Db      292 PKOTLMISTRPEVTCYVDVSHEDBEVKFNNYVDGVEYHNAKTYRBEQONSTRYVSVL 351
OY      292 TVYHOMLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTLNQVSLT 351
Db      352 TVYHOMLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTLNQVSLT 411
OY      352 CLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVFSCS 411
Db      412 CLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVFSCS 471
OY      412 VMHEALHNHYTQKSLSLSPG 431
Db      472 VMHEALHNHYTQKSLSLSPG 491

```

XX	AAAB81972	
ID	AAAB81972	standard; protein; 581 AA.
XX		
AC	AAAB81972;	
XX		
DT	03-JUL-2001	(first entry)
XX		
DE	Ganglioside GD2 specific antibody related protein SEQ ID NO: 31.	
XX		
KW	Ganglioside; CD2; complementation determining region; CDR; antibody;	
KW	mouse; cancer.	
XX		
OS	Synthetic.	
XX		
PN	WO200123573-A1.	
XX		
PD	05-APR-2001.	
XX		
PF	29-SEP-2000; 2000MO-JP006773.	
XX		
PR	30-SEP-1999; 99JP-00278290.	
XX		
PA	(KYOW ) KYOWA HAKKO KOGYO KK.	
XX		
PI	Hanai N, Shitara K, Nakamura K, Niwa R;	
XX		
DR	WPI; 2001-266163/27.	
XX		
PT	Human type complementation-determining domain transplanted antibody and	
PT	derivatives against ganglioside GD2, useful in diagnosis and therapy of	
PT	e.g. tumors, has low antigenicity, little side effects but potent	
XX	activity in cancer.	
PS		
XX	Example 3; Page 111-114; 123pp; Japanese.	
CC	The present invention describes an antibody, which can react specifically	
CC	with ganglioside GD2, and is transplanted with a human type	
CC	complementation-determining domain (CDR), or its fragments. The antibody	

CC and its derivatives are useful in diagnosis and therapy of tumours,  
CC particularly cancer diagnosis. The present sequence is a protein used in  
CC the exemplification of the invention

XX Sequence 581 AA:

Query Match 53.0%; Score 1278.5; DB 4; Length 581;  
Best Local Similarity 57.7%; Pred. No. 3.1e-64;  
Matches 275; Conservative 25; Mismatches 96; Indels 81; Gaps 10;

QY 30 LGKGDVTELTCTAS--QKKSIOFHKNSNQIKILNQSFLTKGPKSLNDRADSRSL- 86  
DB 11 LKPSQTLSTITCTVSGFSFLASVNIHWVROPKGLKMLVWAGSTNYNSALMSRLTIS 70  
QY 87 WQGNPRLIIKNLKIDSDPTVCEVDDQKEVQLVFGILANSPTHLLOGQSITLTLESP 146  
DB 71 KNSKNQVFLKNSSLPAADTAAYVYCAKRSDDYSWEAY-----WGQTLVIVSSA 119  
QY 147 PGSSPVSQCRSPKKNIOGQ-----KTLVS-----QLEIQQDSG 180  
DB 120 STKGPEVFLPLASSKSTSGGTALGCLVNDYFPEPTVMSNGALTSVHTPPAVLQSSG 179  
QY 181 -----TWCTVLQNKQKVEFKIDVPCAPKPKSCDKHTC-----P 217  
DB 180 LYSLSVTVTPSSSLGQTGYICNV--NHRPSNTKVD-----KKEPKSCDKHTCPKCPAP 233  
QY 218 ELGGSVFLFPKPKDQTLMIPTPEVTCVVDVSHEDPEYKFNWVDDEVHNKATKR 277  
DB 234 ELGGSVFLFPKPKDQTLMIPTPEVTCVVDVSHEDPEYKFNWVDDEVHNKATKR 293  
QY 278 EEQYNSTYVSVLYLHODMNLGKCKVSNKALPAIEKTIKSAKQPREPVYTLR 337  
DB 294 EEQYNSTYVSVLYLHODMNLGKCKVSNKALPAIEKTIKSAKQPREPVYTLR 353  
QY 338 PERDELTKNQVSLTCLVKGPYPSPDAVEMESNGQPENNYKTPPVLDSDGSFPLYSKLT 397  
DB 354 PERDELTKNQVSLTCLVKGPYPSPDAVEMESNGQPENNYKTPPVLDSDGSFPLYSKLT 413  
QY 398 DSRMOQGVNFGSVNHEALHNHYTQKSLSLSPG-----LQDFTCAEQ 442  
DB 414 DSRMOQGVNFGSVNHEALHNHYTQKSLSLSPGKAPTSSTKTQQLDLEHLLDLQ 470

RESULT 52

ADD25784  
ID ADD25784 standard; protein; 543 AA.

AC ADD25784;

DT 15-JAN-2004 (first entry)

DE Binding domain-immunoglobulin fusion protein-aassociated protein #158.

KW Binding domain; immunoglobulin; fusion protein; cytoactive;  
KW antiarthritis; immunosuppressive; antidiabetic; antihypertoid;  
KW neuroprotective; hinge region; immunoglobulin heavy chain;  
KW CH2 constant region; CH3 constant region; IgG1;  
KW antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;  
KW malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;  
KW rheumatoid arthritis; myasthenia gravis; Grave's disease;  
KW type I diabetes mellitus; multiple sclerosis; autoimmune disease.

OS Unidentified.

XX US2003118592-A1.

XX 26-JUN-2003.

XX 25-JUL-2002; 2002US-00207655.

XX 17-JAN-2001; 2001US-0367358P.

XX 17-JAN-2002; 2002US-00053530.  
PR 03-JUN-2002; 2002US-0385691P.

XX (GENE-) GENE-CRAFT INC.  
PA Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;

XX WPI; 2003-801317/75.

XX New binding domain-immunoglobulin fusion protein, useful for treating a  
PT subject having or suspected of having a malignant condition or a B-cell  
PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.

XX Disclosure; SEQ ID NO 345; 157bp; English.

XX The invention relates to a binding domain-immunoglobulin fusion protein  
CC comprising a binding domain polypeptide that is fused to an  
CC immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain  
CC CH2 constant region polypeptide that is fused to the hinge region  
CC polypeptide, and an immunoglobulin heavy chain CH3 constant region  
CC polypeptide that is fused to the CH2 constant region polypeptide. The  
CC hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin  
CC hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge  
CC region polypeptide, derived from (a) having 3 or more cysteine residues;  
CC where the mutated human IgG1 immunoglobulin hinge region polypeptide  
CC contains 2 cysteine residues, where the first cysteine is not mutated; a  
CC mutated human IgG1 immunoglobulin hinge region polypeptide, derived from  
CC (a) having 3 or more cysteine residues, where the mutated human IgG1  
CC immunoglobulin hinge region polypeptide contains no more than one  
CC cysteine residue; and a mutated human IgG1 immunoglobulin hinge region  
CC polypeptide, derived from (a) having 3 or more cysteine residues; where  
CC the mutated human IgG1 immunoglobulin hinge region polypeptide contains  
CC no cysteine residues. The binding domain-immunoglobulin fusion protein is  
CC capable of at least one immunological activity comprising antibody  
CC dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The  
CC binding domain polypeptide is capable of specifically binding to an  
CC antigen. Also included are an isolated polynucleotide encoding the  
CC binding domain-immunoglobulin fusion protein, a recombinant expression  
CC construct comprising the polynucleotide (operably linked to a promoter),  
CC a host cell transformed or transfected with a recombinant expression  
CC construct, producing the binding domain-immunoglobulin fusion protein, a  
CC pharmaceutical composition comprising the binding domain-immunoglobulin  
CC fusion protein or polynucleotide and a carrier, and treating a subject  
CC having or suspected of having a malignant condition or a B-cell disorder.  
CC The binding domain-immunoglobulin fusion protein is useful for treating a  
CC subject having or suspected of having a malignant condition or a B-cell  
CC disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis,  
CC myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple  
CC sclerosis or autoimmune disease. The present sequence is a binding domain  
CC -immunoglobulin fusion protein-aassociated protein sequence. Note: The  
CC sequence data for this patent formed part of the printed specification  
CC and is also available in electronic format directly from USPRO at  
CC seqdata.uspro.gov/sequence.html?DocID=20030118592. The authors have not  
CC identified the sequences in the printed specification by their SEQ ID  
CC number therefore none of the sequences can be explicitly identified.

XX Sequence 543 AA;

Query Match 52.9%; Score 1277; DB 7; Length 543;  
Best Local Similarity 55.8%; Pred. No. 3.6e-64;  
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13;

QY 1 MNRGVRPHNLLVLLALPAAQGNKVLKKGDTVLTCTASQKSIQHNKNSNQIK 60  
DB 19 MSRGVD-----IVL-----TOSPPTTAAAPGKRVITCRASSVSVMWYQOKS--- 62  
QY 61 ILNGQSFLLTKGPKSLNDRADSRSLWDOG--NPLIILNKLIEDSDTYICE----- 110  
DB 63 --GASPKLMITDYSKLASGVNRRFSGSGSGSYSLAITMTMETDAATYYCQGWSTPLTF 120  
QY 111 -----VEDQK-----EEVOLVFGILANSPTHLLOGQSITLTLESPGSSP 151  
DB 121 GSGTFLKIRKGGGGGGGGGGGGGQVQLKKAAGPLVPTQL--SLTCTVSGFSPLTSD 177  
QY 152 SVQ-CRSPRGNIQ-----GKKT-----LSVQGLQLDQSGT 181

```

Db      178 GVMHWRQPGKGLWGGIIYYDGGTDYNSAIKSRLSISRDTSKQGVFLKINSLQTDPTAM 237
Qy      182 WTCTVLQNOQKVEFK-----IDIVPCPAPEPKSCDKTHTC-----PELLGGPSVFLFPPK 231
Db      228 YVCA-----RHFPYMGQGVWVWTVSSDLEPKSCDKTHTCPCPAPELLGGPSVFLFPPK 291
Qy      232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNNVYDGEVHNAAKTRPREQYNSTYRVSVL 291
Db      232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNNVYDGEVHNAAKTRPREQYNSTYRVSVL 351
Qy      232 TVLHODMNLNGEKYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 351
Db      232 TVLHODMNLNGEKYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 411
Qy      352 CLVKGFPYSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRMQOGNVFSCS 411
Db      412 CLVKGFPYSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRMQOGNVFSCS 471
Qy      412 VMHEALHNHYTQKSLSLSPG 431
Db      472 VMHEALHNHYTQKSLSLSPG 491

```

```

RESULT 53
ABR39847
ID      ABR39847 standard; protein; 461 AA.
XX
AC      ABR39847;
XX
DT      18-AUG-2003 (first entry)
XX
DE      Hu266 N56S heavy chain.
XX
KW      Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;
KM      immunostimulant.
OS      Homo sapiens.
XX
PN      MO2003016466-A2.
XX
PD      27-FEB-2003.
XX
PF      14-AUG-2002; 2002MO-US021322.
XX
PR      17-AUG-2001; 2001US-0313224P.
XX
PA      (ELIL ) LILLY & CO ELI.
XX
PI      Jia AY, Tsurushita N, Vaequez MJ;
XX
DR      MPI; 2003-278557/27.
XX
DR      N-PSDB; ACC47231.
XX
PT      New antibodies comprising a heavy chain and a light chain complementarily
PT      determining regions from antibody 266, for treating and preventing
PT      conditions associated with the A beta peptide, e.g. Alzheimer's disease
PT      or Down syndrome.
XX
PS      Disclosure; Fig 6; 82pp; English.
XX
XX      The invention relates to an anti-Abeta (amyloid-beta peptide) antibody
XX      266. The antibodies are useful for treating and preventing conditions
XX      associated with the A beta peptide, such as Alzheimer's disease, Down
XX      syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in
XX      humans; for determining whether a human subject will respond to treatment
XX      using humanized antibodies against Abeta; for treating, preventing and
XX      reversing cognitive decline in clinical or pre-clinical Alzheimer's
XX      disease, Down's syndrome or cerebral amyloid angiopathy; for inhibiting
XX      formation of amyloid plaques of the effects of toxic soluble Abeta
XX      species in humans. Treatment of the patients with antibody will inhibit
XX      or prevent cognitive decline typically associated with disease
XX      progression and reverse it. The present sequence represents a humanised
CC

```

```

CC      anti-Abeta antibody 266 N56S heavy chain
XX
XX      Sequence 461 AA;
XX
Query Match      52.8%; Score 1275.5; DB 6; Length 461;
Best Local Similarity 57.0%; Pred. No. 3.0e-64;
Matches 281; Conservative 31; Mismatches 86; Indels 95; Gaps 13;
Qy      1 MNRGVPFRHLILVQLALPLAATQGNKVLGKKDGYELTCTAS--OKKSIQFFMKNS-- 56
Db      1 MNRGLSLIFLVILVILKGLCEVQLVESGGGLVQCGSLRLCAASGFFRSYMSWVAGAP 60
Qy      57 -----NQIKILGNQSF--LTGSPKLNDRADRSRRSLMDQGNFLLINLKIEDSDTY 107
Db      61 GKGLELVAQLINSVSSSTYYPDYVKGREFTIS--RONAKVTLYLQNW-----SLRAEDTAVY 113
Qy      108 ICEVEDQKEVQLVRLDTANSPTHLQCGSLTLTLESFGSSPSVQCRSPRGNIQGG- 166
Db      114 YC-----ASGD--YWGQGLTVYSSASTKGPSVFPPLAPSSKSTSGGT 153
Qy      167 -----KTLSSV-----QLQDSG-----TWRT 183
Db      154 AALGCLVKDYFPEPVTVSNMGSALTSGVHTFPAVLQSSGLYSLSSVTVFSSSLGTQTYI 213
Qy      184 CTVLQNOQKVEFKIDIVPCPAPEPKSCDKTHTC-----PELLGGPSVFLFPPKDTLMI 238
Db      214 CNV--NHKPSNTKVD---KVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKDTLMI 267
Qy      239 SRTPETVCVVVDVSHEDPEVKFNNVYDGEVHNAAKTRPREQYNSTYRVSVLTVLHODW 298
Db      268 SRTPETVCVVVDVSHEDPEVKFNNVYDGEVHNAAKTRPREQYNSTYRVSVLTVLHODW 327
Qy      299 LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFY 358
Db      328 LNGKEYKCKVSNKALPAPIEKTISKAKGQPREQVYTLPPSRDELTKNQVSLTCLVKGFY 387
Qy      359 PSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRMQOGNVFSCSVMHEALH 418
Db      388 PSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRMQOGNVFSCSVMHEALH 447
Qy      419 NHTYQKSLSLSPG 431
Db      448 NHTYQKSLSLSPG 460

```

```

RESULT 54
ABR39843
ID      ABR39843 standard; protein; 461 AA.
XX
XX      ABR39843;
XX
AC      ABR39843;
XX
DT      18-AUG-2003 (first entry)
XX
DE      Hu266 N56S heavy chain.
XX
KW      Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;
KM      immunostimulant.
OS      Homo sapiens.
XX
PN      MO2003016466-A2.
XX
PD      27-FEB-2003.
XX
PF      14-AUG-2002; 2002MO-US021322.
XX
PR      17-AUG-2001; 2001US-0313224P.
XX
PA      (ELIL ) LILLY & CO ELI.
XX
PI      Jia AY, Tsurushita N, Vaequez MJ;
XX
DR      MPI; 2003-278557/27.
XX

```



DR	N-PSDB, ACC47227.
XX	New antibodies comprising a heavy chain and a light chain complementarity
PT	determining regions from antibody 266, for treating and preventing
PT	conditions associated with the A beta peptide, e.g. Alzheimer's disease
PT	or Down syndrome.
XX	
PS	Discloure; Fig 2, 82pp; English.
XX	
CC	The invention relates to an anti-Abeta (amyloid-beta peptide) antibody
CC	266. The antibodies are useful for treating and preventing conditions
CC	associated with the Abeta peptide, such as Alzheimer's disease, Down
CC	syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in
CC	humans; for determining whether a human subject will respond to treatment
CC	using humanized antibodies against Abeta; for treating, preventing and
CC	reversing cognitive decline in clinical or pre-clinical Alzheimer's
CC	diseases, Down's syndrome or cerebral amyloid angiopathy; for inhibiting
CC	formation of amyloid plaques or the effects of toxic soluble Abeta
CC	species in humans. Treatment of the patients with antibody will inhibit
CC	or prevent cognitive decline typically associated with disease
CC	progression and reverses it. The present sequence represents a humanised
CC	anti-Abeta antibody 266 N56S heavy chain
XX	
SQ	Sequence 461 AA;
Query Match	52.8%; Score 1275.5; DB 6; Length 461;
Best Local Similarity	57.0%; Pred. No. 3,6e-64;
Matches 281; Conservative	31; Mismatches 86; Indels 95; Gaps 13
OY	1 MNRGVPRFHLILVLQALLPATQGNKVVLLGKKGDVELTCTAS--QKKSIOFHWNKS-- 56
Db	1 MNFGSLFLVYLVLGVLCVEVOLVESGGGLVPQGSLRLSCAAGFTFSRYMSWVRQAP 60
OY	57 -----NQIKLIGNQGSF--LTGPSKLNDPADSRRLMDQGNPFLITKNLKIEDSDTY 107
Db	61 GKGLELVADINSVGSSITYPDYTKGRFTIS-RDNAKNTIYLQN-----SLRAEDTAVY 113
OY	108 ICEVEDQKEEVOALLVGLTANSDTHLLOGQSLLTLLESPGGSPSYOCRSPGRKNIQGG- 166
Db	114 YC-----ASGD---YMGQGLTVTVSSASTKGVSFPLAPSKNSGT 153
OY	167 -----KITLSVS-----OLELDGSG-----TWTF 183
Db	154 AALGLVKVDYPEPEPTVSNWSNGALTSGVTTPFAVLQSSGLYSLSVTVTPSSSLGTQTYI 213
OY	184 CTVLONOKKVERKIDIVPCPAPEPKSCDKTHRC-----PELLGSPVLFPPRPKDTMI 238
Db	214 CNV--NHRPSNTKV----KRVEPSCDTHTCPPCPAPAEELLGDSVFLLFPKPDTLMI 267
OY	239 SRTPEVTCVVVDVSHEDPEVKFNMYVDGVEYNAAKTAPREEQYNSTYRVAVSLTVLHQM 298
Db	268 SRTPEVTCVVVDVSHEDPEVKFNMYVDGVEYNAAKTAPREEQYNSTYRVAVSLTVLHQM 327
OY	299 LNKGEYKCKKSVKNAKLPAPIEKTIISAKGQPREPQVYTLPPSDELTKNQVSLTCLVKGFY 358
Db	328 LNKGEYKCKKSVKNAKLPAPIEKTIISAKGQPREPQVYTLPPSDELTKNQVSLTCLVKGFY 387
OY	359 PSDIAVENESNQGPENNYKTTTPPVLDSDGSFLYSKLTVDKSRMQQGNVFCGSVWHEAH 418
Db	388 PSDAIAVENESNQGPENNYKTTTPPVLDSDGSFLYSKLTVDKSRMQQGNVFCGSVWHEAH 447
OY	419 NHYTOKSLSLSPG 431
Db	448 NHYTOKSLSLSPG 460
RESULT 55	
ID	AAB33444
AC	AAB33444 standard; protein; 579 AA.
XX	AAB33444;
DT	02-APR-2003 (first entry)

XX	KS antibody heavy chain-interleukin 2 (IL-2) fusion protein.
DE	
XX	Immunoglobulin; diagnosis; epithelial cell adhesion molecule; EPCAM;
KW	cancer; gene therapy; interleukin-2; IL2; fusion protein.
XX	
OS	Unidentified.
XX	
PN	WO200290566-A2.
XX	
PD	14-NOV-2002.
XX	
PF	03-MAY-2002; 2002WO-US013844.
XX	
PR	03-MAY-2001; 2001US-0288564P.
XX	
PA	(LEXI-) LEXIGEN PHARM CORP.
XX	
PI	Gillies SD, Lo K, Qian X;
XX	
DR	WPI; 2003-111985/10.
XX	
DR	N-PSDB; AAD51139.
XX	
PT	New recombinant anti-EPCAM antibody having an amino acid sequence
XX	defining an immunoglobulin light or heavy chain framework region, useful
PT	for the diagnosis, prognosis and treatment of cancer.
XX	
PS	Disclosure; Page 80-82; 82pp; English.
XX	
CC	The present invention relates to novel recombinant anti-EPCAM (human
CC	epithelial cell adhesion molecule) antibodies comprising an amino acid
CC	sequence defining an immunoglobulin light or heavy chain framework
CC	region. Sequences of the present invention are useful for the diagnosis,
CC	prognosis and treatment of cancer. They are also used in gene therapy.
CC	The present sequence is KS antibody heavy chain-interleukin 2 (IL-2)
CC	fusion protein. This sequence is used to illustrate the method of the
CC	invention
XX	
SQ	Sequence 579 AA;
XX	
Query Match	52.8%; Score 1275.5; DB 6; Length 579;
Best Local Similarity	57.7%; Pred. No. 4.6e-64;
Matches 281; Conservative 29; Mismatches 70; Indels 107; Gaps 14	
QY	32 KKGPDELVTCTAASQKSIQF--HMKNINQIKILGNQ--SEFLTKSPSKLANDRARSRLM 87
DB	13 KPGELVAKISCAASGTYFTNYGMNWKQTPGGLKMGKMGINNTYTGPTADD----- 63
QY	88 DQGNFP-----LIINKLIEDSDTYICEVEDQKEVOLLVFLGLTANSDTHLLQG 136
DB	64 FKGRPAFSLETSTAFLOQNNLRSEDTATATFC-----VRFISK-----DYMGQ 109
QY	137 QSLTILTESPPGSSPSVQCRSPKGNIOG-----KTLNIS----- 172
DB	110 TSVTVSSASTYKG--PSVFPILAPSSKTSYGTAALGLVKQFPPEPVTYSMNSGALTSGVH 167
QY	173 --QELIDSG-----TWTCVLQNGKKVEPKFDIYPCAPPEPKSCDK 212
DB	168 TFPRAVLQSGSLYSLSVVTPSSLSIGTQYICNV--NHKPSNTKD---KRVPEKSCDK 221
QY	213 THTC-----PEILGSPSVLEFPPEPKDITLMSRTPEVTCVVVDVSHEDPEVKFMNYVDGV 267
DB	222 THTCPCGAPPLLDGSPVFLFPPEPKDITLMSRPEVTCVVVDVSHEDPEVKFMNYVDGV 281
QY	268 EVANAKTKPEEQINSTRVIVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTTISKAKGQ 327
DB	282 EVANAKTKPEEQYNSTRVIVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTTISKAKGQ 341
QY	328 PREPOVYTLPSRDELTKNOVSLTCLVKGFPSPDIAYVWESNGQPENNYKTTTPPLVDSG 387
DB	342 PREPOVYTLPSRREMTKNQVSLTCLVKGFPSPDIAYVWESNGQPENNYKTTTPPLVDSG 401
QY	388 SFFLYYSKLTVDKSRMOQGNVSCSVMHEALNHYTKSLSLSPG-----LQLD 435

```

Db      402 SFFLYSKLTVDKSRWQGNVFCSCVMHBAHNNHYTKSLSPGKAPRTSSSTKTKTQGLE 461
Qy      436 ETCAEAQ 442
Db      462 HLLDLQ 468

RESULT 56
AAW86003
ID      AAW86003 standard; protein; 595 AA.
XX
AC      AAW86003;
XX
DT      15-MAR-1999 (first entry)
XX
DE      Anti-5T4 single chain antibody 5T4Sabl.
XX
KW      Tumour interacting protein; cancer; gene therapy; vector; 5T4 antigen;
KW      monoclonal antibody; single chain antibody; mouse; human; 5T4Sabl.
XX
OS      Mus sp.
OS      Homo sapiens.
OS      Synthetic.
OS      Chimeric.
XX
PN      WO985607-A2.
XX
PD      10-DEC-1998.
XX
PF      04-JUN-1998; 98WO-GB001627.
XX
PR      04-JUN-1997; 97GB-00011579.
PR      20-JUN-1997; 97GB-00013150.
PR      04-JUL-1997; 97GB-00014230.
XX
PA      (OXFO-) OXFORD BIOMEDICA UK LTD.
XX
PI      Kingman SM, Bebbington CR, Ellard FM, Carroll MW, Myers KA;
XX
DR      WPI; 1999-059910/05.
DR      N-PSDB; AAV80291.
XX
PT      New vector encoding a tumour interacting protein for treating cancer -
PT      contains a desired nucleotide sequence and/or protein which recognises
PT      tumours, and is used as a gene delivery system to treat cancer.
XX
PS      Example 1; Fig 1B; 82pp; English.
XX
CC      This is the amino acid sequence of a single chain antibody (Sabl), termed
CC      5T4Sabl, comprising an scFv derived from murine monoclonal antibody 5T4
CC      (see AAW86002) and the human g1 constant region. CDNA (see AAV80291)
CC      encoding the Sabl has been inserted into vector pCIneo to allow expression
CC      in mammalian cells. The trophoblast cell surface antigen defined by 5T4
CC      is expressed at high levels on the cells of a wide variety of human
CC      tumours. The invention relates to a vector comprising a nucleotide
CC      sequence coding for a tumour interacting protein (TIP) and optionally a
CC      nucleotide sequence of interest (NOI) which encodes a protein of interest
CC      (POI), the vector being capable of delivering the NOI and/or POI to the
CC      tumour recognised by the TIP. Delivery can be in vivo or ex vivo. The
CC      vector is used to treat cancer, and may also be used as a gene delivery
CC      system for introducing at least 1 gene encoding a TIP (preferably a
CC      tumour binding protein) into a haematopoietic cell lineage
XX
SQ      Sequence 595 AA;
Qy      Query Match 52.8%; Score 1275; DB 2; Length 595;
Qy      Best Local Similarity 59.4%; Pred. No. 5,1e-64;
Qy      Matches 277; Conservative .18; Mismatches 81; Indels 90; Gaps 11;
Db      23 TQGNKVVIGKGDYVELTCTASOKSIFPHWKNSTQRIKLNGSFLTKGSKLNDRAIS 82
Db      162 TQTFLLVSAGDVTITCKASQSVSNVAVYQKRP-----GQSPTLLISTYSS 210

```

```

Qy      83 R-RSLMDQ-----GNPPIIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSPTHL 134
Db      211 RYAGVPRDFIGSGYGDFTFTISTIQAEIDLAVFCCQD-----YNSPPTFG 256
Qy      135 QGOSLTLTLESPPGSSPFCRSPRKNIOGG-----KTLSSVS----- 172
Db      257 GGTLEIKRASTKG--PSVFPPLAPSSKSTSGTAAAGCLAKDYFPPEPVTVMNSGALTSG 314
Qy      173 -----QLEIDPSG-----TWTCVYLQNKQKVEFKIDYPCAPAPKSC 210
Db      315 VHTFPVAVLQSSGLXSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD----KKEVKSJC 368
Qy      211 DKHTTC-----PELLGSPSVFLFPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFMYVD 265
Db      369 DKHTTCPPCAPPELLGSPSVFLFPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFMYVD 428
Qy      266 GVEYHNAKTPREBOYNSTRVVSVLTVLHQDWLNGEKYCKVSNKALPAPIEKTISKAK 325
Db      429 GVEYHNAKTPREBOYNSTRVVSVLTVLHQDWLNGEKYCKVSNKALPAPIEKTISKAK 488
Qy      326 GQPREPQVYTLPPSRDELTKNOVSLTGLVKGFPYPSDIAVEMESNGQEPENNYKTTPTVLDS 385
Db      489 GQPREPQVYTLPPSRDELTKNOVSLTGLVKGFPYPSDIAVEMESNGQEPENNYKTTPTVLDS 548
Qy      386 DGSFFLYSKLTVDKSRWQGNVFCSCVMHBAHNNHYTKSLSPG 431
Qy      549 DGSFFLYSKLTVDKSRWQGNVFCSCVMHBAHNNHYTKSLSPG 594

RESULT 57
AAO31101
ID      AAO31101 standard; protein; 445 AA.
XX
AC      AAO31101;
XX
DT      06-OCT-2003 (first entry)
XX
DE      Human A2-G8 SCF antibody heavy chain variable and constant region.
XX
KW      Human; antibody; stem cell factor; mast cell growth factor; asthma; SCF;
KW      steel factor; c-kit ligand; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003051311-A2.
XX
PD      26-JUN-2003.
XX
PF      16-DEC-2002; 2002WO-US040227.
XX
PR      17-DEC-2001; 2001US-0342174P.
XX
PA      (FARB ) BAYER CORP.
XX
PI      Takeuchi T, Tomkinson A, Neben S;
XX
DR      WPI; 2003-523500/49.
XX
PT      New purified human antibody that binds to stem cell factor protein,
PT      useful for preparing a composition for treating asthma.
XX
PS      Claim 9; Page 47; 94pp; English.
XX
CC      The invention provides human antibodies that bind to stem cell factor
CC      (SCF) protein. SCF is also known as mast cell growth factor, steel factor
CC      or c-kit ligand. Antibodies of the invention are useful for preparing
CC      compositions for treating asthma. They are also used in gene therapy. The
CC      present sequence is human SCF antibody heavy chain variable and constant
CC      region
XX
SQ      Sequence 445 AA;

```

Query Match 52.8%; Score 1274.5; DB 6; Length 445;  
Best Local Similarity 59.2%; Pred. No. 4e-64;  
Matches 277; Conservative 27; Mismatches 67; Indels 97; Gaps 13;

QY 30 LGKGGDTVELTCTAS-----QKSIQFHWKNSNOIKILGNQGSFL---TYG 72  
DB 8 LVQPGGSLRLSCAASGFTTSYAMSWVRQAPGKLEWVA---ISGSGSTYYADSVKG 63  
QY 73 PSLNLRADSRSLRMQGNFPLIKIKLKI EDSPTVCEVEDQKEEQLVLFGLTANSDPH 132  
DB 64 RFTIS-RDMSKNTLYLQMN-----SLRAEDTAVVYCARDD-----FFAHFD-- 103  
QY 133 LLOGOSLTLTLSPSSPSVQCRSPRKNIOG-----KTLISVS----- 172  
DB 104 -VMGQGLTVTVSSASTKGPSVFPPLAPSSKSTSGCTALGLVDYVPEEYVTSWNGALT 162  
QY 173 -----QLEIQDSG-----TWCTTVLONOKVEFKIDIVPCAPAEK 208  
DB 163 SGVHTRPAVLQSSGLYSLSSVTVPPSSSLGTQTYICNV--NHKPSNTKYD---KVEBK 216  
QY 209 SCDKTHTC-----PELLGSPSVFLPPKPKDTLMISRTPEYTCVVVDVSHEDPEVKENY 263  
DB 217 SCDKTHTCPPCAPPELLGGPSVFLPPKPKDTLMISRTPEYTCVVVDVSHEDPEVKENY 276  
QY 264 VDGVEVHNAKTKRREQYSTYRVSVLTVLHODMVLNGEKYCKVKSNKALLPAPIETISK 323  
DB 277 VDGVEVHNAKTKRREQYSTYRVSVLTVLHODMVLNGEKYCKVKSNKALLPAPIETISK 336  
QY 324 AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTTPVL 383  
DB 337 AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTTPVL 396  
QY 384 DSDGSFELYSKLTVDKSRWQQGNVFCSCVMEALHNHYTQKSLSLSPG 431  
DB 397 DSDGSFELYSKLTVDKSRWQQGNVFCSCVMEALHNHYTQKSLSLSPG 444

RESULT 58  
ABR39848  
ID ABR39844 standard; protein; 461 AA.  
XX ABR39844;  
XX  
DT 18-AUG-2003 (first entry)  
XX  
DE Hu266 N56T heavy chain.  
XX  
KW Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;  
XX immunostimulant.  
XX  
OS Homo sapiens.  
XX  
XX WO2003016466-A2.  
XX  
XX PD 27-FEB-2003.  
XX  
XX PF 14-AUG-2002; 2002WO-US021322.  
XX  
XX PR 17-AUG-2001; 2001US-0113224P.  
XX  
XX PA (ELIL ) LILLY & CO ELI.  
XX  
XX PI Jia AY, Teurnushita N, Vazquez MJ;  
XX  
XX DR WPI; 2003-278557/27.  
XX  
XX DR N-PSDB; ACC47228.  
XX  
XX PT New antibodies comprising a heavy chain and a light chain complementarity  
XX determining regions from antibody 266, for treating and preventing  
XX conditions associated with the A beta peptide, e.g. Alzheimer's disease  
XX or Down syndrome.  
XX  
XX PS Disclosure; Fig 3; 82pp; English.

XX  
CC The invention relates to an anti-Abeta (amyloid-beta peptide) antibody  
CC 266. The antibodies are useful for treating and preventing conditions  
CC associated with the Abeta peptide, such as Alzheimer's disease, Down  
CC syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in  
CC humans; for determining whether a human subject will respond to treatment  
CC using humanized antibodies against Abeta; for treating, preventing and  
CC reversing cognitive decline in clinical or pre-clinical Alzheimer's  
CC disease. Down's syndrome or cerebral amyloid angiopathy; for inhibiting  
CC formation of amyloid plaques of the effects of toxic soluble Abeta  
CC species in humans. Treatment of the patients with antibody will inhibit  
CC or prevent cognitive decline typically associated with disease  
CC progression and reverses it. The present sequence represents a humanised  
CC anti-Abeta antibody 266 N56t heavy chain

Sequence 461 AA;  
SQ

Query Match 52.8%; Score 1274.5; DB 6; Length 461;  
Best Local Similarity 57.0%; Pred. No. 4.2e-64;  
Matches 281; Conservative 30; Mismatches 87; Indels 95; Gaps 13;

QY 1 NMRGVPFRHLILVQLALPPAATQGNKYVLGKGGDTVELTCTAS--QKSIQFHWKNS-- 56  
DB 1 NMFGSLIFLVLYLVKGVLCVQLVSGGGLVQPGGSLRLSCAASGFTTSYAMSWVRQAP 60  
QY 57 -----NQIKILGNQGSF--LTGKPSKLNDRADSRSLRMQGNFPLIKIKIEDSDTY 107  
DB 61 GKGLELVADINSVGSITTYPTDKRFTIS-RDNKNTLYLQMN-----SLRAEDTAVY 113  
QY 108 ICEVEDQKEEQLVLFGLTANSDPHLLOGOSLTLTLSPSSPSVQCRSPRKNIOG- 166  
DB 114 YC-----YMGQGLTVTVSSASTKGPSVFPPLAPSSKSTSGCT 153  
QY 167 -----KTLISVS-----QLEIQDSG-----TWCT 183  
DB 154 AALGCLVVDYFPEPYTVSWNSGALTSGVHTRPAVLQSSGLYSLSSVTVPPSSSLGTQTYI 213  
QY 184 CTVLONOKKVEFKIDIVPCAPAEPEKSCDKTHTC-----PELLGSPSVFLPPKPKDTLMI 238  
DB 214 CNV--NHKPSNTKYD---KVEBKSCDKTHTCPPCAPPELLGGPSVFLPPKPKDTLMI 267  
QY 239 SRTPEYTCVVVDVSHEDPEVKENMYVDGVEVHNAKTKRREQYSTYRVSVLTVLHODM 298  
DB 268 SRTPEYTCVVVDVSHEDPEVKENMYVDGVEVHNAKTKRREQYSTYRVSVLTVLHODM 327  
QY 299 LMGKEYCKVKSNKALLPAPIETISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY 358  
DB 328 LMGKEYCKVKSNKALLPAPIETISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY 387  
QY 359 PSDIAVWESNGQPENNYKTTTPVLDDSGSFYLSKLTVDKSRWQQGNVFCSCVMEALH 418  
DB 388 PSDIAVWESNGQPENNYKTTTPVLDDSGSFYLSKLTVDKSRWQQGNVFCSCVMEALH 447  
QY 419 NHYTQKSLSLSPG 431  
DB 448 NHYTQKSLSLSPG 460

RESULT 59  
ABR39848  
ID ABR39848 standard; protein; 461 AA.  
XX ABR39848;  
XX  
DT 18-AUG-2003 (first entry)  
XX  
XX AC ABR39848;  
XX  
XX DE Hu266 N56T heavy chain.  
XX  
XX KW Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;  
XX immunostimulant.  
XX  
XX OS Homo sapiens.  
XX

```

PN WO2003016466-A2.
XX
XX 27-FEB-2003.
XX
XX 14-AUG-2002; 2002WO-US021322.
XX
XX PR 17-AUG-2001; 2001US-0313224P.
XX
XX PA (ELI ) LILLY & CO ELI.
XX
XX PI Jia AY, Teunehilta N, Vaequez MJ;
XX
XX DR WPI; 2003-278557/27.
XX
XX DR N-PSDB; ACC47232.
XX
XX PT New antibodies comprising a heavy chain and a light chain complementarity
XX PT determining regions from antibody 266, for treating and preventing
XX PT conditions associated with the A beta peptide, e.g. Alzheimer's disease
XX PT or Down syndrome.
XX
XX PS Disclosure; Fig 7; 82pp; English.
XX
XX CC The invention relates to an anti-Abeta (amyloid-beta peptide) antibody
XX CC 266. The antibodies are useful for treating and preventing conditions
XX CC associated with the Abeta peptide, such as Alzheimer's disease, Down
XX CC syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in
XX CC humans; for determining whether a human subject will respond to treatment
XX CC using humanized antibodies against Abeta; for treating, preventing and
XX CC reversing cognitive decline in clinical or pre-clinical Alzheimer's
XX CC disease, Down's syndrome or cerebral amyloid angiopathy; for inhibiting
XX CC formation of amyloid plaques of the effects of toxic soluble Abeta
XX CC species in humans. Treatment of the patients with antibody will inhibit
XX CC or prevent cognitive decline typically associated with disease
XX CC progression and reverse it. The present sequence represents a humanised
XX CC anti-Abeta antibody 266 N56T heavy chain
XX
XX SQ Sequence 461 AA;

```

```

Query Match 52.8%; Score 1274.5; DB 6; Length 461;
Best Local Similarity 57.0%; Pred. No. 4.2e-64;
Matches 281; Conservative 30; Mismatches 87; Indels 95; Gaps 13;

```

```

QY 1 MNRGVPFPHLLVQLALLPATQGNKVVLGKGGDTVELTCTAS--QKKSIOFHWKNS-- 56
DB 1 MNFGSLFLVLVLCGVLCVQLVSGGLVQPGSLRLSCAASFTSRYSMSVVRQAP 60
QY 57 -----NQIKLGNQGSF--LTGKPSKUNDRADSRSLMDQGNPFLIKLIKIDSDTY 107
DB 61 GKGLVLAQINSVGTSTYPTVKGRFTIS--RDNAKNTLYIQWN-----SLRADTAVY 113
QY 108 ICEVEDQKEBVLVFGLTANSDDTLLOGQSLTLTLESPPGSSPSVQCRSPRGNKIQG- 166
DB 114 YC-----ASGD---YWGQGLTVTSSASATKGPSVFLPFLAFSSKSTSGT 153
QY 167 -----KTLVS-----QLELDQSG-----TW 183
DB 154 AALGCLVNDYFPEPTVSWNSGALTSGVHTFPVAVLQSSGLVSLSSVTVTPSSSLGTQYI 213
QY 164 CTYVLONOKKVEKIDIVPCPAPEPKSCDKITTC-----PELLGSPVLPFPKPKDTLMI 238
DB 214 CNV--NHRPSMTKVD---KKEPEKSCDKITTCPCPAPELLGSPVLPFPKPKDTLMI 267
QY 219 SRTPEVTGVVVDVSHEDPEVKFNMTVVDGVEVNAATKPREQYNSTYRVSVLTVLHDDW 298
DB 268 SRTPEVTGVVVDVSHEDPEVKFNMTVVDGVEVNAATKPREQYNSTYRVSVLTVLHDDW 327
QY 299 LNKGEYKCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFY 358
DB 328 LNKGEYKCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFY 387
QY 359 PSDIAVEMESNGQPENNYKTPPVLDSDGSPFLYSKLTVDKSRWQGVFSCSVWHEALH 418
DB 368 PSDIAVEMESNGQPENNYKTPPVLDSDGSPFLYSKLTVDKSRWQGVFSCSVWHEALH 447

```

```

QY 419 NHYTQKSLSLSPG 431
DB 448 NHYTQKSLSLSPG 460

```

```

RESULT 60
AAB36206
ID AAB36206 standard; protein; 473 AA.
XX
XX AAB36206;
XX
XX 15-FEB-2001 (first entry)
XX
XX DE Human immune system associated protein HISAP-4.
XX
XX KW Human; immune system associated protein; HISAP-4; immune disorder;
XX KW infection; autoimmune disease; cancer.
XX
XX OS Homo sapiens.
XX
XX PN US6135941-A.
XX
XX PD 24-OCT-2000.
XX
XX PF 27-MAR-1998; 98US-00049672.
XX
XX PR 27-MAR-1998; 98US-00049672.
XX
XX PA (INCY-) INCYTE PHARM INC.
XX
XX PI Tang YT, Yue H, Lal P, Corley NC, Guegler KJ, Baughn MR;
XX PI Hillman JL, Au-Young J;
XX
XX DR WPI; 2001-030926/04.
XX
XX DR N-PSDB; AAC66522.
XX
XX

```

```

PT New human immune system associated proteins (HISAP) and polynucleotides
PT encoding the HISAP, useful for diagnosing, treating or preventing immune
PT or cell proliferative disorders or infections.

```

```

Claim 1; Col 53-56; 54pp; English.

```

```

XX
XX CC The present invention provides the coding and protein sequences for a
XX CC number of human immune system associated proteins (HISAPs). These can be
XX CC used in the diagnosis and treatment of various autoimmune disorders,
XX CC infections and cell proliferation diseases. The diseases include AIDS,
XX CC adult respiratory distress syndrome, anaemia, asthma, atherosclerosis,
XX CC Crohn's disease, irritable bowel syndrome, multiple sclerosis, myasthenia
XX CC gravis, osteoarthritis, rheumatoid arthritis, scleroderma, systemic lupus
XX CC erythematosus, arteriosclerosis, cirrhosis and cancer
XX
XX SQ Sequence 473 AA;

```

```

Query Match 52.8%; Score 1274.5; DB 4; Length 473;
Best Local Similarity 57.2%; Pred. No. 4.3e-64;
Matches 278; Conservative 29; Mismatches 102; Indels 77; Gaps 11;

```

```

QY 8 RHLLLVQLALP-----AATQGNKVVLGKGGDTVELTCTAS--QKKSIOFHWKNSQI 59
DB 2 KHLTFPLLVAAAPRWVLQVQLDPSGGLVPSFTLTLTCAVSGSITSGGYWMTROP 61
QY 60 KILQNO--GSPLTKGPSKUNDRADSRSL--MDQGNPFLIKLIKIDSDTYICEVDQ 114
DB 62 PGKLEWIGIYIYSGSLTNPSLSKRVITISVDSKNOFSLKSSVTADTAVYICARD- 120
QY 115 KEVQLVFGLTANSDDTLLOGQSLTLTLESPPGSSPSVQCRSPRGNKIQG----- 166
DB 121 -----VGLRGNYMDVWQGTTLTVSSASATKGPSVFLPFLAFSSKSTSGTALGCLV 172
QY 167 -----KTLVS-----QLELDQSG-----TWCTVLO 190
DB 173 KDYFPEPTVSWNSGALTSGVHTFPVAVLQSSGLVSLSSVTVTPSSSLGTQYICNV--NH 230

```

Qy	191	KKVEFFIDIVPCPAPKPKSCDKHTHC-----PELLGGPSVFLPPPKKDTLMSRTPEVT	245
Db	231	KSSNTKVD---KRAVEPKSCDKHTHTPCCPAPLLGGPSVFLPPPKDTLMSRTPEVT	286
Qy	246	CVVVDVSHDEPVEKFMVYDGVGVHNAKTKPREEQYNSTRVVSVLTVLHQDLNGKEYK	3050
Db	287	CVVVDVSHDEPVEKFMVYDGVGVHNAKTKPREEQYNSTRVVSVLTVLHQDLNGKEYK	3466
Qy	306	CVVSNKALPAPLEKTSKAKGCPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAVE	3655
Db	347	CVVSNKALPAPLEKTSKAKGCPREPOVYTLPPSRREMTKNQVSLTCLVKGFPYSDIAVE	4060
Qy	366	WESNQPENNYKTTTPVLVDSGFFLYSKLTVDKSMQCGNVSCVMHEALNNHYTKS	4255
Db	407	WESNQPENNYKTTTPVLVDSGFFLYSKLTVDKSKMQCGNVSCVMHEALNNHYTKS	4666
Qy	426	LSLSPG 431	
Db	467	LSLSPG 472	
RESULT 61			
AAE27928			
ID	AAE27928	standard; protein; 468 AA.	
AC	AAE27928;		
XX			
DT	27-DEC-2002	(first entry)	
XX			
DE	Human C5E10 antibody heavy chain protein.		
XX			
KW	Human; C649 antibody; C2B8 antibody; tumour associated antigen; TAG-72;		
KM	neoplasm; neoplastic disorder; haematologic neoplasm; colon cancer;		
KM	non-Hodgkin's lymphoma; haematologic malignancy; tumour.		
OS	Homo sapiens.		
XX			
PN	MO200260955-A2.		
XX			
PD	08-AUG-2002.		
XX			
PF	29-JAN-2002; 2002WO-US002373.		
XX			
PR	29-JAN-2001; 2001US-0264318P.		
PR	16-NOV-2001; 2001US-0331481P.		
XX			
PA	(IDEC-) IDEC PHARM CORP.		
XX			
P1	Braeclawsky GR, Hanna N, Chinn P;		
XX			
DR	WPI; 2002-698547/75.		
DR	N-PSDB; AAD45757.		
XX			
PT	Novel domain deleted C649 antibody reactive with tumor associated antigen		
PT	-72, or C2B8 antibody reactive with CD20, useful for treating		
XX	myeloidsuppressed patient suffering from a neoplastic disorder.		
PS	Example 3; Fig 6a, 7a; English.		
XX			
CC	The present invention relates to domain deleted C649 or C2B8 antibodies.		
CC	Domain deleted C649 antibodies comprise a heavy chain human C649 domain		
CC	deleted sequence in which CH2 domain has been deleted and are reactive		
CC	with tumour associated antigen (TAG)-72. The C2B8 antibodies are reactive		
CC	with CD20 and comprise a heavy chain having a sequence of a derived		
CC	domain deleted C2B8 construct where the CH2 domain has been deleted.		
CC	Sequences of the invention are useful for imaging a neoplasm. They are		
CC	also useful for treating myeloidsuppressed patients suffering from		
CC	neoplastic disorder such as haematologic neoplasm, preferably non-		
CC	Hodgkin's lymphoma. Antibodies of the invention are also used to treat		
CC	neoplastic disorder, colon cancer and haematologic malignancy. They are		
CC	useful for reducing tumour size, inhibiting tumour growth and/or		
CC	prolonging the survival time of tumour-bearing animals and for treating		

CC	Sequence	Score	DB	Length	Mismatches	Indels	Gaps
CC	tumours	52.8*	1274	468	95	80	13
CC	The present sequence is human CSE10 heavy chain protein. This sequence is used in the exemplification of the invention	58.0*	28	4.5e-64			
XX	Query Match	52.8*	Score 1274	DB 5	Length 468		
XX	Best Local Similarity	58.0*	Pred. No. 4.5e-64				
XX	Matches	280	Conservative				
XX	Sequence 468 AA						
QY	10 LLLVLIQALLPAAATQGNKVVLGKKG-----DTVELTCTAASQKSIQF--HMKNNSQIK 60						
DB	4 LALLFCLVTPSPCLT-SQVQKESGPGIYVAPSGSLSTCTCTVSGSLNDYGNWVRQPPGX 62						
QY	61 ILGNQGSFLTKGPKLNDRADRSRL-WDQGNPPLIK--NLKTEDSDTYICEVEDQKEE 117						
DB	63 GLEWIGMIWDNGRDYNSALKSRLSINKDNSSKQVFLKMTSLQTDPTARYYC----- 114						
QY	118 VQLLVFGLTANSDFHLQGGSLTLTLESPGSSPSVQCRSPKNGIKQG----- 166						
DB	115 -ARCYGSSPYFD--YWGQGTTLTVSSASTKGPVPEPLAPSSKSTSGTALAGCLVKDY 170						
QY	167 --KTLSSVS-----QLLELDQSG-----TWCTCVLQNOKV 193						
DB	171 FPEEVTVSWSNGALTSQVHFPALVQSSGLYSLSVTVTPSSLSLGTQTYICNV--NRKPS 228						
QY	194 EFKIDIVPCAPAPKPSCKDTHTC-----PELLGSPSVFLPFPKPKDTLMISRPEVTCV 248						
DB	229 NTKVD----KKVEBKSCDKTHTCPPCAPAPELGSPVFLPFPKPKDTLMISRPEVTCV 284						
QY	249 VDVSHEDPEYKFNMYVGVENHNAKKTPEEQNYSYTRVSVLTVLHQMVLNGKEYCKV 308						
DB	285 VDVSHEDPEYKFNMYVGVENHNAKKTPEEQNYSYTRVSVLTVLHQMVLNGKEYCKV 344						
QY	309 SNKALPAPIETKTSKAKGQPREPOVYTLPSRDELTKNQVSLTCLVAGFYPSDIAVWES 368						
DB	345 SNKALPAPIETKTSKAKGQPREPOVYTLPSRDELTKNQVSLTCLVAGFYPSDIAVWES 404						
QY	369 NGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGNVFSQSYMBEALHNHYTQKSLSL 428						
DB	405 NGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGNVFSQSYMBEALHNHYTQKSLSL 464						
QY	429 SPG 431						
DB	465 SPG 467						
RESULT 62							
ABB82837	standard; protein; 468 AA.						
1D	ABB82837						
XX	ABB82837;						
XX	31-MAR-2003 (first entry)						
XX	Antibody CSE10 heavy chain.						
XX	CSE10; antibody; cytototoxic; antiallergic; antianemic; antiaschmatic;						
XX	neurotropic; immunomodulator; protozoacide; antidiabetic; nephrotropic;						
XX	thyromimetic; hepatotropic; haemostatic; antileptotic; antibacterial;						
XX	neuroprotective; antipoxiatic; antirheumatic; antiallergic; antitumor;						
XX	dermatological; immunosuppressive; antiinflammatory.						
OS	Homo sapiens.						
XX	WO200296948-A2.						
XX	05-DEC-2002.						
XX	29-JAN-2002; 2002WO-US002374.						
XX	29-JAN-2001; 2001US-0264318P.						
XX	16-NOV-2001; 2001US-031481P.						
XX	21-DEC-2001; 2001US-0341858P.						

XX (IDEC-) IDEC PHARM CORP.  
XX  
XX Braalsawsky GR, Hanna N, Chinn P, Harinaran K;  
XX  
XX WPI; 2003-140446/13.  
XX N-PSDB; AB224021.  
XX  
XX Novel dimeric antibody useful for treating immune disorder and neoplastic  
XX disorder, has several non-covalently associated monomeric subunits.  
XX  
XX Example 3; Fig 6; 78pp; English.  
XX  
XX The invention relates to a dimeric antibody (I) comprising several  
XX monomeric subunits, where the monomeric subunits are non-covalently  
XX associated. (I) is useful for treating a disorder, especially immune  
XX disorder, and neoplastic disorder such as relapsed Hodgkin's disease,  
XX resistant Hodgkin's disease high grade, low grade and intermediate grade  
XX non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemia (B-CLL),  
XX lymphoplasmacytoid lymphoma (LP), mantle cell lymphoma (MCL), follicular  
XX lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma,  
XX AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic  
XX lymphadenopathy, small lymphocytic, follicular, diffuse large cell,  
XX diffuse small cleaved cell, large cell immunoblastic lymphoblastoma,  
XX small, non-cleaved, Burkitt's and non-Burkitt's, follicular, mixed small  
XX cleaved and large cell lymphomas, in a mammal (see AB224017 for a  
XX detailed description of the various uses of (I)). The present sequence  
XX represents the antibody C5E10 heavy chain

XX Sequence 468 AA;

Query Match 52.8%; Score 1274; DB 6; Length 468;  
Best Local Similarity 58.0%; Pred. No. 4.5e-64;

Matches 280; Conservative 28; Mismatches 95; Indels 80; Gaps 13;

QY 10 LILVQLALPAPATGKNNVLTGKKG-----DTVELTCTASQKSIQF--HWKNSNOIK 60  
DB 4 LALLPCLVTFPSCIL--SQVQLKESGPGLVAPESQISITCTVSGFSLTYGVAMVAVQPPGK 62  
QY 61 ILGNQSGFLTKGPKSLNDRADSRSL--WDQGNFPLIK--NKIKSDSYICEVDQKEE 117  
DB 63 GLEWLGMIWNGRTYNSALKRSLINKNKSKSQVFLKMTSLQTDVTAHYC----- 114  
QY 118 VQLLVFGLTANSDTLHLOQSLLTLTLESPGSSPSVQCSPPRGKNIQGG----- 166  
DB 115 -ARCVYSSSPYFD---YWGQGTTLVSSASSTGKPSVFLAPSSKSTSGTALGCLVDY 170  
QY 167 --KTLSSV-----OLEIQDSG-----TWCTVLQNOKV 193  
DB 171 FPEPVTVSNWNGALTSVHTFPFPAVLQSSGLVSLSSVTVTPSSSLGTQTYICNV--NHRPS 228  
QY 194 EKKIDIVPAPAPKSCDKTHTC-----PELLGGPSVFLPPKPKDTLMISSTPEVTCV 248  
DB 229 NTKVD---KKEVPSCDKTHTCTPCCPAPPELLGGPSVFLPPKPKDTLMISSTPEVTCV 284  
QY 249 VDVSHEDEPEVKENMVDGVEVNAKTKPREEOYNSTYRVSVLTJVLHODMLNGEKYCKV 308  
DB 255 VDVSHEDEPEVKENMVDGVEVNAKTKPREEOYNSTYRVSVLTJVLHODMLNGEKYCKV 344  
QY 309 SNKALPAPLEKTIKAKGQPREPQVYTLPPSDELTKNQVSLTCLVKGPYPSDIAVEMES 368  
DB 345 SNKALPAPLEKTIKAKGQPREPQVYTLPPSDELTKNQVSLTCLVKGPYPSDIAVEMES 404  
QY 369 NGQEPNNYKTPPVLVDSSGFLYSLKLTVDKSRMOQGVFSGSVNHEALHNHYTQKSLSL 428  
DB 405 NGQEPNNYKTPPVLVDSSGFLYSLKLTVDKSRMOQGVFSGSVNHEALHNHYTQKSLSL 464  
QY 429 SPG 431  
DB 465 SPG 467

RESULT 63

AAE35327  
ID AAE35327 standard; protein; 444 AA.  
XX  
XX AAE35327;  
XX  
XX 17-JUN-2003 (first entry)  
XX  
XX Humanised murine antibody BIWA4 heavy chain protein.  
XX  
XX CD44; cytotoxic drug; therapy; cancer; tumour; minimal residual disease;  
XX antigen; cytostatic; BIWA4 antibody; murine.  
XX  
XX Homo sapiens.  
XX  
XX EPI258255-A1.  
XX  
XX 20-NOV-2002.  
XX  
XX 18-MAY-2001; 2001EP-00112227.  
XX  
XX 18-MAY-2001; 2001EP-00112227.  
XX  
XX (BOEH) BOEHRINGER INGELHEIM INT GMBH.  
XX  
XX Adolf G, Heider K, Patzelt E, Sproll M;  
XX  
XX WPI; 2003-177273/18.  
XX N-PSDB; AAD53977.  
XX  
XX New compound useful for treatment of cancer comprises CD44 specific  
XX antibody molecule conjugated to a highly cytotoxic drug, which cleaves  
XX under intracellular conditions.  
XX  
XX Claim 7; Page 15-16; 31pp; English.  
XX  
XX The invention relates to a compound comprising CD44 specific antibody  
XX molecule conjugated to a highly cytotoxic drug, which cleaves under  
XX intracellular conditions. The compound is used in pharmaceutical  
XX composition for the treatment of cancer, solid tumours, and as an  
XX adjuvant to surgical intervention to treat minimal residual disease. The  
XX present sequence is humanised murine antibody BIWA4 heavy chain protein  
XX used in the invention

XX Sequence 444 AA;

Query Match 52.8%; Score 1273.5; DB 6; Length 444;  
Best Local Similarity 59.3%; Pred. No. 4.5e-64;

Matches 275; Conservative 27; Mismatches 69; Indels 93; Gaps 13;

QY 30 LGKKGDTVELTCTAS--QKSIQFHW-----KNSNOIKILGNQSGFL--TKGPSKL 76  
DB 11 LVKGGSLKSLSCAASGTFSSYDMSWRQAPGKLEWVSTISSGGSYTYVIDSKGRFTI 70  
QY 77 NDRADSRSLMDQGNFPLIINKLIKIEDSDTYICEVDQKEEVQLLVFGLTANSDTLHLOG 136  
DB 71 S-RDNANKSLYLQNN-----SLRAEDTAVYYCARQ-----YWG 105  
QY 137 QSLTLTLESPPGSSPSVQCSPPRGKNIQGG-----KTLSSV----- 172  
DB 106 RGLLVTVSSASTKGPSVFLAPSSKSTSGTALGCLVKDYFPEPVTVSNWNGALTSGVH 165  
QY 173 --OLELQDSG-----TWCTVLQNOKVFKIDIVPAPAPKSCDK 212  
DB 166 TFPFPAVLQSSGLVSLSSVTVTPSSSLGTQTYICNV--NHRPSNTKVD---KKEVPKSCDK 219  
QY 213 THTC-----PELLGGPSVFLPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFMVYDGV 267  
DB 220 THTCPCPAPPELLGGPSVFLPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFMVYDGV 279  
QY 268 EVHNAKTKPREEOYNSTYRVSVLTJVLHODMLNGEKYCKVSNKALPAPLEKTIKAKGQ 327  
DB 280 EVHNAKTKPREEOYNSTYRVSVLTJVLHODMLNGEKYCKVSNKALPAPLEKTIKAKGQ 339

Oy		328 PREPOVYTLPERDELTKNOVLSTLCYKCFYSDDIAVEMESQCPENNYKTPRPLDSDG	387
Dd		340 PREPOVYTLPRSRDELTKNQVSLTCLVKGFPSDDIAVEMESQCPENNYKTPRPVLDSDG	399
Oy		368 SFFLSKLTVDSKRWQGNVFSCSVHMEALHNHYTOKSLSPG	431
Dd		400 SFFLSKLTVDSKRWQGNVFSCSVHMEALHNHYTOKSLSPG	443
 RESULT 64			
ID	AAB34876	standard; protein; 444 AA.	
XX	AAB34876;		
AC			
XX			
DT	28-MAY-2003	(first entry)	
XX			
DE	BIMW4/8 antibody heavy chain mature protein.		
XX			
KM	BIMW8 antibody; heavy chain variable region; light chain variable region;		
KM	VH; VL; CD4v6; medicament; cancer; antibody therapy.		
XX			
OS	Unidentified.		
XX			
PN	WO200294879-A1.		
XX			
PD	28-NOV-2002.		
XX			
PF	17-MAY-2002; 2002WC-EP005467.		
XX			
PR	18-MAY-2001; 2001EP-00112237.		
XX			
PR	26-SEP-2001; 2001US-0325147P.		
XX			
PA	(BOEH ) BOEHRINGER INGELHEIM INT GMBH.		
XX	(BOEH ) BOEHRINGER INGELHEIM PHARM INC.		
PI	Adolf G. Ostermann E, Patzelt E, Sproll M, Heider K;		
XX	Miglicetta JF, Van Dongen AAMS;		
DR	N-PESDB; AAD53212, AAD53215.		
XX			
PT	New antibodies specific for an epitope coded by the variant exon of the		
PT	CD4 gene, useful for treating cancer, including non-small cell lung,		
PT	breast, head and neck, ovarian and lung cancer.		
XX			
PS	Claim 24; Col 44; 78pp; English.		
XX			
CC	The present invention relates to novel antibody molecules comprising a		
CC	variable region of the heavy (VH) and/or light chain (VL) of CD4v6		
CC	specific humanised antibody called BIMW8 and BIMW4. Sequences of the		
CC	invention are useful for manufacturing a medicament and for treating		
CC	cancer including colorectum, non-small cell lung, breast, head and neck,		
CC	ovarian, lung, bladder, pancreatic cancer or metastatic cancers of the		
CC	brain. They are also useful in antibody therapy. The present sequence is		
CC	BIMW4/8 antibody heavy chain mature protein. This sequence is used in the		
CC	exemplification of the invention		
XX			
SQ	Sequence 444 AA;		
 Query Match            52.8%; Score 1273.5; DB 6; Length 444; Beat Local Similarity   59.3%; Pred. No. 4.5e-64; Matches 275; Conservative 27; Mismatches 69; Indels 93; Gaps 13			
Oy	30 LAKKDVTVELTTAS--QKKSIOTFH-----KNSNQIKILNGQSFL-----TKGPSRL	76	
Dd	11 LVKPGGSRLSLCSAAGSFTFSYDMGVWRQAPGKGLEWVSTISGGSYTYLLDSIKGRFTI	70	
Oy	77 NDRAOSRRRLTMOCNFPPLIIKULKTEDSDTYICEVDQKEBVLVFGLTANSDFHLLOG	136	
Dd	71 S-RDNANKSLIVIQMN-----SRADVIATVCARO-----GLD-----YWG	105	
Oy	137 GSLLTLESPPSSBSVQCSPRGKNIQG-----KTLVS-----	172	

Db	106	RGTLVAVSSASHSTKGPVFPFLAPSSKSTSGGTLALGCLVKDYFPPEPVTYSPMNSGALTSGVH	165
Qy	173	--OLELQDSG-----TWTCYVLQONKVEYFKIDIVCPGPAPEPKSCDK	212
Db	166	TPPAVLQSSGLVSLSSVTVTPSSLSGTQTYICNV--NHKPSNTRKYD---KKVEPKSCDK	219
Qy	213	THTC-----PELLGSPSVLPFPFKKQKTLMTSRPEVTCVAVYDISHEDPEYKFMWYDGV	267
Db	220	THTCPCPAPELIIQGGSPVLPFPFKKQKTLMTSRPEVTCVAVYDISHEDPEYKFMWYDGV	279
Qy	268	EYVNAATKAPREQYNSTRYAVSVLVTLVHODMLNGKEYCKVSNALPAPLEKITSKAGQ	327
Db	280	EYVNAATKAPREQYNSTRYAVSVLVTLVHODMLNGKEYCKVSNALPAPLEKITSKAGQ	339
Qy	328	PREPOVYTLPSKSDBLTKQVSLTCLVNGFYPSDIAVEMESNGQPENNYKTTPEVLDSG	387
Db	340	PREPOVYTLPSKSDBLTKQVSLTCLVNGFYPSDIAVEMESNGQPENNYKTTPEVLDSG	399
Qy	388	SFFLYSKLTVYDKSRMOQGVFSCVYMHALNNHTYQKSLSLSPG	431
Db	400	SFFLYSKLTVYDKSRMOQGVFSCVYMHALNNHTYQKSLSLSPG	443

XX	AA93553	standard; protein; 475 AA.
XX	AA93553	
XX	AA93553	
XX	20-AUG-1996	(first entry)
XX		
DE		Monoclonal antibody DNA heavy chain against 65 kD hCMV antigen.
XX		
KW		Polymerase chain reaction; primer; amplify; PCR; light chain; Mab;
XX		65 kD antigen; human cytomegalovirus; hCMV; heavy chain; diagnosis.
OS		Synthetic.
XX		
FT	Key	Location/Qualifiers
FT	Peptide	1..19
FT	Protein	/note= "Signal peptide"
FT		20..475
XX		/note= "Mature heavy chain"
XX	JP08038178-A.	
XX		
PD	13-FEB-1996.	
XX		
XX	20-FEB-1995;	95JP-00030742.
XX		
PR	18-FEB-1994;	94JP-00021628.
XX		
PA	(TANAKA H.	
PA	(NISHI ) NISSHINBO IND INC.	
XX		
DR	WPI; 1996-154852/16.	
DR	N-PSDB; AAT18059.	
XX		
PT		Human monoclonal antibody binds to cytomegalovirus 65 kD antigen -
PT		produced by primer amplification, used in the diagnosis of hCMV
PT		infection.
XX		
XX	Claim 4; Page 16-18; 22pp; Japanese.	
XX		
XX		
CC		The sequences given in AA93553-54 represent the heavy and light chains
CC		respectively of a monoclonal antibody against a 65 kD antigen of human
CC		cytomegalovirus (hCMV). The DNA's encoding these sequences were amplified
CC		using the sequences given in AAT18040-58. The monoclonal antibody may be
XX		
XX		
XX	Sequence 475 AA;	
XX		

Query Match	Similarity	Score	ID	Length
Best Local Similarity	58.1%	52.8%	58.1%	52.8%
Matches	283	Conservative	29	Mismatches 98; Indels 77; Gaps 14
QY	RHLLVLDLALLP-----AATQGGKVVAGKKGDIVTELCTAS--QKXSIQPHMKNSNOI	59		
Db	2 KHLMFLLVLAAPRNVLSQLOLQESGPGFLVAPSEFLSLTCTVSGISRSISWCKTQRP	61		
QY	60 KILGNQ--GSFELTKGPSKLTNRADSRSL-WDQGN--FPLIIKNLIKEDSDTYIC-EYED	113		
Db	62 PGKGLIEWIGTIIYSGSTYVNPBLKSRVTIISVDASNNQPSLKLSSTYAADTAVYCAKTPSP	121		
QY	114 QKEEVQLLVFGLTANSPTHLLQGSLLTLTLBSPSSSPSVOCRSFRGNKIQGG-----	166		
Db	122 QYVDL-----LTGSPSPYWGQGLTVIVSSASTKG--PSVFLAPSRSKTSGGTAAIGCL	173		
QY	167 -----KTLTSSV-----QLELDQSG-----TWCTVLIQN	189		
Db	174 VKDYFPEPEVTVSMNSGALTSGVHTFPRAVLQSSGLYSLSSVTVTPSSSLGTOTYICNV--N	231		
QY	190 QKQVEFKIDIIPCPAPREPKSCDKHTTC-----PELLGSPSVFLPPPKEDTLMISRTPEV	244		
Db	232 HKPSTKTD----KQVEPKSCDKHTTCPCPAPRELLGSPSVFLPPPKEDTLMISRTPEV	287		
QY	245 TCVVVDVSHEDPEVEKFNMYVDGVEVNAKTKPREBOYNSTRVSVLTVLHODWINGKEY	304		
Db	288 TCVVVDVSHEDPEVEKFNMYVDGVEVNAKTKPREBOYNSTRVSVLTVLHODWINGKEY	347		
QY	305 KCKVSNKRLPAPIETKTISKAGQREPOVYTLPRERDLTNQVSLTCLVNGFYPSDIAV	364		
Db	348 KCKVSNKRLPAPIETKTISKAGQREPOVYTLPRERDLTNQVSLTCLVNGFYPSDIAV	407		
QY	365 EMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSRMQOQGVFSCSYVMEALAHNYTQK	424		
Db	408 EMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSRMQOQGVFSCSYVMEALAHNYTQK	467		
QY	425 SLSLSPG 431			
Db	468 SLSLSPG 474			
RESULT 66				
AAW11641				
ID	AAW11641	standard; protein; 475 AA.		
XX	AAW11641;			
XX	13-MAY-1997 (first entry)			
DT	13-MAY-1997 (first entry)			
DE	Human anti-RSV monoclonal antibody RF-2 heavy chain.			
XX				
KM	Monoclonal antibody; Mab; RF-1; RF-2; respiratory syncytial virus; RSV;			
KM	fusion protein; F-protein; vaccine; immunotherapy; therapy;			
KM	Egstein Barr virus; immortalization; recombinant antibody.			
XX				
OS	Homo sapiens.			
XX				
XX				
FT	Key	Location/Qualifiers		
FT	Peptide	1..19		
FT		/label= Leader_peptide		
FT	Region	20..49		
FT		/label= FR1		
FT		/note= "framework region 1"		
FT	Region	50..56		
FT		/label= CDR1		
FT		/note= "complementarity determining region 1"		
FT	Region	57..70		
FT		/label= FR2		
FT		/note= "complementarity determining region 2"		
FT	Region	71..86		
FT		/label= CDR2		
FT		/note= "complementarity determining region 2"		
FT	Region	87..118		

FT	/label= FR3
FT	/note= "framework region 3"
FT	119. .134
FT	/label= CDR3
FT	/note= "complementarity determining region 3" .
Region	135. .145
FR4	/label= FR4
FR4	/note= "framework region 4"
Region	146. .475
FR5	/label= Kappa
FR5	/note= "human gamma 1 constant region"
PN	WO9640252-A1.
PD	19-DEC-1996.
XX	
PF	06-JUN-1996; 96WO-US010070.
PR	07-JUN-1995; 95US-00488376.
PA	(IDEC-) IDEC PHARM CORP.
PI	Brams P, Chamat SS, Pan L, Walsh ER, Heard CJ, Newman RA;
DR	WPI: 1997-099892/09.
DR	N-PSTDB; AAT61279.
XX	
PS	Example 6; Fig 11b-c; 85pp; English.
PT	Human monoclonal antibody specific for respiratory syncytial virus fusion protein - used for the prevention and treatment of RSV infection.
XX	
CC	A polypeptide (AAW11641) comprises a leader sequence, RF-2 heavy chain variable region (see also AAW11635), and human gamma 1 constant region.
CC	RF-2 is a human monoclonal antibody (hmab) specific for the fusion protein of respiratory syncytial virus (RSV). The polypeptide can be produced in eukaryotic host (e.g. CHO) cells transfected with vector NBSRPLA incorporating a DNA construct (AAT61279) including the RF-2 VH sequence. RF-1 and RF-2 heavy and light chains (see also AAW11638-40) are similarly produced. The transfectant host cells provide a constant, stable supply of anti-RSV F-protein hmabs for use in the treatment or prevention of RSV infection
CC	
XX	
SQ	Sequence 475 AA;
Query Match	52.8%; Score 1273.5; DB 2; Length 475;
Best Local Similarity	57.1%; Pred. No. 4.9e-64;
Matches 276; Conservativity 29; Mismatches 99; Indels 79; Gaps 11	
Dy	10 LLVLQLALLLAAAGNQNVLVGGKKDVELTCTAS----QKSKIQFHMKNNSQIKL----- 62
Dd	10 LVAVATRVLSVOLOESGPALVKPTQTLLTCYSGFSLSRTGMSVMNMRPGALEWL 69
Oy	63 ----GNQGSFLTKG-PSKLANDRADSRSLMDQGNFLLIKULKIEDSPTYICEVEDOKEE 117
Dd	70 ARIDMDDDTFASASLKTRLSISKDTSKN-----QVLMAMTVNDPVDTATVPCLASLYDS 124
Oy	118 VQLLVFGILTANSDFHLOGQSLLTLLESPSSPSVQCRRSPRGKNIQGS----- 166
Dd	125 DSFYLF-----YHAWGCGGTVTVVTSASTKGSPVFPLAPSSSKSTSGTAALGLVXDY 177
Oy	167 --KTLVS-----QLELDQSG-----TWTCVNLONOKRY 193
Dd	178 FPEEVTSANSGALTGVHTPPAVLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKS 235
Oy	194 EFKIDIVPCPAPRPKSCDKTHTC-----PELLGSPSVELFPKPCKDTMLISRTPEVTCV 248
Dd	236 NTKYD---KKAEPKSCDKHTCCPCAPARILLGGSVLFPKPKDITLMISTPEVTCV 291
Oy	249 VDVSHEDEPEVKFNMYVDGVEVHNAAKTGRREQONSSTRVSVYLTVLHQDLNGKEYKCY 308
Dd	292 VDVSHEDEPEVKFNMYVDGVEVHNAAKTGRREQONSYSTRVSVYLTVLHQDLNGKEYKCY 351



```
Qy 309 SNKALPAPIEKTSKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 368
    |||
Db 352 SNKALPAPIEKTSKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 411
    |||
Qy 369 NGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGNVFCGVMEHALHNHYTQKSLSL 428
    |||
Db 412 NGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGNVFCGVMEHALHNHYTQKSLSL 471
    |||
Qy 429 SPG 431
    |||
Db 472 SPG 474

RESULT 67
AA97172
ID AA97172 standard; protein; 497 AA.
AC
XX AA97172;
DT 04-DEC-2000 (first entry)
XX
XX Human FGF-R1 Extracellular domain-Ig Fc fusion protein 3.
XX
XX FGF-R; fibroblast growth factor receptor; extracellular domain; IgG1;
KM immunoglobulin; G1; oligomerization domain; Fc region; fusion protein;
KM inhibitor; dimer; antagonist; cytostatic; anti-diabetic; vulnerary;
KM opthalmological; anti-proliferative.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Peptide 1..21
FT Domain /label= FGF-R1_signal_peptide
FT 22..257
FT /label= FGF-R1_extracellular_domain
FT /note= "The Ig I segment and acid box are deleted"
FT 59..111
FT /label= Ig_I1_segment
FT 157..222
FT /label= Ig_I1_segment
FT 258..265
FT /label= Linker
FT 266..497
FT /label= Human IgG1_Fc_region
FT /note= "Contains hinge region and domains CH2 and CH3"
XX
XX MO200046380-A2.
XX
XX 10-AUG-2000.
XX
XX 07-FEB-2000; 2000MO-US003166.
XX
XX 08-FEB-1999; 99US-0119002P.
XX
XX (CHIR ) CHIRON CORP.
XX
XX Kavanaugh WM, Ballinger M;
XX MPI; 2000-514961/46.
XX DR N-PSDB; AAA52129.
XX
XX New polypeptide comprising a fibroblast growth factor receptor
PT extracellular domain fused to a heterologous oligomerization domain for
PT treating FGF-, angiogenesis-, or FGF receptor-mediated disorders.
XX
XX Claim 14; Page 58-59; 70pp; English.
XX
XX Novel fusion protein constructs comprise a fibroblast growth factor (FGF)
CC receptor (FGF-R) extracellular domain (ECD) lacking the immunoglobulin
CC (Ig) I segment fused to a heterologous oligomerization domain that
CC comprises an immunoglobulin Fc region, hinge region, CH1, CH2, CH3 or CH4
CC region, or light chain of an immunoglobulin molecule, or a peptide with a
CC leucine zipper motif. The Ig I segment is not necessary for binding of
```

```
CC acidic FGF and basic FGF (bFGF). The Ig I deletion further increases the
CC affinity for aFGF and heparin, protects the core of the molecule from
CC proteolysis, and abrogates the heparin requirement for aFGF binding. The
CC new fusion polypeptides are better FGF inhibitors than FGF-R monomer
CC proteins. The FGF-R-Ig Fc fusion dimers are active as FGF antagonists at
CC subnanomolar concentrations and were 20-fold more potent than the FGF-R
CC monomer protein as competitors of bFGF binding to immobilized FGF-R. The
CC fusion constructs are useful to treat FGF-, angiogenesis-, or FGF-R-
CC mediated disorders, such as tumorigenesis (e.g. bladder, breast, lung,
CC rectal, testis and cervical tumours), neovascularization (e.g. diabetic
CC retinopathy, neovascular glaucoma, wound healing and corneal scarring)
CC and hyper-proliferation of vascular smooth muscle cells (e.g.
CC postangioplasty and postatherectomy restenosis)
XX
SQ Sequence 497 AA;
XX
XX Query Match 52.8%; Score 1273.5; DB 3; Length 497;
XX Best Local Similarity 57.5%; Pred. No. 5,1e-64;
XX Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;
XX
Qy 15 QNALPAAIQGNKVVLGKKGVDELCTASQKSIQFMW-KNSNQK---ILNGQSTL 69
    |||
Db 45 KLAHPAA-----KTVKFKCPSSGTPNPTLRLTKNGKFKPDHRIGYKVRVA 92
    |||
Qy 70 TKG-----PKLNDRADRSRLMDQGNFLLIKNLKIEDSDTYICEVEDQKEVQLLV 122
    |||
Db 93 TWSIIMDSVPS-----DKGNYTCIVENEGSINHYYQLDIVERSPHRPILQ 139
    |||
Qy 123 FGLTANSDTHLQGSGLTLTLSP-----GSS-----PSVQCRSPRGKNI 163
    |||
Db 140 AGLPANKTVALASNVFPMCKVSDPQPHIQLMKHIEVNGSKIGPDNLPVVQLKTAGVMT 199
    |||
Qy 164 --QGKTLVSQLELDSDGTWC-----TVLONQKVEKIDIVPCP--- 203
    |||
Db 200 TKEMEVLHLIRVVSDEADGEYTCLAGNSIGLSHNSMLTVLB---ALERRPVMVTSPLYL 256
    |||
Qy 204 -----APEPKSCDTHNC-----PELIGPSVFLFPKPKDMLMISRPVTCVVVV 251
    |||
Db 257 ESGSGFGLQEPKSCDTHNCPPCPAPBELIGSVFLFPKPKDMLMISRPVTCVVVV 316
    |||
Qy 252 SHEDEPEKENVYVDGVEVNAKTKPREEOYNSTYEVSVLTVLHODMLNGKEYKCKVSNK 311
    |||
Db 317 SHEDEPEKENVYVDGVEVNAKTKPREEOYNSTYEVSVLTVLHODMLNGKEYKCKVSNK 376
    |||
Qy 312 ALPAPIEKTSKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
    |||
Db 377 ALPAPIEKTSKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 436
    |||
Qy 372 PENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGNVFCGVMEHALHNHYTQKSLSLSPG 431
    |||
Db 437 PENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGNVFCGVMEHALHNHYTQKSLSLSPG 496
    |||

RESULT 68
AA97171
ID AA97171 standard; protein; 525 AA.
AC
XX AA97171;
XX
XX 04-DEC-2000 (first entry)
XX
XX Human FGF-R1 Extracellular domain-Ig Fc fusion protein 2.
XX
XX FGF-R; fibroblast growth factor receptor; extracellular domain; IgG1;
KM immunoglobulin; G1; oligomerization domain; Fc region; fusion protein;
KM inhibitor; dimer; antagonist; cytostatic; anti-diabetic; vulnerary;
KM opthalmological; anti-proliferative.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Peptide 1..21
FT Domain /label= FGF-R1_signal_peptide
```

FT	Domain	22. .285	/label= FGF-R1-extracellular_domain
FT			/note="Ig I segment is deleted"
FT	Domain	37. .44	/label= Acid_box_segment
FT	Domain	87. .139	/label= Ig_II_segment
FT	Peptide	266. .293	/label= Linker
FT	Region	294. .525	
FT			/label= Human_IgG1_Fc_region
FT			/note="Contains hinge region and domains CH2 and CH3"
FT	Domain	445. .250	
FT			/label= Ig_III_segment
XX			
PN	W0200046380-A2.		
XX			
PD	10-AUG-2000.		
XX			
PF	07-FEB-2000; 2000MO-US003166.		
XX			
PR	08-FEB-1999; 99US-0119002P.		
XX			
PA	(CHIR ) CHIRON CORP.		
XX			
PI	Kavanaugh MM, Ballinger M;		
DR	WPI: 2000-514961/46.		
XX			
DR	N-PSDB; AAA52128.		
XX			
PT	New polypeptide comprising a fibroblast growth factor receptor		
PT	extracellular domain fused to a heterologous oligomerization domain for		
PT	treating FGF-, angiogenesis-, or FGF receptor-mediated disorders.		
XX			
PS	Claim 14; Page 54-55; 70pp; English.		
XX			
CC	Novel fusion protein constructs comprise a fibroblast growth factor (FGF)		
CC	receptor (FGF-R) extracellular domain (ECD) lacking the immunoglobulin		
CC	(Ig) I segment fused to a heterologous oligomerization domain that		
CC	comprises an immunoglobulin Fc region, hinge region, CH1, CH2, CH3 or CH4		
CC	region, or light chain of an immunoglobulin molecule, or a peptide with a		
CC	leucine zipper motif. The Ig I segment is not necessary for binding of		
CC	acidic FGF and basic FGF (bFGF). The Ig I deletion further increases the		
CC	affinity for aFGF and heparin, protects the core of the molecule from		
CC	proteolysis, and abrogates the heparin requirement for aFGF binding. The		
CC	new fusion polypeptides are better FGF inhibitors than FGF-R monomer		
CC	proteins. The FGF-R-Ig Fc fusion dimers are active as FGF antagonists at		
CC	subnanomolar concentrations and were 20-fold more potent than the FGF-R		
CC	monomer protein as competitors of bFGF binding to immobilized FGF-Rs. The		
CC	fusion constructs are useful to treat FGF-, angiogenesis-, or FGF-R-		
CC	mediated disorders, such as tumorigenesis (e.g. bladder, breast, lung,		
CC	retinal, testis and cervical tumours), neovascularization (e.g. diabetic		
CC	retinopathy, neovascular glaucoma, wound healing and corneal scarring)		
CC	and hyper-proliferation of vascular smooth muscle cells (e.g.		
CC	postangioplasty and postatherectomy restenosis)		
XX			
XX	Sequence 525 AA.		

[illegible]

```

QY 161 --GGKTLISVSOLELDSDSTWTC-----TYLQNKQKVEPKRIDIPCC--- 203
Db 228 TDKEMEVLRHNVSPEDAGEYITCLAGNSITGLSHSAMLTVE--ALPEERAAVNTSPYL 284
QY 204 -----ADPEKSCDKTHTC-----PELLGGPSVFLPEPKKDTLMTSRTEPVTCVVVD 251
Db 285 EGSGSPGLQBPSCDKTHTCPCPAPPELLGGPSVFLPEPKKDTLMTSRTEPVTCVVVD 344
QY 252 SHSDPEVKNNMYVDGVEYVNAKTRERQYNSTRVYVLTVLHQDMINGEKYCKYSNK 311
Db 345 SHSDPEVKNNMYVDGVEYVNAKTRERQYNSTRVYVLTVLHQDMINGEKYCKYSNK 404
QY 312 ALPAPIEKTISKAKGPRAPQVYTLPPSRDELITKNQVSLTCLVGFYPSDIAVEMESNGQ 371
Db 405 ALPAPIEKTISKAKGPRAPQVYTLPPSRDELITKNQVSLTCLVGFYPSDIAVEMESNGQ 464
QY 372 PENNYKTTTPPVLDSDSFFLYSKLTVDSRRMQGVSCSMHRLALNNHTQKSLSLSPG 431
Db 465 PENNYKTTTPPVLDSDSFFLYSKLTVDSRRMQGVSCSMHRLALNNHTQKSLSLSPG 524

```

Accession	Protein Name	Protein Description
AA097170	standard; protein; 622 AA.	
AA097170		
AA097170		
04-DEC-2000	(first entry)	
Human FGF-R1 Extracellular domain-Ig Fc fusion protein 1.		
FGF-R; fibroblast growth factor receptor; extracellular domain; Ig1;		
immunoglobulin; G1; oligomerization domain; Fc region; fusion protein;		
inhibitor; dimer; antagonist; cytostatic; anti-diabetic; vulnerable;		
ophtalmological; anti-proliferative.		
Homo sapiens.		
Key	Location/Qualifiers	
Peptide	1..21	
	/label= FGF-R1_signal_peptide	
Domain	22..374	
	/label= FGF-R1_extracellular_domain	
Domain	55..101	
	/label= Ig_I_segment	
Domain	126..133	
	/label= Acid_box_segment	
Domain	176..228	
	/label= Ig_I1_segment	
Domain	275..339	
	/label= Ig_I1I1 segment	
	/note= "this is the I1I1C variant version"	
Peptide	379..390	
	/label= Linker	
Protein	/note= "Contains trypsin cleavage site"	
	391..622	
	/label= Human IgG1 Fc region	
	/note= "Contains hinge region and domains CH2 and CH3"	
WO200046380-A2.		
10-AUG-2000.		
07-FEB-2000; 2000MO-US00166.		
08-FEB-1999; 99US-0119002P.		
(CHIR ) CHIRON CORP.		
Kavanaugh WM, Ballinger M;		
WPI; 2000-514961/46.		

DR N-PSDB; AAA52127.  
XX  
PT New polypeptide comprising a fibroblast growth factor receptor  
XX extracellular domain fused to a heterologous oligomerization domain for  
PT treating FGF-, angiogenesis-, or FGF receptor-mediated disorders.  
XX  
PS Claim 14; Page 51-52; 70pp; English.  
XX  
CC Novel fusion protein constructs comprise a fibroblast growth factor (FGF)  
CC receptor (FGF-R) extracellular domain (ECD) lacking the immunoglobulin  
CC (Ig) I segment fused to a heterologous oligomerization domain that  
CC comprises an immunoglobulin Fc region, hinge region, CH1, CH2, CH3 or CH4  
CC region, or light chain of an immunoglobulin molecule, or a peptide with a  
CC leucine zipper motif. The Ig I segment is not necessary for binding of  
CC acidic FGF and basic FGF (bFGF). The Ig I deletion further increases the  
CC affinity for aFGF and heparin, protects the core of the molecule from  
CC proteolysis, and abrogates the heparin requirement for aFGF binding. The  
CC new fusion polypeptides are better FGF inhibitors than FGF-R monomer  
CC proteins. The FGF-R-Ig Fc fusion dimers are active as FGF antagonists at  
CC subnanomolar concentrations and were 20-fold more potent than the FGF-R  
CC monomer protein as competitors of bFGF binding to immobilized FGF-Rs. The  
CC fusion constructs are useful to treat FGF-, angiogenesis-, or FGF-R-  
CC mediated disorders, such as tumorigenesis (e.g. bladder, breast, lung,  
CC rectal, testis and cervical tumours), neovascularization (e.g. diabetic  
CC retinopathy, neovascular glaucoma, wound healing and corneal scarring)  
CC and hyper-proliferation of vascular smooth muscle cells (e.g.  
CC postangioplasty and postatherectomy restenosis)  
XX  
XX Sequence 622 AA;  
SQ

Query Match 52.8%; Score 1273.5; DB 3; Length 622;  
Best Local Similarity 57.0%; Pred. No. 6,5e-64;  
Matches 276; Conservative 31; Mismatches 86; Indels 91; Gaps 12;

QY 15 QALLPATGKGVKLGKGDVLTCTASQKSIQFHW-KNSNQIKILGSGSFLTKGP 73  
DB 162 KLAHAVPA-----KTVKFKCPSSGSGTNPFLRMKNGKEFPHRIGYKV--- 206  
QY 74 SKLNDADSRSLM-----DQGNFPLIIKLIKIEDSDTYICEVEQKEVQLVLF 123  
DB 207 -----RYATWSIIMDSVPSDKGNVYCIIVENEGSINHYYQLDVERSPHRILOA 257  
QY 124 GLTANSDTLLQGSLLTLLESPP-----GSS-----PSVQCRSPRGKNI- 163  
DB 258 GLPANKTVALGSNVEFMCKYSPDPRIQWLKHIEVNGSKIGPDNLRYQIILKTAVNTT 317  
QY 164 -GGGKTLVSQLELDGSGTWTC-----TVLQNKQK-----VEFKI 197  
DB 318 DKEMEVLHLNVAEFEDAGEYTCLAGNSIGLSHSAMVLTVLEALERPAAVWTSPLYLESNG 377  
QY 198 DIYP-----CPA-PEPKSCDKTHRC-----PELLGSGSVLPFPKPKDTLMISTPEVTY 247  
DB 378 GLVPRSGSGFGLQEPKSCDKTHRCPPCPABELLGGSPVLFPPKPKDTLMISTPEVTY 437  
QY 248 VDVSHEDPEPKFNMYVDGVEVNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEXKCK 307  
DB 438 VDVSHEDPEPKFNMYVDGVEVNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEXKCK 497  
QY 308 VSNKALPAPIEKTISRAGQPREPOVYTLPPSRDELTKQVSLTCLVKGFPSPDIAVEWE 367  
DB 498 VSNKALPAPIEKTISRAGQPREPOVYTLPPSRDELTKQVSLTCLVKGFPSPDIAVEWE 557  
QY 368 SNGQPENNYKTPPVLDSDGSFLYGLKYDKSRNQGQNVFSSVNHGALHNHYTKQKLS 427  
DB 558 SNGQPENNYKTPPVLDSDGSFLYGLKYDKSRNQGQNVFSSVNHGALHNHYTKQKLS 617  
QY 428 LSPG 431  
DB 618 LSPG 621

RESULT 70  
AAB83838

ID AAB83838 standard; protein; 592 AA.  
XX  
AC AAB83838;  
XX  
DT 23-JUL-2001 (first entry)  
XX  
DE Amino acid sequence of an Ig-5T4 fusion protein.  
XX  
KW Single chain antibody; ScFv; inflammatory disease; arthritis; cancer;  
KW hypersensitivity; autoimmune disease; central nervous system disorder;  
KW Parkinson's disease; periodontal disease; cardiopulmonary disease;  
KW cardiovascular disease; gastrointestinal disorder; infection; diabetes;  
KW Helicobacter-related disease; immune disorder.  
XX  
OS Synthetic.  
OS Mus sp.  
FH Key Location/Qualifiers  
FT Misc-difference 503  
FT /note= "Met encoded by CUG"

PN WO200136486-A2.  
XX  
PD 25-MAY-2001.  
XX  
PP 13-NOV-2000; 2000WO-GB004317.  
XX  
PR 18-NOV-1999; 99WO-GB003859.  
PR 15-FEB-2000; 2000GB-00003527.  
PR 02-MAR-2000; 2000GB-00005071.  
XX

PA (OXFO-) OXFORD BIOMEDICA UK LTD.

XX Kingseman A, Kingseman SM, Bebbington CR, Carroll MW, Ellard FW;  
PI Myers KA;

DR WPI; 2001-343805/36.  
XX

DR N-PSDB; AAF89733.  
XX

PT Use of single chain antibody capable of recognizing a disease associated  
PT molecule for manufacturing a medicament for preventing and/or treating a  
PT disease condition associated with disease associated molecule.  
XX

PS Disclosure; Fig 6, 118pp; English.  
XX

CC The specification describes the use of a single chain antibody (ScFv),  
CC which is capable of recognizing a disease associated molecule in the  
CC manufacture of a medicament for the prevention and treatment of a disease  
CC condition. The ScFv antibody is useful in the manufacture of a  
CC medicament, for affecting a disease in vivo, for preparing a  
CC pharmaceutical composition, for in vivo imaging and/or for adjuvant  
CC treatment of a disease. The ScFv antibody is also useful for treating  
CC inflammatory diseases including arthritis, hypersensitivity, autoimmune  
CC disease, cancers, central nervous system disorders including Parkinson's  
CC disease, periodontal diseases, cardiopulmonary diseases, cardiovascular  
CC disease, gastrointestinal disorders, infections, diabetes, Helicobacter-  
CC related diseases, and other immune disorders. The present sequence  
CC represents an Ig-5T4 fusion protein  
XX

SQ Sequence 592 AA;

Query Match 52.7%; Score 1273; DB 4; Length 592;  
Best Local Similarity 59.2%; Pred. No. 6,5e-64;  
Matches 276; Conservative 19; Mismatches 81; Indels 90; Gaps 11;

QY 23 TQGNKVLGKGDVLTCTASQKSIQFHWKNSNQIKILGSGSFLTKGPSKLNDRADS 82  
DB 159 TQTPFLVASAGDRTYITCKASQSVSNVANTQCP-----GQSPFLLSYSS 207  
QY 83 R-RSLMDQ-----GNFPLIIKLIKIEDSDTYICEVEQKEVQLVFGLTANSDTLL 134  
DB 208 RYAGVPDRFISGSGYGTDFFTISTLTQADLAVFYCQD-----YNSPPTFG 253

```

Qy 135 QGQSLTLTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172
Db 254 GGTLEIKKASTKRG--PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVMSNGALTSG 311
Qy 173 ----QLELDDSG-----TWCTYVLOQKVEFKIDIVPCPAPEPPSC 210
Db 312 VHTFPAVLQSSGLYSLSSVTVPPSSSLGQTYICNV--NHKPSNTKVD---KRVPEPSC 365
Qy 211 DKTHTC-----PELLGGPSVFLFPPPKKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVD 265
Db 366 DKTHTCPCPAPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVD 425
Qy 266 GVEVHNAKTKPRREQYNTYRVVSVLTVLDHQMNGKEVKCKVSNKALPAPIEKTISKAK 325
Db 426 GVEVHNAKTKPRREQYNTYRVVSVLTVLDHQMNGKEVKCKVSNKALPAPIEKTISKAK 485
Qy 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 385
Db 486 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 545
Qy 386 DGSFPLYSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 431
Db 546 DGSFPLYSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 591

```

## RESULT 71

```

ADE64199 ID ADE64199 standard; protein; 465 AA.
AC ADE64199;

```

```

XX 29-JAN-2004 (first entry)

```

```

DE LL2HCF protein related to a novel antibody library.

```

```

XX antibody library; retroviral vector; antibody light chain;
XX antibody heavy chain; human therapy; multiplicity of infection; MOI;
XX plasmid; GATEWAY vector; LL2HCF.

```

```

OS Unidentified.

```

```

FH Key Location/Qualifiers

```

```

FT Misc-difference 153

```

```

PN MO2003083077-A2.

```

```

XX 09-OCT-2003.

```

```

XX 28-MAR-2003; 2003WO-US009662.

```

```

XX 28-MAR-2002; 2002US-0368808P.

```

```

XX 10-APR-2002; 2002US-0371299P.

```

```

XX 28-MAR-2003; 2003US-00371299.

```

```

XX (GALA-) GALA DESIGN INC.

```

```

XX Bremel RD, Eakle K, Imboden M;

```

```

XX MPI, 2003-804051/75.

```

```

XX N-PSDB; ADE64205.

```

```

XX New antibody library comprising cells comprising at least one integrated
XX retroviral vector expressing an antibody light or heavy chain, useful in
XX preparing a composition for diagnosing or treating disorders.

```

```

XX Disclosure; Fig 5; 57bp; English.

```

```

XX This invention relates to a new antibody library which comprises at least
XX 100 cells, each of which comprises at least one integrated retroviral
XX vector expressing an antibody light or heavy chain. Antibodies are of
XX increasing importance in human therapy, assay procedures and diagnostic
XX methods and a need exists for efficient methods of generating and

```

```

CC screening antibody libraries containing large numbers of antibodies. The
CC antibody library of the invention addresses this need, with the
CC additional advantage of strict control over multiplicity of infection
CC (MOI), and is useful in preparing a composition for diagnosing or
CC treating a wide variety of disorders. The present sequence is the amino
CC acid sequence of the LL2HCF protein, which was encoded by the Gateway
CC retroviral vectors used in the exemplification of the invention.

```

```

XX Sequence 465 AA;

```

```

SQ Query Match 52.7%; Score 1272.5; DB 7; Length 465;
Best Local Similarity 58.7%; Pred. No. 5.4e-64;
Matches 270; Conservative 27; Mismatches 76; Indels 87; Gaps 10;

```

```

Qy 32 KKQDVELTCTAS--QKSIQFHKNKNSQIKILNQGSFLTKGPKSLNDRADSRSLMDQ 89
Db 32 KPGSSVAVSCAASGYTSTYIMLW----VRQAFQGLQEMIGYINPRDITRYNQNFQDK 86
Qy 90 GNFP-----LIINKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGSLLT 140
Db 87 ATTADESTNTAYVWELSSLRSEDTPAFYFCARD-----ITTFWGGQOTT 130
Qy 141 LTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS-----QL 174
Db 131 VTVSSASTKGPSVFPLAPSSKSKSGGTALGCLVKDYFPEPTVMSNGALTSGVHTFPA 190
Qy 175 ELDDSG-----TWCTYVLOQKVEFKIDIVPCPAPEPKSCDKTHTC 216
Db 191 VLQSSGLYSLSSVTVPPSSSLGQTYICNV--NHKPSNTKVD---KRVPEKSDKTHTC 244
Qy 217 ----PELLGGPSVFLFPPPKKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVDGVEVHN 271
Db 245 PCPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVDGVEVHN 304
Qy 272 AKTKPREQYNTYRVVSVLTVLDHQMNGKEVKCKVSNKALPAPIEKTISKAKGQPREP 331
Db 305 AKTKPREQYNTYRVVSVLTVLDHQMNGKEVKCKVSNKALPAPIEKTISKAKGQPREP 364
Qy 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPL 391
Db 365 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPL 424
Qy 392 YSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 431
Db 425 YSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 464

```

## RESULT 72

```

AAB49243 ID AAB49243 standard; protein; 476 AA.
XX
XX AAB49243;

```

```

XX 15-MAR-2001 (first entry)

```

```

XX Chimeric 4H6 anti-DR4 antibody heavy chain protein.

```

```

XX Anti-Death receptor 4; DR4; antibody; apoptosis; cancer; arthritis;
XX autoimmune.

```

```

XX Homo sapiens.

```

```

XX Synthetic.

```

```

XX MO2000073349-A1.

```

```

XX 07-DEC-2000.

```

```

XX 25-MAY-2000; 2000WO-US014599.

```

```

XX 28-MAY-1999; 99US-00322875.

```

```

XX (GETH ) GENENTECH INC.

```

```

XX

```



Db	294	KTRPREQNYSTRVAVSLTVLHQMINKCKKCVSKALPAPEKTIISAKQPREPQ	353
Qy	333	VYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFELY	352
Db	354	VYTLPSREMTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFELY	413
Qy	393	SKLTVDKSRMQGQNVFSCGVMEALHNHTOKSLSLSPQ	431
Db	414	SKLTVDKSRMQGQNVFSCGVMEALHNHTOKSLSLSPQ	452
RESULT 74			
ID	ABG31025	standard; protein; 499 AA.	
AC	ABG31025		
CC	05-NOV-2002	(first entry)	
DE	Synthetic mouse/human chimeric fusion protein #1.		
KW	Immunosuppressive; antirheumatic; antithyroid; antidiabetic; mouse;		
KW	neuroprotective; gene therapy; single chain antibody; variable fragment;		
KW	scfv; binding domain-immunoglobulin fusion protein; B-cell disorder;		
KW	malignant condition; rheumatoid arthritis; myasthenia gravis; psoriasis;		
KW	Grave's disease; Hashimoto's thyroiditis; type I diabetes mellitus;		
KW	multiple sclerosis; systemic lupus erythematosus; Sjogrens syndrome;		
KW	immune thrombocytopenic purpura; scleroderma; cancer; Chron's disease;		
KW	ulcerative colitis; inflammatory bowel disease; immunologic effector;		
KW	cell mediated cytotoxicity; complement dependent cytotoxicity;		
OS	complement fixation; mouse; human.		
OS	Mus musculus.		
OS	Homo sapiens.		
OS	Synthetic.		
OS	Chimeric.		
FX	Key	Location/Qualifiers	
FX	Region	1..265	
FT	Fragment	/note= "Mouse anti-human CD20 single chain variable	
FT	Fragment	fragment (scfv) "	
FT	Domain	266..499	
FT	Fragment	/note= "human immunoglobulin1 (IgG1) wild type hinge,	
FT	Fragment	fragment of crystallisation, CH2 and CH3 domains"	
PN	WO200256910-A1.		
PD	25-JUL-2002.		
PP	17-JAN-2002; 2002MO-US001487.		
PR	17-JAN-2001; 2001US-00765208.		
XA	(GENE-) GENERAFT INC.		
PI	Ledbetter JA, Hayden-Ledbetter M;		
DR	WPI; 2002-599691/64.		
DR	N-PSDB; ABK89848.		
PT	New human binding domain-immunoglobulin fusion protein useful for		
PT	treating a subject having or suspected of having a B-cell disorder or		
PT	malignant condition e.g. rheumatoid arthritis.		
PS	Disclosure; Page 120-121; 136pp; English.		
CC	The invention describes a binding domain-immunoglobulin fusion protein		
CC	that is capable of at least one immunological activity, comprising a		
CC	binding domain polypeptide fused to an immunoglobulin hinge region		
CC	polypeptide capable of specifically binding to an antigen, or an		
CC	immunoglobulin heavy chain CH2 or CH3 constant region polypeptide fused		
CC	to the hinge region polypeptide or to the CH2 constant region		

CC		polypeptide. The fusion protein is useful for treating a subject having
CC		or suspected of having a B-cell disorder or malignant condition e.g.,
CC		rheumatoid arthritis, myasthenia gravis, Grave's disease, Hashimoto's
CC		thyroiditis, type I diabetes mellitus, multiple sclerosis, systemic lupus
CC		erythematosus, Sjogrens syndrome, immune thrombocytopenic purpura,
CC		psoriasis, scleroderma, cancer and inflammatory bowel disease such as
CC		Chron's disease and ulcerative colitis. The fusion protein retains the
CC		ability to participate in well known immunological effector activities
CC		including antibody dependent cell mediated cytotoxicity and/or complement
CC		fixation in complement dependent cytotoxicity, despite having structures
CC		that would not be expected to be capable of promoting the effector
CC		activities. It can be produced in substantial quantities that are
CC		typically greater than those routinely attained with single-chain
CC		antibody constructs. This is the amino acid sequence of a chimeric fusion
CC		protein created from the mouse anti-human CD20 single chain antibody
CC		variable fragment (scFv) and the human immunoglobulin G (IgG) fragment of
CC		crystallisation (Fv) tail, wild type hinge, CH2 and CH3 domains
CC		
SQ	Sequence 499 AA;	
	Query Match	52.7%; Score 1271.5; DB 5; Length 499;
	Best Local Similarity	56.6%; Pred. No. 6.7e-64;
	Matches	275; Conservative 27; Mismatches 99; Indels 91; Gaps 12
OY		
Db	23 TQGNKRVVLEGGKADIVELTCTASQKKSIQFHMKNSNQIKILGNQGSFLTGPSKLNDRA	82
	27 SQSPALISASGEKVMTCRASSSVS-YMHVYQKP-----GSPKRWIYAPSLNLSGVPA	81
OY	83 RRLMDQS-NPELLINLKIKIDSDPYITVEVDQKEVOLVNLGL-----	125
Db	82 RPSGGSGTSSTSLTISRVAEDDAITYE----QQMSFNPPPTFGAATKLELKDGGSGGGG	137
OY	126 ---TANSDTHLQ-QGSTLTLLSEPPGSPSYOGR-----SPR-----	159
Db	138 SGGGSSGAYIQGGAEVL-----RPGASVVKMKSASGTPTFSYMMHWKYKPRGLWEI	192
OY	160 -----GKNIOCGKTLNV-----SOLELDGSGTWCTVYLONQKVVER	196
Db	193 GAIPNGNDTSYNOKFKAKATLVYDKSSSTAYMQLSLSSEBSAVYFCARVVYSNSYW	252
OY	197 IDI-----VCPAPEPKSCDKTHC-----PELIGSPSVLFPPPKDQTLMISRPEYT	245
Db	253 FDWMGTGITTVVSODEPKSCDKHTCPGPCPABELLGSGSVLFFPKPKDTLMISRPEYT	312
OY	246 CVVVDVSHDEBEVKFNWYDVGEVHNATKPREEQNSTYRVVSVLTVLHODMLNGKEYK	305
Db	313 CWWVDVSHDEBEVKFNWYDVGEVHNATKPREEQNSTYRVVSVLTVLHODMLNGKEYK	372
OY	306 CKVSKALPAPIEKTIISAQKOPREPOYYTLTPRSDELTKNOVSLTCLVKGYPSPDIAYE	365
Db	373 CKVSKALPAPIEKTIISAQKOPREPOYYTLTPRSDELTKNOVSLTCLVKGYPSPDIAYE	432
OY	366 WESNQEPENNNKTTTPVLVDSGSPFLYSKLTVDKSRMOQGNYFSCSVMEALAHNHYTQS	425
Db	433 WESNQEPENNNKTTTPVLVDSGSPFLYSKLTVDKSRMOQGNYFSCSVMEALAHNHYTQS	492
OY	426 LSLSPG 431	
Db	493 LSLSPG 498	
	RESULT 75	
	ADD25587	
ID	ADD25587 standard; protein; 499 AA.	
XX		
AC	ADD25587;	
XX		
DT	15-JAN-2004 (first entry)	
XX		
Bd	Binding domain-immunoglobulin fusion protein-asassociated protein #71.	
KW	Binding domain; immunoglobulin; fusion protein; cytostatic; antiarthritis; immunosuppressive; antidiabetic; antitumor;	

KM neuroprotective; hinge region; immunoglobulin heavy chain;  
 KM CH2 constant region; CH3 constant region; IgG1;  
 KM antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;  
 KM malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;  
 KM rheumatoid arthritis; myasthenia gravis; Grave's disease;  
 KM type I diabetes mellitus; multiple sclerosis; autoimmune disease.  
 OS Unidentified.  
 XX  
 XX US2003118592-A1.  
 XX  
 XX 26-JUN-2003.  
 XX  
 XX 25-JUL-2002; 2002US-00207655.  
 XX  
 XX 17-JAN-2001; 2001US-0367358P.  
 XX 17-JAN-2002; 2002US-00053530.  
 XX 03-JUN-2002; 2002US-0385691P.  
 XX  
 XX (GENE-) GENECRAFT INC.  
 XX  
 XX Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;  
 XX WPI; 2003-801317/75.  
 XX  
 XX New binding domain-immunoglobulin fusion protein, useful for treating a  
 PT subject having or suspected of having a malignant condition or a B-cell  
 PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.  
 PT  
 XX Disclosure; SEQ ID NO 148; 157bp; English.  
 XX  
 XX The invention relates to a binding domain-immunoglobulin fusion protein  
 CC comprising a binding domain polypeptide that is fused to an  
 CC immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain  
 CC CH2 constant region polypeptide that is fused to the hinge region  
 CC polypeptide, and an immunoglobulin heavy chain CH3 constant region  
 CC polypeptide that is fused to the CH2 constant region polypeptide. The  
 CC hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin  
 CC hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge  
 CC region polypeptide; derived from (a) having 3 or more cysteine residues;  
 CC where the mutated human IgG1 immunoglobulin hinge region polypeptide  
 CC contains 2 cysteine residues, where the first cysteine is not mutated; a  
 CC mutated human IgG1 immunoglobulin hinge region polypeptide; derived from  
 CC (a) having 3 or more cysteine residues, where the mutated human IgG1  
 CC immunoglobulin hinge region polypeptide contains no more than one  
 CC cysteine residue; and a mutated human IgG1 immunoglobulin hinge region  
 CC polypeptide; derived from (a) having 3 or more cysteine residues; where  
 CC the mutated human IgG1 immunoglobulin hinge region polypeptide contains  
 CC no cysteine residues. The binding domain-immunoglobulin fusion protein is  
 CC capable of at least one immunological activity comprising antibody  
 CC dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The  
 CC binding domain polypeptide is capable of specifically binding to an  
 CC antigen. Also included are an isolated polynucleotide encoding the  
 CC binding domain-immunoglobulin fusion protein, a recombinant expression  
 CC construct comprising the polynucleotide (operably linked to a promoter),  
 CC a host cell transformed or transfected with a recombinant expression  
 CC construct, producing the binding domain-immunoglobulin fusion protein, a  
 CC pharmaceutical composition comprising the binding domain-immunoglobulin  
 CC fusion protein or polynucleotide and a carrier, and treating a subject  
 CC having or suspected of having a malignant condition or a B-cell disorder.  
 CC The binding domain-immunoglobulin fusion protein is useful for treating a  
 CC subject having or suspected of having a malignant condition or a B-cell  
 CC disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis,  
 CC myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple  
 CC sclerosis or autoimmune disease. The present sequence is a binding domain  
 CC -immunoglobulin fusion protein-associated protein sequence. Note: The  
 CC sequence data for this patent formed part of the printed specification  
 CC and is also available in electronic format directly from USPTO at  
 CC seqdata.uspto.gov/sequence.html?DocID=20030118592. The authors have not  
 CC identified the sequences in the printed specification by their SEQ ID  
 CC number therefore none of the sequences can be explicitly identified.  
 XX  
 XX Sequence 499 AA;

Query Match 52.7%; Score 1271.5; DB 7; Length 499;  
 Beef Local Similarity 56.6%; Pred No. 6.7e-64;  
 Matches 275; Conservative 27; Mismatches 99; Indels 91; Gaps 12;  
 QY 23 TQGNKRVLAKGKDTVELTCTASQKKSIOFHWKNSNQIKLQNGSFLTKGPKLMDRADS 82  
 DB 27 SGPAILASPEKXTMTCRASSSVS-YMHWYQKRP-----GSSPKFWIYAPSNLSGVDA 81  
 QY 83 RRLMDQC-NPFLITKLNKIEDSDTYICEVEDQKEVQLVFGI----- 125  
 DB 82 RFGSGSGTSYSLTISRVEADPAATYYC-----QQWSFNPFTGACTKLELKGSGSGGG 137  
 QY 126 ---TANSDTHLQ-QGSLTLTLESPGSSPSVQC-----SPR----- 159  
 DB 138 SGGGSSQAYLQSSAEIV-----RPGASVKNKSCASGTYFTSYMMHWVKQTPRGLEMI 192  
 QY 160 -----GKNIOGKTLV-----SOLEODSGTCTVLOQKVEFK 196  
 DB 193 GAIYPNGDTSYNQKFKGKATLTVDKSSSTAYMQLSLTSBDSAVYFCARVYYNSNYWY 252  
 QY 197 IDI-----VPCPAPEPSCDKTHTC-----PELLGFSVFLFPKPKDTLMISTPEVT 245  
 DB 253 FDVWGTTGTVTVSDQEPKSCDKTHTCPCPAPELLGSGSVFLFPKPKDTLMISTPEVT 312  
 QY 246 CVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYNSTVRVSVLTVLHODMLNGKEYK 305  
 DB 313 CVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYNSTVRVSVLTVLHODMLNGKEYK 372  
 QY 306 CKNVSKALPAPIEKTISRAGQPREPOVYTLPPSRDELTKQVSLTCLVKGFPSDIAVE 365  
 DB 373 CKNVSKALPAPIEKTISRAGQPREPOVYTLPPSRDELTKQVSLTCLVKGFPSDIAVE 432  
 QY 366 WESNQPEPNNTYTPPVLDSDGSPFLYSKLTVDKSRMQGVNFGSCVNHGALHNHTQKS 425  
 DB 433 WESNQPEPNNTYTPPVLDSDGSPFLYSKLTVDKSRMQGVNFGSCVNHGALHNHTQKS 492  
 QY 426 LSLSPG 431  
 DB 493 LSLSPG 498  
 RESULT 76  
 ADD25454  
 ID ADD25454 standard; protein; 499 AA.  
 XX  
 XX ADD25454;  
 AC  
 XX  
 XX 15-JAN-2004 (first entry)  
 DT  
 XX  
 XX Binding domain-immunoglobulin fusion protein-associated protein #5.  
 DE  
 XX  
 XX Binding domain; immunoglobulin; fusion protein; cytotatic;  
 KW antiarthritic; immunosuppressive; antidiabetic; antithyroid;  
 KW neuroprotective; hinge region; immunoglobulin heavy chain;  
 KW CH2 constant region; CH3 constant region; IgG1;  
 KW antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;  
 KW malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;  
 KW rheumatoid arthritis; myasthenia gravis; Grave's disease;  
 KW type I diabetes mellitus; multiple sclerosis; autoimmune disease.  
 XX  
 XX Unidentified.  
 OS  
 XX  
 XX US2003118592-A1.  
 XX  
 XX 26-JUN-2003.  
 XX  
 XX 25-JUL-2002; 2002US-00207655.  
 XX  
 XX 17-JAN-2001; 2001US-0367358P.  
 XX 17-JAN-2002; 2002US-00053530.  
 XX 03-JUN-2002; 2002US-0385691P.  
 XX

PA (GENE-) GENE CRAFT INC.

PI Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;

DR WPI; 2003-801317/75.

PT New binding domain-immunoglobulin fusion protein, useful for treating a  
PT subject having or suspected of having a malignant condition or a B-cell  
PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.

PS Disclosure; SEQ ID NO 15; 157pp; English.

The invention relates to a binding domain-immunoglobulin fusion protein comprising a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, and an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide. The hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains 2 cysteine residues, where the first cysteine is not mutated; a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues, where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no more than one cysteine residue; and a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no cysteine residues. The binding domain-immunoglobulin fusion protein is capable of at least one immunological activity and complement fixation. The binding domain polypeptide is capable of specifically binding to an antigen. Also included are an isolated polynucleotide encoding the binding domain-immunoglobulin fusion protein, a recombinant expression construct comprising the polynucleotide (operably linked to a promoter), a host cell transformed or transfected with a recombinant expression construct, producing the binding domain-immunoglobulin fusion protein, a pharmaceutical composition comprising the binding domain-immunoglobulin fusion protein or polynucleotide and a carrier, and treating a subject having or suspected of having a malignant condition or a B-cell disorder. The binding domain-immunoglobulin fusion protein is useful for treating a subject having or suspected of having a malignant condition or a B-cell disorder, e.g., melanoma, carcinoma or sarcoma, rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis or autoimmune disease. The present sequence is a binding domain-immunoglobulin fusion protein-associated protein sequence. Note: The sequence data for this patent formed part of the printed specification and is also available in electronic format directly from USPTO at [seqdata.uspto.gov/sequence.html?DocID=20030118592](http://seqdata.uspto.gov/sequence.html?DocID=20030118592). The authors have not identified the sequences in the printed specification by their SEQ ID number therefore none of the sequences can be explicitly identified.

**SQ Sequence 499 AA;**

Query Match 52.7%; Score 1271.5; DB 7; Length 499;

Matches 275; Conservative 27; Mismatches 93

QY 23 TQGNKVLGKKGDTVELTCTASQKSIQFHWKNSNQIKILGNQGSFLTGP SKLNDRA DS 82

Db 2 / SQSPALISAREKATMTTCRASSVS-YNHVQQR---GSPRPMTIYAPSNLASGVA 81

QY 83 RSLMDQG-NPFLIKLIEDSDTYICEVEDOKEEVLVFGI----- 125

Dd 82 RFGSGSGSTVSLTIRVENDADATYYC---QMSFNPPTFGAGTKELKDGGSGGGG 137

QY 126 ---TANSDTHLD-QGLTLLTESPPGSSPVQCR-----SPR- 159

Dd 138 SGGGSSQAVLQDSGAEIV-----RGASVKMSCAASGYTFTSYNMHVVKQTPRQGLEWI 192

QY 160 -----GKNIQGGKTLV-----SOLEDSGTWTCTVLQNDQKVEFK 196

Db	193	GALYIPDNGDTSYNQKFKGKALITLVDKSSSTAYMQLSSLTSESDAIVFCARVVUYSNSYW	25252
QY	197	IDI-----VPCBAPRPPSCDKTTHC-----PELLGSPVTLFPPKPKDTLMISRTPEVT	24515
		;	
Db	253	FDWVGITGVTVSDSDPPSCDKTTHCPCPCPAPELLGGGSVTLFPPKPKDTLMISRTPEVT	3122
QY	246	CVVVVDSDHSDPEVEKFNMYDVGVEYVNAATKTRREQYNSYVSVLTVLNDOMLNGKEVK	30509
Db	313	CVVVVDSDHSDPEVEKFNMYDVGVEYVNAATKTRREQYNSYVSVLTVLNDOMLNGKEVK	37272
QY	306	CKYSNKLPAPIEKTISAKAKQRPFRQYTLRPSRDELTKQVSLTCLYKGFYSDLAVE	36555
Db	373	CKYSNKLPAPIEKTISAKAKQRPFRQYTLRPSRDELTKQVSLTCLYKGFYSDLAVE	43222
QY	366	WESNGCPENNYYKTPRPVLSDSDGSFPLYSKLTVDKSRMQGQNVFSCSYMHENLHNHYTQKS	42525
Db	433	WESNGCPENNYYKTPRPVLSDSDGSFPLYSKLTVDKSRMQGQNVFSCSYMHENLHNHYTQKS	49323
QY	426	LSLSPG 431	
Db	493	LSLSPG 498	

RESULT 77

ID	ABP58275	standard; protein; 468 AA.
...		

AC ABP58275;

DT	23-OCT-2003	(revised)
DT	23-OCT-2003	(revised)

XX  
DE  
Il:www:ed 3DC anti:bodi: ha

**XX**

human; humanised antibody; antibody; Alzheimer's disease;

3 2 1 0

Homo sapiens

XX  
XX  
You

Peptide  
ET

ET	F1	Protein
----	----	---------

Position  
EFT

Part  
ET

Position  
ET  
ET

FT Position

## XYXY

PN WO200288306-7  
YY

FD 07-NOV-2002.  
YY

26-APR-2002;  
PE  
YY

PR 30-APR-2001;  
YY

PA (ELL) LILLY

[illegible]

DR WP1; 2003-18.  
DB N-PSDB; AB724

New humanized  
XX  
PT

**New humanized forms of mouse 3D6 antibodies, useful for treating Down's**



PT syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral  
amyloid angiopathy, or for inhibiting formation of or reducing Abeta  
plaques in the brain.

XX Disclousure; Page 13-14; 54pp; English.

CC The present sequence is that of a preferred heavy chain of a humanised  
CC antibody of the present invention. In the variable region of this  
CC sequence, the complementarity determining regions (CDRs) originate from  
CC murine monoclonal antibody 3D6 and the framework region from human  
CC germline VH segment DP-45 and J segment JH4. Novel humanised antibodies  
CC of the invention have CDRs from 3D6 and human framework sequences. These  
CC humanised antibodies have binding affinities (affinity and epitope  
CC location) approximately the same as those of the mouse 3D6 antibody. The  
CC invention includes antibodies, single chain antibodies, and their  
CC fragments, as well as nucleotide sequences, vectors, transformed host  
CC cells, and methods of using the humanised antibody to treat, prevent,  
CC alleviate, reverse or otherwise ameliorate symptoms and/or pathology  
CC associated with Down's syndrome, (pre-)clinical Alzheimer's disease or  
CC (pre-)clinical cerebral amyloid angiopathy, and to inhibit formation or  
CC reduce Abeta plaques in the brain. (updated on 23-Oct-2003 to standardise  
CC OS field)

XX Sequence 468 AA;

Query Match 52.7%; Score 1271; DB 6; Length 468;

Best Local Similarity 57.0%; Pred. No. 6.6e-64; Indels 98; Gaps 15;

Matches 264; Conservative 31; Mismatches 85; Indels 98; Gaps 15;

QY 1 MNRGVPRHLLVL---QLALPAAATGKRVVGGKDDVELTCTAS----- 44

DB 1 MNRGLSLFLVLKVGQCEVQLVESGGGLV---QPGSRLSLCASSGTFPSYGMWVR 57

QY 45 QKKSIOFHKNSNOIKILNQGSFL--TKGPSKLNDRADSRRLMDQGNPILIIKULKIE 102

DB 58 QAPGKGLWVAS--IRSGGRTYSDNVKGRFTIS--RENKSNLYIQMN-----SLRAE 108

QY 103 DSDPTICEVEDQKEEVQLVFGILTANSDPHLLGGQSLTLTLSPSSPSVQCRRGRKN 162

DB 109 DTAIVYICVRYDH-----YSGSD--YWGQGLTVVSSASTKGPSVFLPLAPSSKS 155

QY 163 IOGG-----KTLVS-----QLELDSDG----- 180

DB 156 TSGGTALGCLVADYPEPTVSWNSGALTSVHTPAVLQSSGLVSLSSVTVTPSSSLG 215

QY 181 --TWCTVLONQKVEFKIDIVPCPAPEPKSCDKHTC-----PELLGSPVFLPPKPK 233

DB 216 TQTYICNV--NHRPSNTKVD---KKEPKSCDKHTCPCPAPELLGSPVFLPPKPK 269

QY 234 DTLMISRTPEVTCVVVDVSHEDPEVKFENVYVDGVEVHNAKTRKEQYNSTYRVSVLVTV 293

DB 270 DTLMISRTPEVTCVVVDVSHEDPEVKFENVYVDGVEVHNAKTRKEQYNSTYRVSVLVTV 329

QY 294 LHQDWINGKEVKKCVSNKALPAPIEKTISAKAGPREPVYTLPPSRDELTKQVSLTCL 353

DB 330 LHQDWINGKEVKKCVSNKALPAPIEKTISAKAGPREPVYTLPPSRDELTKQVSLTCL 389

QY 354 VKGFYPSDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDYSRMVGQGVNPFSCSYW 413

DB 390 VKGFYPSDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDYSRMVGQGVNPFSCSYW 449

QY 414 HEALNHHYTKQSLSLSPG 431

DB 450 HEALNHHYTKQSLSLSPG 467

RESULT 78

ID AAR93166 standard; protein; 472 AA.

XX AAR93166;

DT 30-OCT-1996 (first entry)

XX Anti-rhesus D recombinant antibody D7C2 heavy chain.

KW Human monoclonal antibody; immunoglobulin isotype IgM; agglutination;

KW rhesus positive; rhesus negative; haemolysis; gamma 1 heavy chain;

OS variable region; insect host cell; baculovirus; recombinant production.

OS Homo sapiens.

OS Synthetic.

FT Key Location/Qualifiers

FT Peptide 1..19

FT /label= signal peptide

FT /note= "mouse VH signal peptide sequence encoded by

FT Protein 20..472

FT /label= heavy\_chain

FT /note= "human gamma 1 chain constant region and the

FT variable region from anti-rhesus D antibody D7C2"

PN FR2724182-A1.

PD 08-MAR-1996.

PF 02-SEP-1994; 94PR-00010566.

PR 02-SEP-1994; 94PR-00010566.

PA (INSP) INST PASTEUR.

PA (PROT-) PROTEINE PERFORMANCE.

PI Edelman L, Margartitte C, Kaczorek W, Chaabih H;

DR WPI; 1996-162018/17.

DR N-PSDB; AAT26889.

PT Recombinant anti-rhesus D monoclonal antibody - expressed by baculovirus-

PT transformed insect cells and useful for preventing haemolysis in new-born

PT babies.

XX Example 2; Page 35-37; 46pp; French.

XX The human monoclonal antibody D7C2, of isotype IgM, recognises a 30-32 kD

CC polypeptide on the membrane of rhesus positive red blood cells. The

CC antibody agglutinates rhesus positive cells but not rhesus negative cells

CC and is useful diagnostically and also for preventing haemolysis in new-

CC born rhesus positive babies. Recombinant IgM-D7C2 can be produced by

CC insect cells which have been transformed by a baculoviral vector

CC comprising a D7C2 expression cassette. The present sequence is that of a

CC recombinant IgM-D7C2 heavy chain fused downstream of a mouse VH signal

CC peptide

SQ Sequence 472 AA;

Query Match 52.7%; Score 1271; DB 2; Length 472;

Best Local Similarity 59.5%; Pred. No. 6.7e-64; Indels 68; Gaps 9;

Matches 270; Conservative 25; Mismatches 91; Indels 68; Gaps 9;

QY 32 KKGDTVELTCTASQKSIQFHKNSNOIKILNQ--GSEFLTKGPSKLNDRADSRSL--- 86

DB 32 KSEETLSLCTCYGGSFSGYVSWIRQPPGKLEWIGELINHGSGSTNYPNLSLSRVTVISVD 91

QY 87 WQGNFPLIIKULKIEDSDTYICEVEDQKEVQLVFGILTANSDPHLLGGQSLTLTLSP 146

DB 92 TSKNOFSLTANSVTADTAIVYCARAPE-----YKWKYGDWDFPWGGCTTVVSSA 143

QY 147 PGSSPSVQCRRGRKNIOGG-----KTLVS-----QLELDSDG 180

DB 144 STKGPSVFLPLAPSSKSTSGGTALGCLVADYPEPTVSWNSGALTSVHTPAVLQSSG 203

QY 181 -----TWCTVLONQKVEFKIDIVPCPAPEPKSCDKHTC-----P 217

DB 204 LVSLSSVTVTPSSSLGTQTYICNV--NHRPSNTKVD---KKEPKSCDKHTCPCPAPE 257

```

QY 218 ELLGGPSVLFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNKYVVDGVEVHNAKTPR 277
    |||||
DB 258 ELLGGPSVLFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNKYVVDGVEVHNAKTPR 317
    |||||
QY 278 EEQYNSTYRVSVLTFLVHODMNLGKEYCKCKVSNKALPAPIEKTISKAKGQPREPQVYTLR 337
    |||||
DB 318 EEQYNSTYRVSVLTFLVHODMNLGKEYCKCKVSNKALPAPIEKTISKAKGQPREPQVYTLR 377
    |||||
QY 338 PERDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTIV 397
    |||||
DB 378 PERDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTIV 437
    |||||
QY 398 DKSRRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 431
    |||||
DB 438 DKSRRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 471
    |||||

RESULT 79
AAW01822
ID AAW01822 standard; protein; 476 AA.
XX
AC AAW01822;
XX
DT 17-OCT-2003 (revised)
DT 25-MAY-1997 (first entry)
XX
DE Primatized anti-human B7.1 antigen antibody 16C10 heavy chain.
XX
KW Monoclonal antibody; cynomolgus monkey; macaque; 16C10;
KW primatized antibody; B7 antigen; CD28; immunosuppressive;
KW autoimmune disease; idiopathic thrombocytopenia purpura;
KW systemic lupus erythematosus; rheumatoid arthritis; psoriasis;
KW type 1 diabetes mellitus; graft versus host disease; hetero-hybridoma;
KW transfectoma.
XX
OS Macaca; cynomolgus.
OS Homo sapiens.
OS Chimeric.
XX
PN WO9640878-A1.
XX
PD 19-DEC-1996.
XX
PF 06-JUN-1996; 96WO-US010053.
XX
PR 07-JUN-1995; 95US-00487550.
XX
PA (IDEC-) IDEC PHARM CORP.
XX
PI Anderson DR, Brame P, Hanna N, Shestowsky WS;
XX
DR WPI, 1997-108638/10.
XX
DR N-PSDB; AAT62513.
XX
PT Monkey monoclonal antibody binding human B7.1 or B7.2 antigen - useful
PT for treating auto-immune disease or graft-versus-host disease.
XX
PS Claim 14; Fig 10B; 81pp; English.
XX
CC 2 Polypeptides (AAW01821 and AAW01822) respectively comprise primatized
CC forms of the light and heavy chains of cynomolgus monkey anti-human B7.1
CC antigen monoclonal antibody 16C10. Cloned 16C10 light and heavy variable
CC genes (see also AAT62512 and AAT62513) are inserted into an expression
CC vector (pRef. NEOSPPLA) which contains human light and heavy chain
CC constant region genes to allow prodn. of the primatized antibody in e.g.
CC CHO cells. Primatized 7C10 and 7B6 anti-B7.1 antibodies have also been
CC produced (see also AAW01817-20). The primatized antibodies inhibit the
CC B7:CD28 pathway, making them useful immunosuppressants for the treatment
CC of autoimmune disorders and graft-versus-host disease. (Updated on 17-OCT
CC -2003 to standardise OS field)
XX
SQ Sequence 476 AA;

```

```

Query Match 52.7%; Score 1271; DB 2; Length 476;
Best Local Similarity 59.8%; Pred. No. 6,86-64;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;

QY 30 LGKKQDVLVELICTASQ--KKSIOFHWKNSNOIKILNQSGFL-TKGPSKLNDRADSRRS 85
    |||||
DB 30 LVKSEFTSLTCAVSGSISGGYGMWIRQPPGKLEIGSFYSSGNTYVNPILKSQVT 89
    |||||
QY 86 L---WDQGNFPLIITKNLKIETSDPTICEVEQKEVQLVPLGRLTANSDTHLLOQSLTLT 142
    |||||
DB 90 ISTDTSKNQFSLKLNMTAADTAVYTC-VRDRLFSVVGMY----NNWFDWGPGLVLT 143
    |||||
QY 143 LESPSPSSPVSQCRSPGKKNIOG-----KTSVS-----QLEL 176
    |||||
DB 144 VSSASTKGPSVFPLAPSSKSTSGGTALGCLVKDYFPEPVYVSNMNSGALTISGHTFPAVL 203
    |||||
QY 177 QDSG-----TWCTVLONQKVEFKIDIVPCPAPEPKSCDKTHRC-- 216
    |||||
DB 204 QSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKAEPKSCDKTHRCPP 257
    |||||
QY 217 ---PELLGGPSVLFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNKYVVDGVEVHNAK 273
    |||||
DB 258 CPAPELLGGPSVLFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNKYVVDGVEVHNAK 317
    |||||
QY 274 TKPREEQYNSTYRVSVLTFLVHODMNLGKEYCKCKVSNKALPAPIEKTISKAKGQPREPQV 333
    |||||
DB 318 TKPREEQYNSTYRVSVLTFLVHODMNLGKEYCKCKVSNKALPAPIEKTISKAKGQPREPQV 377
    |||||
QY 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYS 393
    |||||
DB 378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYS 437
    |||||
QY 394 KLTVDKSRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 431
    |||||
DB 438 KLTVDKSRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 475
    |||||

RESULT 80
AAW63765
ID AAW63765 standard; protein; 476 AA.
XX
AC AAW63765;
XX
DT 29-SEP-1998 (first entry)
XX
DE Macaque primatized 16C10 heavy chain protein.
XX
KW Monoclonal antibody; Mab; macaque; heavy chain; primate; antigen; CD80;
KW CD86; inhibitor; immunosuppressant; treatment; autoimmune disease; IL-2;
KW T cell/B cell interaction; tumour; inflammation; imaging agent; vaccine;
KW immunogen; anti-idiotype reagent; interleukin-2; IgG; immunoglobulin G;
KW T cell proliferation.
XX
OS Macaca fascicularis.
XX
PN WO9819706-A1.
XX
PD 14-MAY-1998.
XX
PF 29-OCT-1997; 97WO-US019906.
XX
PR 08-NOV-1996; 96US-00746361.
XX
PA (IDEC-) IDEC PHARM CORP.
XX
PI Anderson DR, Hanna N, Brame P;
XX
DR WPI, 1998-286601/25.
XX
DR N-PSDB; AAV35489.
XX
PT New monoclonal antibodies specific for B7.1 or B7.2 antigens and
PT inhibiting binding to CD28 - useful as specific immunosuppressants for

```

PT treating diseases that involve interactions between T and B cells, e.g.  
 PT graft rejection or tumours.  
 XX  
 PS Example 7; Fig 5b; 87pp; English.  
 CC This sequence represents a primatized form of the antibody 16C10 heavy  
 CC chain from macaque. This sequence is used in a method which studies new  
 CC monoclonal antibodies (Mab's) that bind selectively to B7.1 (CD80) or to  
 CC B7.2 (CD86) antigens and inhibits binding of these antigens to CD28. Such  
 CC Mab's are specific immunosuppressants for treatment of diseases involving  
 CC T cell/B cell interactions, particularly autoimmune disease, specifically  
 CC idiopathic thrombocytopenia purpura, systemic lupus erythematosus, type  
 CC I diabetes mellitus, rheumatoid arthritis, psoriasis, aplastic anaemia,  
 CC inflammatory bowel disease, allergy and multiple sclerosis, graft vs.  
 CC host diseases, B cell lymphoma, infections (including by human immune  
 CC deficiency virus) or inflammatory disease and tumours. Optionally the Mab  
 CC can be conjugated to a drug or toxin. Mab's, or their fragments, can also  
 CC be used as imaging agents and as vaccines or immunogens to develop anti-  
 CC idioctype reagents. Mab's are optionally combined with other proteins or  
 CC small molecule immunosuppressants. Blocking B7/CD28 interactions induces  
 CC long-term, antigen-specific immunosuppression, i.e. it inhibits  
 CC production of interleukin-2 (IL-2), T cell proliferation and antigen-  
 CC specific immunoglobulin G (IgG) responses  
 CC  
 XX Sequence 476 AA:  
 SQ  
 Query Match 52.7%; Score 1271; DB 2; Length 476;  
 Best Local Similarity 59.8%; Pred. No. 6, 8e-64;  
 Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;  
 QY 30 LGKGGDTVELTCTASQ---KKSIOFHWNKSNQIKILNGSGFL-TKGPSKLNDRADSRSS 85  
 DB 30 LKPSFTSLTCAVSGSGISGCGWGIROPKGLGEMISFYSSSGNTYYPNLSKSYT 89  
 QY 86 L---WDQGNFPLIIRKLIKIEDSDTYICEVEDQKEVQLVFGLTANSSTHLLQSGSLT 142  
 DB 90 ISTDTSKNOFSLKLNMTADTAIVYC-VDRLFVSVMGVY-----NNWFDVWGPGVLVT 143  
 QY 143 LESPSSSPSYOCRSRGNKIOG-----KTLISV-----QLEL 176  
 DB 144 VSSASTKGPSVFLPAPSSKSTSGTALAAGLVDPPEPYTWSNMGALTSVHTPPAVL 203  
 QY 177 QDSG-----TWTCVLOKOKVEFKIDIVCPAPRPSKCDKTHTC-- 216  
 DB 204 QSSGLYSLSVTVTPSSSLGTOTYICNV--NKPSTKVD---KKAEPKSCDKHTTTP 257  
 QY 217 ---PELLGSPVFLPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGEVHNK 273  
 DB 258 CPAPELLGSPVFLPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGEVHNK 317  
 QY 274 TKREQYNSTRVNVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 333  
 DB 318 TKREQYNSTRVNVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 377  
 QY 334 YTLPPSRDELTKNOVSLTLCVKGFPYSDIAVENESGOPEPNYKTTIPVLDSDGSFPLYS 393  
 DB 378 YTLPPSRDELTKNOVSLTLCVKGFPYSDIAVENESGOPEPNYKTTIPVLDSDGSFPLYS 437  
 QY 394 KLTVDKSRMQGQNVFSCSVHREALNNHYTQKSLSLSPG 431  
 DB 438 KLTVDKSRMQGQNVFSCSVHREALNNHYTQKSLSLSPG 475  
 RESULT 81  
 AAU11646  
 ID AAU11646 standard; protein; 476 AA.  
 XX  
 AC AAU11646;  
 XX  
 DT 12-MAR-2002 (first entry)  
 XX  
 DE Protein sequence of primatized form of the heavy chain of 16C10 antibody.  
 XX

KW Human; macaque monkey; light chain; primatized antibody; 16C10 antibody;  
 KW neoprotective; apoptotic inducer; allergy; CD28 receptor antagonist;  
 KW B7.1 antigen; CD80; B7.2 antigen; CD86; B cell cancer; metastasis;  
 KW tumour; B cell lymphoma; B cell leukaemia; autoimmune disease;  
 KW graft-vs-host disease; immunosuppression; organ rejection; interleukin-2;  
 KW IL-2; mutant; mutein.  
 XX  
 OS Homo sapiens.  
 OS Macaca sp.  
 OS Synthetic.  
 OS Chimeric.  
 XX  
 PN MO200189567-A1.  
 PD 29-NOV-2001.  
 XX  
 PF 22-MAY-2001; 2001WO-US016364.  
 XX  
 PR 22-MAY-2000; 2000US-00576424.  
 XX  
 PA (IDEC-) IDEC PHARM CORP.  
 XX  
 PI Anderson DR, Hanna N, Brame P;  
 DR WPI; 2002-089895/12.  
 DR N-PSDB; AAS17247.  
 PT Use of monoclonal antibody which specifically binds to B7.1 antigen CD80  
 PT and/or B7.2 antigen CD86 for inducing apoptosis of B7+ cells, treating  
 PT cancer, graft-vs-host disease and autoimmune disease such as allergy.  
 XX  
 PS Example 8; Fig 5b; 89pp; English.  
 XX  
 CC The present invention relates to a new use of a monoclonal antibody which  
 CC specifically binds to B7.1 antigen (CD80) and/or B7.2 antigen (CD86) for  
 CC inducing the apoptosis of B7+ cells. The invention is useful for treating  
 CC diseases such as B cell cancer, lymphoma, a cancer where B cells promote  
 CC the growth and/or metastasis of tumours, B cell lymphoma, B cell  
 CC leukemia, and autoimmune diseases such as idiopathic thrombocytopenia  
 CC purpura, systemic lupus, erythematosus, type I diabetes mellitus,  
 CC rheumatoid arthritis, psoriasis, aplastic anaemia, inflammatory bile  
 CC disease, allergy, multiple sclerosis or graft-vs-host disease. The  
 CC antibody is useful for immunosuppression in a human or animal and for  
 CC treating or preventing resistance to or rejection of transplanted organ  
 CC or tissue for treating proliferative and hyperproliferative diseases, for  
 CC treating reversible obstructive airways disease, intestinal inflammations  
 CC and allergies e.g. Crohn's disease and ulcerative colitis, food-related  
 CC allergies e.g. migraine, rhinitis and eczema, and other types of  
 CC allergies. The present protein sequence represents the heavy chain of  
 CC 16C10, a primatized antibody used in the invention to induce apoptosis  
 CC and inhibit production of interleukin-2 (IL-2)  
 CC  
 XX Sequence 476 AA:  
 SQ  
 Query Match 52.7%; Score 1271; DB 5; Length 476;  
 Best Local Similarity 59.8%; Pred. No. 6, 8e-64;  
 Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;  
 QY 30 LGKGGDTVELTCTASQ---KKSIOFHWNKSNQIKILNGSGFL-TKGPSKLNDRADSRSS 85  
 DB 30 LKPSFTSLTCAVSGSGISGCGWGIROPKGLGEMISFYSSSGNTYYPNLSKSYT 89  
 QY 86 L---WDQGNFPLIIRKLIKIEDSDTYICEVEDQKEVQLVFGLTANSSTHLLQSGSLT 142  
 DB 90 ISTDTSKNOFSLKLNMTADTAIVYC-VDRLFVSVMGVY-----NNWFDVWGPGVLVT 143  
 QY 143 LESPSSSPSYOCRSRGNKIOG-----KTLISV-----QLEL 176  
 DB 144 VSSASTKGPSVFLPAPSSKSTSGTALAAGLVDPPEPYTWSNMGALTSVHTPPAVL 203  
 QY 177 QDSG-----TWTCVLOKOKVEFKIDIVCPAPRPSKCDKTHTC-- 216  
 DB 204 QSSGLYSLSVTVTPSSSLGTOTYICNV--NKPSTKVD---KKAEPKSCDKHTTTP 257

```
QY 217 ---PELLGSPVFLPPPKKDTLMTSRTPETVCVVVDVSHEDPEVKFNNYVDGVEVHNAK 273
    |||||
DB 258 CAPPELLGGSPVFLPPPKKDTLMTSRTPETVCVVVDVSHEDPEVKFNNYVDGVEVHNAK 317
QY 274 TYPREBOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIETKTSKAGQPREPOV 333
    |||||
DB 318 TYPREBOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIETKTSKAGQPREPOV 377
QY 334 YTLPSRDELTKNOVSLTLVGKFPSPDIAVEMESNGOENNYYKTPPLVLDSDGSFFLYS 393
    |||||
DB 378 YTLPSRDELTKNOVSLTLVGKFPSPDIAVEMESNGOENNYYKTPPLVLDSDGSFFLYS 437
QY 394 KLTVDKSRWQGNVFCSVMEHALNHNYTQKSLSLSPG 431
    |||||
DB 438 KLTVDKSRWQGNVFCSVMEHALNHNYTQKSLSLSPG 475

RESULT 82
ADD25787
ID ADD25787 standard; protein; 504 AA.
AC ADD25787;
DT 15-JAN-2004 (first entry)
XX
DE Binding domain-immunoglobulin fusion protein-associated protein #160.
XX
KM Binding domain; immunoglobulin; fusion protein; cytosolic;
KM antiarthritic; immunosuppressive; antidiabetic; antihypertoid;
KM neuroprotective; hinge region; immunoglobulin heavy chain;
KM CH2 constant region; CH3 constant region; IgG1;
KM antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
KM malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;
KM rheumatoid arthritis; myasthenia gravis; Grave's disease;
KM type I diabetes mellitus; multiple sclerosis; autoimmune disease.
XX
OS Unidentified.
XX
PN US2003118592-A1.
XX
PD 26-JUN-2003.
XX
PF 25-JUL-2002; 2002US-00207655.
XX
PR 17-JAN-2001; 2001US-0367358P.
PR 17-JAN-2002; 2002US-00053530.
PR 03-JUN-2002; 2002US-0385691P.
XX
PA (GENE-) GENE-CRAFT INC.
XX
PI Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;
DR WPI; 2003-801317/75.
XX
PT New binding domain-immunoglobulin fusion protein, useful for treating a
PT subject having or suspected of having a malignant condition or a B-cell
PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.
XX
PS Disclosure; SEQ ID NO 348; 157pp; English.
XX
CC The invention relates to a binding domain-immunoglobulin fusion protein
CC comprising a binding domain polypeptide that is fused to an
CC immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain
CC CH2 constant region polypeptide that is fused to the hinge region
CC polypeptide, and an immunoglobulin heavy chain CH3 constant region
CC polypeptide that is fused to the CH2 constant region polypeptide. The
CC hinge region polypeptide comprises a wild-type human IgG1 immunoglobulin
CC hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge
CC region polypeptide; derived from (a) having 3 or more cysteine residues;
CC where the mutated human IgG1 immunoglobulin hinge region polypeptide
CC contains 2 cysteine residues, where the first cysteine is not mutated; a
CC mutated human IgG1 immunoglobulin hinge region polypeptide, derived from
```

```
CC (a) having 3 or more cysteine residues, where the mutated human IgG1
CC immunoglobulin hinge region polypeptide contains no more than one
CC cysteine residue; and a mutated human IgG1 immunoglobulin hinge region
CC polypeptide, derived from (a) having 3 or more cysteine residues; where
CC the mutated human IgG1 immunoglobulin hinge region polypeptide contains
CC no cysteine residues. The binding domain-immunoglobulin fusion protein is
CC capable of at least one immunological activity comprising antibody
CC dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The
CC binding domain polypeptide is capable of specifically binding to an
CC antigen. Also included are an isolated polynucleotide encoding the
CC binding domain-immunoglobulin fusion protein, a recombinant expression
CC construct comprising the polynucleotide (operably linked to a promoter),
CC a host cell transformed or transfected with a recombinant expression
CC construct, producing the binding domain-immunoglobulin fusion protein, a
CC pharmaceutical composition comprising the binding domain-immunoglobulin
CC fusion protein or polynucleotide and a carrier, and treating a subject
CC having or suspected of having a malignant condition or a B-cell disorder.
CC The binding domain-immunoglobulin fusion protein is useful for treating a
CC subject having or suspected of having a malignant condition or a B-cell
CC disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis,
CC myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple
CC sclerosis or autoimmune disease. The present sequence is a binding domain
CC -immunoglobulin fusion protein-associated protein sequence. Note: The
CC sequence data for this patent formed part of the printed specification
CC and is also available in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?docid=20030118592. The authors have not
CC identified the sequences in the printed specification by their SEQ ID
CC number therefore none of the sequences can be explicitly identified.
```

SQ Sequence 504 AA;

Query Match 52.7%; Score 1271; DB 7; Length 504;

Best Local Similarity 55.0%; Pred. No. 7-26-64;

Matches 282; Conservative 29; Mismatches 92; Indels 110; Gaps 13;

```
QY 1 MNRGVPFRHLLVQLALPRAIQGNKVLAKKQDTVELTASQKSIQFNH--KNSN 57
    ||||| : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 19 MSRGVDIQ-----MTQTSSLSASLDRAVTISCRASQDIRNNLYNMYQKPKDG 65
QY 58 QIKILNGSGSFLTGKPSKLNDRARRSLMOC-NPFLIINKLIEDPTICEDVDKE 116
    : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 66 TVKLL---IYLT---SRLSHGVPFRSGSGSGGFDYSLTIANLPEDATATFCQ----- 112
QY 117 EVQLVFEGLTANSPDTHLQCGSL-----TTLTSP-----GSSPSV 153
    ||||| : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 113 --QNTLPLWTRGGGTLVTKRELGGSGGSGSGGSGSIDVQLQSSPELVKCAASNC 170
QY 154 QC-----RSPRGKNIQ-----GAKTISVSQ----- 173
DB 171 KASGVSFTGYLVNMLKOSHGNLEWIGLINPYKGLTTYNQKFKGKATLTVDKSSSTAYME 230
QY 174 ---LELDSSGWTCVTVLONQKVEFKID-----IYPCAPREPSCDKHTC-----PE 218
    ||||| : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 231 LLSLTSEDSAVYYCARSGYGDSDWYFDWGAGTTTVVSSDQEPKSCDKHTCPPCPAPE 290
QY 219 LLGGSPVFLPPPKKDTLMTSRTPETVCVVVDVSHEDPEVKFNNYVDGVEVHNAKTPRE 278
    |||||
DB 291 LLGGSPVFLPPPKKDTLMTSRTPETVCVVVDVSHEDPEVKFNNYVDGVEVHNAKTPRE 350
QY 279 EQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIETKTSKAGQPREPOVYTLTP 338
    |||||
DB 351 EQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIETKTSKAGQPREPOVYTLTP 410
QY 339 SRDELTKNOVSLTLVGKFPSPDIAVEMESNGOENNYYKTPPLVLDSDGSFFLYSKLTV 398
    |||||
DB 411 SRDELTKNOVSLTLVGKFPSPDIAVEMESNGOENNYYKTPPLVLDSDGSFFLYSKLTV 470
QY 399 KSRWQGNVFCSVMEHALNHNYTQKSLSLSPG 431
    |||||
DB 471 KSRWQGNVFCSVMEHALNHNYTQKSLSLSPG 503
```

RESULT 83

XX	ABP58289	
XX	ABP58289	standard; protein; 472 AA.
XX	ABP58289	
XX	23-OCT-2003	(revised)
XX	31-MAR-2003	(first entry)
XX	Humanised 10D5	antibody heavy chain.
XX	Monoclonal antibody; 10D5	complementarily determining region; CDR;
XX	mouse; human; humanised antibody; antibody; Alzheimer's disease;	
XX	Down's syndrome; cerebral amyloid angiopathy; neuroprotective; nootropic.	
XX	Mus sp.	
XX	Homo sapiens.	
XX	Chimeric.	
XX	Key	Location/Qualifiers
XX	Peptide	1..19
XX	Peptide	/label=Signal_peptide
XX	Peptide	20..472
XX	Peptide	/label=Mature_protein
XX	Region	/note="the mature light chain is claimed in Claim 5"
XX	Region	20..142
XX	Region	/note="light chain variable region, claimed in Claim 4"
XX	Region	50..56
XX	Region	/note="CDR1"
XX	Region	71..86
XX	Region	/note="CDR2"
XX	Region	119..131
XX	Region	/note="CDR3"
XX	MO20028307-A2.	
XX	07-NOV-2002.	
XX	26-APR-2002; 2002MO-US011854.	
XX	30-APR-2001; 2001US-0287653P.	
XX	(ELI ) LILLY & CO ELI.	
XX	Hinton PR, Vaquez M;	
XX	WPI, 2003-183836/18.	
XX	N-PSDB; ABZ24639, ABZ24641.	
XX	New humanized 10D5 antibody, useful for the manufacture of a medicament	
XX	for treating Down's syndrome, clinical or pre-clinical Alzheimer's	
XX	disease or cerebral amyloid angiopathy.	
XX	Disclosure; Page 13-15; 52pp; English.	
XX	The present sequence is the protein sequence of the heavy chain of a	
XX	humanised antibody of the present invention. In the variable portion, the	
XX	complementarity determining regions (CDRs) originate from murine	
XX	monoclonal antibody 10D5 and the framework region originates from human	
XX	germline VH segment DP-28 and J segment JH4. Novel humanised antibodies	
XX	of the invention have CDRs from 10D5 and human framework sequences. These	
XX	humanised antibodies have binding affinities (affinity and epitope	
XX	location) approximately the same as those of the mouse 10D5 antibody. The	
XX	invention includes antibodies, single chain antibodies, and their	
XX	fragments, as well as nucleotide sequences, vectors, transformed host	
XX	cells, and methods of using the humanised antibody to treat, prevent,	
XX	alleviate, reverse or otherwise ameliorate symptoms and/or pathology	
XX	associated with Down's syndrome, (pre-)clinical Alzheimer's disease or	
XX	(pre-)clinical cerebral amyloid angiopathy, and to inhibit formation or	
XX	reduce A-beta plaque in the brain. (Updated on 23-OCT-2003 to standardise	
XX	OS field)	
XX	Sequence 472 AA.	

Query Match	52.6%	Score 1270.5	DB 6	Length 412
Best Local Similarity	58.2%	Pred. No. 7.2e-64		
Matches 279	Conservative 27	Mismatches 100	Indels 73	Gaps 11
QY	10	LLVLVQLALLPAAT--QGNKVLGKGGTVELTCTAS----	QKSIQIFMKNSNOIKILGN	64
DB	9	LLLVIPAVLVLSQVLTAKSGPVLVKPRTLTITCTFSGPSLSTSGMGVSMIRQPPGKALEM		68
QY	65	QGSEFLTKGPSKLTNRADRSRL--WDQGNFLLIKNLIKIEDSTYICEVEDQKEEVLQ		121
DB	69	LAHIVDDDKRYNPSLMSRLTISKDTSGQVLLMTNMDPVDATATYCV--RRPIRPVL		125
QY	122	VFGLTANSDTLLLOGSITLTLESPPSSPSVQCRSPRGKNIQGG-----	KT	168
DB	126	V-----DAMDYGGGTLVTVSSASTKGPSVFPLAPSSKSTSGGTALGCLVADYDEPEP		178
QY	169	LSVS-----QLBQDSG-----TWTCVLQONQKVFKI		197
DB	179	VTVMNSGALTVGVHTPEAVLQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHRKPSNTKV		236
QY	198	DIVCPAPAPKSCDKTHTC-----PELTGGSPVFLPPKPDOTMI	SRTPEVTCVAVDV	252
DB	237	D---KAYEPKSCDKHTCPCPAPPELLGGSPVFLPPKPDOTMISRTPEVTCVAVDV		292
QY	253	HEDEVKFMNVYDGEVYHNAKTKREBOQNSTYRVSVLTIVLADQWLNGKEYCKVSNKA		312
DB	293	HEDEVKFMNVYDGEVYHNAKTKREBOQNSTYRVSVLTIVLADQWLNGKEYCKVSNKA		352
QY	313	LPAPIETKISAKAQPPPEQVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESGQP		372
DB	353	LPAPIETKISKAKQPPPEQVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESGQP		412
QY	373	ENNNKTTIPVLDSDGSEFLYSKLTVDSDRMQOGVFCSWHHEALNHHYQKSLSPG		431
DB	413	ENNNKTTIPVLDSDGSEFLYSKLTVDSDRMQOGVFCSWHHEALNHHYQKSLSPG		471

XX	Claim 41; Page 168-172; 183pp; Japanese.
PS	
PT	
PR	New human type complementation-determining region-transplanted antibody
PT	of e.g. tumors, with low antigenicity, little side effects but potent
PT	activity in cancer.
XX	
PA	(KYOW ) KYOWA HAKKO KOGYO KK.
XX	
PI	Hanai N, Shitara K, Nakamura K, Niwa R;
DR	WPI; 2001-266143/27.
XX	
XX	
DE	Ganglioside GD3 specific antibody related protein SEQ ID NO: 53.
XX	
DT	03-JUL-2001 (first entry)
XX	
AC	AAB81987;
XX	
ID	AAB81987 standard; protein; 582 AA.
RESULT 84	
AAB81987	
OS	Synthetic.
XX	
XX	WO200123432-A1.
PN	
PD	05-APR-2001.
XX	
PF	29-SEP-2000; 2000MO-JP006774.
XX	
PR	30-SEP-1999; 99JP-00278291.
FR	06-APR-2000; 2000JP-00105088.
XX	





CC human foetal brain cDNA clones containing alternatively spliced full-  
 CC length variants of a novel adhesion molecule designated ACAM. ACAM  
 CC nucleic acids and polypeptides may be used in the prevention, treatment  
 CC and diagnosis of diseases associated with inappropriate ACAM expression  
 CC and activity such as dementia, epilepsy, schizophrenia, peripheral nerve  
 CC injuries and diabetic neuropathies. They may be used to rectify mutations  
 CC or deletions in a patient's genome that affect the activity of ACAM or to  
 CC supplement insufficient ACAM production in a patient. Conversely,  
 CC antisense nucleic acid molecules may be administered to down-regulate  
 CC ACAM expression. The nucleotide sequence may also be used as a DNA probe  
 CC in diagnostic assays (e.g. PCR) to detect and quantitate the presence of  
 CC similar nucleic acid sequences in samples, and hence determine which  
 CC patients may be in need of restorative therapy. ACAM polypeptides may be  
 CC used as antigens in the production of antibodies against ACAM and in  
 CC assays to identify modulators (agonists and antagonists) of ACAM  
 CC expression and activity

CC Sequence 744 AA;

Query Match 52.6%; Score 1269.5; DB 3; Length 744;  
 Best Local Similarity 59.1%; Pred. No. 1.3e-63;  
 Matches 264; Conservative 38; Mismatches 65; Indels 80; Gaps 11;

QY 34 GTTVELTCTASQKSIQFHWKNSNQIKILGNQSFUTKGPSTLNDRAISRSLMGNFP 93  
 DB 328 GDSVMTCTCVMGCESPSFSWR-----TQIDSPISGKVSSEGT-----NST 367  
 QY 94 LIIKMLKIEDSDTYICEV-----EDQKEVQLLVFGLTANSDPHLLQGQSLTILSPQS 149  
 DB 368 LTLSPVSEFNEHSYLCCTVTCGHKLEKGIQVELISPRPDPELEMSGG-----LVNQS 419  
 QY 150 SPSSVQCRSP-----RGNKIQGG-----XTLSVSQLE-----LQDSG- 180  
 DB 420 STVTSCKVSVYPLDRLEIELKGETILNIEFLIEDTDMKSLSNSLEMTFTPTIEDGX 479  
 QY 181 TTTCTVQLNQKQKVER-----IDIVCPAPEPSCKTTC-----PELLGPS 224  
 DB 480 ALVCAKALIDMEFPKQROSTQTLVYNAVAV---DPKSCDKTHTCPCPAPPELLGPS 536  
 QY 225 VLFPPPKDQTLMISRTPEVTCVVVDVSHEDPEVKENYVVDVGVHNAKTKRREQVNST 284  
 DB 537 VLFPPPKDQTLMISRTPEVTCVVVDVSHEDPEVKENYVVDVGVHNAKTKRREQVNST 596  
 QY 285 YRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPPVYTLPPSRDEL 344  
 DB 597 YRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPPVYTLPPSRDEL 656  
 QY 345 KQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQ 404  
 DB 657 KQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQ 716  
 QY 405 GNVFSCSVMEHALHNHYTOKSLSLSPG 431  
 DB 717 GNVFSCSVMEHALHNHYTOKSLSLSPG 743

RESULT 88

ABBB2300  
 ID ABBB2300 standard; protein; 634 AA.

XX ABBB2300;

XX 22-JAN-2003 (first entry)

XX CD19:zeta chimeric immunoreceptor.

XX CD19; chimeric; receptor; CD19:zeta; cytosolic; immunosuppressive; CD4;  
 XX antiarthritic; antiinflammatory; gene therapy; CD8; immunotherapy.

XX Synthetic.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 23..634  
 FT /note= "specifically claimed fragment"

XX MO200277029-A2.

XX 03-OCT-2002.

XX 07-NOV-2001; 2001WO-US042397.

XX 07-NOV-2000; 2000US-0246117P.

XX (CITY ) CITY OF HOPE.

XX Jensen MC, Forman S, Raubitschek A;

XX WPI; 2003-01888/01.

XX N-PSDB; ABV73341.

PT Genetically engineered CD19-specific immune cells, useful for cellular  
 PT immunotherapy of CD19 malignancies and for abrogating any untoward B cell  
 PT function in autoimmune disorders such as lupus or rheumatoid arthritis.

PS Claim 12; Fig 1A-C; 8pp; English.

CC The invention relates to genetically engineered CD19-specific immune  
 CC cells which express, and bear on the cell surface membrane, a CD19-  
 CC specific chimeric receptor. The CD19-specific chimeric T cell receptor  
 CC consists of: (a) an intracellular signaling domain selected from zeta,  
 CC eta, delta, gamma or epsilon chain of CD3, MB1 chain, B29, FcgammaRIII  
 CC and FcgammaRIIIc, for an effector function of the immune cell; (b) at  
 CC least 1 transmembrane domain and (c) at least 1 extracellular domain  
 CC comprising a CD19-specific receptor. The compositions and methods of the  
 CC present invention are useful for cellular immunotherapy of CD19  
 CC malignancies and for abrogating any untoward B cell function in  
 CC autoimmune disorders such as lupus or rheumatoid arthritis. The present  
 CC sequence represents a CD19:zeta chimeric immunoreceptor amino acid  
 CC sequence. This chimeric receptor was constructed by PCR splice overlap  
 CC extension and consists of human GM-CSF receptor alpha chain leader  
 CC peptide, FMC3 Vh, G1y-Ser linker, FMC3 Vh, human IgG1 FC, human CD4  
 CC transmembrane domain and human cytoplasmic zeta chain

CC Sequence 634 AA;

Query Match 52.5%; Score 1268; DB 6; Length 634;  
 Best Local Similarity 56.2%; Pred. No. 1.3e-63;  
 Matches 287; Conservative 28; Mismatches 94; Indels 102; Gaps 16;

QY 10 LLLVQLAL--LP-----AATGAKVYLCKKEDVYELTTASQKSIQFHW---K 54  
 DB 2 LLLVTSLLCLPAPAPLLIPDIQMTQTSLSASLSDRYTISCRASQDISKYLINWYQOK 61  
 QY 55 NSNGKILGNQSGFLTKG-PSKLNDRADSRSLDQGNFPLIINKLKIEDSDTYICEVED 113  
 DB 62 PDGTVKLLIYTHSTSLHSGVSRFSGSGGT-----DYLSTLNLEEDATATFCQGN 114  
 QY 114 QKE-----EVQLVFGLTANSDPHLLQGQSLT---LTLESPPG-----SSPSVQC--- 155  
 DB 115 TLPTFGGKTLBITGTSISGKR-GSGEGSTKEVNLQESGGLVAPSGSLSTCTVSG 173  
 QY 156 -----RSPRGKNIQ-----GKLT-----LSVSQLE 175  
 DB 174 VSLPDYGVSWIRQPPRKGLEWLVGIWGSSETTYNSALKSRLLTIKNSKSGVFLKMSLQ 233  
 QY 176 LQDSGWTCTVQLNQKQK---EFKIDI-----VPCPAPKSCDKTHTC-----PELL 220  
 DB 234 TDDTAIYYCA-----KHYTGGSTAMDYWGCGTSVTVSSVEPKSSDKHTTCCPPAPPELL 288  
 QY 221 GGPVFLFPPPKDQTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVHNAKTKRREQ 280  
 DB 289 GGPVFLFPPPKDQTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVHNAKTKRREQ 348  
 QY 281 YNSTYRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPPVYTLPPSR 340



QY	DB	Sequence	Score	DB	Length	442
QY	DB	349 INSTTRAVSVLTIVLHQDMLNGENYECCKYSNKLPLPIEKTISKAGQREPEVYTLPSR	408			
QY	DB	341 DELTNGQVSLTCLVKGFFPSDIAVEMESNGQENNYKTTTPVLDGSGFFLYSKLTVDKS	400			
QY	DB	409 DELTNGQVSLTCLVKGFFPSDIAVEMESNGQENNYKTTTPVLDGSGFFLYSKLTVDKS	468			
QY	DB	401 RMQGNVPSCSVMHEALHNHYTQKSLSLSPG	431			
QY	DB	469 RMQGNVPSCSVMHEALHNHYTQKSLSLSPG	499			
QY	DB	RESULT 69				
QY	DB	ABR39465				
QY	DB	ABR39465 standard; protein; 442 AA.				
QY	DB	ABR39465;				
QY	DB	12-UUN-2003 (first entry)				
QY	DB	Humanised anti-Abeta antibody 266 heavy chain.				
QY	DB	Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;				
QY	DB	immunostimulant.				
QY	DB	Homo sapiens.				
QY	DB	WO2003016467-A2.				
QY	DB	27-FEB-2003.				
QY	DB	14-AUG-2002; 2002WO-US021324.				
QY	DB	17-AUG-2001; 2001US-0313576P.				
QY	DB	28-MAY-2002; 2002US-0383851P.				
QY	DB	(ELIL ) LILLY & CO ELI.				
QY	DB	Bales KR, Paul SM;				
QY	DB	WPI; 2003-289975/28.				
QY	DB	Treating or reducing the progression of diseases associated with amyloid-beta peptide, e.g. Alzheimer's disease, vascular dementia or mild cognitive impairment, comprises administering an anti-amyloid-beta peptide antibody.				
QY	DB	Disclosure; Page 20-22; 84pp; English.				
QY	DB	The invention relates to treating cognitive symptoms or reducing disease progression in a subject having a condition or disease associated with amyloid-beta peptide (Abeta). The method involves administering an amount of an anti-Abeta antibody that has greater affinity for soluble Abeta than 10 <sup>-9</sup> M, that has affinity (KD) for soluble Abeta1-40 or Abeta1-42 higher than 10 <sup>-9</sup> M, or that has greater affinity for soluble Abeta than antibody 266 has. The method or the anti-Abeta antibody is useful in preparing a medicament for treating cognitive symptoms or reducing disease progression in a subject having a condition or disease associated with Abeta. The condition or disease is Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, vascular dementia, or mild cognitive impairment. The present sequence represents a humanised anti-Abeta antibody 266 heavy chain				
QY	DB	Sequence 442 AA;				
QY	DB	Query Match	52.5%;	Score	1267.5;	DB 6; Length 442;
QY	DB	Best Local Similarity	59.1%;	Pred. No.	9.9e-64;	
QY	DB	Matches	274;	Conservative	26;	Mismatches 69; Indels 95; Gaps 13
QY	DB	30 LGKKDDTYELTETAS--OKSKIQPHMKNS-----NQIKLNGQSF--LTGSPSL 76				
QY	DB	11 LVQPGSLRLSCAAGGFTTRSRISMSKWRQAPGKGLVLAQINSVGNSTYIPPTVYKGRFTI 70				
QY	DB	77 NDRAQSRRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVOLLVFGLTANSDTHLQG 136				

Db	71	S-DONAKNTLYLQMN-----SLRADTAIVYC-----ASGD---YWG	103
Qy	137	QSILTLLESPGSSPVCQSPRGKNIQGG-----KTLSSVS-----	172
Db	104	QGLTVYVSSASMTGSPVPLPASLSKSTSGTALAGCLWKDYFPPEPVYVSNMGSALTSGVH	163
Qy	173	--QLEIQDSG-----TWCTVLQNGKQVPEFKIDVPCPAPEPKSCDK	212
Db	164	TFPAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD-----KKVEPKSCDK	211
Qy	213	THNC-----PELLGSSVFLFPKPKDITLMSIRTEGVCVVVDVSHEDPEVKFMWYVDGV	267
Db	218	THTCPCPAPELLIGGSVFLFPKPKPDITLMSIRTEGVCVVVDVSHEDPEVKFMWYVDGV	277
Qy	268	EYHNAAKTPPEEOYNSTRVYVSVLFTVLHODMNGEYKCKVSNKALPAPIEKTISKAKGQ	327
Db	278	EYHNAAKTPPEEOYNSTRVYVSVLFTVLHODMNGEYKCKVSNKALPAPIEKTISKAKGQ	337
Qy	338	PREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPLVDSG	387
Db	338	PREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPLVDSG	397
Qy	388	SFFLYSKLTVDKSRMQQGVFSCSVWHEALHNHTYQSLSLSPG	431
Db	398	SFFLYSKLTVDKSRMQQGVFSCSVWHEALHNHTYQSLSLSPG	441
RESULT 90			
ID	ABU08311	standard; protein; 442 AA.	
XX	ABU08311;		
XX	22-MAY-2003	(first entry)	
XX	Humanised 266 antibody heavy chain.		
XX	Mouse; cognition; Abeta peptide associated disorder; anti-Abeta antibody;		
XX	cognitive impairment; Alzheimer's disease; Down's syndrome;		
XX	cerebral amyloid angiopathy; vascular dementia; neurotropic; neurotropic;		
XX	mild cognitive impairment; antibody 266; heavy chain; humanised; mutant;		
XX	muteln.		
XX	Mus sp.		
XX	Synthetic.		
XX	WO2003015691-A2.		
XX	27-FEB-2003.		
XX	14-AUG-2002; 2002MO-US021323.		
XX	17-AUG-2001; 2001US-0313222P.		
XX	28-MAY-2002; 2002US-0383846P.		
XX	(EIL ) LILLY & CO ELI.		
XX	Bales KR, Dodart JF, Paul SM;		
XX	WPI; 2003-268234/26.		
XX	Effecting rapid improvement of cognition in a subject having Alzheimer's		
XX	disease, Down's syndrome, cerebral amyloid angiopathy, or mild cognitive		
XX	impairment, comprises administering anti-A beta antibody.		
XX	Disclosure; Page 21-23; 85pp; English.		
XX	The present invention relates to a method for effecting rapid improvement		
XX	of cognition in a subject having a condition or disease related to the		
XX	Abeta peptide. The method comprises administering an anti-Abeta antibody.		
XX	The method is useful for treating cognitive impairments associated with		
XX	Abeta peptide including those involved in Alzheimer's disease, Down's		





CC with a yield of 1 g/l obtained using a single promoter system. This is an example of the process of the invention for production of recombinant antibodies in a host cell system, with temporally separated expression of the light and heavy chains. Properly assembled, soluble and functional antibodies (or their fragments) can be produced in high yields for diagnostic or therapeutic applications, including treatment of cancer or autoimmune diseases

XX Sequence 470 AA;

Query Match 52.4%; Score 1266; DB 6; Length 470;

Best Local Similarity 58.8%; Pred. No. 1.3e-63; Matches 275; Conservative 26; Mismatches 69; Indels 98; Gaps 14;

QY 30 LGKGDVTELTCTAS--QKSIQPHW-----KNSNQIKILG-NGGSFLTKGSPKLNRA 80  
 DB 34 LVQPGSLRLSCAASGFNFYSYAMSWRQARGKLEWVSA--IASGH-STYLDVSVGR 91  
 QY 81 -----DSRRSLWDQGNFPLIINKLKIEDSDTYICEVEDQKEVQLVFGLTANSPTHL-- 133  
 DB 92 TISADSKNTAYLQWN-----SLRAEDTAVYYCA-----RDTAAVF 127  
 QY 134 -LQGSILTLTSSPPSSPSVOCRSRCKNIQGS-----KTLSS----- 172  
 DB 128 DVMGGGTIVTSSASTKGPVFPPLAPSSKSTSGTALGCLVKDYFPEPVTVSNMNGALT 187  
 QY 173 -----QLELDQSG-----TWCTVLQNOKQVFEKIDIVPCPAPEPK 208  
 DB 188 SGVHTFPAYLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KVERPK 241  
 QY 209 SCDKTHTC-----PELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEVKFMY 263  
 DB 242 SCDKTHTCPPCPAPPELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEVKFMY 301  
 QY 264 VGVGVHNAKTKPREQYNSTYRVVSVLTVLHQDMLNGKEYCKVSNKALPAPIEKTIISK 323  
 DB 302 VGVGVHNAKTKPREQYNSTYRVVSVLTVLHQDMLNGKEYCKVSNKALPAPIEKTIISK 361  
 QY 324 AGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFPYSDIAVEMESNGQENNYKTTTPVL 383  
 DB 362 AGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFPYSDIAVEMESNGQENNYKTTTPVL 421  
 QY 384 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTQKSLSPG 431  
 DB 422 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTQKSLSPG 469

RESULT 94

AA014065  
 ID AA014065 standard; protein; 474 AA.

XX AA014065;

DT 07-MAY-2002 (first entry)

DE Heavy chain protein of the monoclonal antibody from clone JA.

XX HRIg; human rabies-immune globulin; monoclonal; virucide; heavy chain;  
 KM human monoclonal rabies virus neutralising antibody; immunoglobulin;  
 XX light chain; central nervous system; CNS; prophylactic therapy; clone JA.

OS Homo sapiens.

XX MO20018132-A2.

XX 22-NOV-2001.

PF 04-MAY-2001; 2001WO-US014468.

XX 16-MAY-2000; 2000US-0204518P.

XX (UYJE-) UNIV JEFFERSON THOMAS.

XX PA

PI Hooper DC, Dietzschold B;

XX MPI; 2002-062381/08.

DR N-PSDB; AAK98701.

XX Novel isolated human monoclonal rabies virus neutralizing antibody useful  
 PT for treating individual exposed to rabies virus and for preventing spread  
 of rabies virus to central nervous system.

XX Claim 4; Page 23-24; 25pp; English.

CC This sequence represents the heavy chain protein of the monoclonal  
 CC antibody from clone JA. The invention relates to an isolated human  
 CC monoclonal rabies virus neutralising antibody (virucide) derived from  
 CC cDNA clones encoding the antibody heavy and light chains expressed in  
 CC heterologous expression systems and purified away from deleterious  
 CC contaminants. The invention provides a fused gene encoding a chimeric  
 CC immunoglobulin light chain and a fused gene encoding a chimeric  
 CC immunoglobulin heavy chain. The antibody of the invention is useful for  
 CC treating an individual exposed to a rabies virus by administering to the  
 CC individual a therapeutically effective amount of the antibody, and  
 CC preventing a spread of the rabies virus to the central nervous system  
 CC (CNS). The antibody of the invention provides a safe and efficacious post  
 CC -exposure prophylactic therapy for individuals exposed to a rabies virus

XX Sequence 474 AA;

Query Match 52.4%; Score 1266; DB 5; Length 474;

Best Local Similarity 59.1%; Pred. No. 1.3e-63; Matches 276; Conservative 32; Mismatches 71; Indels 88; Gaps 15;

QY 30 LGKGDVTELTCTAS-----QKSIQPHWKNQIKILGNGSFL--TKGP 73  
 DB 30 LVQPGSLRLSCAASGFNFYSYAMSWRQARGKLEWVSA--IASGH-STYLDVSVGR 86  
 QY 74 SKLNDRADSRSLWDQGNFPLIINKLKIEDSDTYICEVEDQKEVQLVFGLTANSPTHL 133  
 DB 87 FTIS-RDMSKNTLYLQWN-----SLRAEDTAVYYCA---KDEVTMTIVV-LNGGFD--- 132  
 QY 134 LQGSILTLTSSPPSSPSVOCRSRCKNIQGS-----KTLSS----- 172  
 DB 133 YWGQSTRVTVSSASTKGPVFPPLAPSSKSTSGTALGCLVKDYFPEPVTVSNMNGALT 192  
 QY 173 -----QLELDQSG-----TWCTVLQNOKQVFEKIDIVPCPAPEPK 209  
 DB 193 GVHTFPAYLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KVERPK 246  
 QY 210 CDKTHTC-----PELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEVKFMY 264  
 DB 247 CDKTHTCPPCPAPPELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEVKFMY 306  
 QY 265 DGVGVHNAKTKPREQYNSTYRVVSVLTVLHQDMLNGKEYCKVSNKALPAPIEKTIISKA 324  
 DB 307 DGVGVHNAKTKPREQYNSTYRVVSVLTVLHQDMLNGKEYCKVSNKALPAPIEKTIISKA 366  
 QY 325 KGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFPYSDIAVEMESNGQENNYKTTTPVL 384  
 DB 367 KGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFPYSDIAVEMESNGQENNYKTTTPVL 426  
 QY 385 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTQKSLSPG 431  
 DB 427 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTQKSLSPG 473

RESULT 95

ABU08017  
 ID ABU08017 standard; protein; 474 AA.

XX ABU08017;

DT 10-MAY-2003 (first entry)

DE Human monoclonal rabies virus antibody heavy chain, clone JH, protein.

```

XX Human; antibody; constant region; monoclonal antibody 57; Mab 57;
KM variable region; Rabies; neurological disease; infection;
KM central nervous system; rabies virus; Lyssaviridae;
KM pathogen; vaccine; virulence; heavy chain.
OS Homo sapiens.
PN MO2003016501-A2.
PD 27-FEB-2003.
PF 21-AUG-2002; 2002MO-US026584.
PR 21-ANG-2001; 2001US-0314023P.
XX (UYJE-) UNIV JEFFERSON THOMAS.
PA Hooper DC, Dietzschold B;
XX WPI; 2003-278566/27.
DR N-PSDB; ABX12855.
XX
XX New recombinant antibody comprising a constant region of Mab 57 linked to
PT a non-Mab 57 variable region, useful for treating an individual exposed
PT to a pathogen, e.g. rabies infection.
XX
XX Example 1; Page 32-33; 38pp; English.
PS
XX The invention discloses a recombinant antibody comprising a constant
XX region of monoclonal antibody (Mab) 57 linked to a non-Mab 57 variable
XX region. Rabies is an acute, neurological disease caused by infection of
XX the central nervous system with the rabies virus, a member of the
XX Lyssavirus genus of the family Rhabdoviridae. Also disclosed are methods
XX for producing an isolated recombinant antibody by culturing a host cell,
XX containing a recombinant expression vector comprising the nucleic acid
XX molecule encoding the antibody, and isolating the recombinant antibody
XX expressed and treating an individual exposed to a pathogen by
XX administering to the individual the recombinant antibody. The recombinant
XX antibodies are useful for preventing (vaccine) and treating an individual
XX exposed to a pathogen, e.g. rabies infection. They are also useful for
XX the qualitative and quantitative determination of the rabies virus. The
XX sequences presented are the antibody protein fragments, the nucleic acids
XX encoding them or the PCR primers used to construct the recombinant
XX expression vector
XX
XX Sequence 474 AA:
SQ

```

```

Query Match 52.4%; Score 1266; DB 6; Length 474;
Best Local Similarity 59.1%; Pred. No. 1.3e-63;
Matches 276; Conservative 32; Mismatches 71; Indels 88; Gaps 15;

```

```

QY 30 LGKGGDTVELTCTAS-----QKKSIOFHKNKSNQIKILGNQSGF---TKGP 73
DB 30 LVPGGSLRLSCAASGFTFSNYSAMSWVRQAPKGLEWVSA--ISASH-STYLDASVKGR 86
QY 74 SKLNRDASRRSLWDGQNPFLIKNLKIEDSDTYICEVEDQKEVQLVGLTANSDTHL 133
DB 87 FTIS-RDNSKNTLYLQNN-----SLRAEDTAAYYCA---KDRVETWIV-LNGGFD--- 132
QY 134 LQOOSLTLTLESPPGSSPSVQCSPPKKNIOGG-----KTLSSVS----- 172
DB 133 YWQGGTRLVTVSSASTGKPSVFLPAPSSKSTSGGTAALGCLVKDYFPPPVTVSNNGALTS 192
QY 173 -----QLELQDSG-----TWTCYLVQKQKVEFKIDIVPCPAPPEPKS 209
DB 193 GYHTFPFVAVLQSGIYSLSSVTVPSSSLGQTYICNV--NHSKNTKVD---KRVPEKS 246
QY 210 CDKTHTC-----PELLGSPVFLFPPPKDQTLMSRTPEVTCVVDVSHEDPEVKNWY 264
DB 247 CDKTHTCPCPAPPELLGSPVFLFPPPKDQTLMSRTPEVTCVVDVSHEDPEVKNWY 306
QY 265 DGVENVNAKTRPREBOYNSTYRVVSVLTVLHQMNLNKEKCKVSNKALPAPIEKTIKSKA 324

```

```

DB 307 DGVENVNAKTRPREBOYNSTYRVVSVLTVLHQMNLNKEKCKVSNKALPAPIEKTIKSKA 366
QY 325 KQGPREFQYTLTPSRDELTKQVSLTCLVKGFYPSDIAVEWESNQCPENNYKTPPVLD 384
DB 367 KQGPREFQYTLTPSRDEMTKNQVSLTCLVKGFYPSDIAVEWESNQCPENNYKTPPVLD 426
QY 385 SPGSPFLYSKLTVDKSRMQGVNFCGVNHEALAHNYTKQSLSPG 431
DB 427 SDGSPFLYSKLTVDKSRMQGVNFCGVNHEALAHNYTKQSLSPG 473

```

RESULT 96  
ADD25837  
ID ADD25837 standard; protein; 500 AA.  
XX  
XX ADD25837;  
XX  
XX 15-JAN-2004 (first entry)  
XX  
XX Binding domain-immunoglobulin fusion protein-associated protein #181.  
XX  
XX Binding domain; immunoglobulin; fusion protein; cytosolic;  
XX antiarthritic; immunosuppressive; antidiabetic; antihypertoid;  
XX neuroprotective; hinge region; immunoglobulin heavy chain;  
XX CH2 constant region; CH3 constant region; IgG1;  
XX antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;  
XX malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;  
XX rheumatoid arthritis; myasthenia gravis; Grave's disease;  
XX type I diabetes mellitus; multiple sclerosis; autoimmune disease.  
XX  
XX Unidentified.  
XX  
XX US2003118592-A1.  
XX  
XX 26-JUN-2003.  
XX  
XX 25-JUL-2002; 2002US-00207655.  
XX  
XX 17-JAN-2001; 2001US-0367358P.  
XX  
XX 17-JUN-2002; 2002US-00053530.  
XX  
XX 03-JUN-2002; 2002US-0385691P.  
XX  
XX (GENE-) GENE-CRAFT INC.  
XX  
XX Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;  
XX WPI; 2003-801317/75.  
XX  
XX New binding domain-immunoglobulin fusion protein, useful for treating a  
XX subject having or suspected of having a malignant condition or a B-cell  
XX disorder, e.g. melanoma, Grave's disease or autoimmune disease.  
XX  
XX Disclosure; SEQ ID NO 398; 157pp; English.  
XX  
XX The invention relates to a binding domain-immunoglobulin fusion protein  
XX comprising a binding domain polypeptide that is fused to an  
XX immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain  
XX CH2 constant region polypeptide that is fused to the hinge region  
XX polypeptide, and an immunoglobulin heavy chain CH3 constant region  
XX polypeptide that is fused to the CH2 constant region polypeptide. The  
XX hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin  
XX hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge  
XX region polypeptide, derived from (a) having 3 or more cysteine residues;  
XX where the mutated human IgG1 immunoglobulin hinge region polypeptide  
XX contains 2 cysteine residues, where the first cysteine is not mutated; a  
XX mutated human IgG1 immunoglobulin hinge region polypeptide, derived from  
XX (a) having 3 or more cysteine residues, where the mutated human IgG1  
XX immunoglobulin hinge region polypeptide contains no more than one  
XX cysteine residue; and a mutated human IgG1 immunoglobulin hinge region  
XX polypeptide, derived from (a) having 3 or more cysteine residues; where  
XX the mutated human IgG1 immunoglobulin hinge region polypeptide contains  
XX no cysteine residues. The binding domain-immunoglobulin fusion protein is





```

FT      /note= "Humanised heavy chain variable domain of D9D10"
FT      138..467
FT      Domain /note= "Human IgG1 heavy chain constant domain"
FT      Misc-difference 468 /note= "Leu added by cloning strategy"
FT      PN      WO9909055-A2.
FT      PD      25-FEB-1999.
FT      XX      14-AUG-1998; 98WO-EP005165.
FT      XX      18-AUG-1997; 97EP-00870122.
FT      PR      18-JUN-1998; 98EP-00870139.
FT      XX      (INNO-) INNOGENETICS NV.
FT      PI      Buyse M, Sablon E;
FT      DR      WPI; 1999-180969/15.
FT      DR      N-PSDB; AAX08631.
FT      XX      New engineered antibodies which bind and neutralise interferon-gamma -
PT      useful for prevention and treatment of septic shock, cachexia, immune
PT      diseases and skin disorders.
PT      PS      Disclosure; Fig 9; 134pp; English.
XX      New antibodies which bind and neutralise interferon-gamma (IFN gamma) can
XX      be used as a medicant, for preventing or treating septic shock, cachexia,
XX      immune diseases including multiple sclerosis and Crohn's disease and skin
XX      disorders including bullous, inflammatory and neoplastic dermatoses. The
XX      antibody is selected from a single chain antibody (scFv), a chimeric
XX      antibody or diabody comprising the humanised variable domain of the
XX      monoclonal mouse anti-IFN gamma antibody D9D10; a multivalent antibody;
XX      or a ruminant antibody. The antibodies are also useful for determining
XX      IFN gamma levels in a sample. Two fusion cDNA genes encoding heavy and
XX      light chain fusion proteins of the humanised D9D10 antibody were
XX      constructed. The light chain comprised cDNA encoding the mouse D9D10
XX      leader sequence, the humanised D9D10 light chain and a human
XX      immunoglobulin kappa light chain constant region. The heavy chain
XX      comprised cDNA encoding the mouse D9D10 light chain leader sequence
XX      followed by the humanised D9D10 heavy chain variable domain and a human
XX      IgG1 heavy chain constant domain in which the Cq-complement binding site
XX      had been mutated. Four overlapping synthetic oligonucleotides (AAX08585-
XX      88) were used to construct the D9D10 light chain leader sequence. This
XX      was then subsequently amplified using two primers (AAX08589, AAX08590) to
XX      generate PCR-V fragment. The humanised heavy chain variable domain was
XX      amplified from pGEM-T-VH using two primers (AAX08591, AAX08592) to
XX      generate PCR-VI fragment. The two fragments had a base pair overlap and
XX      were fused together using primers (AAX08593, AAX08594) and then cloned
XX      into pGEM-T to give pGEMdrVH. The human heavy chain constant domain was
XX      amplified with two primers (AAX08595, AAX08596) and cloned into pGEM-T to
XX      give pGEM-Tch. Two separate PCR amplifications were then performed using
XX      pGEM-T-ch as a template. The primers used were AAX08598, AAX08599 to
XX      generate PCR-VIII fragment and AAX08597, AAX08600 to generate PCR-IX
XX      fragment. These were then overlapped and fused using primers AAX08599,
XX      AAX08600 and the resulting PCR-X fragment inserted into pGEMdrVH to
XX      generate the complete heavy chain fusion DNA in a vector designated
XX      pGEMHD9D10H. For a description of the construction of the light chain
XX      fusion cDNA see GENESeq records AAX08573-X08584
XX      SO      Sequence 468 AA;
XX
Query Match      52.4%; Score 1265.5; DB 2; Length 468;
Best Local Similarity 57.2%; Pred. No. 1,4e-63;
Matches 277; Conservative 31; Mismatches 79; Indels 97; Gaps 13;

```

```

DB      66 KMGWINTYTGESTYVDDFKGRFVFLSDTSVAAYLQISSLKADDTATYFC----- 116
QY      119 QLVFGLTANDTHLLQ--GQSLTLTLESPPGSSPSVQCSPRKKNIQG----- 166
DB      117 -----ARRGFAMDYWGCTTGTVTSASTKGPVFPPLAPSSKSTSGTALACLVKD 168
QY      167 ---KTLVS-----QLELDSC-----TWTCVLONQKK 192
DB      169 YFPEPTVSNMNSGALTGSHTFPAVLQSSGLYSLSVTVPSSSLGTQTYCNV--NHKP 226
QY      193 VEFKIDIVPCAPPKSCDKTHTC-----PELLGSPVFLPPPKDTLMSRTPEVTCV 247
DB      227 SNTKYD-----KRVAPKSCDKTHTCPCPAPELLGSPVFLPPPKDTLMSRTPEVTCV 282
QY      248 VVDVSHEDPEVKFMWYDGVVHNAKTPREEOVNSYRVVSVTLVHOMLNKEVKCK 307
DB      283 VVDVSHEDPEVKFMWYDGVVHNAKTPREEOVNSYRVVSVTLVHOMLNKEVKCK 342
QY      308 VSNKALPAPLEKTSKAKGPREPOVYTLPPSRDELTKNOVSLCLVKGFPSPDIAYEME 367
DB      343 VSNKALPASIEKTSKAKGPREPOVYTLPPSRDEMTKNVSLCLVKGFPSPDIAYEME 402
QY      368 SNGPPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGNVFCGVMHEALHNHYTKSLS 427
DB      403 SNGPPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGNVFCGVMHEALHNHYTKSLS 462
QY      428 LSPG 431
DB      463 LSPG 466
XX
RESULT 100
AAX85692
ID      AAX85692 standard; protein; 711 AA.
AC      AAX85692;
XX      12-AUG-1999 (first entry)
DT      XX
DE      MoTRb11 fusion protein.
XX      Antibody; humanised; variable region; heavy chain; light chain;
XX      interferon gamma; IFN; treatment; prevention; septic shock; cachexia;
XX      immune disease; multiple sclerosis; Crohn's disease; skin disorders;
XX      inflammation; neoplasia; dermatitis; monoclonal antibody; diabody; scFv;
XX      multivalent; ruminant.
OS      Synthetic.
XX      Key      Location/Qualifiers
XX      FT      1..20
XX      FT      Peptide /label= Mouse_D9D10_light_chain_signal_peptide
XX      FT      21..137
XX      FT      Domain /note= "Humanised heavy chain variable domain of D9D10"
XX      FT      138..467
XX      FT      Misc-difference 468 /note= "Human IgG1 heavy chain constant domain"
XX      FT      Region /note= "Leu added by cloning strategy"
XX      FT      469..472
XX      FT      Domain /label= Gly(3)Ser-linker
XX      FT      473..711
XX      FT      /label= Humanised_D9D10_scFv
XX
PN      WO9909055-A2.
PD      25-FEB-1999.
XX      14-AUG-1998; 98WO-EP005165.
XX      18-AUG-1997; 97EP-00870122.
PR      18-JUN-1998; 98EP-00870139.
XX

```





**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 3, 2004, 13:14:00 ; Search time 38.4271 Seconds  
(without alignments)  
3706.029 Million cell updates/sec

Title: SEQ4  
Perfect score: 2414  
Sequence: 1 NMRGVFRRLLVLQLALP.....DETCAAGDGEJGLWTTDP 454

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1291235 seqs, 313682936 residues

Total number of hits satisfying chosen parameters: 1291235

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 125 summaries

Database :

Published Applications AA.\*  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/PCT\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US06\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/PCTUS\_PUBCOMB.pep.\*  
7: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
9: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep.\*  
10: /cgn2\_6/ptodata/1/pubpaa/US09B\_PUBCOMB.pep.\*  
11: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep.\*  
12: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pep.\*  
13: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
14: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
15: /cgn2\_6/ptodata/1/pubpaa/US10C\_PUBCOMB.pep.\*  
16: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep.\*  
17: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep.\*  
18: /cgn2\_6/ptodata/1/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2122	87.9	432	8	US-08-485-163-3
2	2122	87.9	432	9	US-09-766-995-2
3	2085	86.4	530	8	US-08-485-163-5
4	2085	86.4	530	9	US-09-766-995-4
5	1338.5	55.4	254	10	US-09-939-537-33
6	1291.5	53.5	465	12	US-10-404-724-8
7	1289	53.4	713	16	US-10-679-620-64
8	1289	53.4	715	16	US-10-679-620-62
9	1287.5	53.3	437	14	US-10-363-427-14
10	1285.5	53.3	437	14	US-10-412-406-32
11	1285.5	53.3	4852	12	US-10-412-406-33
12	1282.5	53.1	446	12	US-10-435-299-7
13	1282.5	53.1	617	14	US-10-363-427-18
14	1282.5	53.1	617	14	US-10-363-427-22
15	1282.5	53.1	972	15	US-10-416-836-38

16	1282.5	53.1	975	15	US-10-418-836-39	Sequence 39, Appl
17	1281.5	53.1	465	12	US-10-404-724-23	Sequence 23, Appl
18	1280	53.0	467	16	US-10-656-769-32	Sequence 32, Appl
19	1280	53.0	476	9	US-09-747-669-3	Sequence 3, Appl1
20	1280	53.0	476	14	US-10-290-703-3	Sequence 3, Appl1
21	1279.5	53.0	448	15	US-10-378-567-2	Sequence 2, Appl1
22	1279	53.0	492	14	US-10-207-655-344	Sequence 344, App
23	1277.5	52.9	470	15	US-10-108-260A-4292	Sequence 4292, Ap
24	1277	52.9	543	14	US-10-207-655-345	Sequence 345, App
25	1276.5	52.9	475	9	US-09-740-002-25	Sequence 25, Appl
26	1276.5	52.9	475	16	US-10-325-698-25	Sequence 25, Appl
27	1275.5	52.8	579	14	US-10-138-727A-41	Sequence 41, Appl
28	1275	52.8	600	16	US-10-334-235-38	Sequence 38, Appl
29	1274.5	52.8	445	14	US-10-320-231A-79	Sequence 79, Appl
30	1273.5	52.8	444	14	US-10-150-475A-6	Sequence 6, Appl1
31	1273.5	52.8	444	16	US-10-704-532-6	Sequence 6, Appl1
32	1273.5	52.8	444	16	US-10-645-215-6	Sequence 6, Appl1
33	1273.5	52.8	475	9	US-09-740-002-27	Sequence 27, Appl
34	1273.5	52.8	475	16	US-10-325-698-27	Sequence 27, Appl
35	1273.5	52.8	497	12	US-10-683-285-6	Sequence 6, Appl1
36	1273.5	52.8	525	12	US-10-683-285-4	Sequence 4, Appl1
37	1273.5	52.8	622	12	US-10-683-285-2	Sequence 2, Appl1
38	1272.5	52.7	474	15	US-10-108-260A-4282	Sequence 4282, Ap
39	1272	52.7	476	16	US-10-160-128-12	Sequence 12, Appl
40	1271.5	52.7	453	14	US-10-159-006-18	Sequence 18, Appl
41	1271.5	52.7	465	12	US-10-404-724-25	Sequence 25, Appl
42	1271.5	52.7	499	14	US-10-207-655-15	Sequence 15, Appl
43	1271.5	52.7	499	14	US-10-207-655-148	Sequence 148, App
44	1271.5	52.7	499	14	US-10-207-655-15	Sequence 15, Appl
45	1271.5	52.7	476	9	US-09-948-429B-12	Sequence 12, Appl
46	1271	52.7	476	12	US-09-758-173-12	Sequence 12, Appl
47	1271	52.7	476	13	US-10-124-905-12	Sequence 12, Appl
48	1271	52.7	476	14	US-10-124-907-12	Sequence 12, Appl
49	1271	52.7	504	14	US-10-291-532-12	Sequence 12, Appl
50	1271	52.7	504	14	US-10-207-655-348	Sequence 348, App
51	1270	52.6	473	15	US-10-108-260A-4278	Sequence 4278, Ap
52	1270	52.6	619	15	US-09-910-600-32	Sequence 32, Appl
53	1269.5	52.6	448	16	US-10-467-546-4	Sequence 4, Appl1
54	1269.5	52.6	469	16	US-10-656-769-20	Sequence 20, Appl1
55	1269	52.6	472	15	US-10-108-260A-4073	Sequence 4073, Ap
56	1268.5	52.5	471	15	US-10-108-260A-4285	Sequence 4285, Ap
57	1268	52.5	634	16	US-10-416-011-2	Sequence 2, Appl1
58	1267.5	52.5	442	12	US-10-226-435A-12	Sequence 12, Appl
59	1266.5	52.5	631	15	US-10-120-198B-12	Sequence 2, Appl1
60	1266	52.4	451	10	US-09-925-179-68	Sequence 68, Appl
61	1266	52.4	451	15	US-10-423-299-4	Sequence 4, Appl1
62	1266	52.4	470	14	US-10-020-786-9	Sequence 9, Appl1
63	1266	52.4	470	14	US-10-227-694-5	Sequence 5, Appl1
64	1266	52.4	474	10	US-09-848-832-3	Sequence 3, Appl1
65	1266	52.4	474	14	US-10-225-108A-3	Sequence 3, Appl1
66	1266	52.4	474	15	US-10-461-148-1	Sequence 1, Appl1
67	1266	52.4	500	14	US-10-207-655-240	Sequence 240, App
68	1266	52.4	500	14	US-10-207-655-398	Sequence 398, App
69	1265.5	52.4	468	14	US-10-071-485-67	Sequence 67, Appl
70	1265.5	52.4	711	14	US-10-071-485-90	Sequence 90, Appl
71	1265	52.4	445	16	US-10-408-901-42	Sequence 42, Appl
72	1265	52.4	448	12	US-10-411-037-56	Sequence 56, Appl
73	1265	52.4	448	12	US-10-411-026-56	Sequence 56, Appl
74	1265	52.4	448	16	US-10-410-962-56	Sequence 56, Appl
75	1265	52.4	448	16	US-10-411-049-56	Sequence 56, Appl
76	1265	52.4	448	16	US-10-410-930-56	Sequence 56, Appl
77	1265	52.4	448	16	US-10-410-997-56	Sequence 56, Appl
78	1265	52.4	448	16	US-10-411-012-56	Sequence 56, Appl
79	1265	52.4	448	16	US-10-281-994-56	Sequence 56, Appl
80	1265	52.4	448	16	US-10-410-913-56	Sequence 56, Appl
81	1265	52.4	462	12	US-09-773-877A-18	Sequence 18, Appl
82	1265	52.4	567	12	US-09-773-877A-12	Sequence 12, Appl
83	1265	52.4	698	9	US-09-875-338-9	Sequence 9, Appl1
84	1265	52.4	698	14	US-10-077-023-9	Sequence 9, Appl1
85	1264	52.3	567	12	US-09-773-877A-20	Sequence 20, Appl
86	1263.5	52.3	450	9	US-09-796-848A-17	Sequence 17, Appl
87	1263.5	52.3	450	9	US-09-796-848A-15	Sequence 15, Appl
88	1263.5	52.3	450	9	US-09-996-288-220	Sequence 220, App

89	1263.5	52.3	450	9	US-09-996-288-222
90	1263.5	52.3	450	9	US-09-996-288-222
91	1263.5	52.3	450	9	US-09-996-288-234
92	1263.5	52.3	450	9	US-09-996-288-238
93	1263.5	52.3	450	9	US-09-996-288-238
94	1263.5	52.3	450	9	US-09-996-288-242
95	1263.5	52.3	450	9	US-09-996-288-244
96	1263.5	52.3	450	9	US-09-996-288-246
97	1263.5	52.3	450	9	US-09-996-288-252
98	1263.5	52.3	450	9	US-09-996-288-254
99	1263.5	52.3	450	9	US-09-996-288-256
100	1263.5	52.3	450	10	US-09-996-265-220
101	1263.5	52.3	450	10	US-09-996-265-226
102	1263.5	52.3	450	10	US-09-996-265-232
103	1263.5	52.3	450	10	US-09-996-265-234
104	1263.5	52.3	450	10	US-09-996-265-236
105	1263.5	52.3	450	10	US-09-996-265-238
106	1263.5	52.3	450	10	US-09-996-265-242
107	1263.5	52.3	450	10	US-09-996-265-244
108	1263.5	52.3	450	10	US-09-996-265-246
109	1263.5	52.3	450	10	US-09-996-265-252
110	1263.5	52.3	450	10	US-09-996-265-254
111	1263.5	52.3	450	10	US-09-996-265-256
112	1263.5	52.3	452	10	US-09-726-256-71
113	1263.5	52.3	460	14	US-10-077-021-13
114	1263.5	52.3	472	14	US-10-159-006-30
115	1262.5	52.3	450	9	US-09-996-848R-39
116	1262.5	52.3	450	9	US-09-996-848R-41
117	1262.5	52.3	450	9	US-09-996-848R-47
118	1262.5	52.3	450	9	US-09-996-288-222
119	1262.5	52.3	450	9	US-09-996-288-222
120	1262.5	52.3	450	9	US-09-996-288-228
121	1262.5	52.3	450	10	US-09-996-265-222
122	1262.5	52.3	450	10	US-09-996-265-224
123	1262.5	52.3	450	10	US-09-996-265-228
124	1262.5	52.3	459	16	US-10-656-763-26
125	1262.5	52.3	480	14	US-10-077-021-135

## ALIGNMENTS

Sequence 226,	App
Sequence 232,	App
Sequence 234,	App
Sequence 236,	App
Sequence 238,	App
Sequence 242,	App
Sequence 244,	App
Sequence 246,	App
Sequence 252,	App
Sequence 254,	App
Sequence 256,	App
Sequence 260,	App
Sequence 226,	App
Sequence 232,	App
Sequence 234,	App
Sequence 238,	App
Sequence 242,	App
Sequence 244,	App
Sequence 246,	App
Sequence 252,	App
Sequence 254,	App
Sequence 256,	App
Sequence 71,	App
Sequence 113,	App
Sequence 39,	App
Sequence 41,	App
Sequence 222,	App
Sequence 224,	App
Sequence 228,	App
Sequence 232,	App
Sequence 234,	App
Sequence 238,	App
Sequence 242,	App
Sequence 246,	App
Sequence 252,	App
Sequence 254,	App
Sequence 15,	App

RESULT 1  
US-08-485-163-3  
Sequence 3, Application US/08485163  
Publication No. US20020098191A1  
GENERAL INFORMATION:  
APPLICANT: Beaudry, Gary A.  
APPLICANT: Maddon, Paul J.  
TITLE OF INVENTION: CD4-GAMMA2 CD4-IgG2 CHIMERAS  
NUMBER OF SEQUENCES: 10  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham LLP  
STREET: 1185 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10036  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.24  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/485,163  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 37690-II-1-PCT-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 278-0400

TELEFAX: (212) 391-0525  
TELEX:  
INFORMATION FOR SEQ ID NO:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 432 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
ORIGINAL SOURCE:  
ORGANISM: homo sapien  
CELL TYPE: lymphocyte  
JS-08-483-163-3

Query Match	87.9%;	Score 2122;	DB 8;	Length 432;
Best Local Similarity	91.2%;	Pred. No. 1.9e-141;		
Matches 405; Conservative	8;	Mismatches 5;	Indels 26;	Gaps 2

Qy	1	MNRVPPRHLLVYQLALLPPAOTGNKVLLGKGDVYELTCTASQKSIQFMKXSNQIK	60
Dp	1	MNRVPPRHLLVYQLALLPPAOTGNKVLLGKGDVYELTCTASQKSIQFMKXSNQIK	60
Qy	61	ILGNQGSFLTGPSPKLDNRADSRSLMDQGNPILIKNLKIEDSDTYICEVEDQKEVOQL	120
Dp	61	ILGNQGSFLTGPSPKLDNRADSRSLMDQGNPILIKNLKIEDSDTYICEVEDQKEVOQL	120
Qy	121	LVFELGTANSPTDHLHQQGSLTTLTSSPPSSSSVQCRSRGKNIQGGKTLTSVQLDQSG	180
Dp	121	LVFELGTANSPTDHLHQQGSLTTLTSSPPSSSSVQCRSRGKNIQGGKTLTSVQLDQSG	180
Qy	181	TWCTCTVLONQKKEVEFKIDIV-----PCPAPRPSKCDKHTHCPELLQGSFVFL	227
Dp	181	TWCTCTVLONQKKEVEFKIDIVLAEPRKKVCBCEPBPAP-----VAEPSVFL	227
Qy	228	FPPPKDPTLMSRTPREYTCVVVDVSHEDBEYKFMVYVDGVEVHNAKTYPRBEOFNSTRV	287
Dp	228	FPPPKDPTLMSRTPREYTCVVVDVSHEDBEYQFMVYVDGVEVHNAKTYPRBEOFNSTRV	287
Qy	288	VSUVTLVHODMLNKEKYCKVSNALPRLPIKTTISKAKGOREPOVYLLPSPREDELTKNQ	347
Dp	288	VSUVTLVHODMLNKEKYCKVSNAGLPRLPIKTTISKTKGQPREPOVYLLPSPREDELTKNQ	347
Qy	348	VSUVTCLVKGFPSPDIAVEMESNGQRPENNYKTTPYVLDSGSGFFLYSKULTVDKSRWQOGNV	407
Dp	348	VSUVTCLVKGFPSPDIAVEMESNGQRPENNYKTTPYVLDSGSGFFLYSKULTVDKSRWQOGNV	407
Qy	408	PSCSVMEBALHNHTQKSLSPG	431
Dp	408	PSCSVMEBALHNHTQKSLSPG	431

```

RESULT 2
US-09-766-995-2
; Sequence 2, Application US/09766995
; Patent No. US20020052481A1
; GENERAL INFORMATION:
; APPLICANT: Graham P. Allaway et al.
; TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED CDA-GAMMA2 AND CD4-1GG2 IMMUNOCONJUGATES
; TITLE OF INVENTION: AND USES THEREOF
; FILE REFERENCE: 2048/41215-CB/JPW/SHS
; CURRENT APPLICATION NUMBER: US/09/766,995
; CURRENT FILING DATE: 2001-01-22
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 432
; TYPE: PRT
; ORGANISM: homo sapiens
US-09-766-995-2

Query Match      87.9%; Score 2122; DB 9; Length 432;
Best Local Similarity 91.2%; Pred. No. 1.9e-11;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

```

```

QY 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKKSIOFHMKNSNOIK 60
  |||||||
Db 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKKSIOFHMKNSNOIK 60
QY 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYOL 120
  |||||||
Db 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYOL 120
QY 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPVQCSPRGKNIQGGKTLVSQLELODSG 180
  |||||||
Db 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPVQCSPRGKNIQGGKTLVSQLELODSG 180
QY 181 TWTCTVLQWQKKVEFKIDIV-----PCBAPPEKSCDKHTHTELLGSGSVL 227
  |||||||
Db 181 TWTCTVLQWQKKVEFKIDIVLAFERKCCVCEPCPPAP-----VAGSVFL 227
QY 228 FPKPKDITMISRTPEVTCVVVDVSHEDPEVKENMYVDGVEVHNAKTKPREEOYNSTYRV 287
  |||||||
Db 228 FPKPKDITMISRTPEVTCVVVDVSHEDPEVKENMYVDGVEVHNAKTKPREEOYNSTYRV 287
QY 288 VSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISAKQPREPOVYTLPPSRDELTKNQ 347
  |||||||
Db 288 VSVLTVLHODWLNKGEYKCKVSNKGLPAPIEKTISAKQPREPOVYTLPPSRDEWTKNQ 347
QY 348 VSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPRPVLDSDGPFYLSKLTVDKSRMOQGNV 407
  |||||||
Db 348 VSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPRPVLDSDGPFYLSKLTVDKSRMOQGNV 407
QY 408 FSCSVHNEALHNHYTQKSLSLSPG 431
  |||||||
Db 408 FSCSVHNEALHNHYTQKSLSLSPG 431

```

```

RESULT 3
US-08-485-163-5
; Sequence 5, Application US/08485163
; Publication No. US20020098191A1
; GENERAL INFORMATION:
; APPLICANT: Beaudry, Gary A.
; TITLE OF INVENTION: CD4-GAMMA2 CD4-IgG2 CHIMERAS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,163
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 278-0400
; TELEFAX: (212) 391-0525
; TELEX:
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 530 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown

```

```

; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: homo sapien
; CELL TYPE: lymphocyte
; US-08-485-163-5

```

```

Query Match      86.4%; Score 2085; DB 8; Length 530;
Best Local Similarity 77.3%; Pred. No. 9.9e-139;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

```

QY 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKKSIOFHMKNSNOIK 60
  |||||||
Db 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKKSIOFHMKNSNOIK 60
QY 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYOL 120
  |||||||
Db 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYOL 120
QY 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPVQCSPRGKNIQGGKTLVSQLELODSG 180
  |||||||
Db 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPVQCSPRGKNIQGGKTLVSQLELODSG 180
QY 181 TWTCTVLQWQKKVEFKIDIV-----PCBAPPEKSCDKHTHTELLGSGSVL 227
  |||||||
Db 181 TWTCTVLQWQKKVEFKIDIVLAFSTKQPSVFPLAPCSRSTSESTAALGCLVKDYFPEP 240
  |||||||
QY 208 ----- 207
Db 241 VTSWNSGALTSVHTFPAVLQSSGLYSLSVVTVPSSNFGQTYTCNVDRKPSNTKYDK 300
  |||||||
QY 208 ----KSCDKHTPC-ELLGQPSVFLPPPKDITMISRTPEVTCVVVDVSHEDPEVKFM 262
  |||||||
Db 301 TVERKCCVCEPCPPAPVAGSVFLPPPKDITMISRTPEVTCVVVDVSHEDPEVKFM 360
  |||||||
QY 263 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTIS 322
  |||||||
Db 361 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODWLNKGEYKCKVSNKGLPAPIEKTIS 420
  |||||||
QY 323 KAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSIAVEMESNGQPENNYKTPRPV 382
  |||||||
Db 421 KTKQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFPYPSIAVEMESNGQPENNYKTPRPM 480
  |||||||
QY 383 LPSDSFFLYSLTVDKSRMOQGNVFCSCVHNEALHNHYTQKSLSLSPG 431
  |||||||
Db 481 LPSDSFFLYSLTVDKSRMOQGNVFCSCVHNEALHNHYTQKSLSLSPG 529
  |||||||

```

```

RESULT 4
US-09-766-995-4
; Sequence 4, Application US/09766995
; Patent No. US20020052481A1
; GENERAL INFORMATION:
; APPLICANT: Graham P. Allaway et al.
; TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED CD4-GAMMA2 AND CD4-IgG2 IMMUNOCONJ
; FILE OF INVENTION: AND USES THEREOF
; FILE REFERENCE: 2048/41215-CB/JPW/SHS
; CURRENT APPLICATION NUMBER: US/09/766,995
; FILING DATE: 2001-01-22
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4
; LENGTH: 530
; TYPE: PRT
; ORGANISM: homo sapiens
; US-09-766-995-4

```

```

Query Match      86.4%; Score 2085; DB 9; Length 530;
Best Local Similarity 77.3%; Pred. No. 9.9e-139;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;
QY 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKKSIOFHMKNSNOIK 60
  |||||||
Db 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKKSIOFHMKNSNOIK 60
  |||||||

```

QY 61 ILGNQSFLLTKGPKSLNDRADSRSLMPOGNFLLIKKULKIEDSDTYICEVEDQKEEYQL 120  
DB 61 ILGNQSFLLTKGPKSLNDRADSRSLMPOGNFLLIKKULKIEDSDTYICEVEDQKEEYQL 120  
QY 121 LVFGLTANSDFHLLQGGSLTTLLESPPGSSPSPVQCRSPRGKNIQGGKTLVSQLELQDSG 180  
DB 121 LVFGLTANSDFHLLQGGSLTTLLESPPGSSPSPVQCRSPRGKNIQGGKTLVSQLELQDSG 180  
QY 181 TWTCTVLNOKKVEERKIDV-----PCPA-----PEP 207  
DB 181 TWTCTVLNOKKVEERKIDV-----PCPA-----PEP 207  
QY 208 ----- 207  
DB 241 VIVSNNSGALTSQVHTFPAVLQSSGLYSLSSVTVVPSNFGQTYTCVNDHKPSTKDXK 300  
QY 208 ---KSCDKHTTCPELLGGPSVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFN 262  
DB 301 TVERKCCVECPCPAPVAGPSVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFN 360  
QY 263 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 322  
DB 361 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 420  
QY 323 KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTPPV 382  
DB 421 KTKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTPPV 480  
QY 383 LQSDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNYTKSLSLSPG 431  
DB 481 LQSDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNYTKSLSLSPG 529

## RESULT 5

US-09-939-537-33  
Sequence 33, Application US/09939537  
Publication No. US20030138410A1  
GENERAL INFORMATION:

APPLICANT: Seed, Brian

Banapour, Babak

Romeo, Charles

Kolanus, Waldemar

TITLE OF INVENTION: TARGETED CYTOLYSIS OF HIV-INFECTED

CELLS BY CHIMERIC CD4 RECEPTOR- BEARING CELLS

NUMBER OF SEQUENCES: 53

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Clark &amp; Elbing LLP

STREET: 176 Federal Street

CITY: Boston

STATE: MA

COUNTRY: USA

ZIP: 02110

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/939,537

FILING DATE: 24-Aug-2001

CLASSIFICATION: &lt;Unknown&gt;

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/284,391

FILING DATE: 02-AUG-1994

APPLICATION NUMBER: 08/195,395

FILING DATE: 14-FEB-1994

APPLICATION NUMBER: 07/847,566

FILING DATE: 06-MAR-1992

APPLICATION NUMBER: 07/665,961

FILING DATE: 07-MAR-1991

ATTORNEY/AGENT INFORMATION:

NAME: Elbing, Karen L

REGISTRATION NUMBER: 35,238  
REFERENCE/DOCKET NUMBER: 00786/247001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-428-0200  
TELEFAX: 617-428-7045  
INFORMATION FOR SEQ ID NO: 33:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 254 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
MOLECULE TYPE: linear  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 33:  
US-09-939-537-33

Query Match 55.4%; Score 1338.5; DB 10; Length 254;  
Best Local Similarity 98.0%; Pred. No. 1.8e-86;  
Matches 249; Conservative 0; Mismatches 0; Indels 5; Gaps 1;

QY 206 EPKSCDKHTTC-----PELLGGPSVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKF 260  
DB 1 EPKSCDKHTTCPECPAPVAGPSVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKF 60  
QY 261 NWYDGVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 320  
DB 61 NWYDGVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 120  
QY 321 ISKAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTPPV 380  
DB 121 ISKAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTPPV 180  
QY 381 PVLDSDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNYTKSLSLSPGLQDETCAE 440  
DB 181 PVLDSDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNYTKSLSLSPGLQDETCAE 240  
QY 441 AQDGLDGLMTTDP 454  
DB 241 AQDGLDGLMTTDP 254

## RESULT 6

US-10-404-724-8  
Sequence 8, Application US/10404724  
Publication No. US20030203447A1  
GENERAL INFORMATION:

APPLICANT: Horwitz, Arnold H.

TITLE OF INVENTION: Methods and Materials For Increasing Expression of Recombinant

FILE REFERENCE: 13698US01

CURRENT APPLICATION NUMBER: US/10/404,724

CURRENT FILING DATE: 2003-03-31

PRIOR APPLICATION NUMBER: US 60/368,530

PRIOR FILING DATE: 2002-03-29

NUMBER OF SEQ ID NOS: 79

SOFTWARE: PatentIn version 3.2

SEQ ID NO 8

LENGTH: 465

TYPE: PRT

ORGANISM: Homo Sapiens

US-10-404-724-8

Query Match 53.5%; Score 1291.5; DB 12; Length 465;  
Best Local Similarity 58.1%; Pred. No. 7.9e-83;  
Matches 286; Conservative 23; Mismatches 78; Indels 105; Gaps 13;

QY 11 LVLVQLALLPAAATGKRVVLG---KKGDVVELTCTASQKKSIOFMKNSNQIKILGNQ 66  
DB 7 LFLFMAAAGSAQNIQIVQSGPELKKPGETVTKSCKS---GYFTFYGMWVWQAPGKG 63  
QY 67 -----SFLTKGPKSLNDRADSRSLMPOGNF-----LIKKULKIEDSDTYI 108  
DB 64 LKMMGMINTYTEBPTGDD-----FKGRFAFSIETASSTANLIQINNLSKSDTATYF 114



```

Qy 388 SFFLYSKLTVDKSRWQGNVFCSCVMHEBALHNHYTKSLSPG 431
Db 611 SFFLYSKLTVDKSRWQGNVFCSCVMHEBALHNHYTKSLSPG 714

RESULT 9
US-10-363-427-14
; Sequence 14, Application US/10363427
; Publication No. US20030195538A1
; GENERAL INFORMATION:
; APPLICANT: MedexGen Inc.
; APPLICANT: CHUNG, Yong Hoon
; APPLICANT: HAN, Ji Woong
; APPLICANT: LEE, Hye Ja
; APPLICANT: CHOI, Eun Yong
; APPLICANT: KIM, Jin Mi
; APPLICANT: YIM, Soo Bin
; TITLE OF INVENTION: Concatameric Immunoadhesion
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/363,427
; CURRENT FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: Kopatentin 1.71
; SEQ ID NO 14
; LENGTH: 437
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-363-427-14

Query Match 53.3%; Score 1287.5; DB 14; Length 437;
Best Local Similarity 64.7%; Pred. No. 1.4e-82;
Matches 273; Conservative 22; Mismatches 62; Indels 65; Gaps 11;

Qy 35 DTELTCTASQKKSIOFHMKNSNOIKIINGCSFTKPSKLNDRADRSIMDGNPL 94
Db 55 DDIKEKTSDDKKIAQFRKEK-----TFREKDTYKLFK-----NGTL 92
Qy 95 IIKNLKIEDSPDYICEVEDOK-EEVQLVFGLTANS DTHLQQ-----SLVLT 142
Db 93 KIKHLKTDQDQIKYISTDTKGNVLEKIFDLK-----IOERVKRISMTCTINTLT 145
Qy 143 LESPPSSPSVQCRSPRGKNIQGGKTLVSQLELODSGTWT-----CTVLQNKQKVE 194
Db 146 CEVNMGTDPBLNL-----YDGGHKLKSGKVI--TKMTLSAKFKCTA-GNKVSK 195
Qy 195 FKIDIVPCPAPBPSCDKTHTC-----PELLGGSVFLPPPKKDTLMISRTPEVTCVV 249
Db 196 SSVEPVSCPA-BPKSCDKTHTCPCPAPBELLGSPSVFLPPPKKDTLMISRTPEVTCVV 254
Qy 250 DVSHDDPEVKFMWYDGVVHNAKTKPREBOYNSTYRVVSVLTVLHQMNLNGKEYCKV 309
Db 255 DVSHDDPEVKFMWYDGVVHNAKTKPREBOYNSTYRVVSVLTVLHQMNLNGKEYCKV 314
Qy 310 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDI AVEBESN 369
Db 315 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDI AVEBESN 374
Qy 370 GQPENNYKTTTPVLDSDGSFLLYSKLTVDKSRWQGNVFCSCVMHEBALHNHYTKSLSPG 429
Db 375 GQPENNYKTTTPVLDSDGSFLLYSKLTVDKSRWQGNVFCSCVMHEBALHNHYTKSLSPG 434

Qy 430 PG 431
Db 435 PG 436

RESULT 10
US-10-412-406-32
; Sequence 32, Application US/10412406
; Publication No. US20040058394A1
; GENERAL INFORMATION:
; APPLICANT: BIOGEN, INC.

```

```

; APPLICANT: GARBER, Ellen
; APPLICANT: LYNE, Paul
; APPLICANT: SAIDHANA, Jose W.
; TITLE OF INVENTION: HUMANIZED ANTI-LT-BETA-R ANTIBODIES
; FILE REFERENCE: BINA100CN
; CURRENT APPLICATION NUMBER: US/10/412,406
; CURRENT FILING DATE: 2003-04-10
; PRIOR APPLICATION NUMBER: 60/240,285
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/275,289
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: 60/299,987
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: PCT/US01/32140
; PRIOR FILING DATE: 2001-10-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 663
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-412-406-32

Query Match 53.3%; Score 1285.5; DB 12; Length 663;
Best Local Similarity 59.0%; Pred. No. 3.3e-82;
Matches 275; Conservative 29; Mismatches 71; Indels 91; Gaps 13;

Qy 30 LGKKGDTVELCTRAS--QKSIQFHW-----KNSNOIKILGNGSFLTQKPSLTN----- 77
Db 225 LVKPGGSLRLSCAASGTFSDYWMYFRAQPGKLEWVAITSDGSY-TYYPDSVKGRFT 283
Qy 78 -DRADSRSLMDQGNFLIILKLIKIEDSPDYICEVEDOKSEVQLVFGLTANS DTHLQ- 135
Db 284 ISRNMAKNSLY-----LQMSLRADPTAYYCARE-----NGFYFFDY 323
Qy 136 -GGSVLTLSPSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
Db 324 WGGTTVTVSSASATGKSPVPLAPSSKSTSGTALCLVADYFPEPVTVMNSGALTSG 383
Qy 173 -----QLELOSG-----TWCTVQONKQVEFKIDIVPCPAPBPSC 210
Db 384 VHTFPAVLQSSGLVSLSSVVTVPBSSLTGTQTYICNV--NKPSTNTKVD---KVEKSKC 437
Qy 211 DKTHTC-----PELLGSPSVFLPPPKKDTLMISRTPEVTCVVVDVSHDEPEVKFMWYD 265
Db 438 DKTHTCPCPAPBELLGSPSVFLPPPKKDTLMISRTPEVTCVVVDVSHDEPEVKFMWYD 497
Qy 266 GVEVHNAKTKPREBOYNSTYRVVSVLTVLHQMNLNGKEYCKVSNKALPAPIEKTISKAK 325
Db 498 GVEVHNAKTKPREBOYNSTYRVVSVLTVLHQMNLNGKEYCKVSNKALPAPIEKTISKAK 557
Qy 326 GQPEPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDI AVEBESNGQPENNYKTTTPVLD 385
Db 558 GQPEPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDI AVEBESNGQPENNYKTTTPVLD 617
Qy 386 DGSFLLYSKLTVDKSRWQGNVFCSCVMHEBALHNHYTKSLSPG 431
Db 618 DGSFLLYSKLTVDKSRWQGNVFCSCVMHEBALHNHYTKSLSPG 663

RESULT 11
US-10-412-406-33
; Sequence 33, Application US/10412406
; Publication No. US20040058394A1
; GENERAL INFORMATION:
; APPLICANT: BIOGEN, INC.
; APPLICANT: GARBER, Ellen
; APPLICANT: LYNE, Paul
; APPLICANT: SAIDHANA, Jose W.
; TITLE OF INVENTION: HUMANIZED ANTI-LT-BETA-R ANTIBODIES
; FILE REFERENCE: BINA100CN
; CURRENT APPLICATION NUMBER: US/10/412,406
; CURRENT FILING DATE: 2003-04-10

```



```

; PRIOR APPLICATION NUMBER: 60/240,285
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/275,289
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: 60/299,987
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: PCT/US01/32140
; PRIOR FILING DATE: 2001-10-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatsSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 4852
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-412-406-33

Query Match      53.3%; Score 1285.5; DB 12; Length 4852;
Best Local Similarity 59.0%; Pred. No. 4.1e-81;
Matches 275; Conservative 29; Mismatches 71; Indels 91; Gaps 13;

QY 30 LKKGDTVELTCTAS--QKKSIOFW-----KNSQIKILGNQGSFLTKGFSKLN---- 77
DB 4414 LVKPGSLRLSCAASGFTFSDDYMYWFOAPGKLEWVATISDGSY-TYYPDSYKGRPT 4472
QY 78 -BRADSRRLMDQGNPLIIRKLIKIEDSDTYICEVEDQKEBQVLVFGLTANSDTLLQ- 135
DB 4473 ISRDNAKSLY-----LQMSLRABDTAVYICABE-----NONFYEDY 4512
QY 136 -GOSLTLTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 4513 WCGGTIVTVSASTKGPSVFPLAAPSSTSGGTAALGCLVKQYFPEPVTVSNMNSGALTSG 4572
QY 173 ---QLELDSC-----TWCTYVLOQKKVEFKIDIVPCAPAPKSC 210
DB 4573 VHTFPAVLQSSGIYSSLSVATVPSSSLGTQTYICNV--NHKPSNTKYD---KQVEPKSC 4626
QY 211 DKHTTC-----PELLGSPSVFLPPPKKDTLMISRTPEVTCVAVDSDHEDPEVKFMWYD 265
DB 4627 DKHTTCPCPAPPELLGSPSVFLPPPKKDTLMISRTPEVTCVAVDSDHEDPEVKFMWYD 4686
QY 266 GVEVHNAKTKPREBOYNSTYRVSVLTJVLHODWLNKEVKCKVSNKALPAPIEKTIISKAK 325
DB 4687 GVEVHNAKTKPREBOYNSTYRVSVLTJVLHODWLNKEVKCKVSNKALPAPIEKTIISKAK 4746
QY 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLD 385
DB 4747 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLD 4806
QY 386 DGSFPLYSKLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 431
DB 4807 DGSFPLYSKLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 4852

RESULT 12
US-10-435-299-7
; Sequence 7, Application US/10435299
; Publication No. US20040052783A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Gingrich, Roger
; APPLICANT: Link, Brian
; APPLICANT: Teo, J. Yun
; TITLE OF INVENTION: HUMANIZED ANTIBODIES AGAINST CD3
; FILE REFERENCE: 05882-0176-CNUS04
; CURRENT APPLICATION NUMBER: US/10/435,299
; CURRENT FILING DATE: 2003-05-09
; PRIOR APPLICATION NUMBER: US 09/618,380
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: US 08/397,411
; PRIOR FILING DATE: 1995-03-01
; PRIOR APPLICATION NUMBER: US 07/859,583
; PRIOR FILING DATE: 1992-03-27
; NUMBER OF SEQ ID NOS: 14

```

```

; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 446
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Complete heavy chain of Humanized 1D10 Ab
US-10-435-299-7

Query Match      53.1%; Score 1282.5; DB 12; Length 446;
Best Local Similarity 59.8%; Pred. No. 3.2e-82;
Matches 274; Conservative 25; Mismatches 80; Indels 79; Gaps 10;

QY 30 LKKGDTVELTCTAOKKSIOF--HWKSNQIKILGNQGSFLTKGFSKLNBRADSRRL- 86
DB 11 LVKPSSTLSLCTVSGFLTNVGMVWQSPKGLWIGVWKSSTGEYNAFISRLTIS 70
QY 87 --MDQGNPLIIRKLIKIEDSDTYICEVEDQKEBQVLVFGLTANSDTLLQ--GOSLTLT 142
DB 71 KDTSKNQVSLKNSLTADTAVYIC-----ARDRYAMDYWGQGLVLT 113
QY 143 LESPSSSPSVQCRSPRGKNIQGG-----KTLSSVS-----QLEL 176
DB 114 VSSASTKGPSVFPLAAPSSTSGGTAALGCLVKQYFPEPVTVSNMNSGALTSGVHTFPAVL 173
QY 177 QDSG-----TWCTYVLOQKKVEFKIDIVPCAPAPKSCDKHTTC-- 216
DB 174 QSSGLYSLSVATVPSSSLGTQTYICNV--NHKPSNTKYD---KQVEPKSCDKHTTCPP 227
QY 217 ---PELLGSPSVFLPPPKKDTLMISRTPEVTCVAVDSDHEDPEVKFMWYDGEVHNAK 273
DB 228 CPAPPELLGSPSVFLPPPKKDTLMISRTPEVTCVAVDSDHEDPEVKFMWYDGEVHNAK 287
QY 274 TKPREBOYNSTYRVSVLTJVLHODWLNKEVKCKVSNKALPAPIEKTIISKAKGQPREPOV 333
DB 288 TKPREBOYNSTYRVSVLTJVLHODWLNKEVKCKVSNKALPAPIEKTIISKAKGQPREPOV 347
QY 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYS 393
DB 348 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYS 407
QY 394 KLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 431
DB 408 KLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 445

RESULT 13
US-10-363-427-18
; Sequence 18, Application US/10363427
; Publication No. US20030195338A1
; GENERAL INFORMATION:
; APPLICANT: MedexGen Inc.
; APPLICANT: CHUNG, Yong Hoon
; APPLICANT: HAN, Ji Woong
; APPLICANT: LEE, Hye Ja
; APPLICANT: CHOI, Eun Yong
; APPLICANT: KIM, Jin Mi
; APPLICANT: YIM, Soo Bin
; TITLE OF INVENTION: Concatameric Immunoadhesion
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/363,427
; CURRENT FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: KopatentIn 1.71
; SEQ ID NO 18
; LENGTH: 617
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-363-427-18

Query Match      53.1%; Score 1282.5; DB 14; Length 617;
Best Local Similarity 64.5%; Pred. No. 4.9e-82;
Matches 272; Conservative 22; Mismatches 63; Indels 65; Gaps 11;

```

```

0Y 35 DYVEALCTSAQOKSIQFHHKNSNQIKLONQSSFLTKGSPKUNDRASRBSLMQGNFPL 94
Db 235 DDIIKEMTSDKKKIAGFRKEKE-----TFEKDYKLFK-----NGTL 2722
0Y 95 IINKLKIEDSDTYICEVEDOK-EEVOLLVFGLTANSPTHLLQOQ-----SLTLT 142
Db 273 KIKHLKTDODDIKYSIYDTKGNAVLEKIFDLK-----IQERSKPKISWTCINTLTL 355
0Y 143 LEPSPSSPSVQCRSPRGKNITQGGKTLVSQLELODSGTW-----CTVLONQKVE 194
Db 326 CEVANNGDPEPLNLT-----YODGKHLKLSQREVI--THKMTTSLSAKEKCTA-GNKYSKE 375
0Y 195 FKIDIVCPAPREPKSCDKTHTC-----PELLGSPSVLPFPKPKDITLMIISTPEVTCVV 249
Db 376 SSVEPASCPA-EKSCDKHTHTCPCPAPRELLGSPSVLPFPKPKDITLMIISTPEVTCVV 434
0Y 250 DVSHDEBEVKFNNYVDGVEVHNAKTPREEQYNSTRVAVSVLTVLHODMLNGKEYKCVS 309
Db 435 DVSHDEBEVEFNNYVDGVEVHNAKTPREEQYNSTRVAVSVLTVLCHODMLNGKEYKCVS 494
0Y 310 NKALPAIETKTISKAGQPREPQVYLLPSPRELTKNQVSLTCLVKGFPSPDIAMVESN 359
Db 495 NKALPAIETKTISKAGQPREPQVYLLPSPRELTKNQVSLTCLVKGFPSPDIAMVESN 554
0Y 370 GQPENNNKTTPPVLLDSDGSFFLYSKLTVDYKSRMQGNFVSCSVMEHALAHNNYTOKSLSL 429
Db 555 GQPENNNKTTPPVLLDSDGSFFLYSKLTVDYKSRMQGNFVSCSVMEHALAHNNYTOKSLSL 614
0Y 430 PG 431
Db 615 PG 616

```

```

RESULT 14
US-10-363-427-22
:
: Sequence 22, Application US/10363427
: Publication No. US20030195338A1
: GENERAL INFORMATION:
: APPLICANT: MedexGen Inc.
: APPLICANT: CHUNG, Yong Hoon
: APPLICANT: HAN, Ji Woong
: APPLICANT: LEE, Hye Ja
: APPLICANT: CHOI, Eun Yong
: APPLICANT: KIM, Jin Mi
: APPLICANT: YIM, Soo Bin
: TITLE OF INVENTION: Concatametric Immunoadhesion
: FILE REFERENCE:
: CURRENT APPLICATION NUMBER: US/10/363,427
: CURRENT FILING DATE: 2003-02-28
: NUMBER OF SEQ ID NOS: 52
: SOFTWARE: KopatentIn 1.71
: SEQ ID NO 22
: LENGTH: 617
: TYPE: PRT
: ORGANISM: Homo sapiens
US-10-363-427-22

```

[illegible]

QY	1.95	EKIDVPCAPAPBPKSCDXTHTC----	PELLGSPVFLPBPBKDTLMTSRPEVTCVV	2.49
		::::		
Db	3.76	SSVEVSCPA-EPKSCDXTHTCP	PCAPALPLGGSPVFLPBPBKDTLMTSRPEVTCVV	4.34
QY	2.50	DVSHDEPVEKFMWYDGV	VHNAKTKPREEQVNSTYRVVSVLTVLHODWLNGKEXCKVKS	3.09
Db	4.35	DVSHDEPVEKFMWYDGV	VHNAKTKPREEQVNSTYRVVSVLTVLCHQDWLNGKEXCKVKS	4.94
QY	3.10	NKALPAPLEKITSKAKGQ	PREPOVYTLPPSRBELTKNOVSLCLVKGFPSPDIAVWESN	3.59
Db	4.95	NKALPAPLEKITSKAKGQ	PREPOVYTLPPSRBELTKNOVSLCLVKGFPSPDIAVWESN	5.54
QY	3.70	GQPENNYKTPVPLVSDGS	FPLYSKLTVDKSRMOQGNVSCSVMEHALNHYTKSLIS	4.29
Db	5.55	GQPENNYKTPVPLVSDGS	FPLYSKLTVDKSRMOQGNVSCSVMEHALNHYTKSLIS	6.14
QY	4.30	PG	4.31	
Db	6.15	PG	6.16	

```

/ RESULT 15
/ US-10-418-836-38
/ ; Sequence 38, Application US/10418836
/ ; Publication No. US20040018573a1
/ ; GENERAL INFORMATION:
/ ; APPLICANT: Power, Scott D.
/ ; APPLICANT: Wang, Huang
/ ; APPLICANT: Ward, Michael
/ ; TITLE OF INVENTION: Production of Functional Antibodies in
/ ; TITLE OF INVENTION: Filamentous Fungi
/ ; FILE REFERENCE: GC741-2
/ ; CURRENT APPLICATION NUMBER: US/10/418, 836
/ ; CURRENT FILING DATE: 2003-04-17
/ ; PRIOR APPLICATION NUMBER: US 60/373, 889
/ ; PRIOR FILING DATE: 2002-04-18
/ ; PRIOR APPLICATION NUMBER: US 60/411, 540
/ ; PRIOR FILING DATE: 2002-09-18
/ ; PRIOR APPLICATION NUMBER: US 60/452, 134
/ ; PRIOR FILING DATE: 2003-03-04
/ ; PRIOR APPLICATION NUMBER: US 60/411, 537
/ ; PRIOR FILING DATE: 2002-09-18
/ ; NUMBER OF SEQ ID NOS: 40
/ ; SOFTWARE: FastSeq for Windows Version 4.0
/ ; SEQ ID NO 38
/ ; LENGTH: 972
/ ; TYPE: PRT
/ ; ORGANISM: Artificial Sequence
/ ; FEATURE:
/ ; OTHER INFORMATION: fusion protein
/ US-10-418-836-38

```

Query Match	53.1%	Score 1282.5	DB 15	Length 972
Best Local Similarity	59.8%	Pred. No. 8.7e-82		
Match 274	Conservative 25	Mismatches 80	Indels 79	Gaps 10
QY	30 LGKKDTELCTCTSOAKSIQF--HWKNSNDIKILNGSGSELTGPKPSKLANDRADSRSL	86		
DB	537 LYKQSELTSLCTGVSFGLTNYGVHWNRQSPGKGLGEMIGVMKSGSTERYNAAFISRLTIS	596		
QY	87 --WQGNFPLIKLKLKIHSDPTYICEVEDQKEVQLVGLTANSDTHLQ--QGSLLT	142		
DB	597 KDTSNQVSLNLNLTAADTAVYVC-----ANNDRYAMDYGGTTLT	639		
QY	143 LESPGGSSPYQCRSPRGNIQGG-----KTLSSV-----QLEL	176		
DB	640 VSSASHTKPSFPLPLAPSKSTSGGTALGLCVKDYFPPEPTVYSNMGSLTSGVHTFPVL	699		
QY	177 QDSG-----TWCTYLNQKRYEFKIDIVPCPAPPPKCDKTHTC--	216		
DB	700 QSSGGLYLSAVVTVPSSSLGTQTYICNV--NHKSNTKVD-----KKVPPKCDKTHTCPP	753		

Qy	217	----	PELLGGSPVFLPPPKKDTLMTSRPELV	CVVVDVSHEDPEV	KNNYVDGVEV	HNK	273
Db	754	CPAPELLGGSPVFLPPPKKDTLMTSRPELV	CVVVDVSHEDPEV	KNNYVDGVEV	HNK	813	
Qy	274	TKPREQYNSTRVVS	VLTVLHQDMVNGEKYCKVSNKALPAPIETKISKAKQPREPOV			333	
Db	814	TKPREQYNSTRVVS	VLTVLHQDMVNGEKYCKVSNKALPAPIETKISKAKQPREPOV			873	
Qy	334	YTLPSRDELTKNQVSLTCLVKGF	YPSDIAVEMESNGOE	NNYKTPPV	LDSDGSF	FLYS	393
Db	874	YTLPSRDELTKNQVSLTCLVKGF	YPSDIAVEMESNGOE	NNYKTPPV	LDSDGSF	FLYS	933
Qy	394	KLTVDKSRWQGNVFS	CSYMHALHNHYQKSLSPG			431	
Db	934	KLTVDKSRWQGNVFS	CSYMHALHNHYQKSLSPG			971	
RESULT 16							
		US-10-418-836-39					
		/ Sequence 39, Application US/10418836					
		/ Publication No. US20040018573A1					
		/ GENERAL INFORMATION:					
		/ APPLICANT: Power, Scott D.					
		/ APPLICANT: Wang, Huang					
		/ APPLICANT: Ward, Michael					
		/ TITLE OF INVENTION: Production of Functional Antibodies in					
		/ TITLE OF INVENTION: Filamentous Fungi					
		/ FILE REFERENCE: GC741-2					
		/ CURRENT APPLICATION NUMBER: US/10/418, 836					
		/ PRIOR FILING DATE: 2003-04-17					
		/ PRIOR APPLICATION NUMBER: US 60/373, 889					
		/ PRIOR FILING DATE: 2002-04-18					
		/ PRIOR APPLICATION NUMBER: US 60/411, 540					
		/ PRIOR FILING DATE: 2002-09-18					
		/ PRIOR APPLICATION NUMBER: US 60/452, 134					
		/ PRIOR FILING DATE: 2003-03-04					
		/ PRIOR APPLICATION NUMBER: US 60/411, 537					
		/ PRIOR FILING DATE: 2002-09-18					
		/ NUMBER OF SEQ ID NOS: 40					
		/ SOFTWARE: FastSeq for Windows Version 4.0					
		/ SEQ ID NO: 39					
		/ LENGTH: 975					
		/ TYPE: PRT					
		/ ORGANISM: Artificial Sequence					
		/ FEATURE:					
		/ OTHER INFORMATION: fusion protein					
		US-10-418-836-39					
		Query Match	53.1%;	Score 1282.5;	DB 15;	Length 975;	
		Beet Local Similarity	59.8%;	Pred. No. 8.7e-82;			
		Matches 274; Conservative	25;	Mismatches 80;	Indels 79;	Gaps 10	
Qy	30	LGKKDDYBELTTAQKSIQF--HWKSNQIKLGNQSGFLTKPSKLNDRADSRSL--	86				
Db	540	LVPKETSILTCTVGSGFLTNVGVHWVROSPEKGLWIGVKKWSGSTENNAFISLTIS	599				
Qy	87	--WDGNFPLIKNKIKIEDSDTYICEVEDQKEVQLVGLTANSDTHLQ--GSLTPT	142				
Db	600	KDTSKNQVSLKLNLSLTADTAVYIC-----ARNDRIAMDYWGQSTLV	642				
Qy	143	LESPGSSPSVQCRSPRGNIQSG-----KTLAYS-----QLBL	176				
Db	643	VSSASTKPSVPEPLAPSSKSTSGGFGALGLVDYFPEPEVTYSMNSGALTSGVHPRAYL	702				
Qy	177	QDSG-----TWICTVLQNQKVEFKDIYPCAPPEKSCDKHTTC--	216				
Db	703	QSSGYSLSVVTVPSSSLSGTQYICNV--NHKPSNTKVD-----KKVEPKSCDKHTTCP	756				
Qy	217	---PELLGGSPVFLPPPKKDTLMTSRPELV	CVVVDVSHEDPEV	KNNYVDGVEV	HNK	273	
Db	757	CPAPELLGGSPVFLPPPKKDTLMTSRPELV	CVVVDVSHEDPEV	KNNYVDGVEV	HNK	816	
Qy	274	TKPREQYNSTRVVS	VLTVLHQDMVNGEKYCKVSNKALPAPIETKISKAKQPREPOV			333	

[illegible]

```

Query Match      53.1%; Score 1281.5; DB 12; Length 465;
Best Local Similarity 57.7%; Pred. No. 4e-82;
Matches 284; Conservative 24; Mismatches 79; Indels 105; Gaps 13;

QY      LLVLQLLPLPAATGKRVVLG---KKGDVVELCTASQKKSIOFHKNKSNQIKILINOG 66
DB      7  LLFLMAAAQSHAOIQLVQSGPEYVKKGGESVKISCKAS---GYTFYKGMWYKQAPGG 63
QY      67  -----SPLTKGSPKINDRADSRSLMDQGNF-----LLIKNLKIEDPTTYI 108
DB      64  LKMGWINTYTEETD-----FKGRFTFLIDTSTAYLEISSLRSEDATYF 114
QY      109 CEVEDQKEVQLLVFGLTANSDFHLIQGSLTLTLES PGSSSPSVQGRSPRGKNIQGG-- 166
DB      115 C-----ARFGAVD-----YMGQGLVLTVSASATKGPSVFLPFLAVSSKTSQGT 156
QY      167 -----KITLSV-----QLELDQSG-----TWTC 184
DB      159 ALGLVNDYFPEPVTAVSMNSGALTSGVHTFPALVQSSGLTSLSSVTVPPSSIGTQYIC 218
QY      185 TVLONOKKVEFKDIDVCPARPKSCDKTTC-----PELLGSPVLPFPKPKDTLMIS 239
DB      219 NV--NHRPSMTKVD---KVEPRKSCDKTKTTPCPAPRLLGGSVFLFPKPKDPTLMIS 272
QY      240 RTEPVTCAVVDVSHEDPEVKFENWYVDGVEVHNATKTKREEQVNSTYVVSVLTVLHODWL 299
DB      273 RTEPVTCAVVDVSHEDPEVKFENWYVDGVEVHNATKTKREEQVNSTYVVSVLTVLHODWL 332
QY      300 NGKEYKCKVSNKALPAIEIKTISKAKQPREPOVYTLPSRDELTKQVSLTCLVKGFPY 359
DB      333 NGKEYKCKVSNKALPAIEIKTISKAKQPREPOVYTLPSRDELTKQVSLTCLVKGFPY 392
QY      360 SDIAVEMESNGQEPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGVSCVMEHEALHN 419
DB      393 SDIAVEMESNGQEPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGVSCVMEHEALHN 452
QY      420 HYTKQSLSLSPG 431
DB      453 HYTKQSLSLSPG 464

```





Best Local Similarity 55.8%; Pred. No. 6.5e-82;  
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13;

```

QY 1 MNRGVPFRHLILVQLALLPATQGNKVLGKGGDTVELTCTASQKKSIOFHMKNSNOIK 60
DB 19 MSRGVD-----IVL-----TQSPPTTIAASPGKEKVTITTCRASSSVYMWYQOKS--- 62
QY 61 ILGNQSFLLTKGPKLNDRADSRSLMDQG-NFPLIINKLKIEDSDTYICE----- 110
DB 63 --GASPKLMIYDTSKLASGVNRFSGSGSGTSTSLAINTMETEDATATYCCQMSSTPLTF 120
QY 111 -----VEDOK-----BEVOLVFGLTANSDTHLLOQSITLTLESPPGSSP 151
DB 121 GSGTKLEIKRGGGSGGSGGSGGSOVLKEAGPGLVQPTQL---SLTCTVSGFSLSD 177
QY 152 SVQ-CRSPRGKNIQ-----GGKT-----LSVQLELDQSGT 181
DB 178 GVMHWRQPGKGLMWMGIITYDGGTDYNSAIKSLRSLSRDTSKQVFLKINSLOTDDTAM 237
QY 182 WTCVTVLQNKVVEFK-----IDIVPCAPAPKSCDKHTC-----PELLGSPSVFLPPPK 231
DB 238 YVCA-----RIHFYWGQVWVTVSSDQEPKSCDKHTCPCPCAPPELLGSPSVFLPPPK 291
QY 232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQYNSTYRVSVL 291
DB 232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQYNSTYRVSVL 351
QY 232 TVLHODMLNGEKYCKVSKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 351
DB 352 TVLHODMLNGEKYCKVSKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 411
QY 352 CLVKGFPYSDIAVEMESNQPENNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCS 411
DB 412 CLVKGFPYSDIAVEMESNQPENNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCS 471
QY 412 VMHEALHNHYTOKSLSLSPG 431
DB 472 VMHEALHNHYTOKSLSLSPG 491

```

RESULT 23  
US-10-108-260A-4292  
; Sequence 4292, Application US/10108260A  
; Publication No. US20040005560A1  
; GENERAL INFORMATION:  
; APPLICANT: HELIX RESEARCH INSTITUTE  
; TITLE OF INVENTION: No. US20040005560A1e1 full length cDNA  
; FILE REFERENCE: H1-A0106  
; CURRENT APPLICATION NUMBER: US/10/108,260A  
; CURRENT FILING DATE: 2002-03-27  
; NUMBER OF SEQ ID NOS: 5458  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4292  
; LENGTH: 470  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-108-260A-4292

Query Match 52.9%; Score 1277.5; DB 15; Length 470;  
Best Local Similarity 58.8%; Pred. No. 7.8e-87;  
Matches 281; Conservative 31; Mismatches 77; Indels 89; Gaps 14;

```

QY 15 QLALLPATQGNKVLGKGGDTVELTCTAS--QKKSIOFHMKN-----SNQIKIL 62
DB 20 QVQLVQSGR-----VKRGSVVKVSKRASGSSFSYFTWYKQAPGEGLEMGSIITPL 74
QY 63 GNQGSFLLTKGPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEVOLLV 122
DB 75 G-RPMYAGQFQDRVITSADESSI-----VYMDLRLTIEDTAIFYCAI-----LLE 120
QY 123 FGLTANSDTHLLQSGSLTITLESPPGSSPVQCRSPRGKNIQGS-----KTL 169
DB 121 HEVRLALFD-HWQGGTLTVVSSASTKG--PSVPLAPSSKSTSGGTALGLCLVKDYFPPPV 177

```

QY 170 SVS-----OLELDQSG-----TWTCVTVLQNKVVEFKID 198

DB 178 TVSNNSGALNSGVHTPPAVIQLSSGLYSLSVVYTPSSSLGTYICNV--NHKSNRKVD 235

QY 199 IVPCAPAPKSCDKHTC-----PELLGSPSVFLPPPKDTLMISRTPEVTCVVVDVSH 253

DB 236 ---KVEPKSCDKHTCPCPCAPPELLGSPSVFLPPPKDTLMISRTPEVTCVVVDVSH 291

QY 254 EDPVKFNMYVDGVEVHNAKTKRREQYNSTYRVSVLTVLHODMLNGEKYCKVSKAL 313

DB 292 EDPVKFNMYVDGVEVHNAKTKRREQYNSTYRVSVLTVLHODMLNGEKYCKVSKAL 351

QY 314 PAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVEMESNQPE 373

DB 352 PAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVEMESNQPE 411

QY 374 NNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCVMHEALHNHYTOKSLSLSPG 431

DB 412 NNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCVMHEALHNHYTOKSLSLSPG 469

RESULT 24  
US-10-207-655-345  
; Sequence 345, Application US/10207655  
; Publication No. US20030118592A1  
; GENERAL INFORMATION:  
; APPLICANT: Ledbetter, Jeffrey A.  
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS  
; FILE REFERENCE: 390069.401C1  
; CURRENT APPLICATION NUMBER: US/10/207,655  
; CURRENT FILING DATE: 2002-07-25  
; NUMBER OF SEQ ID NOS: 426  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 345  
; LENGTH: 543  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: fusion polypeptide  
US-10-207-655-345

Query Match 52.9%; Score 1277; DB 14; Length 543;  
Best Local Similarity 55.8%; Pred. No. 1e-81;  
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13;

```

QY 1 MNRGVPFRHLILVQLALLPATQGNKVLGKGGDTVELTCTASQKKSIOFHMKNSNOIK 60
DB 19 MSRGVD-----IVL-----TQSPPTTIAASPGKEKVTITTCRASSSVYMWYQOKS--- 62
QY 61 ILGNQSFLLTKGPKLNDRADSRSLMDQG-NFPLIINKLKIEDSDTYICE----- 110
DB 63 --GASPKLMIYDTSKLASGVNRFSGSGSGTSTSLAINTMETEDATATYCCQMSSTPLTF 120
QY 111 -----VEDOK-----BEVOLVFGLTANSDTHLLOQSITLTLESPPGSSP 151
DB 121 GSGTKLEIKRGGGSGGSGGSGGSOVLKEAGPGLVQPTQL---SLTCTVSGFSLSD 177
QY 152 SVQ-CRSPRGKNIQ-----GGKT-----LSVQLELDQSGT 181
DB 178 GVMHWRQPGKGLMWMGIITYDGGTDYNSAIKSLRSLSRDTSKQVFLKINSLOTDDTAM 237
QY 182 WTCVTVLQNKVVEFK-----IDIVPCAPAPKSCDKHTC-----PELLGSPSVFLPPPK 231
DB 238 YVCA-----RIHFYWGQVWVTVSSDLEPKSCDKHTCPCPCAPPELLGSPSVFLPPPK 291
QY 232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQYNSTYRVSVL 291
DB 292 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQYNSTYRVSVL 351
QY 352 TVLHODMLNGEKYCKVSKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 351

```

Dd	352	TVLHQDMLNKEKEXCKXSNLALPAPLEKTISAKAGPREPGYYTLPLPSRDELITRNQVSLT	411
Oy	352	CLYKGFPSDIAIAYEWESNGOPENNYKTPBPVLDSOSFYLISKLVDSRRMOQNVSCS	411
Dd	412	CLYKGFPSDIAIAYEWESNGOPENNYKTPFPVLDSOSFYLISKLVDSRRMOQNVSCS	477
Oy	412	VMEHALNHHTTKSLSLSPG	431
Dd	472	VMEHALNHHTTKSLSLSPG	491

RESULT 25 US-09-740-002-25  
 ; Sequence 25 Application US/09740002  
 ; Patent No. US20020001798A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: BRAMS, PETER  
 ; APPLICANT: MORROW, PHILLIP  
 ; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES  
 ; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR  
 ; TITLE OF INVENTION: MANUFACTURE AND THERAPEUTIC USE THEREOF  
 ; FILE REFERENCE: 037003-0275759  
 ; CURRENT APPLICATION NUMBER: US/09/740,002  
 ; CURRENT FILING DATE: 2000-12-20  
 ; PRIOR APPLICATION NUMBER: 09/335,697  
 ; PRIOR FILING DATE: 1999-06-18  
 ; PRIOR APPLICATION NUMBER: 08/488,376  
 ; PRIOR FILING DATE: 1995-06-07  
 ; NUMBER OF SEQ ID NOS: 27  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 25  
 ; LENGTH: 475  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 ; US-09-740-002-25

Query Match	52.9%;	Score 1276.5;	DB 9;	Length 475;
Best Local Similarity	57.1%;	Pred. No. 9.3e-82;		
Matches 281;	Conservative 27;	Mismatches 87;	Indels 97;	Gaps 12

```

QY 10 LLVLVLQALLPAPATGNKVLGKKQGVTLCTAS-----OKKSIOFHK 54
D 10 LVAVATRVLSQVQLOESGCVVVKPFETTLTLCTVSGFSLNSPRMGVTWTRQPKGLDW- 68
QY 55 NSNOIKITIGN-----QGSFPTYGSPKLANDRADSRSLMDQGNPILIIKULKIEDSDTYIC 109
D 69 -----LGNIFSSDEKSPSPSLKSLTTSODTSRS-----QVLSLTWVDPDITATYVC 116
QY 110 EVEDQKEEVQLLVFGLTANSPTHL-LQGSLSLTLTSPSPGSSPSVQCSRPGKNIOGS-- 166
D 117 -----ARVLVDINAYLYLYLDWGGGLTVTYSASTKGPBVFPLPSSKSTGGTA 168
QY 167 -----KTLVS-----QLELODSG-----TWTC 184
D 169 ALGLCVKDYFPEPVTVSNMSGALTSGVHTFPAYLQSGGLYLSLSVTVPSSLSGTGYIC 228
QY 185 TYLQKQKVEFKIDIVPCPAPRPKSCDKTHTC-----PELIGSPSFLTPPKKOTLMTS 239
D 229 NV--NHKSNSTVVD---KKAEPKSCDKHKTCPCPAPRLGGSFVLFPPPKOTLMTS 282
QY 240 RTPEVTCVVDVSHEDPEVKFPMVYDGVENHNAKTRPREQVNSTRVVSVLTVLHQDWL 299
D 283 RTPEVTCVVDVSHEDPEVKFPMVYDGVENHNAKTRPREQVNSTRVVSVLTVLHQDWL 342
QY 300 NGKEVKCKVSNKALPAPIEKITSKAKGQRPQVYTLPPSRDELTKNOVSLTCLVKGFPY 359
D 343 NGKEVKCKVSNKALPAPIEKITSKAKGQRPQVYTLPPSRDELTKNOVSLTCLVKGFPY 402
QY 360 SDIAVEMESNGQPENNYKTPPVLVDSGDSFFLYSKLTVPKSRQOQGNVFSCSMHBAHLN 419
D 403 SDIAVEMESNGQPENNYKTPPVLVDSGDSFFLYSKLTVPKSRQOQGNVFSCSMHBAHLN 462
QY 420 HYTKQSLSLSPG 431

```

Db 463 HYTQKSLSLSPG 474

```

RESULT 26
US-10-325-698-25
; Sequence 25, Application US/10325698
; Publication No. US20040076631A1
; GENERAL INFORMATION:
; APPLICANT: BRAMS, PETER
; APPLICANT: MORROW, PHILLIP
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR
; TITLE OF INVENTION: MANUFACTURE AND THERAPEUTIC USE THEREOF
; FILE REFERENCE: 037003-0275759
; CURRENT APPLICATION NUMBER: US/10/325, 698
; CURRENT FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US/09/740, 002
; PRIOR FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 09/335,697
; PRIOR FILING DATE: 1999-06-18
; PRIOR APPLICATION NUMBER: 08/488,376
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: SeqIdn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 475
; TYPE: PRN
; ORGANISM: Homo sapiens
US-10-325-698-25

```

Query Match	52.9%;	Score 1276.5;	DB 16;	Length 475;
Best Local Similarity	57.1%;	Pred. No. 9.3e-82;		
Matches 281; Conservative	27;	Mismatches 87;	Indels 97;	Gaps 12;

Qy	10	LLVLVLQTLALPLAAQGNVYVJGKKGDYELCTAS-----QKXSIOFHFK	54
Db	10	LVAVATRLSQQVLOESGPVVVKPFETILTICTYSGFSLSNRMGVMTWOPPGKALEH-	68
Qy	55	NSNOIKILGN-----QGSFLTGKSPKLNDRADSRRLMDQGNPLIIKNLKITEDSDTYIC	109
Db	69	-----LGNFSSDEKSFSPSLKSRILTTSODTSRS-----QVVLSTVWDVDVDTATYYC	116
Qy	110	EVEDQKEVOLVLFGLTANSDTHL-LOGOSLTLTLESPGSSPSVQCSPREKNOGG--	166
Db	117	-----ARVGLVDINAYLYLYLDYMGQGLTVYSSSTKGPSVPLAPSSKSTSGTRA	168
Qy	167	-----KTLSS-----OLELODQG-----TWTC	184
Db	169	ALGCLVNDYFPEPYLTVSNMNGALTSGVHTPAVLQSSGLYSLSVTVWPSSSLGTQTYIC	228
Qy	185	TVLONOKKVEKIDIVPCPAPBPSCDTHHC-----PELLGSPVLLPBPXKDTLMS	239
Db	229	NV--NHRPSNKTVD--KKAEPSSCDTHHTCPCPAPBELLGSPVFLPBPXKDTLMS	282
Qy	240	RTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTRPREEOYNSTRVVSVTLVLHODWL	299
Db	283	RTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTRPREEOYNSTRVVSVTLVLHQEWL	342
Qy	300	NGKEYKCVNSKALPAPIEKTISAKAGQPREPOVYTLTPPSRDELTKNOVSLTCLYKGFIP	359
Db	343	NGKEYKCVNSKALPAPIEKTISAKAGQPREPOVYTLTPPSRDELTKNOVSLTCLYKGFIP	402
Qy	360	SDIAVEMESNQPENNYKTRPPVLDSDSFLYSLKLYVDKSRMOQGNFSCVMHEALTN	419
Db	403	SDIAVEMESNQPENNYKTRPPVLDSDSFLYSLKLYVDKSRMOQGNFSCVMHEALHN	462
Qy	420	HYTQKSLSLSPG	431
Db	463	HYTQKSLSLSPG	474

## RESULT 27

US-10-138-727A-41  
; Sequence 41, Application US/10138727A  
; Publication No. US20030157054A1  
; GENERAL INFORMATION:  
; APPLICANT: Gillies, Stephen  
; APPLICANT: Lo, Kin-Ming  
; APPLICANT: Qian, Susan  
; TITLE OF INVENTION: Recombinant Tumor Specific Antibody And Use Thereof  
; FILE REFERENCE: LEX-019  
; CURRENT APPLICATION NUMBER: US/10/138,727A  
; PRIOR FILING DATE: 2002-05-03  
; PRIOR APPLICATION NUMBER: US 60/288,564  
; NUMBER OF SEQ ID NOS: 42  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 41  
; LENGTH: 579  
; TYPE: PRT  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: heavy chain-IL2  
US-10-138-727A-41

Query Match 52.8%; Score 1275.5; DB 14; Length 579;  
Best Local Similarity 57.7%; Pred. No. 1.4e-81;  
Matches 281; Conservative 29; Mismatches 70; Indels 107; Gaps 14;

QY 32 KKGDIIVELCTASQKKSIOF--HMKNSNQIKILGNQ--SFLTKGSKLNDRADSRRLW 87  
DB 13 KGEIVTKISCAKSGYTFNNYGMWVKQTPGKGLKMMGINTYTGPTAAD----- 63  
QY 88 DQGNFP-----LIKKLKIEDSDTYICEVEDQKEEYQLVFGLTANSIDLHLLQ 136  
DB 64 FKGRFAFSLSTSTAFIQLNNLASEDPATYFC-----VRFISKG-----DYWGQ 109  
QY 137 QSLITLTSPGSSSVOCRSPRGKNIQGG-----KTLVS----- 172  
DB 110 TSVTVSSASATKG--PSVFPPLAPSSKSTGGTALCLVADYFPEPVTVMNSGALTSGVH 167  
QY 173 --QLELDQSG-----TWCTVQLNQKVEFKIDIVCPAPPEPKSCDK 212  
DB 168 TFPRAVLQSSGLYSLSSVTVTPSSLSGTQTYICNV--NHRPSNTKVD---KVEPKSCDK 221  
QY 213 THTC-----PELLGSPSVFLPPPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFNNYVVDG 267  
DB 222 THTCPCPAPBELDGGPSVFLPPPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFNNYVVDG 281  
QY 268 EYHNAKTKPREQYNSTRYVSVLTVLHODWLNGEKYCKVSNKALPAPIEKTISKAKG 327  
DB 282 EYHNAKTKPREQYNSTRYVSVLTVLHODWLNGEKYCKVSNKALPAPIEKTISKAKG 341  
QY 328 PREPOVYTLPRRDDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 387  
DB 342 PREPOVYTLPRRDDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 401  
QY 388 SFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPG-----LQLD 435  
DB 402 SFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPGAKAPSSSTKKTQLDLE 461  
QY 436 ETCARQ 442  
DB 462 HLLDLQ 468

RESULT 28  
US-10-334-235-38  
; Sequence 38, Application US/10334235  
; Publication No. US20040131591A1  
; GENERAL INFORMATION:  
; APPLICANT: Oxford Biomedica (UK) Ltd.  
; APPLICANT: Kingsman, Alan  
; APPLICANT: Beedington, Christopher  
; APPLICANT: Carroll, Miles

; APPLICANT: Ellard, Fiona  
; APPLICANT: Kingsman, Susan  
; APPLICANT: Myers, Kevin  
; APPLICANT: Lamikandra, Abigail  
; TITLE OF INVENTION: VECTOR SYSTEM  
; FILE REFERENCE: 53268200920  
; CURRENT APPLICATION NUMBER: US/10/334,235  
; PRIOR FILING DATE: 2002-12-30  
; PRIOR APPLICATION NUMBER: US 10/060,585  
; PRIOR FILING DATE: 2002-01-29  
; PRIOR APPLICATION NUMBER: PCT/GB00/04317  
; PRIOR FILING DATE: 2000-11-13  
; PRIOR APPLICATION NUMBER: US 09/445,375  
; NUMBER OF SEQ ID NOS: 40  
; SOFTWARE: PasteSeq for Windows Version 4.0  
; SEQ ID NO 38  
; LENGTH: 600  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: peptide of 574sabl  
US-10-334-235-38

Query Match 52.8%; Score 1275; DB 16; Length 600;  
Best Local Similarity 59.4%; Pred. No. 1.6e-81;  
Matches 277; Conservative 18; Mismatches 81; Indels 90; Gaps 11;

QY 23 TQGNKVVLGKGDIVELCTASQKKSIOFHMKNSNQIKILGNOSFLTKGSKLNDRADSR 82  
DB 162 TQTPFLVSAAGDVTITCKASQSVSNDVAMYQKP-----GQSPFLILISTYSS 210  
QY 83 R-RLMDQ-----GNFPLIKLKIEDSDTYICEVEDQKEEYQLVFGLTANSIDLHLL 134  
DB 211 RYAEVPPRFIGSGYGTDFITISTLQAEADLAIVYCOOD-----YNSPTFG 256  
QY 135 QGQSLTTLSPGSSSVOCRSPRGKNIQGG-----KTLVS----- 172  
DB 257 GGTLEIKRASTKG--PSVFPPLAPSSKSTGGTALCLVADYFPEPVTVMNSGALTSG 314  
QY 173 --QLELDQSG-----TWCTVQLNQKVEFKIDIVCPAPPEPKSCDK 210  
DB 315 VHTFPRAVLQSSGLYSLSSVTVTPSSLSGTQTYICNV--NHRPSNTKVD---KVEPKSCDK 368  
QY 211 DKTHTC-----PELLGSPSVFLPPPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFNNYVD 265  
DB 369 DKTHTCPCAPBELDGGPSVFLPPPKPKDITLMSRTPEVTCVVVDVSHEDPEVKFNNYVD 428  
QY 266 GVEYHNAKTKPREQYNSTRYVSVLTVLHODWLNGEKYCKVSNKALPAPIEKTISKAK 325  
DB 429 GVEYHNAKTKPREQYNSTRYVSVLTVLHODWLNGEKYCKVSNKALPAPIEKTISKAK 488  
QY 326 GQPREPOVYTLPRRDDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 385  
DB 489 GQPREPOVYTLPRRDDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 548  
QY 386 DGSFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPG 431  
DB 549 DGSFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPG 594

RESULT 29  
US-10-320-231A-79  
; Sequence 79, Application US/10320231A  
; Publication No. US20030194405A1  
; GENERAL INFORMATION:  
; APPLICANT: Neben, Steven  
; APPLICANT: Takeuchi, Toshihiko  
; APPLICANT: Tomkinson, Adrian  
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For  
; FILE REFERENCE: 7430\*163  
; CURRENT APPLICATION NUMBER: US/10/320,231A



```
/ CURRENT FILING DATE: 2002-12-19
/ PRIOR APPLICATION NUMBER: US 60/342,174
/ PRIOR FILING DATE: 2001-12-17
/ NUMBER OF SEQ ID NOS: 85
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 79
/ LENGTH: 445
/ TYPE: PR
/ ORGANISM: Artificial
/ FEATURE:
/ OTHER INFORMATION: synthetic sequence
US-10-320-231A-79
```

```
Query Match          52.8%; Score 1274.5; DB 14; Length 445;
Best Local Similarity 59.2%; Pred. No. 1.2e-81;
Matches 277; Conservative 27; Mismatches 67; Indels 97; Gaps 13;
```

```
QY 30 LKKGDPVLELTCTAS-----OKKSIOFHMKNSNOIKILNOSGFL-----TKG 72
| : : : : : | : : : : : | : : : : : | : : : : : |
DB LVQPGGSLRLSCAASGFTSSYAMSVNRQAPKGLEWVSA-----IGSGSGSTYYADSVKG 63

QY 73 PSKLRADSRSLMDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGILTANSDFH 132
| : : : : : | : : : : : | : : : : : | : : : : : |
DB RFTIS-RDMSKNTLYLQMN-----SLRAEDTAVYYCARDD-----FFAHFD-- 103

QY 133 LLOGSLTLTLSPSSPSVOCSPRGKNIQSG-----KTLVS----- 172
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 104 -VWGQQLTVVSSASTKGPSVFPPLAPSSKSTSGTALGCLVKDYPEPEVTVSWNSGALT 162

QY 173 -----QLELDQSG-----TWCTVLONOKVFEKIDIVPCPAPERK 208
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 163 SGVHFRPALVQSGGLXSLSSVTVFPSSSLGTQYICNV--NHKPSNTKYD---KVEERK 216

QY 209 SCDKHTTC-----PELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNY 263
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 217 SCDKHTCPCPAPPELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNY 276

QY 264 VGVGVHNAKTKRREQYVSTRVAVSLTVLHODMNLGKYEKCKVSNKALPAPIETIKSK 323
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 277 VGVGVHNAKTKRREQYVSTRVAVSLTVLHODMNLGKYEKCKVSNKALPAPIETIKSK 336

QY 324 AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 383
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 337 AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 396

QY 384 DSDGSFFLYSKLTVDKSRWQOGNVFSCSYMHREALHNYTQKSLISLSPG 431
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 397 DSDGSFFLYSKLTVDKSRWQOGNVFSCSYMHREALHNYTQKSLISLSPG 444
```

```
RESULT 30
US-10-150-475A-6
/ Sequence 6, Application US/10150475A
/ Publication No. US20030103985A1
/ GENERAL INFORMATION:
/ APPLICANT: Adolf, G. et al.
/ TITLE OF INVENTION: Cytotoxic CD44 Antibody Immunoconjugates
/ FILE REFERENCE: 1/1211
/ CURRENT APPLICATION NUMBER: US/10/150,475A
/ CURRENT FILING DATE: 2002-05-17
/ PRIOR APPLICATION NUMBER: US 60/307,451
/ PRIOR FILING DATE: 2001-07-24
/ NUMBER OF SEQ ID NOS: 9
/ SOFTWARE: PatentIn Ver. 2.1
```

```
/ SEQ ID NO 6
/ LENGTH: 444
/ TYPE: PR
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Humanised
/ OTHER INFORMATION: Murine Antibody BIWA 4 Heavy Chain SEQ ID NO: 6
US-10-150-475A-6
```

```
Query Match          52.8%; Score 1273.5; DB 14; Length 444;
Best Local Similarity 59.3%; Pred. No. 1.4e-81;
Matches 275; Conservative 27; Mismatches 69; Indels 93; Gaps 13;
```

```
QY 30 LKKGDPVLELTCTAS-----KNSIOFHMKNSNOIKILNOSGFL-----TKGPKL 76
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 11 LVQPGGSLRLSCAASGFTSSYDMSVNRQAPKGLEWSTISSGSGSTYYLDSIKGRFTI 70

QY 77 NDRADSRSLMDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGILTANSDFHLOG 136
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 71 S-RDMSKNTLYLQMN-----SLRAEDTAVYYCARQ-----GLD-----YWG 105

QY 137 OSULTLTLSPSSPSVOCSPRGKNIQSG-----KTLVS----- 172
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 106 RGLTVTVSSASTKGPSVFPPLAPSSKSTSGTALGCLVKDYPEPEVTVSWNSGALTSGVH 165

QY 173 --QLELDQSG-----TWCTVLONOKVFEKIDIVPCPAPERKSCDK 212
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 166 TFPVAVLQSGGLXSLSSVTVFPSSSLGTQYICNV--NHKPSNTKYD---KVEERKSCDK 219

QY 213 THTC-----PELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYVDGV 267
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 220 THTCPCPAPPELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYVDGV 279

QY 268 EYHNAKTKRREQYVSTRVAVSLTVLHODMNLGKYEKCKVSNKALPAPIETIKSKAKQ 327
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 280 EYHNAKTKRREQYVSTRVAVSLTVLHODMNLGKYEKCKVSNKALPAPIETIKSKAKQ 339

QY 328 PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPVLDSDG 387
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 340 PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPVLDSDG 399

QY 388 SFFLYSKLTVDKSRWQOGNVFSCSYMHREALHNYTQKSLISLSPG 431
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 400 SFFLYSKLTVDKSRWQOGNVFSCSYMHREALHNYTQKSLISLSPG 443
```

```
RESULT 31
US-10-704-522-6
/ Sequence 6, Application US/10704522
/ Publication No. US20040120949A1
/ GENERAL INFORMATION:
/ APPLICANT: Baumann, Michael
/ APPLICANT: Heider, Karl-Heinz
/ TITLE OF INVENTION: Compositions and methods for treating cancer using
/ FILE REFERENCE: 1/1414
/ CURRENT APPLICATION NUMBER: US/10/704,522
/ CURRENT FILING DATE: 2003-11-07
/ PRIOR APPLICATION NUMBER: US 60/429,516
/ PRIOR FILING DATE: 2002-11-27
/ PRIOR APPLICATION NUMBER: EP 02024881
/ PRIOR FILING DATE: 2002-11-08
/ NUMBER OF SEQ ID NOS: 9
/ SOFTWARE: PatentIn Ver. 2.1
```

```
/ SEQ ID NO 6
/ LENGTH: 444
/ TYPE: PR
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Humanised Murine Antibody BIWA 4 Heavy Chain
US-10-704-522-6
```

```
Query Match          52.8%; Score 1273.5; DB 16; Length 444;
Best Local Similarity 59.3%; Pred. No. 1.4e-81;
Matches 275; Conservative 27; Mismatches 69; Indels 93; Gaps 13;
```

```
QY 30 LKKGDPVLELTCTAS-----KNSIOFHMKNSNOIKILNOSGFL-----TKGPKL 76
| : : : : : | : : : : : | : : : : : | : : : : : |
DB 11 LVQPGGSLRLSCAASGFTSSYDMSVNRQAPKGLEWSTISSGSGSTYYLDSIKGRFTI 70

QY 77 NDRADSRSLMDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGILTANSDFHLOG 136
```

Db 71 S-RDAAKSLVYQNM-----SLRAEDTAIVYVCARQ-----GLD-----YWG 105  
Qy 137 QSLITLESPPSSSSVQCRRKGNKIOGG-----KTLSS----- 172  
Db 106 RGLTVSSASTKGPVFPPLAPSSKSTSGGTALACLVKDYFPPEVTVSNMNGALTSGVH 165  
Qy 173 --QLELDQSG-----TWCTVLQONOKVVEFKDIYPCAPAPFKSCDK 212  
Db 166 TFPVALQSSGLYSLSVTVVPSSSLGTQTYICNV--NHKPSNTKYD----KVEPKSCDK 219  
Qy 213 THTC-----PELLGSPVFLPFPKPKDTLMSRTPETCVVVDVSHEDPEVKFMVYDGV 267  
Db 220 THTCPCPAPABELLGSPVFLPFPKPKDTLMSRTPETCVVVDVSHEDPEVKFMVYDGV 279  
Qy 268 EVHNAKTRPREQVNSTYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQ 327  
Db 280 EVHNAKTRPREQVNSTYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQ 339  
Qy 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSG 387  
Db 340 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSG 399  
Qy 368 SFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTQKSLSPG 431  
Db 400 SFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTQKSLSPG 443

## RESULT 32

US-10-645-215-6  
; Sequence 6, Application US/10645215  
; Publication No. US20040126379A1  
; GENERAL INFORMATION:  
; APPLICANT: Adolf, Guenther  
; APPLICANT: Baum, Anke  
; TITLE OF INVENTION: Helder, Karl-Heinz  
; TITLE OF INVENTION: Compositions and Methods for Treating Cancer using  
; TITLE OF INVENTION: Cytotoxic CD4 Antibody Immunocongulates and  
; FILE REFERENCE: 1/1383  
; CURRENT APPLICATION NUMBER: US/10/645,215  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: EP 02 018 686.2  
; PRIOR FILING DATE: August 21, 2002  
; PRIOR APPLICATION NUMBER: US 60/405,956  
; PRIOR FILING DATE: August 26, 2002  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: Patentin Ver. 2.1  
; SEQ ID NO 6  
; LENGTH: 444  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Humanised Murine Antibody B1W4 4 Heavy Chain  
US-10-645-215-6

Query Match 52.8%; Score 1273.5; DB 16; Length 444;  
Best Local Similarity 59.3%; Pred. No. 1.4e-81;

Matches 275; Conservative 27; Mismatches 69; Indels 93; Gaps 13;

Qy 30 LGKKDITVELTCTAS--QKSIQFMW-----KNSNQIKILNQGSL-----TKGPKL 76  
Db 11 LKPGGSLRLSCAAGFTFSSYDMWVNAQPKGLBWTSTISSGSIYYLDSIGRFTI 70  
Qy 77 NDRADSRSLMDQGNFPLIKLKIEDSDTYICEVEDQKEVQLVFGLTANSDTHLQ 136  
Db 71 S-RDAAKSLVYQNM-----SLRAEDTAIVYVCARQ-----GLD-----YWG 105  
Qy 137 QSLITLESPPSSSSVQCRRKGNKIOGG-----KTLSS----- 172  
Db 106 RGLTVSSASTKGPVFPPLAPSSKSTSGGTALACLVKDYFPPEVTVSNMNGALTSGVH 165  
Qy 173 --QLELDQSG-----TWCTVLQONOKVVEFKDIYPCAPAPFKSCDK 212

Db 166 TFPVALQSSGLYSLSVTVVPSSSLGTQTYICNV--NHKPSNTKYD----KVEPKSCDK 219  
Qy 213 THTC-----PELLGSPVFLPFPKPKDTLMSRTPETCVVVDVSHEDPEVKFMVYDGV 267  
Db 220 THTCPCPAPABELLGSPVFLPFPKPKDTLMSRTPETCVVVDVSHEDPEVKFMVYDGV 279  
Qy 268 EVHNAKTRPREQVNSTYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQ 327  
Db 280 EVHNAKTRPREQVNSTYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQ 339  
Qy 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSG 387  
Db 340 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSG 399  
Qy 368 SFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTQKSLSPG 431  
Db 400 SFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTQKSLSPG 443

## RESULT 33

US-09-740-002-27  
; Sequence 27, Application US/09740002  
; Patent No. US20020001798A1  
; GENERAL INFORMATION:  
; APPLICANT: BRAMS, PETER  
; APPLICANT: MORROW, PHILLIP  
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES  
; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR  
; FILE REFERENCE: 037003-0275759  
; CURRENT APPLICATION NUMBER: US/09/740,002  
; CURRENT FILING DATE: 2000-12-20  
; PRIOR APPLICATION NUMBER: 09/335,697  
; PRIOR FILING DATE: 1999-06-18  
; PRIOR APPLICATION NUMBER: 08/488,376  
; PRIOR FILING DATE: 1995-06-07  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: Patentin Ver. 2.1  
; SEQ ID NO 27  
; LENGTH: 475  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-740-002-27

Query Match 52.8%; Score 1273.5; DB 9; Length 475;  
Best Local Similarity 57.1%; Pred. No. 1.5e-81;  
Matches 276; Conservative 29; Mismatches 99; Indels 79; Gaps 11;

Qy 10 LLAIVQLALPAAATQGNKVVLGKKDITVELTCTAS--QKSIQFMKNSNQIKIL-- 62  
Db 10 LVAIVATRVLSGVQVQESGPAIVKPTQTLTCTSSGSLSRGNSVMWIRPPKALEWL 69  
Qy 63 ---GNQSPITKG--PSKLNDRADSRSLMDQGNFPLIKLKIEDSDTYICEVEDQKEE 117  
Db 70 ARIDMDDTFYSASLKTRLSISKOTSXN-----QVLRMTNVVDVDTATYCAASLYDS 124  
Qy 118 VQLLVFGLTANSDTHLQGSITLLESPPSSSPVQCRRKGNKIOGG----- 166  
Db 125 DSFLYF-----YHAYWGGTIVTVSSASTKGPVFPPLAPSSKSTSGGTALACLVKDY 177  
Qy 167 --KTLSS-----QLELDQSG-----TWCTVLQONOKV 193  
Db 178 PREPVTVSNMNGALTSGVHFPVALQSSGLYSLSVTVVPSSSLGTQTYICNV--NHKPS 235  
Qy 194 EFKIDIVPCAPAPFKSCDKTHTC-----PELLGSPVFLPFPKPKDTLMSRTPETCVV 248  
Db 236 NTKVD-----KKAEPKSCDKTHTCPCPAPABELLGSPVFLPFPKPKDTLMSRTPETCVV 291  
Qy 249 VDVSHEDPEVKFMVYDGVVEHNAKTRPREQVNSTYRVVSVLTVLHODWLNKGEYKCKV 308  
Db 292 VDVSHEDPEVKFMVYDGVVEHNAKTRPREQVNSTYRVVSVLTVLHODWLNKGEYKCKV 351

```
QY 309 SNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 368
|||
DB 352 SNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 411
|||
QY 369 NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGVNFSSCVMEHALHNYTQKSL 428
|||
DB 412 NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGVNFSSCVMEHALHNYTQKSL 471
|||
QY 429 SPG 431
|||
DB 472 SPG 474

RESULT 34
US-10-325-698-27
; Sequence 27, Application US/10325698
; Publication No. US20040076631A1
; GENERAL INFORMATION:
; APPLICANT: BRAMS, PETER
; APPLICANT: MORROW, PHILIP
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR
; FILE REFERENCE: 037003-0275759
; CURRENT APPLICATION NUMBER: US/10/325,698
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US/09/740,002
; PRIOR FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 09/335,697
; PRIOR FILING DATE: 1999-06-18
; PRIOR APPLICATION NUMBER: 08/488,376
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 475
; TYPE: PR
; ORGANISM: Homo sapiens
US-10-325-698-27

Query Match 52.8%; Score 1273.5; DB 16; Length 475;
Best Local Similarity 57.1%; Pred. No. 1.5e-81;
Matches 276; Conservative 29; Mismatches 99; Indels 79; Gaps 11;

QY 10 LLLVLDLALLPAATQGNKVVYLGKKDVELTCTAS-----QKSIQFHMKNSNOIKL--- 62
|||
DB 10 LVAVATRVLSQVQLQESGPALVPQTTLTCTFSGPSLSTRGMSVNWIRQPGKALEW 69
|||
QY 63 ---GNQGSFLLTKG-PSKLNDRADSRSLWDQGNFPLIINKLKIEDSDTYICEVEDQKEE 117
|||
DB 70 ARIDMDDTFFYSASLTKRLSISKDTSKN-----QVVLKMTNVDPVTATYFCARASLYDS 124
|||
QY 118 VOLIVEGLTANSDDLHLLQGSLLTLLSPGSSPSVQCSPRGKNIQGG----- 166
|||
DB 125 DSFYLF-----YHAWGQGVTVTVSSASTKGSVFPLAPSEKSTSGGTAALGCLVKDY 177
|||
QY 167 --KTLSSV-----QLELDSC-----TTCVTYLNQOKV 193
|||
DB 178 FEPFVTVSNWNSGALITGVHTFPFPAVLQSSGLYSLSVTVSSSLGTQTYICNV--NHKPS 235
|||
QY 194 EFLIDIVPCPAPRPKSCDKTHTC-----PELLGSPVFLFPPPKDITLMISRTPEVTCV 248
|||
DB 236 NTKYD-----KKAEPKSCDKTHTCPCPAPPELLGSPVFLFPPPKDITLMISRTPEVTCV 291
|||
QY 249 VDVSHEDEPVKFMVYDGEVHNNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKV 308
|||
DB 292 VDVSHEDEPVKFMVYDGEVHNNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKV 351
|||
QY 309 SNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 368
|||
DB 352 SNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 411
|||
QY 369 NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGVNFSSCVMEHALHNYTQKSL 428
|||
```

```
DB 412 NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGVNFSSCVMEHALHNYTQKSL 471
|||
QY 429 SPG 431
|||
DB 472 SPG 474

RESULT 35
US-10-683-255-6
; Sequence 6, Application US/10683255
; Publication No. US20040063910A1
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh, William M.
; APPLICANT: Ballinger, Marcus
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: PP01474.101
; CURRENT APPLICATION NUMBER: US/10/683,255
; PRIOR FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: 09/499,846
; PRIOR FILING DATE: 2000-02-07
; PRIOR APPLICATION NUMBER: 60/119,002
; PRIOR FILING DATE: 1999-02-08
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 497
; TYPE: PR
; ORGANISM: Homo sapiens
US-10-683-255-6

Query Match 52.8%; Score 1273.5; DB 12; Length 497;
Best Local Similarity 57.5%; Pred. No. 1.6e-81;
Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;

QY 15 QIALPAPATQGNKVVYLGKKDVELTCTASQKSIQFHMKNSNOIK-----ILGNQGSFL 69
|||
DB 45 KHAVPAA-----KTVKFCPSSTGPNFTLKLNGKGFKPDHRIGYKRVYA 92
|||
QY 70 TKG-----PSKLNDRADSRSLWDQGNFPLIINKLKIEDSDTYICEVEDQKEEVOLLY 122
|||
DB 93 TSIIMDSVPS-----DKGNYTCIVENXGSIHNTYQLDIVERSPHRPILQ 139
|||
QY 123 FGLTANSDDLHLLQGSLLTLLSP-----GSS-----PSVQCRSRGKNI 163
|||
DB 140 ACLPANKTVVALGSNVEFMCKVYSDPQPHIQLMKHIEVNGSKIGPNLPPVQILKTAGVNT 199
|||
QY 164 ---QGGKTLSSVQLQESGTVTC-----TVLNQKKVEFKIDIVPCP--- 203
|||
DB 200 TKMEVHLNRVNSFEDAGEYTCLAGNSIGLSHSAMLTVLE--ALERRPAVMTSPLYL 256
|||
QY 204 -----APEPKSCDKTHTC-----PELLGSPVFLFPPPKDITLMISRTPEVTCV 251
|||
DB 251 EGGSPGLQEPKSCDKTHTCPCPAPPELLGSPVFLFPPPKDITLMISRTPEVTCV 316
|||
QY 252 SHEDEPVKFMVYDGEVHNNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKVSNK 311
|||
DB 317 SHEDEPVKFMVYDGEVHNNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKVSNK 376
|||
QY 312 ALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQ 371
|||
DB 377 ALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQ 436
|||
QY 372 PENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGVNFSSCVMEHALHNYTQKSLSPG 431
|||
DB 437 PENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGVNFSSCVMEHALHNYTQKSLSPG 496
|||
```

```
RESULT 36
US-10-683-255-4
; Sequence 4, Application US/10683255
; Publication No. US20040063910A1
```



```

Db      11 LAVAPEGANSGAOLLSGSEVVRKPGASVKSCKAS---GPDFTRDPLQWVRQABGQGLEMM 67
Qy      66 GSFUTKPSKLT-----NDRADSRRLMDQGNFPLIITKLIKIEDSDTYC--EVED 113
Db      68 GFIDPSSGSLTYKONFGRTMTREKSTTTVY-----MELSSLSKSEDTATYFCCGSVN 120
Qy      114 QKEEVOVLVGLTANSDTHLLQOSLTLTLESPPGSSPSVQCRSPRGKNIQGG-----166
Db      121 -----IVSTTSGGPDCLMDGGTVTVTSSASTKGPVFLPLAPSKSISGGTALGLCL 172
Qy      167 -----KTLSSV-----QLELDSC-----TWCTVYLON 189
Db      173 VMDYFPEPVTVSNMNSGALTSGVHTFPAYVLSQSGISLSSVTVTPSSSLGTQTYICNV--N 230
Qy      190 QKVEFKIDIVPCPAPRPSKCDKTHTC-----BELLGSPVFLPPPKKOTLMISRPV 244
Db      231 HKSNSTKVD---KKVEPSSCDKTHTCPPCPAPBELLGSPVFLPPPKKOTLMISRPV 286
Qy      245 TCVVVDVSHEDPEVKFMWYVDGVEVHNAKTPREEQNSTYRVSVLTVLHODMLNGKEY 304
Db      287 TCVVVDVSHEDPEVKFMWYVDGVEVHNAKTPREEQNSTYRVSVLTVLHODMLNGKEY 346
Qy      305 KCVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAY 364
Db      347 KCVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAY 406
Qy      365 EMESNGOPENNYKTPPVLDSDGSFLYSKLTVDKSRMOQGNVFCSSVMHEALHNHYTOK 424
Db      407 EMESNGOPENNYKTPPVLDSDGSFLYSKLTVDKSRMOQGNVFCSSVMHEALHNHYTOK 466
Qy      425 SLSLSPG 431
Db      467 SLSLSPG 473

RESULT 39
US-10-660-128-12
; Sequence 12, Application US/10660128
; Publication No. US20040120947A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Chuncharapai, Anan
; APPLICANT: Dodge, Kelly
; APPLICANT: Kim, Kyung Jin
; TITLE OF INVENTION: DR4 Antibodies and Uses Thereof
; FILE REFERENCE: PI245R1P2B
; CURRENT APPLICATION NUMBER: US/10/660,128
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: US/09/584,166
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: US 09/322,875
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/237,299
; PRIOR FILING DATE: 1999-01-25
; PRIOR APPLICATION NUMBER: US 60/072,481
; PRIOR FILING DATE: 1998-01-26
; NUMBER OF SEQ ID NOS: 12
; SEQ ID NO 12
; LENGTH: 476
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
; NAME/KEY: Misc_Feature
; LOCATION: 20
; OTHER INFORMATION: Xaa may be glutamine or glutamic acid
US-10-660-128-12

Query Match      52.7%; Score 1272; DB 16; Length 476;
Best Local Similarity 60.4%; Pred. No. 1.9e-81;
Matches 273; Conservative 29; Mismatches 82; Indels 68; Gaps 12;

```

```

Qy      36 TWELTCTAS--QKSIQIFMKNSNOIKILGNQGSFLTKPSKLTNDRADSRRL--WDQGNF 92
Db      36 SLSITCTVSGFSLTSGVHWARQPPCKGLEMLGVIMAVGSTYNNKALMRLSLSKDNKGS 95
Qy      93 PLIIR--NIKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLLQ--GQSLTLTLESPPG 148
Db      96 QVFLKNNSIQTDITAMYYCARREGFD-----YGSLSLS--YHSMFWCGGTSTVSSAKT 149
Qy      149 SSGPSQCRSPRGKNIQGG-----KTLSSV-----QLELDSC-- 180
Db      150 TGPVSFPLAPSSKSTSGGTAALGLVQDYFPEPVTVSNMNSGALTSGVHTFPAYVLSQSGSLY 209
Qy      181 -----TWCTVYLONQKVEFKIDIVPCPAPRPSKCDKTHTC-----PEL 219
Db      210 SLSVTVTPSSSLGTQTYICNV--HKPSNTKVD---KKVEPKCDKTHTCPPCPAPBL 263
Qy      220 LGSPSVFLPPPKKOTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVHNAKTPRRE 279
Db      264 LGSPSVFLPPPKKOTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVHNAKTPRRE 323
Qy      280 QNSTYRVSVLTVLHODMLNGKEYKCVSNKALPAPIEKTISKAKGPREPQVYTLPPS 339
Db      324 QNSTYRVSVLTVLHODMLNGKEYKCVSNKALPAPIEKTISKAKGPREPQVYTLPPS 383
Qy      340 RDELTKNOVSLTCLVKGFPSPDIAYEMESNGOPENNYKTPPVLDSDGSFFLYSKLTVDK 399
Db      384 RDELTKNOVSLTCLVKGFPSPDIAYEMESNGOPENNYKTPPVLDSDGSFFLYSKLTVDK 443
Qy      400 SRMOQGNVFCSSVMHEALHNHYTOKSLSLSPG 431
Db      444 SRMOQGNVFCSSVMHEALHNHYTOKSLSLSPG 475

RESULT 40
US-10-159-006-18
; Sequence 18, Application US/10159006
; Publication No. US20030143229A1
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saldanha, Jose W.
; APPLICANT: Rettig, Wolfgang J.
; TITLE OF INVENTION: Para-specific Antibody with Improved Producibility
; FILE REFERENCE: 0652.1890002
; CURRENT APPLICATION NUMBER: US/10/159,006
; CURRENT FILING DATE: 2002-06-03
; PRIOR APPLICATION NUMBER: US 09/301,593
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: EP 98107925.4
; PRIOR FILING DATE: 1998-04-30
; PRIOR APPLICATION NUMBER: US 60/086,049
; PRIOR FILING DATE: 1998-05-18
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 453
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-159-006-18

Query Match      52.7%; Score 1271.5; DB 14; Length 453;
Best Local Similarity 59.0%; Pred. No. 2e-81;
Matches 271; Conservative 31; Mismatches 84; Indels 73; Gaps 12;

```

```

Qy      30 LGKKDDYELCTASQKSIQF--HKNSNQIKILGNQGSF--LTGSPKLTNDRADSRRL 86
Db      10 LVKPGASVMSCKTSKTSRYFTETTHVWRQSGKSLWETGINPNNGINPNVQKFKGRATL 69
Qy      87 W---DQGNFPLIKLIKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLLQ--GQSLTL 141
Db      70 TVGKSSSTAYMELRLTSEDSAVYFC-----ARRIAYGV---DEGHANDYMGQGISV 119

```

```

0Y      14Z TLSPSSSPSYOCARPRGNIGG-----KITLSV-----QLE 175
      120 TVSSASTKGPBPVPLPSSKSTSGGALACLVKDYFPPEPVTVNSGALTSGVHTPPAV 179
0Y      176 LOBSG-----TWTCYLOHQKVEFKIDIVECPAPEPKSCDKHTTC- 216
      180 LOSSGLYLSBVTVTPSSSLGTOTYICNV--NHKSNKTVD----KAYEPKSCDKHTTC 233
0Y      217 ----PELLGGPSVLEPPPKKDTLMSRTPEVTCVVDVSHDEPVEKKNVYDGEVHNA 272
0b      234 PCPAPELLGGPSVLEPPPKKDTLMSRTPEVTCVVDVSHDEPVEKKNVYDGEVHNA 293
0Y      273 KTPRBEQONSTYRVVSVLTVLHODMNLKEKYCKVSKALPAPIEKTISAKQOPREPQ 332
0b      294 KTPRBEQONSTYRVVSVLTVLHODMNLKEKYCKVSKALPAPIEKTISAKQOPREPQ 353
0Y      333 VYTLPPSRDGLTNQVSLTCLVKGFPSDIAWEMESNQPENNYKTPPVLDISGSPFLY 392
0b      354 VYTLPPSRREMTNQVSLTCLVKGFPSDIAWEMESNQPENNYKTPPVLDISGSPFLY 413
0Y      393 SKLTVDKSRMQQGNVSCSWMEBALHNHTQKSLSPG 431
0b      414 SKLTVDKSRMQQGNVSCSWMEBALHNHTQKSLSPG 452

```

```

RESULT 41
US-10-404-724-25
: Sequence 25, Application US/10404724
: Publication No. US20030203447A1
: GENERAL INFORMATION:
: APPLICANT: Horwitz, Arnold H.
: TITLE OF INVENTION: Methods and Materials For Increasing Expression of Recombinant
: TITLE OF INVENTION: Polypeptides
: FILE REFERENCE: 13698US01
: CURRENT APPLICATION NUMBER: US/10/404,724
: CURRENT FILING DATE: 2003-03-31
: PRIOR APPLICATION NUMBER: US 60/368,530
: PRIOR FILING DATE: 2002-03-29
: NUMBER OF SEQ ID NOS: 79
: SOFTWARE: PatentIn version 3.2
: SEQ ID NO 25
: LENGTH: 465
: TYPE: PRT
: ORGANISM: Homo Sapiens
US-10-404-724-25

```

```

Query March 52.7%; Score 1271.5; DB 12; Length 465;
Best Local Similarity 57.2%, Pred. No. 26-81;
Matches 283; Conservative 23; Mismatches 78; Indels 111; Gaps 14.

QY LVLVLATLLPATQGNKTVLG---KKQDYTELTCTAQQKSIQHMWNSNOIKILGNQG 66
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db LLLFMAAASAOAQQLVQSGAEVKKPQGSVKISKAS---GYTTKIGMWWVRAPGG 63
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY -----SPLTKGPS--KLNDRADSRRLMDQGNFP-----LIINKLIEDSD 105
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db LEMMGWIMTYEEEPYGGKF-----QGPFITLDISTATLLEISLSBEDTA 111
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY TYICEVEDQKEVOLVLFGLTANSOTHLIQGSLTLTLESPPGSSPVQCRSPRGKNIQG 165
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db VYFC-----ARFGSAVD---YMGGLTLVTYSASATKSPSVFLPAPSSKNSIG 155
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 166 G-----KTLVS-----QLQLDSG-----T 181
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db GTALGLCKDYFPEPPTVSNWSGALTSGVHTFPALVQSSGLYLSVTVVPSSSLGT 215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 182 WTCYVLQKQKVEFKIDIVCPAPRPKSCDKHTHC-----PDLGGSPVFLPPPKYDTL 236
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db YICNV--NHKPSMTKVD---KRVPRKSCDKHTHCPCPAPPELLGSPVFLPPPKYDTL 269
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 237 MISRTPEYTCVVDVDSHDEPKFWMYVDGVENHAKTKPREQVQNSYTRVVSULTVHQ 296
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

Db	270	MISRPEPTECVVVDVSHDEPEVKEFWYDGYEVNNAKTKRREQVNSTYRVVSVLTVLVHG	329
QY	297	DLNGKEKYCKVSNKALPAPIEKKTSKAKGQPREPOVYTLTPSRDELTKNOVSLTCLVYG	356
Db	330	DLNGKEKYCKVSNKALPAPIEKKTSKAKGQPREPOVYTLTPSRDELTKNOVSLTCLVYG	389
QY	357	FYPSDIAVWESNCGPENNYKTTTPVLVDSGDFLYSLKLTVDKSRWQGNVSVSCSYMHRA	416
Db	390	FYPSDIAVWESNCGPENNYKTTTPVLVDSGDFLYSLKLTVDKSRWQGNVSVSCSYMHRA	449
QY	417	LHNHYTKSLSLSPG 431	
Db	450	LHNHYTKSLSLSPG 464	

```

RESULT 42
US-10-207-655-15
; Sequence 15, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 390069.401C1
; CURRENT APPLICATION NUMBER: US/10/207,655
; CURRENT FILING DATE: 2002-07-25
; NUMBER OF SEQ ID NOS: 426
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 499
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MOUSE-HUMAN HYBRID FUSION PROTEIN
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (1)..(265)
; OTHER INFORMATION: MOUSE ANTI-HUMAN CD20 SCFV: 2H7
; FEATURE:
; NAME/KEY: DOMAIN
; LOCATION: (266)..(499)
; OTHER INFORMATION: HUMAN IGG1 WILD TYPE HINGE, CH2, CH3 FC
; US-10-207-655-15

```

	Query Match	52.7%	Score 1271.5;	DB 14;	Length 499;
	Best Local Similarity	56.6%	Pred. No. 2.2e-81;		
	Matches 275;	Conservative	27;	Mismatches 93;	Indels 91; Gaps 12;
OY	23 TQGNKVVYLGGKKDPIVELCTTASQCKSLQFPHKNSNQIKLGNOSFLTGSGSKLNDRA	DS	82		
Dd	27 SQSPAILLSAPGEKYVTWTCRASSVS-YMHYYQQP----	GSSPKPWITVPSNLASGVPA	81		
OY	83 RRLMDQG-NPELLIKULKIEDSDPTCYCEVDQKEEYQLLVFGI-----		125		
Dd	82 RFSSGSSTISLTISRVEADAAITYYC----QQMSFNPPTFAGTYELKDGGSGSGCGG		137		
OY	126 ---TANSDFHLIQ-GQSILTLLEAPPSSPSVOC-----SPR-----		159		
Dd	138 SGGGSSGOAYIQSGAELV---RPDASYMCKSACGYFTTSINMEHWKOTPRQGLEMI		192		
OY	160 -----GRNIOGKTLV-----SOLEODSGSTWTCTVLONOKVEFK		196		
Dd	193 GAIPNGDNDSYNOKFKGAKATLYTDKSSSTRAYMOLSLTSEDSAVYCARVVIYSNSWY		252		
OY	197 IDI-----VPCPAPEPKSCDKHTTC-----PELLGSPSYFLPPPKEDTLMTSRTEVT		245		
Dd	253 FDVWGIGTIVTVDSQEKSKCDKHITCCPCPAPELLGSPSYFLPPPKXDTLMISRTPEVT		312		
OY	246 CVAVDVSHEDPEVKFMNYVDGVEVHNAKTKPREEQNSTYRVSVLTVLHQDWMLNGKEYK		305		
Dd	313 CVAVDVSHEDPEVKFMNYVDGVEVHNAKTKPREEQNSTYRVSVLTVLHQDWMLNGKEYK		372		
OY	306 CKVSNKALPAPIETKTISKAGQREPOVYTLPSRDELTKNQVSLTCLVKGFPDSIAVE		365		

```
Db 373 CKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKQVSLTCLVKGFPSPDIAYE 432
|
|
|
Qy 366 MESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMOQGNVSCSVMEALHNHYTKS 425
|
|
|
Db 433 MESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMOQGNVSCSVMEALHNHYTKS 492
|
|
|
Qy 426 LSLSPG 431
|
|
|
Db 493 LSLSPG 498

RESULT 43
US-10-207-655-148
; Sequence 148, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden-Ledbetter, Martha S.
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 390069.401C1
; CURRENT APPLICATION NUMBER: US/10/207,655
; CURRENT FILING DATE: 2002-07-25
; NUMBER OF SEQ ID NOS: 426
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 148
; LENGTH: 499
; TYPE: PR
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Mouse-Human hybrid fusion protein
US-10-207-655-148

Query Match 52.7%; Score 1271.5; DB 14; Length 499;
Best Local Similarity 56.6%; Pred. No. 2.2e-81;
Matches 275; Conservative 27; Mismatches 93; Indels 91; Gaps 12;

Qy 23 TQGNKVVLGKKDPTVELTCTASQKSIQPHMKNSNOIKILGNQGSFLTGPSTLNDRAD 82
|
|
|
Db 27 SQSPAILLASPGEKVTMTCRASSSVS-YMHWYQQR---GSSPKWITAPSNLASGVPA 81
|
|
|
Qy 83 RSLMDQG-NFPLIINKLKIEDSDTYICEVEDQKEVQLLVGL----- 125
|
|
|
Db 82 RFGSGSGTSYSLTISRVEADEATYYC---QQMSFNPTFGAGTKLELKGSGSGGGG 137
|
|
|
Qy 126 ---TANSDTHLQ-GQSLTFLTLESPGSSPSVQCR-----SPR----- 159
|
|
|
Db 138 SGGGSSQAYLQSGAEV---RPGASVMSCKASGYTFSTYNNHMWVKQTPROGLEMI 192
|
|
|
Qy 160 -----GKNIQGGKTLV-----SOLELDGSGTWCTVLQNKVVERK 196
|
|
|
Db 193 GAIIYPNGDTSYNQKFKGKATLTVDKSSSTAYMQLSLTSEDSAVYFCARVYYNSNY 252
|
|
|
Qy 197 IDI-----VPCPAPEPKSCDKHTHC-----PELLGGPSVFLPPPKKDTLMI 245
|
|
|
Db 253 FDVWGIGTITVTVDDQEKSCDKHTHCPCPAPPELLGGPSVFLPPPKKDTLMI 312
|
|
|
Qy 246 CVVVDVSHEDPEVKFMNYVDGVEVHNAKTPREEDYNSTYRVSVLTJVLHQM 305
|
|
|
Db 313 CVVVDVSHEDPEVKFMNYVDGVEVHNAKTPREEDYNSTYRVSVLTJVLHQM 372
|
|
|
Qy 306 CKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKQVSLTCLVKGFPSPDIAYE 365
|
|
|
Db 373 CKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKQVSLTCLVKGFPSPDIAYE 432
|
|
|
Qy 366 MESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMOQGNVSCSVMEALHNHYTKS 425
|
|
|
Db 433 MESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMOQGNVSCSVMEALHNHYTKS 492
|
|
|
Qy 426 LSLSPG 431
|
|
|
Db 493 LSLSPG 498
```

```
RESULT 44
US-10-053-530-15
; Sequence 15, Application US/10053530
; Publication No. US20030133939A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey
; APPLICANT: Hayden-Ledbetter, Martha
; TITLE OF INVENTION: Binding Domain-Immunoglobulin Fusion Proteins
; FILE REFERENCE: 390069.401
; CURRENT APPLICATION NUMBER: US/10/053,530
; CURRENT FILING DATE: 2002-01-17
; PRIOR APPLICATION NUMBER: US 09/765,208
; PRIOR FILING DATE: 2001-01-17
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 499
; TYPE: PR
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MOUSE-HUMAN HYBRID FUSION PROTEIN
; NAME/KEY: SITE
; LOCATION: (1)..(265)
; OTHER INFORMATION: MOUSE ANTI-HUMAN CD20 SCFV. 2H7
; NAME/KEY: DOMAIN
; LOCATION: (266)..(499)
; OTHER INFORMATION: HUMAN IGG1 WILD TYPE HINGE, CH2, CH3 FC
US-10-053-530-15
```

Query Match 52.7%; Score 1271.5; DB 14; Length 499;

Best Local Similarity 56.6%; Pred. No. 2.2e-81;

Matches 275; Conservative 27; Mismatches 93; Indels 91; Gaps 12;

```
Qy 23 TQGNKVVLGKKDPTVELTCTASQKSIQPHMKNSNOIKILGNQGSFLTGPSTLNDRAD 82
|
|
|
Db 27 SQSPAILLASPGEKVTMTCRASSSVS-YMHWYQQR---GSSPKWITAPSNLASGVPA 81
|
|
|
Qy 83 RSLMDQG-NFPLIINKLKIEDSDTYICEVEDQKEVQLLVGL----- 125
|
|
|
Db 82 RFGSGSGTSYSLTISRVEADEATYYC---QQMSFNPTFGAGTKLELKGSGSGGGG 137
|
|
|
Qy 126 ---TANSDTHLQ-GQSLTFLTLESPGSSPSVQCR-----SPR----- 159
|
|
|
Db 138 SGGGSSQAYLQSGAEV---RPGASVMSCKASGYTFSTYNNHMWVKQTPROGLEMI 192
|
|
|
Qy 160 -----GKNIQGGKTLV-----SOLELDGSGTWCTVLQNKVVERK 196
|
|
|
Db 193 GAIIYPNGDTSYNQKFKGKATLTVDKSSSTAYMQLSLTSEDSAVYFCARVYYNSNY 252
|
|
|
Qy 197 IDI-----VPCPAPEPKSCDKHTHC-----PELLGGPSVFLPPPKKDTLMI 245
|
|
|
Db 253 FDVWGIGTITVTVDDQEKSCDKHTHCPCPAPPELLGGPSVFLPPPKKDTLMI 312
|
|
|
Qy 246 CVVVDVSHEDPEVKFMNYVDGVEVHNAKTPREEDYNSTYRVSVLTJVLHQM 305
|
|
|
Db 313 CVVVDVSHEDPEVKFMNYVDGVEVHNAKTPREEDYNSTYRVSVLTJVLHQM 372
|
|
|
Qy 306 CKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKQVSLTCLVKGFPSPDIAYE 365
|
|
|
Db 373 CKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKQVSLTCLVKGFPSPDIAYE 432
|
|
|
Qy 366 MESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMOQGNVSCSVMEALHNHYTKS 425
|
|
|
Db 433 MESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMOQGNVSCSVMEALHNHYTKS 492
|
|
|
Qy 426 LSLSPG 431
|
|
|
Db 493 LSLSPG 498
```

RESULT 45  
US-09-948-429B-12

```
/ Sequence 12, Application US/09948429B
/ Patent No. US20020177689A1
/ GENERAL INFORMATION:
/ APPLICANT: Anderson, Darrell R.
/ TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
/ TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
/ TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
/ TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
/ NUMBER OF SEQUENCES: 12
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
/ STREET: 699 Prince Street
/ CITY: Alexandria
/ STATE: VA
/ COUNTRY: USA
/ ZIP: 22314
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/948,429B
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/383,916
/ FILING DATE:
/ APPLICATION NUMBER: US 08/487,550
/ FILING DATE: 07-JUN-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Teskin, Robin L.
/ REGISTRATION NUMBER: 35,030
/ REFERENCE/DOCKET NUMBER: 012712-131
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-836-6620
/ TELEFAX: 703-836-2021
/ INFORMATION FOR SEQ ID NO: 12:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 476 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: Protein
/ US-09-948-429B-12

Query Match      52.7%; Score 1271; DB 9; Length 476;
Best Local Similarity 59.8%; Pred. No. 2,3e-81;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;

QY 30 LGKKGDVLELTCTASQ---KKSIOFHWKNSNOIKILNGSGFLL-TKGPSKLNDRADSRRS 85
DB 30 LVKPSSETLSLTCVAVSGSGSISGGYGMWIRQPGKGLWISGFYSSSGNTYYPSLKSGVT 89
QY 86 L---WDQGNFPLIITKILKIEDSDTYICEVEDOKEEVQLVFGLTANS DTHLQGSLLT 142
DB 90 ISTDTSKQFSLKLNKSTADTAAYYC-VRDRLFSYVGMY-----NNWFDVWGPGVLVT 143
QY 143 LSPSPSSSVQCRSPRGKNIQGG-----KTLSSV-----QLEL 176
DB 144 VSSASTKGPSVFLPAPSKSTSGGTALAGCLVKDYFPEPVTVSNMNSGALTSGVHTFPAVL 203
QY 177 QDSG-----TWCTVLQNKVEFKIDIVPCPAPRPSCKDTHTC-- 216
DB 204 QSSGYSLSLVTVPSSSLGTQTYICNV--NHKPSNTKVD-----KKAEPKSGCDKTHTCPP 257
QY 217 ---PELLGSPSVFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVKFMYVDGVEVNAK 273
DB 258 CPAPPELLGSPSVFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVKFMYVDGVEVNAK 317
QY 274 TKPREEOVNSTYRWVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTTISKAKGQREPOV 333
DB 318 TKPREEOINSTYRWVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTTISKAKGQREPOV 377
```

```
QY 334 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQENNNYKTTTPVLDSDGSFLLYS 393
DB 378 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQENNNYKTTTPVLDSDGSFLLYS 437
QY 394 KLTVDKSRWQGNVFCSSVWHEALHNNHYTQKSLSLSG 431
DB 438 KLTVDKSRWQGNVFCSSVWHEALHNNHYTQKSLSLSG 475

RESULT 46
US-09-758-173-12
/ Sequence 12, Application US/09758173
/ Publication No. US20010024648A1
/ GENERAL INFORMATION:
/ APPLICANT: Anderson, Darrell R.
/ TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
/ TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
/ TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
/ TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
/ NUMBER OF SEQUENCES: 12
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
/ STREET: 699 Prince Street
/ CITY: Alexandria
/ STATE: VA
/ COUNTRY: USA
/ ZIP: 22314
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/758,173
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/383,916
/ FILING DATE:
/ APPLICATION NUMBER: US 08/487,550
/ FILING DATE: 07-JUN-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Teskin, Robin L.
/ REGISTRATION NUMBER: 35,030
/ REFERENCE/DOCKET NUMBER: 012712-131
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-836-6620
/ TELEFAX: 703-836-2021
/ INFORMATION FOR SEQ ID NO: 12:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 476 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: Protein
/ US-09-758-173-12

Query Match      52.7%; Score 1271; DB 12; Length 476;
Best Local Similarity 59.8%; Pred. No. 2,3e-81;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;

QY 30 LGKKGDVLELTCTASQ---KKSIOFHWKNSNOIKILNGSGFLL-TKGPSKLNDRADSRRS 85
DB 30 LVKPSSETLSLTCVAVSGSGSISGGYGMWIRQPGKGLWISGFYSSSGNTYYPSLKSGVT 89
QY 86 L---WDQGNFPLIITKILKIEDSDTYICEVEDOKEEVQLVFGLTANS DTHLQGSLLT 142
DB 90 ISTDTSKQFSLKLNKSTADTAAYYC-VRDRLFSYVGMY-----NNWFDVWGPGVLVT 143
QY 143 LSPSPSSSVQCRSPRGKNIQGG-----KTLSSV-----QLEL 176
DB 144 VSSASTKGPSVFLPAPSKSTSGGTALAGCLVKDYFPEPVTVSNMNSGALTSGVHTFPAVL 203
QY 177 QDSG-----TWCTVLQNKVEFKIDIVPCPAPRPSCKDTHTC-- 216
```



Db 204 QSSGLVSLSSVTVTPSSLSGTQTYICNV--NHKPSMTKVD---KKAEPKSCDKHTTCTP 257  
Qy 217 ---PELLGSPVFLFPPEPKDITMISRTPEVTCVVVDVSHEDPEVKFMYVDGVEVHNAAK 273  
Db 258 CPAPELLGGPSVFLFPPPKDITMISRTPEVTCVVVDVSHEDPEVKFMYVDGVEVHNAAK 317  
Qy 274 TKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 333  
Db 318 TKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 377  
Qy 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPVLDSDGSFFLYS 393  
Db 378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPVLDSDGSFFLYS 437  
Qy 394 KLTVDKSRWQOGNVFSCSVMEHALHNHYTQKSLSLSPG 431  
Db 438 KLTVDKSRWQOGNVFSCSVMEHALHNHYTQKSLSLSPG 475  
RESULT 47  
US-10-124-905-12  
; Sequence 12, Application US/10124905  
; Publication No. US20020166136A1  
; GENERAL INFORMATION:  
; APPLICANT: Anderson, Darrell R.  
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC  
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,  
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS  
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS  
; STREET: 699 Prince Street  
; CITY: Alexandria  
; STATE: VA  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/124,905  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/383,916  
; FILING DATE:  
; APPLICATION NUMBER: US 08/487,550  
; FILING DATE: 07-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Teskin, Robin L.  
; REGISTRATION NUMBER: 35,030  
; REFERENCE/DOCKET NUMBER: 012712-131  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-836-6620  
; TELEFAX: 703-836-2021  
; INFORMATION FOR SEQ ID NO: 12:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 476 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-10-124-905-12  
Query Match 52.7%; Score 1271; DB 13; Length 476;  
Best Local Similarity 59.8%; Pred. No. 2.3e-81;  
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;  
Qy 30 LGKGGTVELTCTASQ---KKSIOFHKNSKQIKILGNOSFL--TKGPSKLNBRADSRSP 85

Db 30 LVKPSSETLSLTCAVAGSGSISGGYGMWIRQPPGKGLWETIGSFYSSSGNTYNNPSLKSQVT 89  
Qy 86 L--WDQGNFPLITIKMLKIEDDTYICVEDEQKEEVQLVPLGLTANSDTHLLQGSLLT 142  
Db 90 ISTDTSKQGFSLKMLSMTAADTAAYYC--VRDLFSVVGMYV-----NNMFVWGPGVLT 143  
Qy 143 LESPPSSPSVOCRSPRGNIQGG-----KTLSSV-----QLEL 176  
Db 144 VSSASTKGPSVFPLPSSKSTSGGTAALGCLVKDYFPEPEVYSNNSGALTSGVHTFPAVL 203  
Qy 177 QDSG-----TWTCYVLQNGKVEFKIDIVCPAPPEKSCDKHTTCTP 216  
Db 204 QSSGLVSLSSVTVTPSSLSGTQTYICNV--NHKPSMTKVD---KKAEPKSCDKHTTCTP 257  
Qy 217 ---PELLGSPVFLFPPEPKDITMISRTPEVTCVVVDVSHEDPEVKFMYVDGVEVHNAAK 273  
Db 258 CPAPELLGGPSVFLFPPPKDITMISRTPEVTCVVVDVSHEDPEVKFMYVDGVEVHNAAK 317  
Qy 274 TKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 333  
Db 318 TKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 377  
Qy 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPVLDSDGSFFLYS 393  
Db 378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPVLDSDGSFFLYS 437  
Qy 394 KLTVDKSRWQOGNVFSCSVMEHALHNHYTQKSLSLSPG 431  
Db 438 KLTVDKSRWQOGNVFSCSVMEHALHNHYTQKSLSLSPG 475  
RESULT 48  
US-10-124-807-12  
; Sequence 12, Application US/10124807  
; Publication No. US20030166207A1  
; GENERAL INFORMATION:  
; APPLICANT: Anderson, Darrell R.  
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC  
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,  
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS  
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS  
; STREET: 699 Prince Street  
; CITY: Alexandria  
; STATE: VA  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/124,807  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/383,916  
; FILING DATE:  
; APPLICATION NUMBER: US 08/487,550  
; FILING DATE: 07-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Teskin, Robin L.  
; REGISTRATION NUMBER: 35,030  
; REFERENCE/DOCKET NUMBER: 012712-131  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-836-6620  
; TELEFAX: 703-836-2021  
; INFORMATION FOR SEQ ID NO: 12:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 476 amino acids







```
Db 30 LAQPGSLRLSCASGFRLLINVAVMNRQAPEGKLEISALISGSGGNTHTADSVR----- 84
Qy 90 GNPPL---IIXN-----LKTEDSDTYICEVEDQKEVQLVFGLTANSDTHLLOGS 138
Db 85 GRFTIRSDLSKMNWFMQMSLRAEDTAIVFCAKNQPR-----VIVASIEN---WGQG 135
Qy 139 LTTLESPPGSSPVOCRSRPGKNIQGG-----KTLVS----- 172
Db 136 TLVTVSASTKGPSPVPLPABSSKSTSGTALACLVKDYFPEPVTSNMSGALTSGVHTF 195
Qy 173 QLELDQSG-----TWCTVLQONKVEFKIDIVPCRAPEKSCDKTH 214
Db 196 PAVLGSSGLYSLASVTVTPSSSLGTQTYICNV--NKKPSNTKYD-----KVKPEKSCDKTH 249
Qy 215 TC-----PELLGPPSVFLPPPKPKDTLMSRTPREVTCVVVDVSHEDPEVKFNNYVVDGVEY 269
Db 250 TCPPCPAPELLGPPSVFLPPPKPKDTLMSRTPREVTCVVVDVSHEDPEVKFNNYVVDGVEY 309
Qy 270 HNAKTPREBOVNSTRVVSVLTVLHODMNLNGEKYCKVSNKALPAPIEKTISKAKGPR 329
Db 310 HNAKTPREBOVNSTRVVSVLTVLHODMNLNGEKYCKVSNKALPAPIEKTISKAKGPR 369
Qy 330 EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTPPVLDSDGSE 389
Db 370 EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTPPVLDSDGSE 429
Qy 390 FLYSKLTVDKSRMQGVNFSQSVMEHALHNHYTQKSLSLSPG 431
Db 430 FLYSKLTVDKSRMQGVNFSQSVMEHALHNHYTQKSLSLSPG 471
```

```
RESULT 56
US-10-108-260A-4285
; Sequence 4285, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US20040005560A1 full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 4285
; LENGTH: 471
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-4285
```

```
Query Match 52.5%; Score 1268.5; DB 15; Length 471;
Best Local Similarity 57.2%; Pred. No. 3,4e-81;
Matches 277; Conservative 37; Mismatches 85; Indels 85; Gaps 14;

Db 10 LLLVL-----QLALLPAATQGNKVVLAGKGDVTELCTASQKKSIGF--HMKN---SNQI 59
Qy 10 LLLVL-----QLALLPAATQGNKVVLAGKGDVTELCTASQKKSIGF--HMKN---SNQI 59
Db 10 LLAIVISGGGQVPLVSGTE---VKPEASVNISSCKAPGYFTFTYHMMWRQAPGGI 64
Qy 60 KILGNQGSFLTKGPKSLNDRADSRSLMDQGNP---LIIKNLIKEDSDTYICEVEDQKE 116
Db 65 EMMGGINP---SSGRSSVSQKFEGRLLTLTADTSTTTAHMELRNLTSDTGYYCTTRRWK 122
Qy 117 EVOLLVFGLTANSDTHLLOGSJLTLTLESPPGSSPVOCRSRPGKNIQGG----- 166
Db 123 VVR-----GSDNYWGQGLTVIVSASTKG--PSVFLPAPBSKSTSGGTALACLVND 172
Qy 167 ---KTLVS-----QLELDQSG-----TWCTVLQONK 192
Db 173 YPEPEPVTSNMSGALTSGVHTFPAVLQSSGLYSLASVTVTPSSSLGTQTYICNV--NKKP 230
Qy 193 VEFKIDIVPCRAPEKSCDKTHTC-----PELLGPPSVFLPPPKPKDTLMSRTPREVTCV 247
Db 231 SNRKVD---EKVEPKSCDKTHTCPPCPAPELLGPPSVFLPPPKPKDTLMSRTPREVTCV 286
```

```
Qy 248 VVDVSHEDPEVKFNNYVVDGVEYHNAKTPREBOVNSTRVVSVLTVLHODMNLNGEKYCK 307
Db 287 VVDVSHEDPEVKFNNYVVDGVEYHNAKTPREBOVNSTRVVSVLTVLHODMNLNGEKYCK 346
Qy 308 VSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEME 367
Db 347 VSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEME 406
Qy 368 SNGQPENNYKTPPVLDSDGSEFFLYSKLTVDKSRMQGVNFSQSVMEHALHNHYTQKSLS 427
Db 407 SNGQPENNYKTPPVLDSDGSEFFLYSKLTVDKSRMQGVNFSQSVMEHALHNHYTQKSLS 466
Qy 428 LSPG 431
Db 467 LSPG 470
```

```
RESULT 57
US-10-416-011-2
; Sequence 2, Application US/10416011
; Publication No. US20040126363A1
; GENERAL INFORMATION:
; APPLICANT: Jensen, Michael
; APPLICANT: Forman, Stephen
; APPLICANT: Raubitschek, Andrew
; TITLE OF INVENTION: CD19-specific redirected immune cells
; FILE REFERENCE: 1954-338
; CURRENT APPLICATION NUMBER: US/10/416,011
; CURRENT FILING DATE: 2003-05-07
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentln version 3.1
; SEQ ID NO 2
; LENGTH: 634
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: CD19R: zeta chimeric receptor
US-10-416-011-2
```

```
Query Match 52.5%; Score 1268; DB 16; Length 634;
Best Local Similarity 56.2%; Pred. No. 5,3e-81;
Matches 287; Conservative 28; Mismatches 94; Indels 102; Gaps 16;

Qy 10 LLLVLQAL--LP-----AATQGNKVVLAGKGDVTELCTASQKKSIOFHW---K 54
Db 2 LLLVTSLLCELPHPAFLIPDIQMTQTTSSLASLGDVRVTSICRASODISKTLNMYQOK 61
Qy 55 NSNQIKILGNQGSFLTKG--PSKLNDRADSRSLMDQGNPFLIYKLIKEDSDTYICEVED 113
Db 62 PGGTVKLLIYHTSRILHSGVPSRFGSGSGT-----DLSLITSNLEQDIATTFCCQGN 114
Qy 114 QKE-----EVOLLVFGLTANSDTHLLOGSJLT---LTLESPPG-----SSPVOC--- 155
Db 115 TLPTFGGTGKLEIIGTSGSGKP--GSGEGSTKGEVQLQESGELVAPQSISVTCYVSG 173
Qy 156 -----RSPRGKNIQ-----GKGT-----LSVSQLE 175
Db 174 VELPVGYSWIRQPRKGLEWLVIGSETTYNSALSKRLTIINDNSKSGVFLKMNISIQ 233
Qy 176 LODSGTWCTVLQONKVV---EFKIDI-----VPCRAPEKSCDKTHTC-----PELL 220
Db 234 TDDTAIYYCA-----KHYYGGSYAMDWGQGSTVSVSVEPKSSDKTHTCPPCPAPELL 288
Qy 221 GGPSPVFLPPPKPKDTLMSRTPREVTCVVVDVSHEDPEVKFNNYVVDGVEYHNAKTPREBO 280
Db 289 GGPSPVFLPPPKPKDTLMSRTPREVTCVVVDVSHEDPEVKFNNYVVDGVEYHNAKTPREBO 348
Qy 281 YNSTRVSVSVLTVLHODMNLNGEKYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSR 340
Db 349 YNSTRVSVSVLTVLHODMNLNGEKYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSR 408
Qy 341 DELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTPPVLDSDGSEFFLYSKLTVDKS 400
```

```

Db      409 DELTKQVSLTCLVKGFPSPDIAVEMESNGQPENNYKTPVLDSGDFLYSKLTVDKS 468
QY      401 RMQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      469 RMQGNVFCSCVMHEALHNHYTKSLSPG 499

```

# RESULT 58 US-10-226-435A-12

```

; Sequence 12, Application US/10226435A
; Publication No. US20040043418A1
; GENERAL INFORMATION:
; APPLICANT: ELI LILLY AND COMPANY AND WASHINGTON UNIVERSITY
; TITLE OF INVENTION: Humanized Antibodies that Sequester Amyloid Beta Peptide
; FILE REFERENCE: 8792/293
; CURRENT APPLICATION NUMBER: US/10/226,435A
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US01/06191
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: 60/184,601
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: 60/254,465
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/254,498
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 442
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Humanized antibodies
US-10-226-435A-12

```

```

Query Match      52.5%; Score 1267.5; DB 12; Length 442;
Best Local Similarity 59.1%; Pred. No. 3.7e-81;
Matches 274; Conservative 26; Mismatches 69; Indels 95; Gaps 13;

```

```

QY      30 LKKGDIYELTGTAS--QKKSIQFMKNS-----NQIKLNGQSF--LTGSPSKL 76
Db      11 LVQPGSLRLSCAAGFTFSRYSMSWVRQAPGKGLVLAQINVSNGSTYPPVTVGRFTI 70
QY      77 NDRADSRRLDOGNPRLIKNLKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHLQ 136
Db      71 S-RDAKATLYLQNM-----SLRADTAIVYC-----ASGD---YWG 103
QY      137 QSLTLTLSPGSSSPSVOCSPRGKNIQGG-----KTLVS----- 172
Db      104 QGTLTVSSASATKGPSVFLAPSSKSTSGTALGCLVMDYFPEPVTVSWMNSGALTSQVH 163
QY      173 --QLELDGSG-----TWCTVYLNQKVAEFKIDYPCRPAREKSCDK 212
Db      164 TFPVAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHRPSNTKYD---KKEPEKSCDK 217
QY      213 THTC-----PELLGSPVFLPPPKPDOTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGV 267
Db      218 THTCPCPAPPELLGSPSVFLPPPKPDOTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGV 277
QY      268 EVHNAKTKPREQYNSTYRVVSVLTVLHQDWLNGKEVYCKCKVSNKALPAPIETKTIISKAKGQ 327
Db      278 EVHNAKTKPREQYNSTYRVVSVLTVLHQDWLNGKEVYCKCKVSNKALPAPIETKTIISKAKGQ 337
QY      328 PREPQVYTLPPSRDELTKQVSLTCLVKGFPSPDIAVEMESNGQPENNYKTPVLDSG 387
Db      338 PREPQVYTLPPSRDELTKQVSLTCLVKGFPSPDIAVEMESNGQPENNYKTPVLDSG 397
QY      368 SFFLYSKLTVDSKRMQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      398 SFFLYSKLTVDSKRMQGNVFCSCVMHEALHNHYTKSLSPG 441

```

```

RESULT 59
US-10-120-198B-2

```

```

; Sequence 2, Application US/10120198B
; Publication No. US20030215427A1
; GENERAL INFORMATION:
; APPLICANT: Jensen, Michael
; TITLE OF INVENTION: CB7-SPECIFIC REDIRECTED IMMUNE CELLS
; FILE REFERENCE: 1954-337
; CURRENT APPLICATION NUMBER: US/10/120,198B
; CURRENT FILING DATE: 2002-04-11
; PRIOR APPLICATION NUMBER: 60/282,859
; PRIOR FILING DATE: 2001-04-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 631
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: mouse-human chimera
US-10-120-198B-2

```

```

Query Match      52.5%; Score 1266.5; DB 15; Length 631;
Best Local Similarity 54.2%; Pred. No. 6.8e-81;
Matches 277; Conservative 39; Mismatches 84; Indels 111; Gaps 14;

```

```

QY      5 VPRHLLVQLALPPAATGNKVLGKKGDIYELTGTASQKSIQF--HW---KNSNQI 59
Db      13 LHPAFLIPQVQLQDQGAE-----LVKPGASVRLSKASGYRTTGIMHMKVRPGHGL 67
QY      60 KILNGQSFLLTKGSKLNDRAISRSLW--DQGNP--LIKNLKIEDSDTYICEVEDQKE 116
Db      68 EWIGEINP--SNGRITNERKSKATLVDSKSTTAFMQLSGLTSEDNAVYFCARD---- 121
QY      117 EVQLLVFGLTANSSTHLQGSLLTLESPPGSS----- 150
Db      122 ----YGTSYNFD---YWGQGTTLTVSSGGGGSGGGGGGGGSDIQMTQSSSPSVSLG 173
QY      151 --PSVQGR-----SPR-----GKNIQGGKTLVS 172
Db      174 DRVITTCANEDINNRLAMTQOTPGNSPRLISGATNLVGVPSRFSGSGSKDYTLIT 233
QY      173 QLELDGSGTWCT-----VLQNKVPEFKIDYPCRPAREKSCDKTHTC----DELL 220
Db      234 SLQMEDPATYVCCQGYWSTPFPFGSTELERKV-----EPKSSDHTHTCPCPAPPELL 285
QY      221 GGEVFLFPPPKPDOTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVYVHNAKTKPREEQ 280
Db      286 GGPVFLFPPPKPDOTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVYVHNAKTKPREEQ 345
QY      281 YNSTYRVVSVLTVLHQDWLNGKEVYCKCKVSNKALPAPIETKTIISKAKGQPREPQVYTLPPSR 340
Db      346 YNSTYRVVSVLTVLHQDWLNGKEVYCKCKVSNKALPAPIETKTIISKAKGQPREPQVYTLPPSR 405
QY      341 DELTKQVSLTCLVKGFPSPDIAVEMESNGQPENNYKTPVLDSGDFLYSKLTVDKS 400
Db      406 DELTKQVSLTCLVKGFPSPDIAVEMESNGQPENNYKTPVLDSGDFLYSKLTVDKS 465
QY      401 RMQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      466 RMQGNVFCSCVMHEALHNHYTKSLSPG 496

```

## RESULT 60

```

US-09-925-179-68
; Sequence 68, Application US/09925179
; Publication No. US20030044858A1
; GENERAL INFORMATION:
; APPLICANT: Jardiou, Paula M.
; TITLE OF INVENTION: Anti-19E Antibodies (as amended)
; FILE REFERENCE: P0718P2CID1C1US
; CURRENT APPLICATION NUMBER: US/09/925,179

```

```
/ CURRENT FILING DATE: 2001-08-08
/ PRIOR APPLICATION NUMBER: US 08/466,163
/ PRIOR FILING DATE: 1995-06-06
/ PRIOR APPLICATION NUMBER: US 08/405,617
/ PRIOR FILING DATE: 1995-03-15
/ PRIOR APPLICATION NUMBER: US 08/185,899
/ PRIOR FILING DATE: 1994-01-26
/ PRIOR APPLICATION NUMBER: PCT/US92/06860
/ PRIOR FILING DATE: 1992-08-14
/ PRIOR APPLICATION NUMBER: US 07/879,495
/ PRIOR FILING DATE: 1992-05-07
/ PRIOR APPLICATION NUMBER: US 07/744,768
/ PRIOR FILING DATE: 1991-08-14
/ NUMBER OF SEQ ID NOS: 68
/ SEQ ID NO 68
/ LENGTH: 451
/ TYPE: PRT
/ ORGANISM: Artificial sequence
/ FEATURE:
/ OTHER INFORMATION: Full-length heavy chain sequence corresponding to F(ab)9 of Table
US-09-925-179-68
```

```
Query Match          52.4%; Score 1266; DB 10; Length 451;
Best Local Similarity 58.6%; Pred. No. 4,8e-81;
Matches 273; Conservative 25; Mismatches 78; Indels 90; Gaps 12;

QY 30 LKKGDTVELTCTASQ---KKSIOFHMKNSNOIKILGNQSFITKGPSKLNDR-----78
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 11 LVQPGSLRLSCAAS-GYSGFTGHMNNWVROAPGKLEWGMTHPSDFERNYQKFKDRPT 70
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 79 -RADSRSLMDQGNFPLIIRKILKIEDSDTYICEVEDQKEEVQLVFGLTANSPTH---LL 134
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 71 SRDSSKNT-----FLQLNSAAEDTAYVYCGARSH-----YFG-----HHMFAY 110
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 135 QGSLTLTLSPSPSSPVQCRSPRGKNIQCG-----KTLSSV-----172
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 111 WGQGLVTVSSASTKGPSVFLPPLAPSSKSGTALGCLVKDYFPEPTVSNMNSGALTSG 170
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 173 ---QLELQDSG-----TWTCYVLQNOKKVEFKIDIVPCAPAPKSC 210
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 171 VHTFPAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVKPKSC 224
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 211 DKHTTC-----PELLGSPSVFLPFPKPKDTLMTSRTPEVTCVVDVSHEDPEVKFMVYDG 265
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 225 DKHTTPPCAPAPFLDLGGPSVFLEPFPKPKDTLMTSRTPEVTCVVDVSHEDPEVKFMVYDG 284
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 266 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTIISKAK 325
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 285 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTIISKAK 344
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 326 GQPREQVYTLTPSRDELTKNQVSLTCLYGKFYPSDIAVEMESNGQPENNYKTTTPVLDSD 385
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 345 GQPREQVYTLTPSRDELTKNQVSLTCLYGKFYPSDIAVEMESNGQPENNYKTTTPVLDSD 404
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 386 DGSFPLYSKLTVDKSRMGOQGNVFSQVMEHALHNHTOKSLSLSPG 431
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 405 DGSFPLYSKLTVDKSRMGOQGNVFSQVMEHALHNHTOKSLSLSPG 450
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

```
RESULT 61
US-10-423-299-4
/ Sequence 4, Application US/104232299
/ Publication No. US20030229212A1
/ GENERAL INFORMATION:
/ APPLICANT: FAHRNER, ROBERT
/ APPLICANT: FOLLMAN, DEBORAH
/ APPLICANT: LEBRETTON, BENEDICTE
/ APPLICANT: VAN REIS, ROBERT
/ TITLE OF INVENTION: NON-AFFINITY PURIFICATION OF PROTEINS
/ FILE REFERENCE: 39766-0121A
/ CURRENT APPLICATION NUMBER: US/10/423,299
/ CURRENT FILING DATE: 2003-04-25
/ PRIOR APPLICATION NUMBER: US 60/375,953
```

```
/ PRIOR FILING DATE: 2002-04-26
/ NUMBER OF SEQ ID NOS: 4
/ SEQ ID NO 4
/ LENGTH: 451
/ TYPE: PRT
/ ORGANISM: Artificial sequence
/ FEATURE:
/ OTHER INFORMATION: Sequence is synthesized
US-10-423-299-4
```

```
Query Match          52.4%; Score 1266; DB 15; Length 451;
Best Local Similarity 58.9%; Pred. No. 4,8e-81;
Matches 274; Conservative 28; Mismatches 75; Indels 88; Gaps 13;

QY 30 LKKGDTVELTCTASQKSIQFHMKNSNOIKILG--NQSFITKGPSKLNDR--79
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 11 LVQPGSLRLSCAAS-GYSGFTGHMNNWVROAPGKLEWGMTHPSDFERNYQKFKDRPT 69
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 80 ---ADSRSLMDQGNFPLIIRKILKIEDSDTYICEVEDQKEEVQLVFGLTANSPTH--LQ 135
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 70 ISVDKSKNTLYLQNN-----SLRAEDTAYVYCGARSH-----ARGIYFGITTFPDY 111
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 136 QGSLTLTLSPSPSSPVQCRSPRGKNIQCG-----KTLSSV-----172
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 112 WGQGLVTVSSASTKGPSVFLPPLAPSSKSGTALGCLVKDYFPEPTVSNMNSGALTSG 171
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 173 ---QLELQDSG-----TWTCYVLQNOKKVEFKIDIVPCAPAPKSCD 211
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 172 VHTFPAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVKPKSCD 225
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 212 DKHTTC-----PELLGSPSVFLPFPKPKDTLMTSRTPEVTCVVDVSHEDPEVKFMVYDG 266
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 226 DKHTTPPCAPAPFLDLGGPSVFLEPFPKPKDTLMTSRTPEVTCVVDVSHEDPEVKFMVYDG 285
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 267 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTIISKAKG 326
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 286 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTIISKAKG 345
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 327 GQPREQVYTLTPSRDELTKNQVSLTCLYGKFYPSDIAVEMESNGQPENNYKTTTPVLDSD 386
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 346 GQPREQVYTLTPSRDELTKNQVSLTCLYGKFYPSDIAVEMESNGQPENNYKTTTPVLDSD 405
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 387 GSFPLYSKLTVDKSRMGOQGNVFSQVMEHALHNHTOKSLSLSPG 431
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 406 GSFPLYSKLTVDKSRMGOQGNVFSQVMEHALHNHTOKSLSLSPG 450
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

```
RESULT 62
US-10-020-786-9
/ Sequence 9, Application US/10020786
/ Publication No. US20030073164A1
/ GENERAL INFORMATION:
/ APPLICANT: Simmons, Laura C.
/ APPLICANT: Klimowski, Laura
/ APPLICANT: Reilly, Dorothea
/ APPLICANT: Yansura, Daniel G.
/ TITLE OF INVENTION: PROKARYOTICALLY PRODUCED ANTIBODIES AND USES THEREOF
/ FILE REFERENCE: P1793R1
/ CURRENT APPLICATION NUMBER: US/10/020,786
/ CURRENT FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: US 60/256,164
/ PRIOR FILING DATE: 2000-12-14
/ NUMBER OF SEQ ID NOS: 11
/ SEQ ID NO 9
/ LENGTH: 470
/ TYPE: PRT
/ ORGANISM: Artificial sequence
/ FEATURE:
/ OTHER INFORMATION: anti-TF heavy chain
US-10-020-786-9

Query Match          52.4%; Score 1266; DB 14; Length 470;
Best Local Similarity 58.8%; Pred. No. 5.1e-81;
```

```

Matches 275; Conservative 26; Mismatches 69; Indels 98; Gaps 14;
QY 30 LGKGGDTVELTCTAS--QKKSIOFHM-----KNSNOIKILG-NGGSFLTQKSPSLNRA 80
DB 34 LVQPGGSLRLSCAAGGFINKEYYMMWVROAPGKLEWGLIDPEGN--TIYDPKFORA 91
QY 81 -----DSRRSLWDQGNFLLIKNLKIEDSDYICEVEDQKEVOLLVGLTANSPTHL-- 133
DB 92 TISADNSKVTALQWN-----SLRAEDTAVYYCA-----RDTAAYF 127
QY 134 -LOGSGLTLTLESPPGSSPSVQCRRPRGKNIOGG-----KTLSSV----- 172
DB 128 DYGEGGTIVTSSASTKGPSVFLPAPSSKSTSGGTAALGCLVKDYFPPPVTVSNMGSALT 187
QY 173 -----QLELDQSG-----TWCTVLQNOKKVEFKIDIVPCAPAPK 208
DB 168 SGVHTFPRAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD----KVEPK 241
QY 209 SCDKTHTC-----PELLGSPSVFLPPPKPKDTLMI SRTPRYTCVVVDVSHEDPEVKFMWY 263
DB 242 SCDKTHTCPPCAPPELLGGPSVFLFPPPKPKDTLMI SRTPRYTCVVVDVSHEDPEVKFMWY 301
QY 264 VDGEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKEKEYCKCNKALPAPIETISK 323
DB 302 VDGEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKEKEYCKCNKALPAPIETISK 361
QY 324 AKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLT 383
DB 362 AKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLT 421
QY 384 DSDGSFFLYSKLTVDKSRWQOGNVFSCSYMEHALHNYTQKSLSLSPG 431
DB 422 DSDGSFFLYSKLTVDKSRWQOGNVFSCSYMEHALHNYTQKSLSLSPG 469

RESULT 63
US-10-227-694-5
; Sequence 5, Application US/10227694
; Publication No. US2003007739A1
; GENERAL INFORMATION:
; APPLICANT: Simmons, Laura
; APPLICANT: Andersen, Dana
; TITLE OF INVENTION: A SYSTEM FOR ANTIBODY EXPRESSION AND ASSEMBLY
; FILE REFERENCE: P1867R1
; CURRENT APPLICATION NUMBER: US/10/227,694
; PRIOR FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: US 60/315,209
; PRIOR FILING DATE: 2001-08-27
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 5
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-227-694-5

Query Match 52.4%; Score 1266; DB 14; Length 470;
Best Local Similarity 58.8%; Pred. No. 5.1e-81;
Matches 275; Conservative 26; Mismatches 69; Indels 98; Gaps 14;
QY 30 LGKGGDTVELTCTAS--QKKSIOFHM-----KNSNOIKILG-NGGSFLTQKSPSLNRA 80
DB 34 LVQPGGSLRLSCAAGGFINKEYYMMWVROAPGKLEWGLIDPEGN--TIYDPKFORA 91
QY 81 -----DSRRSLWDQGNFLLIKNLKIEDSDYICEVEDQKEVOLLVGLTANSPTHL-- 133
DB 92 TISADNSKVTALQWN-----SLRAEDTAVYYCA-----RDTAAYF 127
QY 134 -LOGSGLTLTLESPPGSSPSVQCRRPRGKNIOGG-----KTLSSV----- 172
DB 128 DYGEGGTIVTSSASTKGPSVFLPAPSSKSTSGGTAALGCLVKDYFPPPVTVSNMGSALT 187

```

```

QY 173 -----QLELDQSG-----TWCTVLQNOKKVEFKIDIVPCAPAPK 208
DB 168 SGVHTFPRAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD----KVEPK 241
QY 209 SCDKTHTC-----PELLGSPSVFLPPPKPKDTLMI SRTPRYTCVVVDVSHEDPEVKFMWY 263
DB 242 SCDKTHTCPPCAPPELLGGPSVFLFPPPKPKDTLMI SRTPRYTCVVVDVSHEDPEVKFMWY 301
QY 264 VDGEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKEKEYCKCNKALPAPIETISK 323
DB 302 VDGEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKEKEYCKCNKALPAPIETISK 361
QY 324 AKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLT 383
DB 362 AKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLT 421
QY 384 DSDGSFFLYSKLTVDKSRWQOGNVFSCSYMEHALHNYTQKSLSLSPG 431
DB 422 DSDGSFFLYSKLTVDKSRWQOGNVFSCSYMEHALHNYTQKSLSLSPG 469

RESULT 64
US-09-848-832-3
; Sequence 3, Application US/09848832
; Publication No. US20030165507A1
; GENERAL INFORMATION:
; APPLICANT: Hooper, Douglas
; APPLICANT: Dietzschold, Bernhard
; TITLE OF INVENTION: RABIES VIRUS-SPECIFIC NEUTRALIZING HUMAN
; FILE REFERENCE: H0001.NP0002
; CURRENT APPLICATION NUMBER: US/09/848,832
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: 60/204,518
; PRIOR FILING DATE: 2000-05-16
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 474
; TYPE: PRT
; ORGANISM: Homo sapien
US-09-848-832-3

Query Match 52.4%; Score 1266; DB 10; Length 474;
Best Local Similarity 59.1%; Pred. No. 5.1e-81;
Matches 276; Conservative 32; Mismatches 71; Indels 88; Gaps 15;
QY 30 LGKGGDTVELTCTAS-----QKKSIOFHMNSNOIKILGNGSFL--TKGP 73
DB 30 LVQPGGSLRLSCAAGGFTPSNYAMSWVROAPGKLEWVSA--ISASGH-STYLADSVYGR 86
QY 74 SKLNDRAISRSLWDQGNFLLIKNLKIEDSDYICEVEDQKEVOLLVGLTANSPTHL 133
DB 87 FTIS-RDNSKVTALQWN-----SLRAEDTAVYYCA--KDRVTVIIV-LNGGFD-- 132
QY 134 LOGSGLTLTLESPPGSSPSVQCRRPRGKNIOGG-----KTLSSV----- 172
DB 133 YMGGCTIVTSSASTKGPSVFLPAPSSKSTSGGTAALGCLVKDYFPPPVTVSNMGSALT 192
QY 173 -----QLELDQSG-----TWCTVLQNOKKVEFKIDIVPCAPAPK 209
DB 193 GVHTFPRAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD----KVEPK 246
QY 210 CDKTHTC-----PELLGSPSVFLPPPKPKDTLMI SRTPRYTCVVVDVSHEDPEVKFMWY 264
DB 247 CDKTHTCPPCAPPELLGGPSVFLFPPPKPKDTLMI SRTPRYTCVVVDVSHEDPEVKFMWY 306
QY 265 DGEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKEKEYCKCNKALPAPIETISKA 324
DB 307 DGEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKEKEYCKCNKALPAPIETISKA 366
QY 325 KGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLT 384

```



```
Db      367 KGOPREPOVYTLPPSBEEMTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTTTPVLD 426
Qy      385 SDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      427 SDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 473

RESULT 65
US-10-225-108A-3
; Sequence 3, Application US/10225108A
; Publication No. US20030157112A1
; GENERAL INFORMATION:
; APPLICANT: HOOPER, Craig
; APPLICANT: DIETZSCHOLD, Bernhard
; TITLE OF INVENTION: Recombinant Antibodies, and Compositions
; TITLE OF INVENTION: and Methods for Making Them
; FILE REFERENCE: 8321-110
; CURRENT APPLICATION NUMBER: US/10/225,108A
; CURRENT FILING DATE: 2003-04-10
; PRIOR APPLICATION NUMBER: US 09/848,832
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/204,518
; PRIOR FILING DATE: 2001-05-16
; PRIOR APPLICATION NUMBER: US 60/314,023
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FaastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 474
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-225-108A-3

Query Match      52.4%; Score 1266; DB 14; Length 474;
Best Local Similarity 59.1%; Pred. No. 5.1e-81;
Matches 2/6; Conservative 32; Mismatches 71; Indels 88; Gaps 15;

Qy      30 LGKGDVTELTCTAS-----OKKSIOFHKNSNOIKILGNQGSFL---TKGP 73
Db      30 LVQPGSLRLSCAAGFTFSNYAMSWRAQPGKLEWISA--ISASGH-STYLAASVKR 86
Qy      74 SKLNDRADSRSLMDQGNFPLIILKLIKIEDSDTYICEVEDQKEVQLVFGILTANSDTHL 133
Db      87 FTIS-RDNSKNTLYLQMN-----SLRAEDTAVYYCA--KOREVTMIIV-LNGGFD--- 132
Qy      134 LQGSLTLTLSPSSPSVQCRSPRGKNIQGS-----KTLSSV----- 172
Db      133 YWGGGTRVTVSSASTKGPSVFPLAPSSKSTSGGTALGCLVKDYFPEPTVWSNNGALTS 192
Qy      173 -----QLELDSG-----TWCTVLOKCKVEKFKIDIVPCPAPEPS 209
Db      193 GVHTPAVLQSSGLVSLSSVTVTYPSSSLGTQYICNV--NHKPSNTKVD---KVERPS 246
Qy      210 CDKHTTC-----PELLGSPSVFLPPPKPDITLMISRTPEVTCVVDVSHEDDEVKFNMY 264
Db      247 CDKHTCCPCPAPELLGSPSVFLPPPKPDITLMISRTPEVTCVVDVSHEDDEVKFNMY 306
Qy      265 DGEVHNATKTPREEDQYNSTYRVSVLTYLHODWLNKGEYCKCKVSNKALPAPIETKISKA 324
Db      307 DGEVHNATKTPREEDQYNSTYRVSVLTYLHODWLNKGEYCKCKVSNKALPAPIETKISKA 366
Qy      325 KGOPREPOVYTLPPSBEEMTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTTTPVLD 384
Db      367 KGOPREPOVYTLPPSBEEMTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTTTPVLD 426
Qy      385 SDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      427 SDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 473

RESULT 66
US-10-461-148-1
; Sequence 1, Application US/10461148
```

```
; Publication No. US20040013672A1
; GENERAL INFORMATION:
; APPLICANT: Dietzschold, Bernhard
; APPLICANT: Hooper, Douglas C.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES AND COMPOSITIONS
; TITLE OF INVENTION: AND METHODS FOR MAKING AND USING THE SAME
; FILE REFERENCE: 8321-110C11-185685
; CURRENT APPLICATION NUMBER: US/10/461,148
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: US 10/225,108
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/314,023
; PRIOR FILING DATE: 2001-08-21
; PRIOR APPLICATION NUMBER: US 09/848,832
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/204,518
; PRIOR FILING DATE: 2000-05-16
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FaastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 474
; TYPE: PRT
; ORGANISM: Human
US-10-461-148-1

Query Match      52.4%; Score 1266; DB 15; Length 474;
Best Local Similarity 59.1%; Pred. No. 5.1e-81;
Matches 2/6; Conservative 32; Mismatches 71; Indels 88; Gaps 15;

Qy      30 LGKGDVTELTCTAS-----OKKSIOFHKNSNOIKILGNQGSFL---TKGP 73
Db      30 LVQPGSLRLSCAAGFTFSNYAMSWRAQPGKLEWISA--ISASGH-STYLAASVKR 86
Qy      74 SKLNDRADSRSLMDQGNFPLIILKLIKIEDSDTYICEVEDQKEVQLVFGILTANSDTHL 133
Db      87 FTIS-RDNSKNTLYLQMN-----SLRAEDTAVYYCA--KOREVTMIIV-LNGGFD--- 132
Qy      134 LQGSLTLTLSPSSPSVQCRSPRGKNIQGS-----KTLSSV----- 172
Db      133 YWGGGTRVTVSSASTKGPSVFPLAPSSKSTSGGTALGCLVKDYFPEPTVWSNNGALTS 192
Qy      173 -----QLELDSG-----TWCTVLOKCKVEKFKIDIVPCPAPEPS 209
Db      193 GVHTPAVLQSSGLVSLSSVTVTYPSSSLGTQYICNV--NHKPSNTKVD---KVERPS 246
Qy      210 CDKHTTC-----PELLGSPSVFLPPPKPDITLMISRTPEVTCVVDVSHEDDEVKFNMY 264
Db      247 CDKHTCCPCPAPELLGSPSVFLPPPKPDITLMISRTPEVTCVVDVSHEDDEVKFNMY 306
Qy      265 DGEVHNATKTPREEDQYNSTYRVSVLTYLHODWLNKGEYCKCKVSNKALPAPIETKISKA 324
Db      307 DGEVHNATKTPREEDQYNSTYRVSVLTYLHODWLNKGEYCKCKVSNKALPAPIETKISKA 366
Qy      325 KGOPREPOVYTLPPSBEEMTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTTTPVLD 384
Db      367 KGOPREPOVYTLPPSBEEMTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTTTPVLD 426
Qy      385 SDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      427 SDGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 473

RESULT 67
US-10-207-655-240
; Sequence 240, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden-Ledbetter, Martha S.
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 390069.401C1
; CURRENT APPLICATION NUMBER: US/10/207,655
; CURRENT FILING DATE: 2002-07-25
```

```

? NUMBER OF SEQ ID NOS: 426
? SOFTWARE: Patent version 3.0
? SEQ ID NO 240
? LENGTH: 500
? TYPE: prt
? ORGANISM: Artificial Sequence
? FEATURE:
? OTHER INFORMATION: fusion polypeptide
US-10-207-655-240

```

Query Match	52.4%	Score 1266	DB 14	Length 500
Best Local Similarity	56.3%	Pred No. 5.5e-81		
Matches 274	Conservative 27	Mismatches 94	Indels 92	Gaps 12

QY	23	TOONKVLGKGGGTJVLCTTASQKSIQPHMNSNQIILINOGSLFKTKGSLKNDGADS	82
Db	27	SQSPALLASPGKATMTCTCRASSYS-YMHVYQQR-----GSPKPMYATPSNLASGVA	81
QY	83	RRLIMOG-NFLIITNKLKIEDSDTYICEVEDQKEVQLLVFGL-----	125
Db	82	RFGSGSGSYSLTISRVAEDAAATYYC-----QQWSFNPPTFGAGTKLELKDGGSGGGG	137
QY	126	---TANSDTHLD-QGSLITLLESPGSSPSVOCR-----SPR-----	159
Db	138	SGGGSSGALQDSGAEIV-----RGASVMSKCSAGVTFTSYMHVVKQTPPGGLEMI	192
QY	160	-----GKNIQGGKTLV-----SOLEODSGTWTCTVLONOKVYEFK	196
Db	193	GAIVPNGDTSYNQKFKRKAITLTVDKSSSTAYMOLSLTSEBSAAYFCARVVVYSNSWY	252
QY	197	ID-----IVPCAPPEPKSCDKTHTC-----PELLGGPSVFLPPPKDITLMI-SRPREV	244
Db	253	FDVMGCTGTVTVSSDDEPKSCDKHTCPCPAPPELLGGPSVFLPPPKDITLMI-SRPREV	312
QY	245	TCVAVDVSHDEPVEKFNMYVDGEVNAKTKRREBOQNSYRVRVSVLTVLHQDLANKKEY	304
Db	313	TCVAVDVSHDEPVEKFNMYVDGEVNAKTKRREBOQNSYRVRVSVLTVLHQDLANKKEY	372
QY	305	KCVKSNKALPAPLEKTIISKAKGQPREPOVYTLTPERDELTKNOVSLTCLVYGFPSPDIAY	364
Db	373	KCVKSNKALPAPLEKTIISKAKGQPREPOVYTLTPERDELTKNOVSLTCLVYGFPSPDIAY	432
QY	365	EMESNQGPENNYKTPPVLVSDGSFELYSKLTVDSRWQOGNVSCSYMHBALNNHTQK	424
Db	433	EMESNQGPENNYKTPPVLVSDGSFELYSKLTVDSRWQOGNVSCSYMHBALNNHTQK	492
QY	425	SLSLSPG 431	
Db	493	SLSLSPG 499	

```

RESULT 68
US-10-207-655-398
: Sequence 398, Application US/10207655
: Publication No. US20030118592A1
: GENERAL INFORMATION:
: APPLICANT: Ledbetter, Jeffrey A.
: APPLICANT: Hayden-Ledbetter, Martha S.
: TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
: FILE REFERENCE: 390069.401C1
: CURRENT APPLICATION NUMBER: US/10/207,655
: CURRENT FILING DATE: 2002-07-25
: NUMBER OF SEQ ID NOS: 426
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 398
: LENGTH: 500
: TYPE: PRT
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: fusion polypeptide
US-10-207-655-398

```

Query Match      52.4%;    Score 1266;    DB 14;    Length 500;

Best Local Similarity 56.3%; Pred. No. 5.5e-81;  
Matches 274; Conservative 27; Mismatches 94; Indels 92; Gaps 12;

Qy	23	TOGNKVLAKKKDYTELCTASOKSIOFHMKNSQIKLONQSGFLTKGSKLNRADS	82
Db	27	SOSPALSASPEEKYTMTCRASSYS-YMHYYQOKP-----GSSPKPIYAPSNLASGVA	81
Qy	83	RNSLMDQG-NPFLIITKNEKIEDSDTYICEVEDQKEVQLVFLG-----	125
Db	82	RFSGSGSGTSYSLTISRVEAEADAAATYYC-----QQMSFNPPTFGAGTKLELKDGGSGGGG	137
Qy	126	---TANSDTHLQ-QGSLITLLESPGSGSPVOCR-----SPR-----	159
Db	138	SGGGGSSAYLOQSGAEVY-----RPGASVYMSCASGYTTSTYNMHMYKOTPPQGLHMI	192
Qy	160	-----GKNIQGGKITLSV-----SOLEODSGTMTCTYLOKQKVEFK	196
Db	193	GAIPGNAGDTSYNOKFKGKATLTVDKSSSTAYMQLSLTSEDSAVYFCARVVVYSNSYMY	252
Qy	197	ID-----IYPCAPAPPKSCDKHTTC-----PELLGGSPSYFLPPPKDTLMI.SRTPEV	244
Db	253	FDWMGTGTTVYSSDDEPKSCDKHTTCPPSAPELGGSPSYFLPPPKDTLMI.SRTPEV	312
Qy	245	TCVVVDVSHEDDEVKFNMYVDGEVHNATKTRPEQYNSTYRVVSVLTVLIHQDWLNKEY	304
Db	313	TCVVVDVSHEDDEVFNMYVDGEVHNATKTRPEQYNSTYRVVSVLTVLIHQDWLNKEY	372
Qy	305	KCVNKKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPSPIAV	366
Db	373	KCVNKKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPSPIAV	432
Qy	365	EMESNQGPENNYKTTPEVLVDSGFFLYSKLTVDKSRWQGNVPSCSYMEHALHNHYTQK	424
Db	433	EMESNQGPENNYKTTPEVLVDSGFFLYSKLTVDKSRWQGNVPSCSYMEHALHNHYTQK	492
Qy	425	SLSLSPG 431	
Db	493	SLSLSPG 499	

```

: RESULT 69
: US-10-071-485-67
: Sequence 67, Application US/10071485
: Publication No. US20030099648A1
: GENERAL INFORMATION:
: APPLICANT: Buysse, Marie-Ange
: APPLICANT: Sablon, Erwin
: TITLE OF INVENTION: INTERFERON-gamma-BINDING MOLECULES FOR TREATING SEPTIC
: TITLE OF INVENTION: SHOCK.
: TITLE OF INVENTION: CACHEXIA, IMMUNE DISEASES AND SKIN DISORDERS
: FILE REFERENCE: INNS:015
: CURRENT APPLICATION NUMBER: US/10/071,485
: CURRENT FILING DATE: 2002-02-07
: PRIOR APPLICATION NUMBER: 09/485,737
: PRIOR FILING DATE: 2000-02-14
: PRIOR APPLICATION NUMBER: PCT/EP 98/05165
: PRIOR FILING DATE: 1998-08-14
: PRIOR APPLICATION NUMBER: EPO 98870139.7
: PRIOR FILING DATE: 1998-06-18
: PRIOR APPLICATION NUMBER: EPO 97870122.5
: PRIOR FILING DATE: 1997-08-18
: NUMBER OF SEQ ID NOS: 104
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 67
: LENGTH: 468
: TYPE: PRT
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: SYNTHETIC
: US-10-071-485-67

```

Query Match	52.4%;	Score 1265.5;	DB 14;	Length 468
Best Local Similarity	57.2%;	Pred. NO. 5.5e-81;		

Matches	277;	Conservative	31;	Mismatches	79;	Indels	97;	Gaps	13;
Qy		11	LVLTQALLPATQGNKVLGKGDVTELTCTASQKSIQTHMKNNOIKILGNQGSFLT	70					
Db		17	VILSVQVLQVQSGSE-----LKKPGASVXISCKAS-----GYTFDYGMNVVKAQPGG---L	65					
Qy		71	KGPSKLNDRADSRSLMD-QGNFP-----LIIKNLKIEDSDPYICEVDEQKEV	118					
Db		66	KMMGMINTYGESESTYDDPFKRFVPSLDTSVSAAVLQISLSLAEDTATYFC-----	116					
Qy		119	QLVLFGLTANSDTHLLQ--GSLTLTLESPPGSSPSVQCRSPRGKNIQSG-----	166					
Db		117	-----ARRGFAMDYWGQGTYYTTSASATKGSVFPPLAPSSKTSGGTALAGCLVKD	168					
Qy		167	---KTLVS-----QLELDQSG-----TWTCYLVQNOCK	192					
Db		169	YFPFPTVTVSNMNGALTSVGHTEFPAVLQSSGLYSLSSVTVPESSLSGTQTYICNV--NHKP	226					
Qy		193	VEFKIDIVCPAPPEPKGCDKTHTC-----PELLGSPSVFLPPPKKOTLMSRPEVTCV	247					
Db		227	SNTRYD---KREVEKSCDKHTHTCPCPAPPELLGSPSVFLPPPKKOTLMSRPEVTCV	282					
Qy		248	VVDVSHEDPEVKFMNVYVDGVEVHNNAKTKPREBOYSTFRVVSVLTVLVHQDMINGKEYCK	307					
Db		283	VVDVSHEDPEVKFMNVYVDGVEVHNNAKTKPREBOYSTFRVVSVLTVLVHQDMINGKEYCK	342					
Qy		308	VSNAKLPAPIEKTSISKAGQPREPOVYTLPPSRDELITNOVSLTCLVGFYPSDIADWE	367					
Db		343	VSNAKLPASIEKTSISKAGQPREPOVYTLPPSRDEMTNQVSLTCLVGFYPSDIADWE	402					
Qy		368	SNQGPENNYKTTTPPLVLDSDGSFPLYSKLTVDKSRQGNVSCSYMEALHNHTYQKSL	427					
Db		403	SNQGPENNYKTTTPPLVLDSDGSFPLYSKLTVDKSRQGNVSCSYMEALHNHTYQKSL	462					
Qy		428	LSPG 431						
Db		463	LSPG 466						
RESULT 70									
US-10-071-485-90									
Sequence 90, Application US/10071485									
Publication NO. US2003009648A1									
GENERAL INFORMATION:									
APPLICANT: Buysse, Marie-Ange									
APPLICANT: Sablon, Erwin									
TITLE OF INVENTION: INTERFERON-gamma-BINDING MOLECULES FOR TREATING SEPTIC									
TITLE OF INVENTION: SHOCK,									
TITLE OF INVENTION: CACHEKIA, IMMUNE DISEASES AND SKIN DISORDERS									
FILE REFERENCE: INNS:015									
CURRENT APPLICATION NUMBER: US/10/071.485									
CURRENT FILING DATE: 2002-02-07									
PRIOR APPLICATION NUMBER: 09/485.737									
PRIOR FILING DATE: 2000-02-14									
PRIOR APPLICATION NUMBER: PCT/EP 98/05165									
PRIOR FILING DATE: 1998-08-14									
PRIOR APPLICATION NUMBER: EPO 96870139.7									
PRIOR FILING DATE: 1998-06-18									
PRIOR APPLICATION NUMBER: EPO 97870122.5									
PRIOR FILING DATE: 1997-08-18									
NUMBER OF SEQ ID NOS: 104									
SOFTWARE: PatentIn version 3.0									
SEQ ID NO 90									
LENGTH: 711									
TYPE: PRT									
ORGANISM: Artificial Sequence									
FEATURE:									
OTHER INFORMATION: SYNTHETIC									
US-10-071-485-90									
Query Match		52.4%	Score 1265.5;	DB 14;	Length 711;				
Best Local Similarity		57.2%	Pred. No. 9.2e-81;						
Matches 277;		Conservative 31;	Mismatches 79;	Indels 97;	Gaps 13;				

```

OY 11 LVLVLALLPAATGKGNVVLGKKGDVLELCTASQSKSIQIEMHKNISQIILNDOSFLT 70
Db 17 VILSVQVLVVGSGE-----LKKPGASVKISCKAS--GYFTFTGYAMWVAQAPGQC--L 65
OY 71 KGPSEKLNDRADSRSLMD--QGNEP-----LIKNLKIEDSDTYICEVEDQKEEV 118
Db 66 KMMGMINTYTGSESTYVDPFKGRFVFSLDTSVSAAYILQISSLKAEDETATYTC----- 116
OY 119 QLVLFGLTANSDFHLLQ--GQSLLTLIESPPSSPSVQCSPPGKXIQGG----- 166
Db 117 -----ARGFYAMDYWGQGTIVTVSSASTKGPSVFPLPASPSTSGGTALGCLVKD 168
OY 167 ---KTLSSV-----QLELIDSG-----TWTCITVLQNOCK 192
Db 169 YFPEPPTVSNMNSGALTSIGCHTTPPAVLQSSGLYSLSVYTVSSSLGTYITICV--NHK 226
OY 193 VEFKIDIVPCPAPPEPKSCDKTHTC-----DELLGGPSVFLPPPKPDITLISRTPEVTCV 247
Db 227 SNTKVD-----KRVPEPKSCDKTHTCPPCPAPELLGGPSVFLPPPKPDITLISRTPEVTCV 282
OY 248 VVDVSHEDPEVKFMYVDGYEVNNAKTKRPEEQYNSYRVSVLTVLHQMNGKEYKCK 307
Db 283 VVDVSHEDPEVKFMYVDGYEVNNAKTKRPEEQYNSYRVSVLTVLHQMNGKEYKCK 342
OY 308 VSNNALEPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGYPSPDIAYEVE 367
Db 343 VSNKALPASLEKITSKAKGQPREPOVYTLPPSRDEMTKNOVSLTCLVKGYPSPDIAYEVE 402
OY 368 SNGQPENNYKTTPEVLDSGDSFFLYSKLTVDKSRMOQGNVSCSVNHEALHNHYTQSKLS 427
Db 403 SNGQPENNYKTTPEVLDSGDSFFLYSKLTVDKSRMOQGNVSCSVNHEALHNHYTQSKLS 462
OY 428 LSPG 431
Db 463 LSPG 466

RESULT 71
US-10-408-901-42
; Sequence 42, Application US/10408901
; Publication No. US20040023131AI
; GENERAL INFORMATION:
; APPLICANT: Boyle, William
; APPLICANT: Huang, Hailun
; APPLICANT: Elliot, Robin
; APPLICANT: Sullivan, John
; APPLICANT: Medlock, Eugene
; TITLE OF INVENTION: Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway
; TITLE OF INVENTION: Inhibitors
; FILE REFERENCE: MBHB 01-1145-A
; CURRENT APPLICATION NUMBER: US/10/408,901
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 42
; LENGTH: 445
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-408-901-42

Query Match 52.4%; Score 1265; DB 16; Length 445;
Best Local Similarity 59.0%; Pred. No. 5.5e-81;
Matches 271; Mismatches 71; Indels 90; Gaps 12;

OY 34 GDTVELCTASQ--KKSIOFHW-----KXNSNOIKILANGG-----SFLTKGPSEKLNDRAD 81
Db 15 GGSILRLSCVGSRTFFSAYPMHWVRQAPGKGLIEWVSGISGCGGTNADSVXGRFTIS-RDT 73
OY 82 SRSLMNGGNFPLLIKLNKLIKIEDSDTYICEVEDQKEEVQLVLFGLTANSDFHLLQSGSLTL 141
Db 74 AKNSLTVIQNM-----SLRAEDMAVYYC-----ARGRNSFDWYGGGCTIV 111

```

```

Oy 14z TLSPSSSSVOCRAPRGNLOGS-----KITLSVS-----QLE 175
    ||| ||| |||
Db 112 TVSSASTKGPVPEPLAPSSKTSIGGALGLVKDY PEPPTVSNNSGALTSGVHTPEAV 171
    ||| ||| |||
Oy 176 LODSG-----TWTCYLOXOKKVEFKIDIVPCPAPPEPKSCDTHTC- 216
    ||| ||| |||
Db 172 LOSSGLYSLSSVYTVBSSSLGTOTYICNV--NHKSNKTVD---KKVEPKSCDKHTCP 225
    ||| ||| |||
Oy 217 ----PELLGSPVLEPPPKPKDTLMSRTPEVTCVVDVSHDEPEKNMYVDGEVHNA 272
    ||| ||| |||
Db 226 PCPAPPELLGSPVFLPEPPKPKDTLMSRTPEVTCVVDVSHDEPEKNMYVDGEVHNA 265
    ||| ||| |||
Oy 273 KTKPREEQYNSTRVVSVLTVLHODMLNKEKYCKVSNKALPAPIEKTISPAKQPREPQ 322
    ||| ||| |||
Db 286 KTKPREEQYNSTRVVSVLTVLHODMLNKEKYCKVSNKALPAPIEKTISPAKQPREPQ 345
    ||| ||| |||
Oy 333 VYTLPERDELTKNOVSLTCLVKGFPSPDIANWESNQGPENNYKTPPVLDSDGSFFLY 352
    ||| ||| |||
Db 346 VYTLPERDELTKNOVSLTCLVKGFPSPDIANWESNQGPENNYKTPPVLDSDGSFFLY 405
    ||| ||| |||
Oy 393 SKTLVDSKRMQGNVSPSCSVMHEALNNHTQSLSPG 431
    ||| ||| |||
Db 406 SKTLVDSKRMQGNVSPSCSVMHEALNNHTQSLSPG 444
    ||| ||| |||

```

```

RESULT 72
US-10-411-037-56
; Sequence 56, Application US/10411037
; Publication No. US2004003446A1
; GENERAL INFORMATION:
; APPLICANT: Necore Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A
; TITLE OF INVENTION: GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-037-56

```

	Query Match	52.4%	Score 1265	DB 12,	Length 448;
	Best Local Similarity	58.7%	Pred. No. 5	6e-81;	
	Matches	270;	Conservative	26;	Mismatches 80;
					Indels 84;
					Gaps 11
Oy	32 KKGDIVELCTASQKKSIOF--HWKNSNOIKILGNQ---- <td>83</td> <td></td> <td></td> <td></td>	83			
b	13 KPGSSVAKSCSKSGAFTNYLLIET-----VRAPAGGGLMIGVITLII:::	67			

```

QY      84 RSLW---DQGNPLLIKNLKIETDSTQTYCEVDEQKEBQVLVFGJLANSJDTHLQOQSLT 140
Db      68 VTLTYDSESTNAYWMLSSRSRESDIAVYFCARD-----GNYGFWAYMGQGLT 114
QY      141 LTLSEPPSSPSVQCRSPRGKNIOGG-----KTLSVS-----OL 174
Db      115 VTVSSASTKRGSVFPLAPSSKSTSGTALGCLVMDPEPEYLTVMNSGALTSQVHTFPA 174
QY      175 ELQDSG-----TWCTVLONQKKVEFKIDIVPCPAPBPYSCDKTHTC 216
Db      175 VLQSSGLYLSLSVAVTPSSSLGTQTYICNV--NHRPSMTKVD---KVEBPYSCDKTHTC 228
QY      217 -----PELLGGSVFLFPKPKDQTLMISTRPEVTCVVVDVSHEDPEVKRWYVDGVEVNH 271
Db      229 PPCPAPELLGGSVFLFPKPKDQTLMISTRPEVTCVVVDVSHEDPEVKRWYVDGVEVNH 288
QY      272 AKTKREEQYNSTYVSVVLTVLHODMVLNGKEYCKKSVNSKALPAPIEKTISAKQOPREP 331
Db      269 AKTKREEQYNSTYVSVVLTVLHODMVLNGKEYCKKSVNSKALPAPIEKTISAKQOPREP 348
QY      332 QVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLVLDGGSFFL 391
Db      349 QVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLVLDGGSFFL 408
QY      352 YSKLTVDSKRWQQGNVFCSCVWHEHLNHHYTKQSLSLSPG 431
Db      409 YSKLTVDSKRWQQGNVFCSCVWHEHLNHHYTKQSLSLSPG 448

```

```

RESULT 73
US-10-411-026-56
/ Sequence 56, Application US/10411026
/ Publication No. US20040063911A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: DeFrees, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
/ APPLICANT: Hakes, David
/ APPLICANT: Chen, Xi
/ TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THEM
/ TITLE OF INVENTION: METHODS
/ FILE REFERENCE: 040853-01-5053
/ CURRENT APPLICATION NUMBER: US/10/411,026
/ CURRENT FILING DATE: 2003-04-09
/ PRIOR APPLICATION NUMBER: US 60/328,523
/ PRIOR FILING DATE: 2001-10-10
/ PRIOR APPLICATION NUMBER: US 60/344,692
/ PRIOR FILING DATE: 2001-10-19
/ PRIOR APPLICATION NUMBER: US 60/387,292
/ PRIOR FILING DATE: 2002-06-07
/ PRIOR APPLICATION NUMBER: US 60/391,777
/ PRIOR FILING DATE: 2002-06-25
/ PRIOR APPLICATION NUMBER: US 60/396,594
/ PRIOR FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US 60/404,249
/ PRIOR FILING DATE: 2002-08-16
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ PRIOR FILING DATE: 2002-08-28
/ NUMBER OF SEQ ID NOS: 75
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 56
/ LENGTH: 448
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-10-411-026-56

```

	Query Match	52.4%	Score 1265;	DB 12;	Length 448;
	Best Local Similarity	58.7%	Pred. No. 5.6e-81;		
	Matches 270;	Conservative 26;	Mismatches 80;	Indels 84;	Gaps 11.
QY	32 KKSDVELTCASQKSIQF--HKNSNQITLGNOC-----SFLTYGSPKINDRADRSR 83	: : : :   :	:	: :   :	: : :

Db 13 KPGSVKVSCKASGAFTNYLIEW-----VRQAPGGGLEWIGVYIPGSGGTNYNEKFKGR 67  
Qy 84 RSLM---DQGNFLLIKNLKIEDSDTYICEVDQKEEVLVFGLTANSDFHLQOQSFLT 140  
Db 68 VTLTVDESTNTAYMELSSLRSEDTAVYFCARD-----GNYGMFAYMGQGTU 114  
Qy 141 LTLSPGSSPSVQCRSPRGKNIQGG-----KTLVS-----QL 174  
Db 115 VTVSSASTGPGSVFPLAPSSKSTSGGTALGCLVKDYFPPEVTVSMNSGALTSVHTFPA 174  
Qy 175 ELQDSG-----TWCTVLQNKVEFKIDIVPCPAPPEKSCDKTHTC 216  
Db 175 VQSSGLVSLSSVTVPPSSSLGTQYICNV--NHKPSNTKVD---KYPEKSCDKTHTC 228  
Qy 217 -----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 271  
Db 229 PCCPAPPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 288  
Qy 272 AKTKPREBOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKGQPREP 331  
Db 289 AKTKPREBOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKGQPREP 348  
Qy 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPL 391  
Db 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPL 408  
Qy 392 YSKLTVDKSRMQQGNVFCGSVMHEALHNHYTQKSLSLSPG 431  
Db 409 YSKLTVDKSRMQQGNVFCGSVMHEALHNHYTQKSLSLSPG 448

## RESULT 74

US-10-410-962-56  
/ Sequence 56, Application US/10410962  
/ Publication No. US20040077836A1  
/ GENERAL INFORMATION:  
/ APPLICANT: Neose Technologies, Inc.  
/ APPLICANT: DeFreese, Shawn  
/ APPLICANT: Zopf, David  
/ APPLICANT: Bayer, Robert  
/ APPLICANT: Hakes, David  
/ APPLICANT: Chen, Xi  
/ APPLICANT: Bove, Caryn  
/ TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND  
/ FILE REFERENCE: 040853-01-5054  
/ CURRENT APPLICATION NUMBER: US/10/410,962  
/ PRIOR FILING DATE: 2003-04-09  
/ PRIOR APPLICATION NUMBER: US 60/328,523  
/ PRIOR FILING DATE: 2001-10-10  
/ PRIOR APPLICATION NUMBER: US 60/344,692  
/ PRIOR FILING DATE: 2001-10-19  
/ PRIOR APPLICATION NUMBER: US 60/387,292  
/ PRIOR FILING DATE: 2002-06-07  
/ PRIOR APPLICATION NUMBER: US 60/391,777  
/ PRIOR FILING DATE: 2002-06-25  
/ PRIOR APPLICATION NUMBER: US 60/396,594  
/ PRIOR FILING DATE: 2002-07-17  
/ PRIOR APPLICATION NUMBER: US 60/404,249  
/ PRIOR FILING DATE: 2002-08-16  
/ PRIOR APPLICATION NUMBER: US 60/407,527  
/ PRIOR FILING DATE: 2002-08-28  
/ NUMBER OF SEQ ID NOS: 75  
/ SOFTWARE: PatentIn version 3.2  
/ SEQ ID NO 56  
/ LENGTH: 448  
/ TYPE: PRT  
/ ORGANISM: Homo sapiens  
US-10-410-962-56

Query Match 52.4%; Score 1265; DB 16; Length 448;  
Best Local Similarity 58.7%; Pred. No. 5.6e-81;  
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

Qy 32 KKGDTVELTCTASQKKSIOF--HMKSNQIKILNQG-----SFLTKGPSKLNRADSR 83  
Db 13 KPGSVKVSCKASGAFTNYLIEW-----VRQAPGGGLEWIGVYIPGSGGTNYNEKFKGR 67  
Qy 84 RSLM---DQGNFLLIKNLKIEDSDTYICEVDQKEEVLVFGLTANSDFHLQOQSFLT 140  
Db 68 VTLTVDESTNTAYMELSSLRSEDTAVYFCARD-----GNYGMFAYMGQGTU 114  
Qy 141 LTLSPGSSPSVQCRSPRGKNIQGG-----KTLVS-----QL 174  
Db 115 VTVSSASTGPGSVFPLAPSSKSTSGGTALGCLVKDYFPPEVTVSMNSGALTSVHTFPA 174  
Qy 175 ELQDSG-----TWCTVLQNKVEFKIDIVPCPAPPEKSCDKTHTC 216  
Db 175 VQSSGLVSLSSVTVPPSSSLGTQYICNV--NHKPSNTKVD---KYPEKSCDKTHTC 228  
Qy 217 -----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 271  
Db 229 PCCPAPPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 288  
Qy 272 AKTKPREBOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKGQPREP 331  
Db 289 AKTKPREBOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKGQPREP 348  
Qy 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPL 391  
Db 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPL 408  
Qy 392 YSKLTVDKSRMQQGNVFCGSVMHEALHNHYTQKSLSLSPG 431  
Db 409 YSKLTVDKSRMQQGNVFCGSVMHEALHNHYTQKSLSLSPG 448

## RESULT 75

US-10-411-049-56  
/ Sequence 56, Application US/10411049  
/ Publication No. US20040082026A1  
/ GENERAL INFORMATION:  
/ APPLICANT: Neose Technologies, Inc.  
/ APPLICANT: DeFreese, Shawn  
/ APPLICANT: Zopf, David  
/ APPLICANT: Bayer, Robert  
/ APPLICANT: Hakes, David  
/ APPLICANT: Chen, Xi  
/ APPLICANT: Bove, Caryn  
/ TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON  
/ FILE REFERENCE: 040853-01-5055  
/ CURRENT APPLICATION NUMBER: US/10/411,049  
/ PRIOR FILING DATE: 2003-04-09  
/ PRIOR APPLICATION NUMBER: US 60/328,523  
/ PRIOR FILING DATE: 2001-10-10  
/ PRIOR APPLICATION NUMBER: US 60/344,692  
/ PRIOR FILING DATE: 2001-10-19  
/ PRIOR APPLICATION NUMBER: US 60/387,292  
/ PRIOR FILING DATE: 2002-06-07  
/ PRIOR APPLICATION NUMBER: US 60/391,777  
/ PRIOR FILING DATE: 2002-06-25  
/ PRIOR APPLICATION NUMBER: US 60/396,594  
/ PRIOR FILING DATE: 2002-07-17  
/ PRIOR APPLICATION NUMBER: US 60/404,249  
/ PRIOR FILING DATE: 2002-08-16  
/ PRIOR APPLICATION NUMBER: US 60/407,527  
/ PRIOR FILING DATE: 2002-08-28  
/ NUMBER OF SEQ ID NOS: 75  
/ SOFTWARE: PatentIn version 3.2  
/ SEQ ID NO 56  
/ LENGTH: 448  
/ TYPE: PRT  
/ ORGANISM: Homo sapiens  
US-10-411-049-56

```

Query Match          52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDTVELTCTASQKKSIOF--HWKNSNQIKILGNQ-----SFLTKGPSKLNDRASR 83
DB 13 KGGSSVAVSCAKSGVATNTYLIEM-----VRQAPQGLEMIIGVIPPSSGGTNNYKFKGR 67
QY 84 RSLM---DQGNFPLIITKNLIKIEDSDTYICEVEDQKEEVQLVFGLTANS DTHLQGSFLT 140
DB 68 VTLTVDESTNTAYMELSLRSSEDTAVYFCARD-----GNYGMFAVMGQGT 114
QY 141 LTLSPGSSPSVQCRSPRKNIOG-----KTLSSV-----QL 174
DB 115 VTVSSASTKGPSPVFLPAPSSKSTSGTALGCLVQDYFPEPTVSNMNGALTSGVHTPPA 174
QY 175 ELQDSG-----TWTCVLOQOKVEKIDIVPCPAPRPSCKDTHTC 216
DB 175 VLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVPKSCDKTHTC 228
QY 217 -----PELLGSPSVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVDGVEVHN 271
DB 229 PCPAPRLLGSPSVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVDGVEVHN 288
QY 272 AKTKREEOYNSTRVAVSVLTVLHODMLNGKEYCKKVSNNALPAPIEKTISKAKGQPREP 331
DB 289 AKTKREEOYNSTRVAVSVLTVLHODMLNGKEYCKKVSNNALPAPIEKTISKAKGQPREP 348
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFL 391
DB 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFL 408
QY 392 YSKLTVDKSRMQQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
DB 409 YSKLTVDKSRMQQGNVFCSCVMHEALHNHYTOKSLSLSPG 448

RESULT 76
US-10-410-930-56
; Sequence 56, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defreese, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bower, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 448
; TYPE: PRT

```

```

; ORGANISM: Homo sapiens
US-10-410-930-56

Query Match          52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDTVELTCTASQKKSIOF--HWKNSNQIKILGNQ-----SFLTKGPSKLNDRASR 83
DB 13 KGGSSVAVSCAKSGVATNTYLIEM-----VRQAPQGLEMIIGVIPPSSGGTNNYKFKGR 67
QY 84 RSLM---DQGNFPLIITKNLIKIEDSDTYICEVEDQKEEVQLVFGLTANS DTHLQGSFLT 140
DB 68 VTLTVDESTNTAYMELSLRSSEDTAVYFCARD-----GNYGMFAVMGQGT 114
QY 141 LTLSPGSSPSVQCRSPRKNIOG-----KTLSSV-----QL 174
DB 115 VTVSSASTKGPSPVFLPAPSSKSTSGTALGCLVQDYFPEPTVSNMNGALTSGVHTPPA 174
QY 175 ELQDSG-----TWTCVLOQOKVEKIDIVPCPAPRPSCKDTHTC 216
DB 175 VLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVPKSCDKTHTC 228
QY 217 -----PELLGSPSVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVDGVEVHN 271
DB 229 PCPAPRLLGSPSVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVDGVEVHN 288
QY 272 AKTKREEOYNSTRVAVSVLTVLHODMLNGKEYCKKVSNNALPAPIEKTISKAKGQPREP 331
DB 289 AKTKREEOYNSTRVAVSVLTVLHODMLNGKEYCKKVSNNALPAPIEKTISKAKGQPREP 348
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFL 391
DB 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFL 408
QY 392 YSKLTVDKSRMQQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
DB 409 YSKLTVDKSRMQQGNVFCSCVMHEALHNHYTOKSLSLSPG 448

RESULT 77
US-10-410-997-56
; Sequence 56, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defreese, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bower, Caryn
; TITLE OF INVENTION: POLYCLAL STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2

```

SEQ ID NO 56  
LENGTH: 448  
TYPE: PR  
ORGANISM: Homo sapiens  
US-10-410-997-56

Query Match 52.4%; Score 1265; DB 16; Length 448;  
Best Local Similarity 58.7%; Pred. No. 5.6e-81;  
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDTVELTCTASQKSIQF--HMKNNOIKILGNQ-----SFLTKGPSKLNDRADR 83  
D 13 KPGSSVKSCKASGYAFTNYLIEW-----VROAPQGLEWIGVYIPGSGGTINNEKFKGR 67  
QY 84 RSLM---DQGNFPLIIRKLIKIEDSDTYICEVEQKEEVQLVFGLTANSDTLLQGSILT 140  
D 68 VTLTDESTNTAYMELSSLSRSEDYAVFCARD-----GNYGMFAVWGQGTLL 114  
QY 141 LTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS-----QL 174  
D 115 VTVSSASTKGPVFLPAPSSKSTSGTALGCLVRODFPEPVTVSMNSGALTSVHTFPA 174  
QY 175 ELQDSG-----TWCTVLONQKVEFKIDIVPCPAPBPKSCDKTHTC 216  
D 175 VQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHRKPSNTKVD---KQVEPKSCDKTHTC 228  
QY 217 -----PELLGGSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 271  
D 229 PCPAPBELLGGSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 288  
QY 272 AKTKPREEQYNSTYRVSVLTVLHODMLNGKEYCKKVSNAKALPAPIEKTISKAKQPREP 331  
D 289 AKTKPREEQYNSTYRVSVLTVLHODMLNGKEYCKKVSNAKALPAPIEKTISKAKQPREP 348  
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNQGPENNYKTTTPVLDSDGSFPL 391  
D 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNQGPENNYKTTTPVLDSDGSFPL 408  
QY 392 YSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 431  
D 409 YSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 448

## RESULT 78

US-10-411-012-56  
Sequence 56, Application US/10411012  
Publication No. US20040132640A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: Defreese, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
APPLICANT: Bower, Caryn  
TITLE OF INVENTION: GLYCOSYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
FILE REFERENCE: 040853-01-5051  
CURRENT APPLICATION NUMBER: US/10/411,012  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 56  
LENGTH: 448  
TYPE: PR  
ORGANISM: Homo sapiens  
US-10-411-012-56

Query Match 52.4%; Score 1265; DB 16; Length 448;  
Best Local Similarity 58.7%; Pred. No. 5.6e-81;  
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDTVELTCTASQKSIQF--HMKNNOIKILGNQ-----SFLTKGPSKLNDRADR 83  
D 13 KPGSSVKSCKASGYAFTNYLIEW-----VROAPQGLEWIGVYIPGSGGTINNEKFKGR 67  
QY 84 RSLM---DQGNFPLIIRKLIKIEDSDTYICEVEQKEEVQLVFGLTANSDTLLQGSILT 140  
D 68 VTLTDESTNTAYMELSSLSRSEDYAVFCARD-----GNYGMFAVWGQGTLL 114  
QY 141 LTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS-----QL 174  
D 115 VTVSSASTKGPVFLPAPSSKSTSGTALGCLVRODFPEPVTVSMNSGALTSVHTFPA 174  
QY 175 ELQDSG-----TWCTVLONQKVEFKIDIVPCPAPBPKSCDKTHTC 216  
D 175 VQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHRKPSNTKVD---KQVEPKSCDKTHTC 228  
QY 217 -----PELLGGSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 271  
D 229 PCPAPBELLGGSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 288  
QY 272 AKTKPREEQYNSTYRVSVLTVLHODMLNGKEYCKKVSNAKALPAPIEKTISKAKQPREP 331  
D 289 AKTKPREEQYNSTYRVSVLTVLHODMLNGKEYCKKVSNAKALPAPIEKTISKAKQPREP 348  
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNQGPENNYKTTTPVLDSDGSFPL 391  
D 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNQGPENNYKTTTPVLDSDGSFPL 408  
QY 392 YSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 431  
D 409 YSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 448

## RESULT 79

US-10-287-994-56  
Sequence 56, Application US/10287994  
Publication No. US2004013757A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: Defreese, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, Caryn  
APPLICANT: Chen, Xi  
TITLE OF INVENTION: REMODELING AND GLYCOCONGUATION OF PEPTIDES  
FILE REFERENCE: 040853-01-5052-00  
CURRENT APPLICATION NUMBER: US/10/287,994  
CURRENT FILING DATE: 2002-11-05  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249

;; PRIOR FILING DATE: 2002-08-16  
;; PRIOR APPLICATION NUMBER: US 60/407,527  
;; PRIOR FILING DATE: 2002-08-28  
;; NUMBER OF SEQ ID NOS: 62  
;; SOFTWARE: Patentin version 3.1  
;; SEQ ID NO 56  
;; LENGTH: 448  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
US-10-287-994-56

Query Match 52.4%; Score 1265; DB 16; Length 448;  
Best Local Similarity 58.7%; Pred. No. 5.6e-81;  
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDVELTCTASQKSIQF--HWKNSNQIKILGNQ-----SFLTKGPSKLNDRADSR 83  
DB 13 KPGSSVAVSCAKSGYAFNTYLIEM-----VRQAPGQGLEWIGVYIPSGGNTNVEKFKGR 67  
QY 84 RSLW---DQGNFPLIITNKLKIEDSDTYICEVEDQKEVQLVFGLTANSDTHLQGSFLT 140  
DB 68 VTLTVDSTNTAYMELSLRSSEDTAVYFCARD-----GNYGMFAWYGQGT 114  
QY 141 LTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS-----QL 174  
DB 115 VTVSSASTKGPSPVFLPAPSKSKTSJGTAALGCLVADYFPEPVTVSMNSGALTSVHTFPA 174  
QY 175 ELQDSG-----TWTCVLONOKKVEFKIDIVPCPAPRPSCKDKTHTC 216  
DB 175 VLQSSGLYLSVSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KVEPESCDKTHTC 228  
QY 217 -----PELLGSPSVFLPFPKPKDTLMSRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 271  
DB 229 PCPAPPELLGSPSVFLPFPKPKDTLMSRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 288  
QY 272 AKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 331  
DB 289 AKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 348  
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 391  
DB 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 408  
QY 392 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLSPG 431  
DB 409 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLSPG 448

RESULT 80  
US-10-410-913-56  
; Sequence 56, Application US/10410913  
; Publication No. US20040142856A1

;; GENERAL INFORMATION:  
;; APPLICANT: Neose Technologies, Inc.  
;; APPLICANT: Defreese, Shawn  
;; APPLICANT: Zopf, David  
;; APPLICANT: Bayer, Robert  
;; APPLICANT: Hakee, David  
;; APPLICANT: Chen, Xi  
;; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
;; FILE REFERENCE: 040853-01-5081  
;; CURRENT APPLICATION NUMBER: US/10/410,913  
;; PRIOR FILING DATE: 2003-04-09  
;; PRIOR APPLICATION NUMBER: US 60/328,523  
;; PRIOR FILING DATE: 2001-10-10  
;; PRIOR APPLICATION NUMBER: US 60/344,692  
;; PRIOR FILING DATE: 2001-10-19  
;; PRIOR APPLICATION NUMBER: US 60/387,292  
;; PRIOR FILING DATE: 2002-06-07  
;; PRIOR APPLICATION NUMBER: US 60/391,777  
;; PRIOR FILING DATE: 2002-06-25

;; PRIOR APPLICATION NUMBER: US 60/396,594  
;; PRIOR FILING DATE: 2002-07-17  
;; PRIOR APPLICATION NUMBER: US 60/404,249  
;; PRIOR FILING DATE: 2002-08-16  
;; PRIOR APPLICATION NUMBER: US 60/407,527  
;; PRIOR FILING DATE: 2002-08-28  
;; NUMBER OF SEQ ID NOS: 75  
;; SOFTWARE: Patentin version 3.2  
;; SEQ ID NO 56  
;; LENGTH: 448  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
US-10-410-913-56

Query Match 52.4%; Score 1265; DB 16; Length 448;  
Best Local Similarity 58.7%; Pred. No. 5.6e-81;  
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDVELTCTASQKSIQF--HWKNSNQIKILGNQ-----SFLTKGPSKLNDRADSR 83  
DB 13 KPGSSVAVSCAKSGYAFNTYLIEM-----VRQAPGQGLEWIGVYIPSGGNTNVEKFKGR 67  
QY 84 RSLW---DQGNFPLIITNKLKIEDSDTYICEVEDQKEVQLVFGLTANSDTHLQGSFLT 140  
DB 68 VTLTVDSTNTAYMELSLRSSEDTAVYFCARD-----GNYGMFAWYGQGT 114  
QY 141 LTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS-----QL 174  
DB 115 VTVSSASTKGPSPVFLPAPSKSKTSJGTAALGCLVADYFPEPVTVSMNSGALTSVHTFPA 174  
QY 175 ELQDSG-----TWTCVLONOKKVEFKIDIVPCPAPRPSCKDKTHTC 216  
DB 175 VLQSSGLYLSVSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KVEPESCDKTHTC 228  
QY 217 -----PELLGSPSVFLPFPKPKDTLMSRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 271  
DB 229 PCPAPPELLGSPSVFLPFPKPKDTLMSRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHN 288  
QY 272 AKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 331  
DB 289 AKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 348  
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 391  
DB 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 408  
QY 392 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLSPG 431  
DB 409 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLSPG 448

RESULT 81  
US-09-773-877A-18  
; Sequence 18, Application US/09773877A  
; Publication No. US20030017977A1

;; GENERAL INFORMATION:  
;; APPLICANT: Xia, Yu-Ping et al.  
;; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES  
;; FILE REFERENCE: REG 710B  
;; CURRENT APPLICATION NUMBER: US/09/773,877A  
;; NUMBER OF SEQ ID NOS: 27  
;; SOFTWARE: Patentin version 3.0  
;; SEQ ID NO 18  
;; LENGTH: 462  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: F1c1(2-3)-Fc (Muc3)  
US-09-773-877A-18

Query Match 52.4%; Score 1265; DB 12; Length 462;  
Best Local Similarity 65.7%; Pred. No. 5.8e-81;





Db 673 VFSCSVMEALHNHYTKSLSPG 697

RESULT 84

US-10-077-023-9

Sequence 9, Application US/10077023

Publication No. US20030031675A1

GENERAL INFORMATION:

APPLICANT: MIKESELL, GLEN E.

APPLICANT: CHANG, HAN

APPLICANT: FINGER, JOSHUA N.

APPLICANT: YANG, GUOCHEN

APPLICANT: LU, PIN

APPLICANT: ZHOU, XIA-DI

APPLICANT: PEACH, ROBERT

TITLE OF INVENTION: B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR

TITLE OF INVENTION: IMMUNOMODULATION

FILE REFERENCE: 3053-4071053

CURRENT APPLICATION NUMBER: US/10/077,023

PRIOR FILING DATE: 2002-02-15

PRIOR APPLICATION NUMBER: 60/272,107

PRIOR FILING DATE: 2001-02-28

PRIOR APPLICATION NUMBER: 60/209,811

NUMBER OF SEQ ID NOS: 138

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 9

LENGTH: 698

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: fusion construct

US-10-077-023-9

Query Match 52.4%; Score 1265; DB 14; Length 698;

Best Local Similarity 67.8%; Pred. No. 9, 8e-81;

Matches 261; Conservative 18; Mismatches 57; Indels 49; Gaps 7;

Qy 89 QGNFLLIKNLKIEDSDTYICEVEDQKEVOLVFGLTANSSTHLLQGSLLTLES--- 145

Db 320 QGNASLRQRYAVNADEGSFTC-----FVSLRDFGSAVSLQVAPYKSDSMLEPKD 372

Qy 146 -PPGSSPVQCRSPRG-----KNIQG-KTILSVSGLHED 178

Db 373 LRPGDTVTITSSYRGYBEAEVFMQDGGVLTGNVTTSSQMANEGGLDVHSVLKRVLGA 432

Qy 179 SGTWTCT---TVLQNKQKVEFKIDIVPCPAP--EPKSCDKTHTC-----PELLGSPSVF 226

Db 433 NGTYSCLVRNPVLQODAHGSVITIGPMTFPPEFEPKSCDKTHTCPCPAPPELLGSPSVF 492

Qy 227 LFPPPKDTLMSIRPEVTCVVDVSHDEPEVKFMWYVDGVEVNAKTRPEEQNSTYR 286

Db 493 LFPPPKDTLMSIRPEVTCVVDVSHDEPEVKFMWYVDGVEVNAKTRPEEQNSTYR 552

Qy 287 VVSVLTVLHODWLNKEKCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKN 346

Db 553 VVSVLTVLHODWLNKEKCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKN 612

Qy 347 QVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGN 406

Db 613 QVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGN 672

Qy 407 VFSCSVMEALHNHYTKSLSPG 431

Db 673 VFSCSVMEALHNHYTKSLSPG 697

RESULT 85

US-09-773-877A-20

Sequence 20, Application US/09773877A

Publication No. US20030017977A1

GENERAL INFORMATION:

APPLICANT: Xia, Yu-ping et al.

TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES

FILE REFERENCE: REG 710b

CURRENT APPLICATION NUMBER: US/09/773,877A

PRIOR FILING DATE: 2001-01-31

NUMBER OF SEQ ID NOS: 27

SOFTWARE: PatentIn version 3.0

SEQ ID NO 20

LENGTH: 567

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Flt1(1-3 R->N) -Fc (Muc4)

US-09-773-877A-20

Query Match 52.4%; Score 1264; DB 12; Length 567;

Best Local Similarity 65.7%; Pred. No. 8, 9e-81;

Matches 255; Conservative 23; Mismatches 72; Indels 38; Gaps 7;

Qy 81 DSRSLMDQGNFLLIKNLKIEDSDTYICEVE-----DQKEVOLVFGLTANS 129

Db 180 DGRKIINDSK-GRTISNATYKEIGLTCEATYNGHLYKTNVLTNRQTNTIIDVQISTPR 238

Qy 130 DTHLLQGSLLT---TLSPGSSPSVQCRSPRGKNIQG-----KTLVS 171

Db 239 PVKLLRGHTLVNCTATTPLNTRVQMTWSYDEKKNQASVRRIDQNSHANIFYSVLTI 298

Qy 172 SQELQDSGTWTCTVYLQNO--KYVEFKIDIVPCPAP--EPKSCDKTHTC-----PELLGSP 223

Db 299 DKMNKDKGLYTCVRSRGSFESVNTSVHLYDKAGPEEPKSCDKTHTCPCPAPPELLGSP 358

Qy 224 SVFLFPPPKDTLMSIRPEVTCVVDVSHDEPEVKFMWYVDGVEVNAKTRPEEQNSTYR 283

Db 359 SVFLFPPPKDTLMSIRPEVTCVVDVSHDEPEVKFMWYVDGVEVNAKTRPEEQNSTYR 418

Qy 284 TYRVSVLTVLHODWLNKEKCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDEL 343

Db 419 TYRVSVLTVLHODWLNKEKCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDEL 478

Qy 344 TKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ 403

Db 479 TKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ 538

Qy 404 QGNVFCSVMEALHNHYTKSLSPG 431

Db 539 QGNVFCSVMEALHNHYTKSLSPG 566

RESULT 86

US-09-796-848A-37

Sequence 37, Application US/09796848A

Patent No. US20020098189A1

GENERAL INFORMATION:

APPLICANT: Young, James F.

APPLICANT: Johnson, Leslie S.

APPLICANT: Huse, William D.

APPLICANT: Wu, Herten

APPLICANT: Watkins, Jeffrey D.

TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of

TITLE OF INVENTION: Producing Them

FILE REFERENCE: 469201-526

CURRENT APPLICATION NUMBER: US/09/796,848A

PRIOR FILING DATE: 2001-10-30

PRIOR APPLICATION NUMBER: U.S. 60/186,252

NUMBER OF SEQ ID NOS: 59

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 37

LENGTH: 450

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Heavy chain of

```
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-37

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LGKKGDVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTQGPSKL-----NDRA 80
DB 11 LKPGTQTLTLTCTFS-----GFSISTAGMSVGMIRQPGKALEMLADIWMDGK 59
QY 81 DSRRLMD-----QGNFPLIINKLIKIEDSDTYICEVEDQKEVQLLVFGLTANSPT 131
DB 60 DYNPSLKRLTLISKOTSKNQVVLKVTNMDPADATATYYCARD-----MIFNYFD--- 108
QY 132 HLQGSGLTLTLSPSPSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
DB 109 --VMGGTTVTYSSASTKGPSVFLPLAPSSKSTSGGTALGCLVKDYFPEPVTVSNMNGAL 166
QY 173 -----QLELDQSG-----TWCTVLQNKQKVEFKIDIVPCPAPBP 207
DB 167 TSGVHTFPFVAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVEP 220
QY 208 KSCDKTHTC-----PELLGSPVFLPPPKKDTLMISTRPEVTCVVDVSHEDPEVKFNW 262
DB 221 KSCDKTHTCPCPAPPELLGSPVFLPPPKKDTLMISTRPEVTCVVDVSHEDPEVKFNW 280
QY 263 YVDGVEVHNAAKTPREBOYNSTRVAVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 322
DB 281 YVDGVEVHNAAKTPREBOYNSTRVAVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 340
QY 323 KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 382
DB 341 KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 400
QY 383 LDSGDSFFLYSKLTVDKSRMQGNVPSCSVMHEALHNHYTQKSLSLSPG 431
DB 401 LDSGDSFFLYSKLTVDKSRMQGNVPSCSVMHEALHNHYTQKSLSLSPG 449

RESULT 87
US-09-796-848A-45
; Sequence 45, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; TITLE OF INVENTION: Producing Them
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 45
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Heavy chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-45

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LGKKGDVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTQGPSKL-----NDRA 80
```

```
DB 11 LKPGTQTLTLTCTFS-----GFSISTAGMSVGMIRQPGKALEMLADIWMDGK 59
QY 81 DSRRLMD-----QGNFPLIINKLIKIEDSDTYICEVEDQKEVQLLVFGLTANSPT 131
DB 60 HYNPSLKRLTLISKOTSKNQVVLKVTNMDPADATATYYCARD-----MIFNYFD--- 108
QY 132 HLQGSGLTLTLSPSPSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
DB 109 --VMGGTTVTYSSASTKGPSVFLPLAPSSKSTSGGTALGCLVKDYFPEPVTVSNMNGAL 166
QY 173 -----QLELDQSG-----TWCTVLQNKQKVEFKIDIVPCPAPBP 207
DB 167 TSGVHTFPFVAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVEP 220
QY 208 KSCDKTHTC-----PELLGSPVFLPPPKKDTLMISTRPEVTCVVDVSHEDPEVKFNW 262
DB 221 KSCDKTHTCPCPAPPELLGSPVFLPPPKKDTLMISTRPEVTCVVDVSHEDPEVKFNW 280
QY 263 YVDGVEVHNAAKTPREBOYNSTRVAVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 322
DB 281 YVDGVEVHNAAKTPREBOYNSTRVAVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 340
QY 323 KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 382
DB 341 KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 400
QY 383 LDSGDSFFLYSKLTVDKSRMQGNVPSCSVMHEALHNHYTQKSLSLSPG 431
DB 401 LDSGDSFFLYSKLTVDKSRMQGNVPSCSVMHEALHNHYTQKSLSLSPG 449

RESULT 88
US-09-996-288-220
; Sequence 220, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 220
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-220

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LGKKGDVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTQGPSKL-----NDRA 80
DB 11 LKPGTQTLTLTCTFS-----GFSISTAGMSVGMIRQPGKALEMLADIWMDGK 59
QY 81 DSRRLMD-----QGNFPLIINKLIKIEDSDTYICEVEDQKEVQLLVFGLTANSPT 131
DB 60 DYNPSLKRLTLISKOTSKNQVVLKVTNMDPADATATYYCARD-----MIFNYFD--- 108
QY 132 HLQGSGLTLTLSPSPSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
DB 109 --VMGGTTVTYSSASTKGPSVFLPLAPSSKSTSGGTALGCLVKDYFPEPVTVSNMNGAL 166
QY 173 -----QLELDQSG-----TWCTVLQNKQKVEFKIDIVPCPAPBP 207
DB 167 TSGVHTFPFVAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVEP 220
```

Qy	208	ISCDKTHTC-----PELLGSPSVFLPPKPKDITLMIISTPEYTCVAVVSHEDDEVKKNM	262
Db	221	KSCDKHTCPCPCPAPELLGSPSVFLPPKPKDITLMIISTPEYTCVAVVSHEDDEVKKNM	280
Qy	263	YVDGVEVNAKTKPREEOYNSTYRVVSVLTVLHQDLMGKEKCKCVSNKALPAPIEKTIS	322
Db	281	YVDGVEVNAKTKPREEOYNSTYRVVSVLTVLHQDLMGKEKCKCVSNKALPAPIEKTIS	340
Qy	323	KAKGPREPQYTYLPPSRDELTKNOVSLTCLVKGRYPSDIDAVEMESNQPENNYKTPPV	382
Db	341	KAKGPREPQYTYLPPSRDEMTKNOVSLTCLVKGRYPSDIDAVEMESNQPENNYKTPPV	400
Qy	383	LDSDGSFPLYSKLTVDKSRMOQGNFSCSVNHEALAHNHYTQKSLISLSPG	431
Db	401	LDSDGSFPLYSKLTVDKSRMOQGNFSCSVNHEALAHNHYTQKSLISLSPG	449

```

RESULT 89
US-09-996-288-226
: Sequence 226: Application US/09996288
: Patent No US20020177126A1
: GENERAL INFORMATION:
: APPLICANT: Young, James
: APPLICANT: Scott, Koenig
: APPLICANT: Leslie, Johnson
: TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
: TITLE OF INVENTION: and Treatment
: FILE REFERENCE: 10271-047-999
: CURRENT APPLICATION NUMBER: US/09/996,288
: CURRENT FILING DATE: 2001-11-28
: NUMBER OF SEQ ID NOS: 259
: SOFTWARE: PatentIn version 3.1
: SEQ ID NO 226
: LENGTH: 450
: TYPE: PRT
: ORGANISM: Homo sapiens
US-09-996-288-226

```

Query Match	52.3%;	Score 1263.5;	DB 9;	Length 450;
Best Local Similarity	57.8%;	Pred. No. 7.2e-81;		
Matches 271;	Conservative 27;	Mismatches 74;	Indels 97;	Gaps 11

```

Db      11 LVKPTQLTILCTFS-----GFSLSSTAGSVMGIRQPEKALEMLADITWMDPK 59
Qy      81 DSRSLMD-----QGNFPLIIKULKIEDSDTYICEVEDOKREVOLLFGLTANSID 131
Db      60 HYNPSLKRLRTISKDTSKNQVVLKVTNMDPADTATYICARD-----MIFNFYFD-- 108
Qy      132 HLLOGQSILTLIESPSSSPVQCSPPGKNIQGG-----KITLSVS----- 172
Db      109 --VMGQGTIVVSSASTGSPSVFLAPSGSKSTSGTALAGCLVKDYPPEPYTVMNSGAL 166
Qy      173 -----QLELQDSG-----TWCTVTLQNKVEKIDIVCPAPER 207
Db      167 TSGVHTFPAVLQSSGLSVLSVSVTVPSSSLGTQITICNV--NHKPSNTKVD---KREVP 220
Qy      208 KSCDKTHTC-----PELLGSPSVFLFPPKPKDITIMI SRTPEVTCVVDVSHEDPEVKFNW 262
Db      221 KSCDKTHTCPCPCPAPELLGSPSVFLFPPKPKDITIMISTPEVTCVVDVSHEDPEVKFNW 280
Qy      263 YVDGEVHNAAKTKPREEQYNSTYRVVSVLTVLHODVLNGKEYKCKVNSKALPADIEKTIS 322
Db      281 YVDGEVHNAAKTKPREEQYNSTYRVVSVLTVLHODVLNGKEYKCKVNSKALPADIEKTIS 340
Qy      323 KAKGQPREPQVYTLPEPSRDELTKQVSLTCLVKGFYPSDIAVEMESNQCPENNTKTTTPV 382
Db      341 KAKGQPREPQVYTLPEPSREEMTKQVSLTCLVKGFYPSDIAVEMESNQCPENNTKTTTPV 400
Qy      383 LDSGGSFLYLSKLTVDKSRMOQGNVFCSVNHEALAHNHYTQKSLSLASG 431
Db      401 LDSGGSFLYLSKLTVDKSRMOQGNVFCSVNHEALAHNHYTQKSLSLASG 449

```

```

RESULT 90
US-09-996-288-232
; Sequence 232. Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 232
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-232

```

Query Match	52.3%;	Score 1263.5;	DB 9;	Length 450;
Best Local Similarity	57.8%;	Pred. No. 7.2e-81;		
Matches 271; Conservative	27;	Mismatches 74;	Indels 97;	Gaps 11;

```

QY 30 GKKGDVLELTCRASQKKSLQFHMKNSNOIKILGNOSFLTKPSPK-----NDRA 80
Db 11 LVKTQTLTLTKTFS-----GFSLSTGMVGMTRQPPCKLMLADIWDDK 59
QY 81 DSRSL-----WDQNPFLIKNLKIEDPTIICEVEDQKEEVOLLVFGLTANSDT 131
Db 60 DYNPSLKSRLTILSKDTSKNQVVLKVTMMDPADTATYCARD-----MIFWYFD-- 108
QY 132 HLOGQSLTLTLBSPSSPSVQCRSPRGNIQG-----KTLSS----- 172
Db 109 --VWGQGTAVVSSASTKGPVSFPLAPSSKSTGGTALGLVKDYFPPEPVTWSMGAL 166
QY 173 -----QLEHODSG-----TWCTVLQONQKVEFKIDIVCPAPRP 207
Db 167 TSGVTHPRAVLQSSGLXSLSSVTVBSSSLGTQTYICNV--NHKPSNTKYD----XRP 220
QY 208 KSCDKTHTC-----PELLGDPVSFLPPPKRDTLMTSRPEVTCVVVDVSHEDPEVK 262
Db 221 KSCDKTHTCPCPAPPELLGDPVSFLPPPKRDTLMTSRPEVTCVVVDVSHEDPEVK 280
QY 263 YVDSEVHNAAKTKREBOVNSTYRVVSVLTVLHODMNGEKYCKSNKKLPAPIEK 322
Db 281 YVDSEVHNAAKTKREBOVNSTYRVVSVLTVLHODMNGEKYCKSNKKLPAPIEK 340
QY 323 KAKQPREPOVYTLPPSRDELTKNOVSLTCLVNGFYPSDIAVEMESNGQEPENNYK 382
Db 341 KAKQPREPOVYTLPPSRDEMTKNQVSLTCLVNGFYPSDIAVEMESNGQEPENNYK 400
QY 383 LDSGGSFFLYSKLTVDSKRWQGNVPSCSYMHKALNHHYQKSLSPG 431
Db 401 LDSGGSFFLYSKLTVDSKRWQGNVPSCSYMHKALNHHYQKSLSPG 449

```

```

RESULT 91
US-09-996-288-234
; Sequence 234, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-NSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28

```

NUMBER OF SEQ ID NOS: 259  
 SOFTWARE: Patentin version 3.1  
 SEQ ID NO 234  
 LENGTH: 450  
 TYPE: PRT  
 ORGANISM: Homo sapiens  
 US-09-996-288-234

Query Match 52.3%; Score 1263.5; DB 9; Length 450;  
 Best Local Similarity 57.8%; Pred. No. 7.2e-81;  
 Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LKKGDTVELTCTAOKSIOFHMKNSNOIKILNGQSFITKGPSTL-----NDRA 80  
 DB 11 LVKPTOTLTCTFS-----GFLSTAGSVGMIRPPKALEMTADIWDDKK 59  
 QY 81 DSRRLT-----WDQNFPLIKNLKIEDSDTYICEVEDQKEVOLVFGLTANSPT 131  
 DB 60 DYNPSLKSRLTISKOTSKNQVVLKTNMDPADTATYYCARD-----MIFMWYFD--- 108  
 QY 132 HLLOGQSLLTLESPPGSSPSVOCRSPRGKNIQGG-----KTLSSVS----- 172  
 DB 109 --VMGQGTIVTVSSASTKGPVFLPAPSSKSTSGGTALGCLVKDYFPPEPTVSNNSGAL 166  
 QY 173 -----QLELDQSG-----TWTCTVLQNKVKEFKIDIVPCPAPPP 207  
 DB 167 TSGVHTFPAVLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KRVBP 220  
 QY 208 KSCDKTHTC-----PELLGSPVFLPPPKDITLMSRTEPEVTCVVVDVSHEDPEVKFNW 262  
 DB 221 KSCDKTHTCPCPAPPELLGSPVFLPPPKDITLMSRTEPEVTCVVVDVSHEDPEVKFNW 280  
 QY 263 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 322  
 DB 281 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 340  
 QY 323 KAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESNGOPENNYKTTTPPV 382  
 DB 341 KAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESNGOPENNYKTTTPPV 400  
 QY 383 LQSDGSFPLYSKLTVDKSRMOQGNVFCSVHMEALHNHYTKSLSPG 431  
 DB 401 LQSDGSFPLYSKLTVDKSRMOQGNVFCSVHMEALHNHYTKSLSPG 449

RESULT 92  
 US-09-996-288-236  
 Sequence 236, Application US/09996288  
 Patent No. US20020177126A1  
 GENERAL INFORMATION:

APPLICANT: Young, James  
 APPLICANT: Scott, Koenig  
 APPLICANT: Leslie, Johnson  
 TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis  
 FILE REFERENCE: 10271-047-999  
 CURRENT APPLICATION NUMBER: US/09/996,288  
 NUMBER OF SEQ ID NOS: 259  
 SOFTWARE: Patentin version 3.1  
 SEQ ID NO 236  
 LENGTH: 450  
 TYPE: PRT  
 ORGANISM: Homo sapiens  
 US-09-996-288-236

Query Match 52.3%; Score 1263.5; DB 9; Length 450;  
 Best Local Similarity 57.8%; Pred. No. 7.2e-81;  
 Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;  
 QY 30 LKKGDTVELTCTAOKSIOFHMKNSNOIKILNGQSFITKGPSTL-----NDRA 80  
 DB 11 LVKPTOTLTCTFS-----GFLSTAGSVGMIRPPKALEMTADIWDDKK 59

QY 81 DSRRLT-----WDQNFPLIKNLKIEDSDTYICEVEDQKEVOLVFGLTANSPT 131  
 DB 60 DYNPSLKSRLTISKOTSKNQVVLKTNMDPADTATYYCARD-----MIFMWYFD--- 108  
 QY 132 HLLOGQSLLTLESPPGSSPSVOCRSPRGKNIQGG-----KTLSSVS----- 172  
 DB 109 --VMGQGTIVTVSSASTKGPVFLPAPSSKSTSGGTALGCLVKDYFPPEPTVSNNSGAL 166  
 QY 173 -----QLELDQSG-----TWTCTVLQNKVKEFKIDIVPCPAPPP 207  
 DB 167 TSGVHTFPAVLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KRVBP 220  
 QY 208 KSCDKTHTC-----PELLGSPVFLPPPKDITLMSRTEPEVTCVVVDVSHEDPEVKFNW 262  
 DB 221 KSCDKTHTCPCPAPPELLGSPVFLPPPKDITLMSRTEPEVTCVVVDVSHEDPEVKFNW 280  
 QY 263 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 322  
 DB 281 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 340  
 QY 323 KAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESNGOPENNYKTTTPPV 382  
 DB 341 KAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESNGOPENNYKTTTPPV 400  
 QY 383 LQSDGSFPLYSKLTVDKSRMOQGNVFCSVHMEALHNHYTKSLSPG 431  
 DB 401 LQSDGSFPLYSKLTVDKSRMOQGNVFCSVHMEALHNHYTKSLSPG 449

RESULT 93  
 US-09-996-288-238

Sequence 238, Application US/09996288  
 Patent No. US20020177126A1  
 GENERAL INFORMATION:  
 APPLICANT: Young, James  
 APPLICANT: Scott, Koenig  
 APPLICANT: Leslie, Johnson  
 TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis  
 FILE REFERENCE: 10271-047-999  
 CURRENT APPLICATION NUMBER: US/09/996,288  
 NUMBER OF SEQ ID NOS: 259  
 SOFTWARE: Patentin version 3.1  
 SEQ ID NO 238  
 LENGTH: 450  
 TYPE: PRT  
 ORGANISM: Homo sapiens  
 US-09-996-288-238

Query Match 52.3%; Score 1263.5; DB 9; Length 450;  
 Best Local Similarity 57.8%; Pred. No. 7.2e-81;  
 Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;

QY 30 LKKGDTVELTCTAOKSIOFHMKNSNOIKILNGQSFITKGPSTL-----NDRA 80  
 DB 11 LVKPTOTLTCTFS-----GFLSTAGSVGMIRPPKALEMTADIWDDKK 59  
 QY 81 DSRRLT-----WDQNFPLIKNLKIEDSDTYICEVEDQKEVOLVFGLTANSPT 131  
 DB 60 DYNPSLKSRLTISKOTSKNQVVLKTNMDPADTATYYC---ARMDINIFYD----- 108  
 QY 132 HLLOGQSLLTLESPPGSSPSVOCRSPRGKNIQGG-----KTLSSVS----- 172  
 DB 109 --VMGQGTIVTVSSASTKGPVFLPAPSSKSTSGGTALGCLVKDYFPPEPTVSNNSGAL 166  
 QY 173 -----QLELDQSG-----TWTCTVLQNKVKEFKIDIVPCPAPPP 207  
 DB 167 TSGVHTFPAVLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KRVBP 220  
 QY 208 KSCDKTHTC-----PELLGSPVFLPPPKDITLMSRTEPEVTCVVVDVSHEDPEVKFNW 262

```
Db      221 KSCDKHTCTPCPAPBELLGGPSVFLPPKPKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 280
QY      263 YVDGEVHNAAKTKPREEOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db      281 YVDGEVHNAAKTKPREEOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
QY      323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 382
Db      341 KAKGQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 400
QY      383 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db      401 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 449
```

```
RESULT 94
US-09-996-288-242
; Sequence 242, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 242
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-242
```

```
Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;
```

```
QY      30 LGKKGDVLELTCTASQKSIQFHMKNNOIKILGNQGSFLTKGSPKL-----NDRA 80
Db      11 LVKPTQTTLTCTFS-----GFSLSTAGMSVGMIRQPGKALEWLADIWMDKK 59
QY      81 DSRASL-----WDQGNFPLIINKLIKIEDSDTYICEVEDQKEVOLVFGLTANSDT 131
Db      60 DYNPBLKRLTISKDTSKNQVLLKVTNMDPADTATYYC---ARDMINTFYD----- 108
QY      122 HLQGSLLTLLESPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
Db      109 --VMQGGTTVVSASATKGPSVFPLAPSSKSTSGGTAAAGCLVADYPPPEPTVSWNSGAL 166
QY      173 -----QLELQDSG-----TWCTVLONOKKEVERKIDIVPCPAP 207
Db      167 TSGVHTFPRAVLQSSGLYSLSVTVPPSSSLGTQTYICNV--NHKPSNTKVD---KRV 220
QY      208 KSCDKHTCTPCPAPBELLGGPSVFLPPKPKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 262
Db      221 KSCDKHTCTPCPAPBELLGGPSVFLPPKPKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 280
QY      263 YVDGEVHNAAKTKPREEOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db      281 YVDGEVHNAAKTKPREEOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
QY      323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 382
Db      341 KAKGQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 400
QY      383 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db      401 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 449
```

```
RESULT 95
US-09-996-288-244
; Sequence 244, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 244
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-244
```

```
Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;
```

```
QY      30 LGKKGDVLELTCTASQKSIQFHMKNNOIKILGNQGSFLTKGSPKL-----NDRA 80
Db      11 LVKPTQTTLTCTFS-----GFSLSTAGMSVGMIRQPGKALEWLADIWMDKK 59
QY      81 DSRASL-----WDQGNFPLIINKLIKIEDSDTYICEVEDQKEVOLVFGLTANSDT 131
Db      60 DYNPBLKRLTISKDTSKNQVLLKVTNMDPADTATYYC---ARDMINTFYD----- 108
QY      122 HLQGSLLTLLESPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
Db      109 --VMQGGTTVVSASATKGPSVFPLAPSSKSTSGGTAAAGCLVADYPPPEPTVSWNSGAL 166
QY      173 -----QLELQDSG-----TWCTVLONOKKEVERKIDIVPCPAP 207
Db      167 TSGVHTFPRAVLQSSGLYSLSVTVPPSSSLGTQTYICNV--NHKPSNTKVD---KRV 220
QY      208 KSCDKHTCTPCPAPBELLGGPSVFLPPKPKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 262
Db      221 KSCDKHTCTPCPAPBELLGGPSVFLPPKPKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 280
QY      263 YVDGEVHNAAKTKPREEOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db      281 YVDGEVHNAAKTKPREEOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
QY      323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 382
Db      341 KAKGQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 400
QY      383 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db      401 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 449
```

```
RESULT 96
US-09-996-288-246
; Sequence 246, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1
```

```
/ SEQ ID NO 246
/ LENGTH: 450
/ TYPE: PRF
/ ORGANISM: Homo sapiens
US-09-996-288-246

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;

30 LGKKDDTVELTCTAAGKKSIOFHMKNSNOIKILNGSGSFLTKGPKSL-----NDRA 80
11 LVKPTQTLTLCTFS-----GFSLSAGMSVGWIRQPPKALEMLADIWDDKK 59
81 DSRRL-----WDQNFPLIKNLKIEDSDTYICEVEDQKEVOLLVGLTANSPT 131
60 DYNPSLKSRLTISKOTSKNQVLLKVTNMDPADATATYCC---ARDMITFYPD----- 108
132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSV----- 172
109 --VMGCGTTVTSSASTKGSVFPLAPSSKSTSGGTALGCLVKDYFPPEPVTSNNSGAL 166
173 -----QELQDSG-----TWTCVVLQNKVKEFKIDIVPCPAPR 207
167 TSGVHTFPVAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KRAVP 220
208 KSCDKTHTC-----PELGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
221 KSCDKTHTCPCPAPPELLGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
263 YVDGVEVHNAKTPREEQYNSTYRVVSVLTVLHQDLNMEKEVKCKVSNKALPAPIEKTIS 322
281 YVDGVEVHNAKTPREEQYNSTYRVVSVLTVLHQDLNMEKEVKCKVSNKALPAPIEKTIS 340
323 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 382
341 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 400
383 LPSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPG 431
401 LPSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPG 449

RESULT 97
US-09-996-288-252
/ Sequence 252; Application US/09996288
/ Patent No. US20020177126A1
/ GENERAL INFORMATION:
/ APPLICANT: Young, James
/ APPLICANT: Scott, Koenig
/ APPLICANT: Leslie, Johnson
/ TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
/ FILE REFERENCE: 10271-047-999
/ CURRENT APPLICATION NUMBER: US/09/996,288
/ CURRENT FILING DATE: 2001-11-28
/ NUMBER OF SEQ ID NOS: 259
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 252
/ LENGTH: 450
/ TYPE: PRF
/ ORGANISM: Homo sapiens
US-09-996-288-252

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

30 LGKKDDTVELTCTAAGKKSIOFHMKNSNOIKILNGSGSFLTKGPKSL-----NDRA 80
11 LVKPTQTLTLCTFS-----GFSLSAGMSVGWIRQPPKALEMLADIWDDKK 59
81 DSRRL-----WDQNFPLIKNLKIEDSDTYICEVEDQKEVOLLVGLTANSPT 131
60 DYNPSLKSRLTISKOTSKNQVLLKVTNMDPADATATYCC---ARDMITFYPD----- 108
132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSV----- 172
109 --VMGCGTTVTSSASTKGSVFPLAPSSKSTSGGTALGCLVKDYFPPEPVTSNNSGAL 166
173 -----QELQDSG-----TWTCVVLQNKVKEFKIDIVPCPAPR 207
167 TSGVHTFPVAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KRAVP 220
208 KSCDKTHTC-----PELGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
221 KSCDKTHTCPCPAPPELLGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
263 YVDGVEVHNAKTPREEQYNSTYRVVSVLTVLHQDLNMEKEVKCKVSNKALPAPIEKTIS 322
281 YVDGVEVHNAKTPREEQYNSTYRVVSVLTVLHQDLNMEKEVKCKVSNKALPAPIEKTIS 340
323 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 382
341 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 400
383 LPSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPG 431
401 LPSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPG 449
```

```
DB 60 HYNPSLKSRLTISKOTSKNQVLLKVTNMDPADATATYCCARD-----MINFYPD--- 108
QY 132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSV----- 172
DB 109 --VMGCGTTVTSSASTKGSVFPLAPSSKSTSGGTALGCLVKDYFPPEPVTSNNSGAL 166
QY 173 -----QELQDSG-----TWTCVVLQNKVKEFKIDIVPCPAPR 207
DB 167 TSGVHTFPVAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KRAVP 220
QY 208 KSCDKTHTC-----PELGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
DB 221 KSCDKTHTCPCPAPPELLGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
QY 263 YVDGVEVHNAKTPREEQYNSTYRVVSVLTVLHQDLNMEKEVKCKVSNKALPAPIEKTIS 322
DB 281 YVDGVEVHNAKTPREEQYNSTYRVVSVLTVLHQDLNMEKEVKCKVSNKALPAPIEKTIS 340
QY 323 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 382
DB 341 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 400
QY 383 LPSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPG 431
DB 401 LPSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPG 449

RESULT 98
US-09-996-288-254
/ Sequence 254; Application US/09996288
/ Patent No. US20020177126A1
/ GENERAL INFORMATION:
/ APPLICANT: Young, James
/ APPLICANT: Scott, Koenig
/ APPLICANT: Leslie, Johnson
/ TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
/ FILE REFERENCE: 10271-047-999
/ CURRENT APPLICATION NUMBER: US/09/996,288
/ CURRENT FILING DATE: 2001-11-28
/ NUMBER OF SEQ ID NOS: 259
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 254
/ LENGTH: 450
/ TYPE: PRF
/ ORGANISM: Homo sapiens
US-09-996-288-254

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

30 LGKKDDTVELTCTAAGKKSIOFHMKNSNOIKILNGSGSFLTKGPKSL-----NDRA 80
11 LVKPTQTLTLCTFS-----GFSLSAGMSVGWIRQPPKALEMLADIWDDKK 59
81 DSRRL-----WDQNFPLIKNLKIEDSDTYICEVEDQKEVOLLVGLTANSPT 131
60 HYNPSLKSRLTISKOTSKNQVLLKVTNMDPADATATYCCARD-----MINFYPD--- 108
132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSV----- 172
109 --VMGCGTTVTSSASTKGSVFPLAPSSKSTSGGTALGCLVKDYFPPEPVTSNNSGAL 166
173 -----QELQDSG-----TWTCVVLQNKVKEFKIDIVPCPAPR 207
167 TSGVHTFPVAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KRAVP 220
QY 208 KSCDKTHTC-----PELGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
DB 221 KSCDKTHTCPCPAPPELLGGPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
```

```

Qy 263 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
    |||||
Db 261 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy 323 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 382
    |||||
Db 341 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 400
Qy 383 LDSDSFFLYSKLTVDKSRMQGNVFCSCVMEALHNHYTQKSLSLSPG 431
    |||||
Db 401 LDSDSFFLYSKLTVDKSRMQGNVFCSCVMEALHNHYTQKSLSLSPG 449

```

RESULT 99  
US-09-996-265

Sequence 256 Application US/09996288

Patent No. US20020177126A1

GENERAL INFORMATION:

APPLICANT: Young, James

APPLICANT: Scott, Koenig

APPLICANT: Leslie, Johnson

TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi

TITLE OF INVENTION: and Treatment

FILE REFERENCE: 10271-047-999

CURRENT APPLICATION NUMBER: US/09/996,288

CURRENT FILING DATE: 2001-11-28

NUMBER OF SEQ ID NOS: 259

SOFTWARE: PatentIn version 3.1

SEQ ID NO 256

LENGTH: 450

TYPE: PR

ORGANISM: Homo sapiens

US-09-996-288-256

Query Match 52.3%; Score 1263.5; DB 9; Length 450;

Best Local Similarity 57.8%; Pred. No. 7.2e-81;

Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

```

Qy 30 LGKKGDVVELTCTASQKKSIOFHWNKSNQIKILGNQGSFLTKGPKSL-----NDRA 80
    |||||
Db 11 LVKPTQTTLTCTFS-----GFSLTAGMSVGMIRQPPGKALEMLADIWMDKK 59
Qy 81 DSRSLMD-----QGNPFLIKNLKIEDSDTYICEVEDQKEBVLVFGLTANSDT 131
    |||||
Db 60 HYNPDLKDLRTISKDTSKNQVVKVTNMDPADTATYTCARD-----MIFNFFD--- 108
Qy 132 HLLQGSLLTLLESPPGSSPVQCRSPRGKNIQGG-----KTLVS----- 172
    |||||
Db 109 --VMGQGTIVTVSSASTKGPSVFPLAAPSSTSGGTALGCLVKDYFPEPTVWSNMGAL 166
    |||||
Qy 173 -----QLELQDSG-----TWCTTVLONQKVEFKIDIVPCPAPEP 207
    |||||
Db 167 TSGVHTFPFPAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KVEP 220
Qy 208 KSCDKTHTC-----PELLGGSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
    |||||
Db 221 KSCDKTHTCPCPAPPELLGGSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 280
Qy 263 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
    |||||
Db 281 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy 323 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 382
    |||||
Db 341 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 400
Qy 383 LDSDSFFLYSKLTVDKSRMQGNVFCSCVMEALHNHYTQKSLSLSPG 431
    |||||
Db 401 LDSDSFFLYSKLTVDKSRMQGNVFCSCVMEALHNHYTQKSLSLSPG 449

```

RESULT 100  
US-09-996-265-220

```

; Sequence 220 Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 220
; LENGTH: 450
; TYPE: PR
; ORGANISM: Homo sapiens
; US-09-996-265-220

```

Query Match 52.3%; Score 1263.5; DB 10; Length 450;

Best Local Similarity 57.8%; Pred. No. 7.2e-81;

Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

```

Qy 30 LGKKGDVVELTCTASQKKSIOFHWNKSNQIKILGNQGSFLTKGPKSL-----NDRA 80
    |||||
Db 11 LVKPTQTTLTCTFS-----GFSLTAGMSVGMIRQPPGKALEMLADIWMDKK 59
Qy 81 DSRSLMD-----QGNPFLIKNLKIEDSDTYICEVEDQKEBVLVFGLTANSDT 131
    |||||
Db 60 DYNPDLKDLRTISKDTSKNQVVKVTNMDPADTATYTCARD-----MIFNFFD--- 108
Qy 132 HLLQGSLLTLLESPPGSSPVQCRSPRGKNIQGG-----KTLVS----- 172
    |||||
Db 109 --VMGQGTIVTVSSASTKGPSVFPLAAPSSTSGGTALGCLVKDYFPEPTVWSNMGAL 166
    |||||
Qy 173 -----QLELQDSG-----TWCTTVLONQKVEFKIDIVPCPAPEP 207
    |||||
Db 167 TSGVHTFPFPAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KVEP 220
Qy 208 KSCDKTHTC-----PELLGGSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
    |||||
Db 221 KSCDKTHTCPCPAPPELLGGSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 280
Qy 263 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
    |||||
Db 281 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy 323 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 382
    |||||
Db 341 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 400
Qy 383 LDSDSFFLYSKLTVDKSRMQGNVFCSCVMEALHNHYTQKSLSLSPG 431
    |||||
Db 401 LDSDSFFLYSKLTVDKSRMQGNVFCSCVMEALHNHYTQKSLSLSPG 449

```

Search completed: August 3, 2004, 13:47:37

Job time : 46.4271 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

## OM protein - protein search, using SW model

Run on: August 3, 2004, 13:01:34 ; Search time 13,3604 Seconds  
(without alignments)  
1754,300 Million cell updates/sec

Title: SEQ4  
Perfect score: 2414  
Sequence: 1 MRGVFPRHLVLVLQALLP.....DENCAADQDGLDGLMTTDP 454

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues  
Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 125 summaries

Database : Issued Patents AA:  
1: /cgn2\_6/prodata/2/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/prodata/2/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/prodata/2/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/prodata/2/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/prodata/2/iaa/PCITUS\_COMB.pep.\*  
6: /cgn2\_6/prodata/2/iaa/backfile1.pep.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	* Query Match	Length	DB ID	Description
1	2122	87.9	432	3	US-08-477-460B-2
2	2122	87.9	432	3	US-08-379-516-2
3	2122	87.9	432	3	US-09-329-916-2
4	2122	87.9	432	3	US-08-485-372A-2
5	2122	87.9	432	4	US-09-409-006A-2
6	2122	87.9	432	4	US-08-484-681-2
7	2122	87.9	432	5	PCT-US93-07422-2
8	2092	86.7	630	4	US-08-472-888A-6
9	2085	86.4	530	3	US-08-477-460B-4
10	2085	86.4	530	3	US-08-379-516-4
11	2085	86.4	530	3	US-09-329-916-4
12	2085	86.4	530	4	US-08-485-372A-4
13	2085	86.4	530	4	US-09-409-006A-4
14	2085	86.4	530	4	US-08-484-681-4
15	2085	86.4	530	5	PCT-US93-07422-4
16	1647.5	68.2	410	3	US-08-630-172-17
17	1647.5	68.2	410	3	US-09-375-919-17
18	1338.5	55.4	254	2	US-08-284-391B-33
19	1338.5	55.4	254	3	US-09-218-950-33
20	1284.5	53.2	459	1	US-08-157-101A-7
21	1282.5	53.1	446	3	US-08-397-411-7
22	1276.5	52.9	455	4	US-09-740-002-25
23	1274.5	52.8	454	2	US-07-934-373C-22
24	1274.5	52.8	454	3	US-08-437-642B-22
25	1274.5	52.8	454	4	US-08-146-206C-22
26	1274.5	52.8	454	4	US-09-705-686-22
27	1274.5	52.8	454	5	PCT-US93-07832-22

28	1274.5	52.8	473	3	US-09-049-672A-4	Sequence 4, Appl
29	1273.5	52.8	475	4	US-09-740-002-27	Sequence 27, Appl
30	1273.5	52.8	497	4	US-09-499-846-6	Sequence 6, Appl
31	1273.5	52.8	525	4	US-09-499-846-4	Sequence 4, Appl
32	1273.5	52.8	622	4	US-09-499-846-2	Sequence 2, Appl
33	1271.5	52.7	453	4	US-09-301-593-18	Sequence 18, Appl
34	1271	52.7	476	3	US-08-487-550-12	Sequence 12, Appl
35	1271	52.7	476	4	US-09-526-098-12	Sequence 12, Appl
36	1265.5	52.4	468	4	US-09-485-737B-67	Sequence 67, Appl
37	1265.5	52.4	711	4	US-09-485-737B-90	Sequence 90, Appl
38	1265	52.4	449	1	US-08-458-516-13	Sequence 13, Appl
39	1264	52.4	451	4	US-09-247-352-3	Sequence 3, Appl
40	1264	52.4	451	4	US-09-466-635-3	Sequence 3, Appl
41	1263.5	52.3	452	3	US-09-027-449-71	Sequence 71, Appl
42	1263.5	52.3	452	3	US-09-026-985-71	Sequence 71, Appl
43	1263.5	52.3	452	4	US-09-121-952A-71	Sequence 71, Appl
44	1263.5	52.3	452	4	US-09-334-340A-71	Sequence 71, Appl
45	1263	52.3	472	4	US-09-301-593-30	Sequence 30, Appl
46	1262	52.3	451	2	US-08-887-352B-18	Sequence 18, Appl
47	1262	52.3	451	3	US-09-109-207C-18	Sequence 18, Appl
48	1262	52.3	451	3	US-09-282-505-2	Sequence 2, Appl
49	1262	52.3	451	3	US-09-054-255-2	Sequence 2, Appl
50	1262	52.3	451	3	US-09-296-005-18	Sequence 18, Appl
51	1262	52.3	451	4	US-09-282-846-2	Sequence 2, Appl
52	1262	52.3	451	4	US-09-680-145-2	Sequence 2, Appl
53	1262	52.3	451	4	US-09-920-171-18	Sequence 18, Appl
54	1261.5	52.3	467	4	US-09-049-672A-8	Sequence 8, Appl
55	1261	52.2	488	4	US-09-499-846-12	Sequence 12, Appl
56	1259	52.2	453	3	US-08-466-151-8	Sequence 8, Appl
57	1259	52.2	453	4	US-08-466-163B-8	Sequence 8, Appl
58	1259	52.2	453	4	US-09-802-096-8	Sequence 8, Appl
59	1259	52.2	476	2	US-08-378-936-10	Sequence 10, Appl
60	1259	52.2	478	3	US-08-487-550-8	Sequence 8, Appl
61	1259	52.2	478	4	US-09-526-098-8	Sequence 8, Appl
62	1258.5	52.1	497	4	US-09-499-846-10	Sequence 10, Appl
63	1258.5	52.1	525	4	US-09-499-846-8	Sequence 8, Appl
64	1257	52.1	451	2	US-08-887-352B-14	Sequence 14, Appl
65	1257	52.1	451	2	US-08-887-352B-16	Sequence 16, Appl
66	1257	52.1	451	3	US-08-466-151-65	Sequence 65, Appl
67	1257	52.1	451	3	US-09-109-207C-14	Sequence 14, Appl
68	1257	52.1	451	3	US-09-109-207C-16	Sequence 16, Appl
69	1257	52.1	451	3	US-09-296-005-14	Sequence 14, Appl
70	1257	52.1	451	3	US-09-296-005-16	Sequence 16, Appl
71	1257	52.1	451	4	US-09-920-171-14	Sequence 14, Appl
72	1257	52.1	451	4	US-09-920-171-16	Sequence 16, Appl
73	1257	52.1	472	4	US-08-793-450-8	Sequence 8, Appl
74	1256.5	52.1	472	4	US-09-301-593-43	Sequence 43, Appl
75	1254.5	52.0	462	4	US-09-289-942A-7	Sequence 2, Appl
76	1254.5	52.0	449	4	US-09-679-397-2	Sequence 2, Appl
77	1254.5	52.0	449	4	US-09-680-148-2	Sequence 2, Appl
78	1254.5	52.0	449	4	US-09-304-465A-2	Sequence 2, Appl
79	1248	51.7	476	4	US-08-487-550-4	Sequence 4, Appl
80	1248	51.7	476	4	US-09-526-098-4	Sequence 4, Appl
81	1240.5	51.4	951	4	US-09-313-942-9	Sequence 9, Appl
82	1238	51.3	442	4	US-08-472-888A-7	Sequence 7, Appl
83	1238	51.3	442	5	PCT-US96-10043-9	Sequence 9, Appl
84	1238	51.3	547	4	US-09-746-359A-54	Sequence 54, Appl
85	1238	51.3	571	4	US-09-746-359A-53	Sequence 53, Appl
86	1236.5	51.2	371	1	US-08-236-317-7	Sequence 7, Appl
87	1236.5	51.2	371	3	US-08-457-918-7	Sequence 7, Appl
88	1234.5	51.1	446	4	US-09-157-452B-12	Sequence 12, Appl
89	1232	51.0	704	4	US-09-590-656-2	Sequence 2, Appl
90	1232	51.0	704	4	US-09-733-764-2	Sequence 2, Appl
91	1226	50.8	442	1	US-08-461-968A-5	Sequence 5, Appl
92	1226	50.8	442	2	US-08-462-571-5	Sequence 2, Appl
93	1224	50.7	437	5	PCT-US96-10043-11	Sequence 11, Appl
94	1221.5	50.6	530	4	US-09-301-593-22	Sequence 22, Appl
95	1221	50.6	532	4	US-09-313-942-8	Sequence 8, Appl
96	1219	50.5	424	5	PCT-US95-03866-12	Sequence 12, Appl
97	1219	50.5	424	5	PCT-US95-03866-14	Sequence 14, Appl
98	1215	50.3	360	4	US-09-180-100-11	Sequence 11, Appl
99	1215	50.3	376	4	US-09-180-100-22	Sequence 22, Appl
100	1215	50.3	424	4	US-09-333-593A-8	Sequence 8, Appl



```

QY 61 IIGNQSFLTKGSPSKINDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYVL 120
    |||
Db 61 IIGNQSFLTKGSPSKINDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYVL 120
QY 121 LVFGLTANSDTHLLQGOSLTLTLSPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
    |||
Db 121 LVFGLTANSDTHLLQGOSLTLTLSPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWCTVLOQOKKVEFKIDIV-----PCPAPBKSCDKTHTCPBLGSPSVFL 227
    |||
Db 181 TWCTVLOQOKKVEFKIDIVLAFERKCCVECPCPAP-----VAGPSVFL 227
QY 228 FPKPKDITLMIISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
    |||
Db 228 FPKPKDITLMIISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
QY 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
    |||
Db 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFFPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGNY 407
    |||
Db 348 VSLTCLVKGFFPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGNY 407
QY 408 FSCSVNHEALHNHYTQKSLSLSPG 431
    |||
Db 408 FSCSVNHEALHNHYTQKSLSLSPG 431

```

## RESULT 3

US-09-329-916-2

Sequence 2, Application US/09329916

Patent No. 6177549

GENERAL INFORMATION:

APPLICANT: Progenice Pharmaceuticals, Inc.

TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED

TITLE OF INVENTION: CD4-GAMMA2 AND CD4-19G2 IMMUNOCONJUGATES, AND USES THEREOF

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESS:

ADDRESSEE: Cooper &amp; Dunham

STREET: 30 Rockefeller Plaza

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10112

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.24

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/329,916

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/477,460

FILING DATE: 07-JUN-1995

APPLICATION NUMBER: US 07/927,931

FILING DATE: 07-AUG-1992

ATTORNEY/AGENT INFORMATION:

NAME: White, John P.

REGISTRATION NUMBER: 28,678

REFERENCE/DOCKET NUMBER: 41215-A-PCT/JWP/AJM

TELEPHONE: (212) 977-9550

TELEFAX: (212) 977-9809

TELEX: 422523 COOP UT

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 432 amino acids

TYPE: amino acid

STRANDEDNESS: unknown

TOPOLOGY: unknown  
 MOLECULE TYPE: protein  
 ORIGINAL SOURCE:  
 ORGANISM: homo sapien  
 CELL TYPE: lymphocyte  
 US-09-329-916-2

Query Match 87.9%; Score 2122; DB 3; Length 432;  
 Best Local Similarity 91.2%; Pred. No. 36-164;  
 Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

```

QY 1 MRGVPFRLLILVLOLALLPATQGNKVLGKGGTVELTCTASQKSIQFMKSNQIK 60
    |||
Db 1 MRGVPFRLLILVLOLALLPATQGNKVLGKGGTVELTCTASQKSIQFMKSNQIK 60
QY 61 IIGNQSFLTKGSPSKINDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYVL 120
    |||
Db 61 IIGNQSFLTKGSPSKINDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVEDQKEEYVL 120
QY 121 LVFGLTANSDTHLLQGOSLTLTLSPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
    |||
Db 121 LVFGLTANSDTHLLQGOSLTLTLSPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWCTVLOQOKKVEFKIDIV-----PCPAPBKSCDKTHTCPBLGSPSVFL 227
    |||
Db 181 TWCTVLOQOKKVEFKIDIVLAFERKCCVECPCPAP-----VAGPSVFL 227
QY 228 FPKPKDITLMIISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
    |||
Db 228 FPKPKDITLMIISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
QY 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
    |||
Db 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFFPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGNY 407
    |||
Db 348 VSLTCLVKGFFPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRMQQGNY 407
QY 408 FSCSVNHEALHNHYTQKSLSLSPG 431
    |||
Db 408 FSCSVNHEALHNHYTQKSLSLSPG 431

```

## RESULT 4

US-08-485-372A-2

Sequence 2, Application US/08485372A

Patent No. 6187748

GENERAL INFORMATION:

APPLICANT: Beaudry, Gary A.

TITLE OF INVENTION: Maddon, Paul J.

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESS:

ADDRESSEE: Cooper &amp; Dunham LLP

STREET: 1185 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.24

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/485,372A

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/476,227

FILING DATE: 07-JUN-1995

ATTORNEY/AGENT INFORMATION:

NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 37690-II-A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 278-0400  
TELEFAX: (212) 391-0525  
TELEX:  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 432 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
ORIGINAL SOURCE:  
ORGANISM: homo sapien  
CELL TYPE: lymphocyte  
US-08-485-372A-2

Query Match 87.9%; Score 2122; DB 3; Length 432;  
Best Local Similarity 91.2%; Pred. No. 3e-164;  
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY 1 NMRGVPFRHLILVQLALPAAATGKNTVLGKKGDVETLTCTASQKSIQFHWKNSNOIK 60  
DB 1 NMRGVPFRHLILVQLALPAAATGKNTVLGKKGDVETLTCTASQKSIQFHWKNSNOIK 60  
QY 61 ILGNQSFLLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120  
DB 61 ILGNQSFLLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120  
QY 121 LVFGLTANSDTHLLOQGSILTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180  
DB 121 LVFGLTANSDTHLLOQGSILTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180  
QY 181 TWCTCVLONQKVEFKIDIVLAFERKCCVECPCPAP-----VAGPSVFL 227  
DB 181 TWCTCVLONQKVEFKIDIVLAFERKCCVECPCPAP-----VAGPSVFL 227  
QY 228 PPPKPDITLMISRTPEVTCVVVDVSHEDPEVKFMNVDGVEVHNAKTKPREEOYNSTRV 287  
DB 228 PPPKPDITLMISRTPEVTCVVVDVSHEDPEVKFMNVDGVEVHNAKTKPREEOYNSTRV 287  
QY 288 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 347  
DB 288 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 347  
QY 348 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 407  
DB 348 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 407  
QY 408 FSCSVMEALHNHYTOKSLSLSPG 431  
DB 408 FSCSVMEALHNHYTOKSLSLSPG 431

RESULT 5  
US-09-409-006A-2

Sequence 2, Application US/09409006A  
Patent No. 6342586  
GENERAL INFORMATION:  
APPLICANT: Progenics Pharmaceuticals, Inc.  
TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10112  
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.24  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/409,006A  
FILING DATE: 29-SEP-1999  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/927,931  
FILING DATE: 07-AUG-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/AJM  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 977-9550  
TELEFAX: (212) 977-9809  
TELEX: 422523 COOP UI  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 432 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
ORIGINAL SOURCE:  
ORGANISM: homo sapien  
CELL TYPE: lymphocyte  
US-09-409-006A-2

Query Match 87.9%; Score 2122; DB 4; Length 432;  
Best Local Similarity 91.2%; Pred. No. 3e-164;  
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY 1 NMRGVPFRHLILVQLALPAAATGKNTVLGKKGDVETLTCTASQKSIQFHWKNSNOIK 60  
DB 1 NMRGVPFRHLILVQLALPAAATGKNTVLGKKGDVETLTCTASQKSIQFHWKNSNOIK 60  
QY 61 ILGNQSFLLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120  
DB 61 ILGNQSFLLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120  
QY 121 LVFGLTANSDTHLLOQGSILTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180  
DB 121 LVFGLTANSDTHLLOQGSILTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180  
QY 181 TWCTCVLONQKVEFKIDIVLAFERKCCVECPCPAP-----VAGPSVFL 227  
DB 181 TWCTCVLONQKVEFKIDIVLAFERKCCVECPCPAP-----VAGPSVFL 227  
QY 228 PPPKPDITLMISRTPEVTCVVVDVSHEDPEVKFMNVDGVEVHNAKTKPREEOYNSTRV 287  
DB 228 PPPKPDITLMISRTPEVTCVVVDVSHEDPEVKFMNVDGVEVHNAKTKPREEOYNSTRV 287  
QY 288 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 347  
DB 288 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 347  
QY 348 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 407  
DB 348 VSVLTCLVKGFPSPDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSKRMQOGNV 407  
QY 408 FSCSVMEALHNHYTOKSLSLSPG 431  
DB 408 FSCSVMEALHNHYTOKSLSLSPG 431

RESULT 6

US-08-484-681-2  
Sequence 2, Application US/08484681  
Patent No. 6451313  
GENERAL INFORMATION:

```
/ APPLICANT: Beaudry, Gary A.
/ APPLICANT: Maddon, Paul J.
/ TITLE OF INVENTION: CD4-GAMMA2 CD4-IGG2 CHIMERAS
/ NUMBER OF SEQUENCES: 9
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Cooper & Dunham LLP
/ STREET: 1185 Avenue of the Americas
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10036
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent Release #1.24
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/484,681
/ FILING DATE: 07-JUN-1995
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: White, John P.
/ REGISTRATION NUMBER: 28,678
/ REFERENCE/DOCKET NUMBER: 37690-II-B
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 278-0400
/ TELEFAX: (212) 391-0525
/ TELEX:
/ INFORMATION FOR SEQ ID NO: 2:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 432 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: unknown
/ TOPOLOGY: unknown
/ MOLECULE TYPE: protein
/ ORIGINAL SOURCE:
/ ORGANISM: homo sapien
/ CELL TYPE: lymphocyte
/
US-08-484-681-2

Query Match      87.9%; Score 2122; DB 4; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY 1 NMRGVFRRLLLVLTALPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKSNQIK 60
DB 1 NMRGVFRRLLLVLTALPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKSNQIK 60
QY 61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
DB 61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
QY 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWTCTVLQNKQKVEKIDIV-----PCPAPEPKSCDKTHTCPELIGSPVFL 227
DB 181 TWTCTVLQNKQKVEKIDIVLVLAFERKCCVECPCPAP-----VAGPSVFL 227
QY 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTKPREBOYSTYRV 287
DB 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTKPREBOYSTYRV 287
QY 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTKPREBOYSTYRV 287
DB 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTKPREBOYSTYRV 287
QY 288 VSVLTVLHODMLNGKEVKCKVSNKALPAPIEKTISRKGPQREPVYTLPPSRDELTKNQ 347
DB 288 VSVLTVLHODMLNGKEVKCKVSNKALPAPIEKTISRKGPQREPVYTLPPSRDELTKNQ 347
QY 348 VSVLTVLHODMLNGKEVKCKVSNKALPAPIEKTISRKGPQREPVYTLPPSRDELTKNQ 347
DB 348 VSVLTVLHODMLNGKEVKCKVSNKALPAPIEKTISRKGPQREPVYTLPPSRDELTKNQ 347
QY 348 VSVLTVLHODMLNGKEVKCKVSNKALPAPIEKTISRKGPQREPVYTLPPSRDELTKNQ 347
DB 348 VSVLTVLHODMLNGKEVKCKVSNKALPAPIEKTISRKGPQREPVYTLPPSRDELTKNQ 347
QY 408 FSCSVVHEALHNHYTQKSLSLSPG 431
```

```
DB 408 FSCSVVHEALHNHYTQKSLSLSPG 431

RESULT 7
PCT-US93-07422-2
Sequence 2, Application PC/TUS9307422
GENERAL INFORMATION:
APPLICANT: Progenics Pharmaceuticals, Inc.
TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/07422
FILING DATE: 19930806
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/927,931
FILING DATE: 07-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/AJM
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 977-9550
TELEFAX: (212) 977-9809
TELEX: 422523 COOP UT
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 432 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: protein
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
PCT-US93-07422-2

Query Match      87.9%; Score 2122; DB 5; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY 1 NMRGVFRRLLLVLTALPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKSNQIK 60
DB 1 NMRGVFRRLLLVLTALPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKSNQIK 60
QY 61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
DB 61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
QY 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGLTANSDFHLLQGOSLTLTLSPSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWTCTVLQNKQKVEKIDIV-----PCPAPEPKSCDKTHTCPELIGSPVFL 227
DB 181 TWTCTVLQNKQKVEKIDIVLVLAFERKCCVECPCPAP-----VAGPSVFL 227
QY 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTKPREBOYSTYRV 287
DB 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVNAKTKPREBOYSTYRV 287
```

Db 228 FPPKPDITLMSRTEVTCVVVDVSHEDPEVQFNMYVDGVEVHNAKTKRPREQFNSTRV 287  
 QY 288 VSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDLTQ 347  
 Db 288 VSVLTVLHODMLNGKEYCKVSNKGLPAPIEKTISKAKGPREPOVYTLPPSRDMTQ 347  
 QY 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPYLSDSGSFYLSKLTVDKSRMQGNV 407  
 Db 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPYLSDSGSFYLSKLTVDKSRMQGNV 407  
 QY 408 FSCSVMEALHNHYTQKSLSLSPG 431  
 Db 408 FSCSVMEALHNHYTQKSLSLSPG 431

RESULT 8  
 US-08-472-888A-6  
 ; Sequence 6, Application US/08472888A  
 ; Patent No. 6613746  
 ; GENERAL INFORMATION:

; APPLICANT: Seed, Brian  
 ; TITLE OF INVENTION: AGP-ANTIBODY FUSION PROTEINS  
 ; NUMBER OF SEQUENCES: 9  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESS: Clark & Ribling LLP  
 ; STREET: 176 Federal Street  
 ; CITY: Boston  
 ; STATE: MA  
 ; COUNTRY: USA  
 ; ZIP: 02110

; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette  
 ; COMPUTER: IBM Compatible  
 ; OPERATING SYSTEM: DOS  
 ; SOFTWARE: FASTSEQ for Windows Version 2.0  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/472,888A  
 ; FILING DATE: 07-JUN-1995  
 ; CLASSIFICATION: 424

; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER: 07/618,314  
 ; FILING DATE: 23-NOV-1990  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Ribling, Karen L.  
 ; REGISTRATION NUMBER: 35,238  
 ; REFERENCE/DOCKET NUMBER: 00786/258001  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 617-428-0200  
 ; TELEFAX: 617-428-7045  
 ; TELEX:

; INFORMATION FOR SEQ ID NO: 6:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 630 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: unknown  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 ; US-08-472-888A-6

Query Match 86.7%; Score 2092; DB 4; Length 630;  
 Best Local Similarity 67.2%; Pred. No. 1,4e-161;  
 Matches 424; Conservative 0; Mismatches 5; Indels 202; Gaps 5;

QY 1 NNRGVFRRLLLVLTALLPAATQGNKVVLGKKGTVELTCTAAGKKSIOFHMKNNOIK 60  
 Db 1 NNRGVFRRLLLVLTALLPAATQGNKVVLGKKGTVELTCTAAGKKSIOFHMKNNOIK 60  
 QY 61 ILNGGSEFLTKGPKSLNDPDRSRSLMOGNFPLIKNKIKIDSDTYICEVDQEEVQL 120  
 Db 61 ILNGGSEFLTKGPKSLNDPDRSRSLMOGNFPLIKNKIKIDSDTYICEVDQEEVQL 120

QY 121 LVFGLTANSDTHLLQGSLLTLLSPSSPSVQCRSPRGKNIQGGKTLVSQLELDSG 180  
 Db 121 LVFGLTANSDTHLLQGSLLTLLSPSSPSVQCRSPRGKNIQGGKTLVSQLELDSG 180  
 QY 181 TWCTCTVIONQKVEFKIDIV----- 200  
 Db 181 TWCTCTVIONQKVEFKIDIVLAFOKASSIYKKKEGQVERSPFLAFTVEKLTGSGELMW 240  
 QY 201 ----- 200  
 Db 241 QAERASSKSWITFDLKNKEVSVKRVTDQPKLQMGKPLHLTLPOLPOYAGSGNLTIA 300  
 QY 201 ----- 200  
 Db 301 LEAKTGKLGQEVNLVWBRATQLOKNLTCEWGPPTSPLMLSLKENKAKVSKREKPYW 360  
 QY 201 -----PC-----PAPBPKSCDYTHTC-----PELL 220  
 Db 361 LNPEAGMWQCLSDSGVLLSNIKVLPTWSTPVHADPEGEPKSCDXHTHTCPPCPABELL 420  
 QY 221 GGSVFLFPPPKDITLMSRTEVTCVVVDVSHEDPEVKFMVYDGVVHNAKTKPREQ 280  
 Db 421 GGSVFLFPPPKDITLMSRTEVTC-VVDVSHEDPEVKFMVYDGVVHNAKTKPREQ 479  
 QY 281 YNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSR 340  
 Db 480 YNSTYR-MSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSR 538  
 QY 341 DELTKNOVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPYLSDSGSFYLSKLTVDKS 400  
 Db 539 DELTKNOVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPYLSDSGSFYLSKLTVDKS 598  
 QY 401 RMQGNVFSQSVMEALHNHYTQKSLSLSPG 431  
 Db 599 RMQGNVFSQSVMEALHNHYTQKSLSLSPG 629

RESULT 9  
 US-08-477-4608-4

; Sequence 4, Application US/084774608  
 ; Patent No. 6034223  
 ; GENERAL INFORMATION:

; APPLICANT: Progenics Pharmaceuticals, Inc.  
 ; TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED  
 ; TITLE OF INVENTION: CD4-GAMMA2 AND CD4-IGG2 IMMUNOCONJUGATES, AND USES THEREOF  
 ; NUMBER OF SEQUENCES: 9  
 ; CORRESPONDENCE ADDRESS:

; ADDRESS: Cooper & Dunham  
 ; STREET: 30 Rockefeller Plaza  
 ; CITY: New York  
 ; STATE: New York  
 ; COUNTRY: USA  
 ; ZIP: 10112

; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: Patent in Release #1.24  
 ; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/477,460B  
 ; FILING DATE: 07-JUN-1995  
 ; CLASSIFICATION: 530  
 ; PRIORITY APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/927,931  
 ; FILING DATE: 07-AUG-1992

; ATTORNEY/AGENT INFORMATION:  
 ; NAME: White, John P.  
 ; REGISTRATION NUMBER: 28,678  
 ; REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/AJM  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (212) 977-9550  
 ; TELEFAX: (212) 977-9809  
 ; TELEX: 422523 COOP UI

```

; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 530 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: homo sapien
; CELL TYPE: lymphocyte
US-08-477-460B-4

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

QY      1  NMRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
DB      1  NMRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
QY      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKNLIKIEDSDTYICEVEDQKEEYQL 120
DB      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKNLIKIEDSDTYICEVEDQKEEYQL 120
QY      121  LVFGLTANSDFHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121  LVFGLTANSDFHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      181  TWTCVTLQNKQKVEFKIDIV-----PCPA-----PEP 207
DB      181  TWTCVTLQNKQKVEFKIDIV-----PCPA-----PEP 207
QY      208  TWTCVTLQNKQKVEFKIDIVLAFASTKGPSVPLAPCSRSTSESTALGCLVKDYFPEP 240
DB      208  TWTCVTLQNKQKVEFKIDIVLAFASTKGPSVPLAPCSRSTSESTALGCLVKDYFPEP 240
QY      241  VTVMNSGALTSGVHTFPAVLQSSGLYSLSVTVVPSNFGQTYTCNVDHKPSMTKYDK 300
DB      241  VTVMNSGALTSGVHTFPAVLQSSGLYSLSVTVVPSNFGQTYTCNVDHKPSMTKYDK 300
QY      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 262
DB      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 262
QY      301  TVERKCCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 360
DB      301  TVERKCCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 360
QY      263  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 322
DB      263  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 322
QY      361  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 420
DB      361  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 420
QY      323  KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 382
DB      323  KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 382
QY      421  KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPM 480
DB      421  KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPM 480
QY      383  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
DB      383  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
QY      481  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 529
DB      481  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 529

RESULT 10
US-08-379-516-4
; Sequence 4, Application US/08379516
; Patent No. 6083478
; GENERAL INFORMATION:
; APPLICANT: Allaway, Graham P.
; TITLE OF INVENTION: No. 6083478-Peptidyl Moiety-Conjugated CD4-Gamma2 and CD4-IgG2
; TITLE OF INVENTION: Immunocjugates and Uses Thereof
; FILE REFERENCE: 41215-A-PCT-US
; CURRENT APPLICATION NUMBER: US/08/379,516
; CURRENT FILING DATE: 1996-06-10
; EARLIER APPLICATION NUMBER: PCT/US93/07422
; EARLIER FILING DATE: 1993-08-06
; EARLIER APPLICATION NUMBER: 07/927,931
; EARLIER FILING DATE: 1992-08-07
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 530
```

```

; TYPE: PRT
; ORGANISM: Homo sapiens
US-08-379-516-4

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

QY      1  NMRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
DB      1  NMRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
QY      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKNLIKIEDSDTYICEVEDQKEEYQL 120
DB      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKNLIKIEDSDTYICEVEDQKEEYQL 120
QY      121  LVFGLTANSDFHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121  LVFGLTANSDFHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      181  TWTCVTLQNKQKVEFKIDIV-----PCPA-----PEP 207
DB      181  TWTCVTLQNKQKVEFKIDIV-----PCPA-----PEP 207
QY      208  TWTCVTLQNKQKVEFKIDIVLAFASTKGPSVPLAPCSRSTSESTALGCLVKDYFPEP 240
DB      208  TWTCVTLQNKQKVEFKIDIVLAFASTKGPSVPLAPCSRSTSESTALGCLVKDYFPEP 240
QY      241  VTVMNSGALTSGVHTFPAVLQSSGLYSLSVTVVPSNFGQTYTCNVDHKPSMTKYDK 300
DB      241  VTVMNSGALTSGVHTFPAVLQSSGLYSLSVTVVPSNFGQTYTCNVDHKPSMTKYDK 300
QY      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 262
DB      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 262
QY      301  TVERKCCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 360
DB      301  TVERKCCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNW 360
QY      263  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 322
DB      263  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 322
QY      361  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 420
DB      361  YVDGVEVNAKTKPREEOYNSTYRVSVLTVLHQMNLNGKEYKCKVSNKALPAPIEKTIS 420
QY      323  KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 382
DB      323  KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 382
QY      421  KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPM 480
DB      421  KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPM 480
QY      383  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
DB      383  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
QY      481  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 529
DB      481  LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSLSPG 529

RESULT 11
US-09-329-916-4
; Sequence 4, Application US/09329916
; Patent No. 617549
; GENERAL INFORMATION:
; APPLICANT: Progenice Pharmaceuticals, Inc.
; TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED
; TITLE OF INVENTION: CD4-GAMMA2 AND CD4-IgG2 IMMUNOCJUGATES, AND USES THEREOF
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Cooper & Dunham
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10112
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/329,916
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/477,460
; FILING DATE: 07-JUN-1995
```

```

APPLICATION NUMBER: US 07/927,931
FILING DATE: 07-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPM/ALM
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 977-9550
TELEFAX: (212) 977-9809
TELEX: 422523 COOP UT
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 530 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-09-329-916-4

```

```

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

```

QY 1 MNRGVPFRHLILVQLALPPATQGNKVLGKKGDTVELTCTASQKKSIOFMKNSNQIK 60
DB 1 MNRGVPFRHLILVQLALPPATQGNKVLGKKGDTVELTCTASQKKSIOFMKNSNQIK 60
QY 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
DB 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
QY 121 LVFGILTANSDTHLLOQGSILTLLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGILTANSDTHLLOQGSILTLLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWTCTVLONQKQKVEFKIDIV-----PCPA-----PEP 207
DB 181 TWTCTVLONQKQKVEFKIDIVLAFASTKGPSVFLAPCSRSTSESTALGCLVKDYFPEP 240
QY 208 ----- 207
DB 208 ----- 207
QY 241 VTWSNMGALTSGVHTPAVLQSSGLYSLSSVTVTPSSNFGTQTYTCNVDHKPSNTKYDK 300
DB 241 VTWSNMGALTSGVHTPAVLQSSGLYSLSSVTVTPSSNFGTQTYTCNVDHKPSNTKYDK 300
QY 208 ----KSCDKHTHCP-ELLGGPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
DB 208 ----KSCDKHTHCP-ELLGGPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
QY 301 TVERKCCVECPCPAPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 360
DB 301 TVERKCCVECPCPAPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 360
QY 263 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 322
DB 263 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 322
QY 361 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 420
DB 361 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 420
QY 323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPV 382
DB 323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPV 382
QY 421 KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPM 480
DB 421 KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPM 480
QY 383 LDSDSGFFLYSKLTYDKSRMGOGNVFGSVHMEALHNHYTQKSLSLSPG 431
DB 383 LDSDSGFFLYSKLTYDKSRMGOGNVFGSVHMEALHNHYTQKSLSLSPG 431
QY 481 LDSDSGFFLYSKLTYDKSRMGOGNVFGSVHMEALHNHYTQKSLSLSPG 529
DB 481 LDSDSGFFLYSKLTYDKSRMGOGNVFGSVHMEALHNHYTQKSLSLSPG 529

```

```

RESULT 12
US-08-485-372A-4
Sequence 4, Application US/08485372A
Patent No. 6187748
GENERAL INFORMATION:
APPLICANT: Beadon, Gary A.
APPLICANT: Maddon, Paul J.
TITLE OF INVENTION: CD4-GAMMA2 CD4-1gG2 CHIMERAS
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:

```

```

ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,372A
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/476,227
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 37690-II-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 278-0400
TELEFAX: (212) 391-0525
TELEX:
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 530 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-08-485-372A-4

```

```

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

```

QY 1 MNRGVPFRHLILVQLALPPATQGNKVLGKKGDTVELTCTASQKKSIOFMKNSNQIK 60
DB 1 MNRGVPFRHLILVQLALPPATQGNKVLGKKGDTVELTCTASQKKSIOFMKNSNQIK 60
QY 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
DB 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
QY 121 LVFGILTANSDTHLLOQGSILTLLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGILTANSDTHLLOQGSILTLLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWTCTVLONQKQKVEFKIDIV-----PCPA-----PEP 207
DB 181 TWTCTVLONQKQKVEFKIDIVLAFASTKGPSVFLAPCSRSTSESTALGCLVKDYFPEP 240
QY 208 ----- 207
DB 208 ----- 207
QY 241 VTWSNMGALTSGVHTPAVLQSSGLYSLSSVTVTPSSNFGTQTYTCNVDHKPSNTKYDK 300
DB 241 VTWSNMGALTSGVHTPAVLQSSGLYSLSSVTVTPSSNFGTQTYTCNVDHKPSNTKYDK 300
QY 208 ----KSCDKHTHCP-ELLGGPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
DB 208 ----KSCDKHTHCP-ELLGGPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
QY 301 TVERKCCVECPCPAPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 360
DB 301 TVERKCCVECPCPAPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 360
QY 263 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 322
DB 263 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 322
QY 361 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 420
DB 361 YVDGVEVHNAKTKRREBOYNSTYRVSVLTVLHODMNLGKEYKCKVSNKALPAPIEKTIS 420
QY 323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPV 382
DB 323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPV 382
QY 421 KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPM 480
DB 421 KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPM 480

```



QY 383 LSDSGSFLLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 431  
DB 481 LSDSGSFLLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 529

RESULT 13  
US-09-409-006A-4  
Sequence 4, Application US/09409006A  
Patent No. 6342586  
GENERAL INFORMATION:  
APPLICANT: Progenics Pharmaceuticals, Inc.  
TITLE OF INVENTION: NON-PEPTIDYL MOIEFY-CONJUGATED  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10112  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.24  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/409,006A  
FILING DATE: 29-SEP-1999  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/927,931  
FILING DATE: 07-AUG-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/AJM  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 977-9550  
TELEFAX: (212) 977-9809  
TELEX: 422523 COOP UI  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 530 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: CDNA  
ORIGINAL SOURCE:  
ORGANISM: homo sapien  
CELL TYPE: lymphocyte  
US-09-409-006A-4

Query Match 86.4%; Score 2085; DB 4; Length 530;  
Best Local Similarity 77.3%; Pred. No. 4e-161;  
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;  
QY 1 MNRGVFRRLLLVQLALPAAATQGNKVYGGKGDVLTCTASOKKSIOFHMKNSNOIK 60  
DB 1 MNRGVFRRLLLVQLALPAAATQGNKVYGGKGDVLTCTASOKKSIOFHMKNSNOIK 60  
QY 61 ILGNQGSFLLTKGSKLNDRADSRSLMDQGNFPLIINKLIEDSDTYICEVEQKEEVOL 120  
DB 61 ILGNQGSFLLTKGSKLNDRADSRSLMDQGNFPLIINKLIEDSDTYICEVEQKEEVOL 120  
QY 121 LVFGLTRANSPTHLLOGOSLTLTLESPPGSSPVQCSPPRGKNIQGGKTLISVSQLELODGS 180  
DB 121 LVFGLTRANSPTHLLOGOSLTLTLESPPGSSPVQCSPPRGKNIQGGKTLISVSQLELODGS 180  
QY 181 TWTCTVLQNGKVEFKIDIV-----PCPA-----PPB 207  
DB 181 TWTCTVLQNGKVEFKIDIVLAFASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPER 240

QY 208 ----- 207  
DB 241 VIVSNKSGALTSGWTFPPAVLOSGLYLSAVVTVSSNFGTQTTICNVDKRPSNTKDK 300  
QY 208 ---KSCDKTHPC-ELIGPSVFLPPPKKDTLMISRTPEYTCVVVDVSHEDPEVKFNW 262  
DB 301 TVERKCCVCPGPCPAPVAGPSVFLPPPKKDTLMISRTPEYTCVVVDVSHEDPEVKFNW 360  
QY 263 YVDGVEVNAKTKPREEQYNSTYRVVSVLTVTHQDMLNKEVKCKSNALPAPIEKTIS 322  
DB 361 YVDGVEVNAKTKPREEQYNSTYRVVSVLTVTHQDMLNKEVKCKSNALPAPIEKTIS 420  
QY 323 KKGQREPOVYTLPPSRDELTKNOVSLCLVKGFPSPDIAVBWESNGQPENNYKTPPV 382  
DB 421 KTGQREPOVYTLPPSRDELTKNOVSLCLVKGFPSPDIAVBWESNGQPENNYKTPPV 480  
QY 383 LSDSGSFLLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 431  
DB 481 LSDSGSFLLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 529

RESULT 14  
US-08-484-681-4  
Sequence 4, Application US/08484681  
Patent No. 6451313  
GENERAL INFORMATION:  
APPLICANT: Beaudry, Gary A.  
APPLICANT: Maddon, Paul J.  
TITLE OF INVENTION: CD4-GAMMA2 CD4-IgG2 CHIMERAS  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Cooper & Dunham LLP  
STREET: 1185 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10036  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.24  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/484,681  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: White, John P.  
REGISTRATION NUMBER: 28,678  
REFERENCE/DOCKET NUMBER: 37690-II-B  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 278-0400  
TELEFAX: (212) 391-0525  
TELEX:  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 530 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: CDNA  
ORIGINAL SOURCE:  
ORGANISM: homo sapien  
CELL TYPE: lymphocyte  
US-08-484-681-4

Query Match 86.4%; Score 2085; DB 4; Length 530;  
Best Local Similarity 77.3%; Pred. No. 4e-161;  
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;  
QY 1 MNRGVFRRLLLVQLALPAAATQGNKVYGGKGDVLTCTASOKKSIOFHMKNSNOIK 60

```

Db      1  MNRGVPFRHLLVLQALLPAATQGNKVVLGKKGDTVELTCTASQKSIQFHMKNSNOIK 60
Qy      61  ILNGQSFLLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Db      61  ILNGQSFLLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Qy      121  LVFGLTANSDBTHLQOGSLTLLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Db      121  LVFGLTANSDBTHLQOGSLTLLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Qy      181  TWTCTVLQNKQKVEFKIDIV-----PCPA-----PEP 207
Db      181  TWTCTVLQNKQKVEFKIDIVLAFSTKGPVFLAPCSRSTSESTALGCLVKDYFPBP 240
Qy      208  ----- 207
Db      241  VTVMNSGALTSGVHTFPAVLQSSGLYSLSVTVTPSSNFGOTYTCNVDHKPSNTKYDK 300
Qy      208  ----KSCDKHTPC-ELLGSPSVFLPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 262
Db      301  TVERKCCVCPCPAPVAGSVFLPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 360
Qy      263  YVDGEVHNATKTRPEEQNSTFRVSVLTVVHODMLNGEKYCKVSNKGLPAPIEKTIS 322
Db      361  YVDGEVHNATKTRPEEQNSTFRVSVLTVVHODMLNGEKYCKVSNKGLPAPIEKTIS 420
Qy      323  KAKQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPV 382
Db      421  KTKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPM 480
Qy      383  LDSGSFFLYSKLTVDKSRMQGNVFSQSVHMEALHNHYTQKSLSLSPG 431
Db      481  LDSGSFFLYSKLTVDKSRMQGNVFSQSVHMEALHNHYTQKSLSLSPG 529

```

## RESULT 15

PCT-US93-07422-4

Sequence 4, Application PC/TUS9307422

GENERAL INFORMATION:

APPLICANT: Progenice Pharmaceuticals, Inc.

TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED

TITLE OF INVENTION: CD4-GAMMA2 AND CD4-IGG2 IMMUNOCONJUGATES, AND USES THEREOF

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Cooper &amp; Dunham

STREET: 30 Rockefeller Plaza

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10112

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.24

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US93/07422

FILING DATE: 19930806

CLASSIFICATION:

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US 07/927,931

FILING DATE: 07-AUG-1992

ATTORNEY/AGENT INFORMATION:

NAME: White, John P.

REGISTRATION NUMBER: 28,678

REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPM/AJM

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 977-9550

TELEFAX: (212) 977-9809

TELEX: 422523 COOP UI

INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 530 amino acids

```

; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: CDNA
; ORIGINAL SOURCE:
; ORGANISM: homo sapien
; CELL TYPE: lymphocyte
PCT-US93-07422-4

```

Query Match 86.4%; Score 2085; DB 5; Length 530;  
 Best Local Similarity 77.3%; Pred. No. 4e-161;  
 Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

Qy      1  MNRGVPFRHLLVLQALLPAATQGNKVVLGKKGDTVELTCTASQKSIQFHMKNSNOIK 60
Db      1  MNRGVPFRHLLVLQALLPAATQGNKVVLGKKGDTVELTCTASQKSIQFHMKNSNOIK 60
Qy      61  ILNGQSFLLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Db      61  ILNGQSFLLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Qy      121  LVFGLTANSDBTHLQOGSLTLLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Db      121  LVFGLTANSDBTHLQOGSLTLLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Qy      181  TWTCTVLQNKQKVEFKIDIV-----PCPA-----PEP 207
Db      181  TWTCTVLQNKQKVEFKIDIVLAFSTKGPVFLAPCSRSTSESTALGCLVKDYFPBP 240
Qy      208  ----- 207
Db      241  VTVMNSGALTSGVHTFPAVLQSSGLYSLSVTVTPSSNFGOTYTCNVDHKPSNTKYDK 300
Qy      208  ----KSCDKHTPC-ELLGSPSVFLPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 262
Db      301  TVERKCCVCPCPAPVAGSVFLPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 360
Qy      263  YVDGEVHNATKTRPEEQNSTFRVSVLTVVHODMLNGEKYCKVSNKGLPAPIEKTIS 322
Db      361  YVDGEVHNATKTRPEEQNSTFRVSVLTVVHODMLNGEKYCKVSNKGLPAPIEKTIS 420
Qy      323  KAKQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPV 382
Db      421  KTKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPM 480
Qy      383  LDSGSFFLYSKLTVDKSRMQGNVFSQSVHMEALHNHYTQKSLSLSPG 431
Db      481  LDSGSFFLYSKLTVDKSRMQGNVFSQSVHMEALHNHYTQKSLSLSPG 529

```

## RESULT 16

US-08-630-172-17

Sequence 17, Application US/08630172

Patent No. 6060054

GENERAL INFORMATION:

APPLICANT: Staerz, Uwe

TITLE OF INVENTION: NOVEL PRODUCT AND PROCESS FOR T

TITLE OF INVENTION: LYMPHOCYTE VETO

NUMBER OF SEQUENCES: 41

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Sheridan Ross &amp; McIntosh

STREET: 1700 Lincoln Street, 35th Floor

CITY: Denver

STATE: Colorado

COUNTRY: U.S.

ZIP: 80203

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/630.172

```
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Connell, Gary J.
/ REGISTRATION NUMBER: 32,020
/ REFERENCE/DOCKET NUMBER: 2879-36
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (303) 863-9700
/ TELEFAX: (303) 863-0223
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 410 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
US-08-630-172-17
```

```
Query Match 68.2%; Score 1647.5; DB 3; Length 410;
Best Local Similarity 75.8%; Pred. No. 9,4e-126;
Matches 316; Conservative 31; Mismatches 51; Indels 19; Gaps 4;
```

```
QY 26 NKVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTKGPKLNDRADSRSS 85
DB 1 NKVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTKGPKLNDRADSRSS 60
QY 86 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLES 145
DB 61 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLES 120
QY 146 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIV----- 200
DB 121 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIVLAMP 180
QY 201 -----PCPAPPEKSCDKHTHCELLGGSVFLFPKPKDMLISTPEVTCVVDVSH 254
DB 181 RGPITKPCP-----PCCK-----PAPNLLGGPSVFLFPKPKDMLISTPEVTCVVDVSD 233
QY 255 DPEVKNMYVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKYEKCKVSNKALP 314
DB 234 DPEVQISWVNNVEVHTAQOTHRREDYNSRLRVVSALPIQHDQWMSGKEFKCKVNNKDL 293
QY 315 APIEKTISKAKQPREPOVYTLPPSRDELTKQVSLTLCYKGFYSDIAVENESQOPEN 374
DB 294 APIERTISKPKGSVRAPQVYVLPPE-BEWTKKQVTLTCWTDPMEDIVYEWTTNGKTEL 352
QY 375 NYKTTPEVLDSDGSFELYSKLTVDKSRMOQGVFSCVHREALHNHYTKSLSLSPG 431
DB 353 NYKNTPEVLDSDGSFYFYSKLRVEKKNWERNYSCSVHREALHNHHTTKSFSTRPG 409
```

```
RESULT 17
US-09-375-419-17
/ Sequence 17, Application US/09375419
/ Patent No. 6264950
/ GENERAL INFORMATION:
/ APPLICANT: Stearz, Uwe
/ TITLE OF INVENTION: NOVEL PRODUCT AND PROCESS FOR T
/ NUMBER OF SEQUENCES: 41
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sheridan Rose & McIntosh
/ STREET: 1700 Lincoln Street, 35ch Floor
/ CITY: Denver
/ STATE: Colorado
/ COUNTRY: U.S.
/ ZIP: 80203
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentm Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/375,419
```

```
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/630,172
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Connell, Gary J.
/ REGISTRATION NUMBER: 32,020
/ REFERENCE/DOCKET NUMBER: 2879-36
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (303) 863-9700
/ TELEFAX: (303) 863-0223
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 410 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
US-09-375-419-17
```

```
Query Match 68.2%; Score 1647.5; DB 3; Length 410;
Best Local Similarity 75.8%; Pred. No. 9,4e-126;
Matches 316; Conservative 31; Mismatches 51; Indels 19; Gaps 4;
```

```
QY 26 NKVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTKGPKLNDRADSRSS 85
DB 1 NKVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTKGPKLNDRADSRSS 60
QY 86 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLES 145
DB 61 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLES 120
QY 146 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIV----- 200
DB 121 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIVLAMP 180
QY 201 -----PCPAPPEKSCDKHTHCELLGGSVFLFPKPKDMLISTPEVTCVVDVSH 254
DB 181 RGPITKPCP-----PCCK-----PAPNLLGGPSVFLFPKPKDMLISTPEVTCVVDVSD 233
QY 255 DPEVKNMYVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKYEKCKVSNKALP 314
DB 234 DPEVQISWVNNVEVHTAQOTHRREDYNSRLRVVSALPIQHDQWMSGKEFKCKVNNKDL 293
QY 315 APIEKTISKAKQPREPOVYTLPPSRDELTKQVSLTLCYKGFYSDIAVENESQOPEN 374
DB 294 APIERTISKPKGSVRAPQVYVLPPE-BEWTKKQVTLTCWTDPMEDIVYEWTTNGKTEL 352
QY 375 NYKTTPEVLDSDGSFELYSKLTVDKSRMOQGVFSCVHREALHNHYTKSLSLSPG 431
DB 353 NYKNTPEVLDSDGSFYFYSKLRVEKKNWERNYSCSVHREALHNHHTTKSFSTRPG 409
```

```
RESULT 18
US-08-284-391B-33
/ Sequence 33, Application US/08284391B
/ Patent No. 5851828
/ GENERAL INFORMATION:
/ APPLICANT: Seed, Brian
/ APPLICANT: Banapour, Babak
/ APPLICANT: Romeo, Charles
/ APPLICANT: Kolanus, Waldemar
/ TITLE OF INVENTION: TARGETED CYTOLYSIS OF HIV-INFECTED
/ NUMBER OF SEQUENCES: 53
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Clark & Biding LLP
/ STREET: 176 Federal Street
/ CITY: Boston
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110
/ COMPUTER READABLE FORM:
```

```
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FASTSEQ for Windows Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/284,391B
/ FILING DATE: 02-AUG-1994
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/195,395
/ FILING DATE: 14-FEB-1994
/ APPLICATION NUMBER: 07/847,566
/ FILING DATE: 06-MAR-1992
/ APPLICATION NUMBER: 07/665,961
/ FILING DATE: 07-MAR-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Eibing, Karen L
/ REGISTRATION NUMBER: 35,238
/ REFERENCE/DOCKET NUMBER: 00786/247001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617-428-0200
/ TELEFAX: 617-428-7045
/
/
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 254 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/
/ US-08-284-391B-33
```

```
Query Match 55.4%; Score 1338.5; DB 2; Length 254;
Best Local Similarity 98.0%; Pred. No. 66-101;
Matches 249; Conservative 0; Mismatches 0; Indels 5; Gaps 1;
```

```
QY 206 EPKSCDKHTHC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVAVDVSHDEPEVKF 260
DB 1 EPKSCDKHTHCPCPAPBELLGSPSVFLPPPKPKDTLMISRTPEVTCVAVDVSHDEPEVKF 60
QY 261 NMYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 320
DB 61 NMYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 120
QY 321 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 380
DB 121 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 180
QY 381 PVLDSGSEFFLYSKLTVDKSRWQGNVFSCSVMEALAHNHYTKSLSPGLQDETCAE 440
DB 181 PVLDSGSEFFLYSKLTVDKSRWQGNVFSCSVMEALAHNHYTKSLSPGLQDETCAE 240
QY 441 AODGELDGLWTTDP 454
DB 241 AODGELDGLWTTDP 254
```

```
RESULT 19
US-09-218-950-33
/ Sequence 33, Application US/09218950
/ Patent No. 6284240
/ GENERAL INFORMATION:
/ APPLICANT: Seed, Brian
/ APPLICANT: Banapur, Babak
/ APPLICANT: Romeo, Charles
/ APPLICANT: Kolanus, Waldemar
/ TITLE OF INVENTION: TARGETED CYTOLYSIS OF HIV-INFECTED
/ TITLE OF INVENTION: CELLS BY CHIMERIC CD4 RECEPTOR- BEARING CELLS
/ NUMBER OF SEQUENCES: 53
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Clark & Eibing LLP
/ STREET: 176 Federal Street
/ CITY: Boston
```

```
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FASTSEQ for Windows Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/218,950
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/284,391
/ FILING DATE: 02-AUG-1994
/ APPLICATION NUMBER: 08/195,395
/ FILING DATE: 14-FEB-1994
/ APPLICATION NUMBER: 07/847,566
/ FILING DATE: 06-MAR-1992
/ APPLICATION NUMBER: 07/665,961
/ FILING DATE: 07-MAR-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Eibing, Karen L
/ REGISTRATION NUMBER: 35,238
/ REFERENCE/DOCKET NUMBER: 00786/247001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617-428-0200
/ TELEFAX: 617-428-7045
/
/
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 254 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/
/ US-09-218-950-33
```

```
Query Match 55.4%; Score 1338.5; DB 3; Length 254;
Best Local Similarity 98.0%; Pred. No. 66-101;
Matches 249; Conservative 0; Mismatches 0; Indels 5; Gaps 1;
```

```
QY 206 EPKSCDKHTHC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVAVDVSHDEPEVKF 260
DB 1 EPKSCDKHTHCPCPAPBELLGSPSVFLPPPKPKDTLMISRTPEVTCVAVDVSHDEPEVKF 60
QY 261 NMYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 320
DB 61 NMYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 120
QY 321 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 380
DB 121 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTT 180
QY 381 PVLDSGSEFFLYSKLTVDKSRWQGNVFSCSVMEALAHNHYTKSLSPGLQDETCAE 440
DB 181 PVLDSGSEFFLYSKLTVDKSRWQGNVFSCSVMEALAHNHYTKSLSPGLQDETCAE 240
QY 441 AODGELDGLWTTDP 454
DB 241 AODGELDGLWTTDP 254
```

```
RESULT 20
US-08-157-101A-7
/ Sequence 7, Application US/08157101A
/ Patent No. 5808032
/ GENERAL INFORMATION:
/ APPLICANT: KURIHARA, TATSUYA
/ APPLICANT: MATSUKURA, SHIGEKAZU
/ APPLICANT: TSUROOKA, NOBUO
/ APPLICANT: ARIMA, KENJI
/ APPLICANT: NISHIHARA, TATSURO
```

```

/ TITLE OF INVENTION: ANTI-HBs ANTIBODY GENES AND EXPRESSION
/ TITLE OF INVENTION: PLASMIDS THEREFOR
/ NUMBER OF SEQUENCES: 9
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: FILLSBURY, MADISON & SUTRO
/ STREET: 1100 NEW YORK AVENUE, N.W.
/ CITY: WASHINGTON
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20005

/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/157,101A
/ FILING DATE: 05-APR-1994
/ CLASSIFICATION: 530
/ ATTORNEY/AGENT INFORMATION:
/ NAME: TITUS, MARLANA K
/ REGISTRATION NUMBER: 35843
/ REFERENCE/DOCKET NUMBER: 9437/204199
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-861-3711
/ TELEFAX: 202-862-0944
/ TELETYPE: 6714627 CUCH
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 459 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-157-101A-7

```

```

Query Match      53.2%; Score 1284.5; DB 1; Length 459;
Best Local Similarity 59.4%; Pred. No. 3.3e-96;
Matches 280; Conservative 30; Mismatches 68; Indels 93; Gaps 17;

```

```

25 GAKVLAAGKADIVELTCTAS--OKKSIQFHW-----KNSNQIKIL--GNQGSFL--TK 71
17 GCGVIV--QGRSRLRLSCAAGTFSSNSMHWQARQKGLWVAVILYGNHMFVADSVK 74
72 GPEKLNDRADRSRLNDQGFPLIRKLIKEDSDTYICEVEDQKEVQLLVGLTANSDT 131
75 GRTTIS--RONSKNVTL-----LEVKSLQTEDTGVYYC--IRDQ-----TYGV----- 113
132 HLLQ--GQSLTLTLESPPGSPFVQCRSPGKNIQGG-----KTLVS----- 172
114 HRDMSGQGTLYVSSASTKGPVFPPLABSKSTSGTALGCLVKDYFPEPVTVSWMNG 173
173 -----QLEIQDSG-----TWCTVLOQKQVEFKIDIVPCPAP 205
174 ALASGVHTPEPAVLQSSGLYSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KKV 227
206 EPKSCDKTHTC-----PELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 260
228 EPPSCDKTHTCPCPAPPELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 287
261 NMYVDGEVNAKTKPREQYNSTYRVSVLTVLHODMLNGEKYCKKVSNNKALPAPIEKT 320
288 NMYVDGEVNAKTKPREQYNSTYRVSVLTVLHODMLNGEKYCKKVSNNKALPAPIEKT 347
321 ISKAKQPREPQYTLPPSHDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTP 380
348 ISKAKQPREPQYTLPPSHDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTP 407
381 PVLDSGSPFLYKLTVDKSRMOQGVNFGSGVNHGLAHNYTKQSLSPG 431
408 PVLDSGSPFLYKLTVDKSRMOQGVNFGSGVNHGLAHNYTKQSLSPG 458

```

```

RESULT 21
US-08-397-411-7
/ Sequence 7, Application US/08397411
/ Patent No. 6129914
/ GENERAL INFORMATION:
/ APPLICANT: Weiner, George
/ APPLICANT: Gingrich, Roger
/ APPLICANT: Link, Brian
/ APPLICANT: Tso, J. Yun
/ TITLE OF INVENTION: Bisppecific Antibody Effective to Treat
/ TITLE OF INVENTION: B-Cell Lymphoma and Cell Line
/ NUMBER OF SEQUENCES: 14
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Townsend and Townsend and Crew
/ STREET: One Market Plaza, Stewart Tower, Suite 2000
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94105

```

```

/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/397,411
/ FILING DATE: 01-MAR-1995
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/859,583
/ FILING DATE: 27-MAR-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Smith, William M.
/ REGISTRATION NUMBER: 30,223
/ REFERENCE/DOCKET NUMBER: 011823-004901
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-326-2400
/ TELEFAX: 415-326-2422
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 446 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-397-411-7

```

```

Query Match      53.1%; Score 1282.5; DB 3; Length 446;
Best Local Similarity 59.8%; Pred. No. 4.6e-96;
Matches 274; Conservative 25; Mismatches 80; Indels 79; Gaps 10;

```

```

30 LAKKGDVLELTCTASQKSIQF--HWKNSNQIKILGNQGSFLTKGPSKLNDRADSRSL- 86
11 LVKPSSETLSLTCTVSGSLTVNGVAMVWQSPGKGLWIGVKKVSGSTENAFISRLTIS 70
87 --WDQGNFPLIRKLIKEDSDTYICEVEDQKEVQLLVGLTANSDTHLQ--GQSLTLT 142
71 KQTSKNQVSLKINSLTADTAAYTC-----ARNDRYAMDWYGGTTLVT 113
143 LESPPGSPVQCRSPGKNIQGG-----KTLVS-----QLEI 176
114 VSSASTKGPVFPPLABSKSTSGTALGCLVKDYFPEPVTVSWMNGALTSQVHTFPAPVL 173
177 QDSG-----TWCTVLOQKQVEFKIDIVPCPAPPKSCDKTHTC-- 216
174 QSSGLYSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KVEPKSCDKTHTCP 227
217 ---PELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFWYVDGVEVNAK 273
228 CPAPPELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFWYVDGVEVNAK 287
274 TKPREQYNSTYRVSVLTVLHODMLNGEKYCKKVSNNKALPAPIEKTISKAKQPREPQV 333

```

```

Db      288 TKPREOYNSTYRVVSVLTVLHQMNGEKYKCKVSNKALPAPIEKTSKAGQPREPOV 347
Qy      334 YTLPSRDELTKNOYSLTCLVKGFPYPSDIAVEMESNGOPENNYKTPVLDSDGSFFLYS 393
Db      348 YTLPSRDELTKNOYSLTCLVKGFPYPSDIAVEMESNGOPENNYKTPVLDSDGSFFLYS 407
Qy      394 KLTVDKSRMOQGNVSCSVMEALNNHYTKSLSLSPG 431
Db      408 KLTVDKSRMOQGNVSCSVMEALNNHYTKSLSLSPG 445

RESULT 22
US-09-740-002-25
; Sequence 25, Application US/09740002
; Patent No. 6537809
; GENERAL INFORMATION:
; APPLICANT: BRAMS, PETER
; APPLICANT: MORROW, PHILIP
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR
; FILE REFERENCE: 037003-0275759
; CURRENT APPLICATION NUMBER: US/09/740,002
; CURRENT FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 09/335,697
; PRIOR FILING DATE: 1999-06-18
; PRIOR APPLICATION NUMBER: 08/488,376
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patencin Ver. 2.1
; SEQ ID NO 25
; LENGTH: 475
; TYPE: PR
; ORGANISM: Homo sapiens
US-09-740-002-25

Query Match      52.9%; Score 1276.5; DB 4; Length 475;
Best Local Similarity 57.1%; Pred. No. 1.5e-95;
Matches 281; Conservative 27; Mismatches 87; Indels 97; Gaps 12;

Qy      10 LLLVQLALLPAATGQNKVYLGKGDYVELTCTAS-----QKKSLQIFHWK 54
Db      10 LVAVATRVLSQVQLQESGPVYVVKPTETLTCTVSGFSLSNRMGVWIRPPGKALBW- 68
Qy      55 NSNQKIILGN-----QGSFLTKGPKLNDRADRSRLMDQGNFPLIKLTKIEDSDTYIC 109
Db      69 -----LGNITSSDEKSPSLKSLRLTTSQDTSRS-----QVLSLTNVDPVDTATYYC 116
Qy      110 EVEDQKEVEVQLLVFGLTANSDTHL-LQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGG-- 166
Db      117 -----ARVGLYDINAVLYLYLDYWGQGLVVTSSASTKGPVFLPLAPSSKTSGGTA 168
Qy      167 -----KTLSS-----QLELDQSG-----TWTC 184
Db      169 ALGCLVKDYFPEPVYTVSNMNGALTSQVHTFPAVLQSSGLYSISVTVPSSSLGTQTYIC 228
Qy      185 TYLONOKVEFKIDIVPCAPAPKSCDKTHTC-----PELLGSPSVLPFPKPKDTLMIS 239
Db      229 NW--NHKPSNTKVD-----KKAEPKSCDKTHTCPCPAPRELGGPSVFLFPPKPKDTLMIS 282
Qy      240 RTPEVTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREEOYNSTYRVVSVLTVLHQMNL 299
Db      283 RPEVTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREEOYNSTYRVVSVLTVLHQMNL 342
Qy      300 NGKEVYCKSNKALPAPIEKTSKAGQPREPOVYTLTPSRDELTKNOYSLTCLVKGFP 359
Db      343 NGKEVYCKSNKALPAPIEKTSKAGQPREPOVYTLTPSRDELTKNOYSLTCLVKGFP 402
Qy      360 SDIAVEMESNGOPENNYKTPVLDSDGSFFLYSKLTVDKSRMOQGNVSCSVMEALNN 419
Db      403 SDIAVEMESNGOPENNYKTPVLDSDGSFFLYSKLTVDKSRMOQGNVSCSVMEALNN 462
Qy      420 HYTKSLSLSPG 431

```

```

Db      463 HYTKSLSLSPG 474

RESULT 23
US-07-934-373C-22
; Sequence 22, Application US/07934373C
; Patent No. 5821337
; GENERAL INFORMATION:
; APPLICANT: Paul J. Carter
; APPLICANT: Leonard G. Presta
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/934,373C
; FILING DATE: 21-Aug-1992
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/05126
; FILING DATE: 15-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/715272
; FILING DATE: 14-JUN-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER: 40,378
; REFERENCE/DOCKET NUMBER: P0709P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1994
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 454 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-07-934-373C-22

Query Match      52.8%; Score 1274.5; DB 2; Length 454;
Best Local Similarity 59.9%; Pred. No. 2.1e-95;
Matches 275; Conservative 24; Mismatches 87; Indels 73; Gaps 11;

Qy      30 LGKKGDTVELTCTASQKSLIOF--HWKNSQIKLGNQGSFLTK-GPSKLNDRADRSRL 86
Db      11 LVKPGASVYKISCKTSKGTFTLEYTHMMKQSHGSLLEWIGGFNPKNQGSSSHQRFMDEXTL 70
Qy      87 ---WDQGNFPLIKNLTKIEDSDTYICEVEDQKEVEVQLLVFGLTANSDTHLQ--GQSLTL 141
Db      71 AVDKSTSTAYWELSLTSEDSGIYYC-----ARMRGLNYGFVRYFDVWAGATTV 120
Qy      142 TLSEPPSSPSVQCRSPRGKNIQGG-----KTLSS-----QLE 175
Db      121 TVSSASTKGPVFLPLABSSKTSKGTALAGLVKDYFPEPVTVSNMNGALTSQVHTFPAV 180
Qy      176 LDQSG-----TWCTVLYONOKVEFKIDIVPCAPAPKSCDKTHTC- 216
Db      181 LQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD-----KVEPKSCDKTHTCP 234
Qy      217 ---PELLGSPSVLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVNA 272
Db      235 PCAPPELLGSPSVLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVNA 294

```



```

QY      30 LGKKGDVVELTCAASQKKIQQF--HHKNSNQIKILANGOSFLTK--GPKLNDPRADSRSL 86
Db      11 LVKFGASVKISCTSGTTFTEYTHMMKMSHGSLSEMTGGFPPKNGGSSHNQRMDATL 70
QY      87 ---WDQGNFPLIKNLKIEDSDTYICEVEDQKEVOLVFGILTANSDHLLQ--GOSLTL 141
Db      71 AVDKSTAYAMELRSLTSEDSGIYYC-----ARMRLGNYGFVDRYFDVWAGATTV 120
QY      142 TLSPSPSSSVQCRSPRGKNIQGG-----KILSVS-----QLE 175
Db      121 TVSSASTKGPVPEPLAPSSKSTSGGALGLVKQYFPFPVTVSNNSGALTSVGHTEPAV 180
QY      176 LODSG-----TWTCYLOQNKYVEFKIDIVPCPAEPKSCDKTHTC- 216
Db      181 LQSGGLVSLSSVTVTPSSSLGTQTYICNV--HHKNSNKTVD---KKYEPKSCDKHTCP 234
QY      217 ---PELLGSPVFLFPPPKPCKDTLMSRPPEVTCVVDVSHEDPEVKNNVYDGEVYNA 272
Db      235 PCPAPELLGSPVFLFPPPKPCKDTLMSRPPEVTCVVDVSHEDPEVKNNVYDGEVYNA 294
QY      273 KTKRREQVNSTRVVSVLTVLHODPLNKEKCKVSKNKAAPAPLEKTIISAKQOPREPQ 332
Db      295 KTKRREQVNSTRVVSVLTVLHODPLNKEKCKVSKNKAAPAPLEKTIISAKQOPREPQ 354
QY      333 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNNYKTPRPVLDSDGSFFLY 392
Db      355 VYTLPPSRREMTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNNYKTPRPVLDSDGSFFLY 414
QY      393 SKLTVDSKRWQGNVPSCSVMHEALNNHTQSLSLSPG 431
Db      415 SKLTVDSKRWQGNVPSCSVMHEALNNHTQSLSLSPG 453

```

RESULT 26  
 US-09-705-686-22  
 Sequence 22, Application US/09705686  
 Patent No. 6639055  
 GENERAL INFORMATION:  
 APPLICANT: Carter, Paul J.  
 Presta, Leonard G.  
 TITLE OF INVENTION: Method for Making Humanized Antibodies  
 NUMBER OF SEQUENCES: 26  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Genentech, Inc.  
 STREET: 1 DNA Way  
 CITY: South San Francisco  
 STATE: California  
 COUNTRY: USA  
 ZIP: 94080  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: WinPatIn (Genentech)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/705,686  
 FILING DATE: 02-NO. 6639055-2000  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 08/146206  
 FILING DATE: 17-NOV-1993  
 APPLICATION NUMBER: 07/715272  
 FILING DATE: 14-JUN-1991  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Lee, Wendy M.  
 REGISTRATION NUMBER: 40,378  
 REFERENCE/DOCKET NUMBER: P0709P1D3  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650/225-1994  
 TELEFAX: 650/952-9881  
 INFORMATION FOR SEQ ID NO: 22:  
 SEQUENCE CHARACTERISTICS:

```

;          LENGTH: 454 amino acids
;          TYPE: Amino Acid
;          TOPOLOGY: Linear
;          SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-705-666-22

```

Query Match 52.8%; Score 1274.5; DB 4; Length 454;  
Best Local Similarity -59.9%; Pred. No. 2.1e-95;  
Matches 275; Conservative 24; Mismatches 87; Gaps 11;

```

OY 30 LGKGJGVETLTCASOKKSIOF--HMKSNOIKILGNQGSFLTC-GPSKLNDRADRSRL 86
Db 11 LVKPGASVAKISCTBSYTTETETMMQMOSHGKSLMFIQGFNPNGGSSHNQPMKATL 70
OY 87 ---WDQGNPPLIIKLIKIEDSDPTYCEVEDQKEEVOLLVFGLTANSDTHLLQ--GOSLTL 141
Db 71 AVDKSTSTYMEIARSLTSEDSGIYXC-----ARMRLNGFYDVRFTDWGAQTTV 120
OY 142 TLESPPGSSPSVOCSSPRKNIQGG-----KTLSTVS-----QLE 175
Db 121 TVSSASTKPSVFPPLAPSSKSTSGGTALGCLVNDYRPEPEPTVBSMSGALTSVHTFPRAV 180
OY 176 LQDSG-----TWTCVLQNOKVEFKIDIVCAPAPEKSCDKHTTC- 216
Db 181 LQSSGLYLSSTVYTVSSSLGTQYIICNV--NHKPSMTKVD---KVEPEKSCDKHTTCC 234
OY 217 ----PELLGSPSYFLFPPEPKOTLMIISTPEVTCVVDVSHEDPEVFKNMYVDGVEYHNA 272
Db 235 PCPAPRLTGSPSYFLFPPEPKOTLMIISTPEVTCVVDVSHEDPEVFKNMYVDGVEYHNA 294
OY 273 KTRPREEOYNSTYRVVSVLTVLHOMLNGKCYKCKVSNKALPAIIEKTIISKAGOPREPO 332
Db 295 KTRPREEOYNSTRVVSULTVLHOMLNGKCYKCKVSNKALPAIIEKTIISKAGOPREPO 354
OY 333 VYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQEPENNYKTPPYVLDSGSEFFLY 392
Db 355 VYTLPPSRREMTKNQVSLTCLVKGFPSPDIAVEMESNGQEPENNYKTPPYVLDSGSEFFLY 414
OY 393 SKLTVDKSRWQGNVPSGCSWHEALAHNNYTKSLSTSPG 431
Db 415 SKLTVDKSRWQGNVPSGCSWHEALAHNNYTKSLSTSPG 453

```

```

1 RESULT 27
2 PCT-US93-07832-22
3 / Sequence 22, Application PC/TUS9307832
4 / GENERAL INFORMATION:
5 / APPLICANT: Genentech, Inc.
6 / TITLE OF INVENTION: Immunoglobulin Variants
7 / NUMBER OF SEQUENCES: 40
8 / CORRESPONDENCE ADDRESS:
9 / ADDRESSEE: Genentech, Inc.
10 / STREET: 460 Point San Bruno Blvd
11 / CITY: South San Francisco
12 / STATE: California
13 / COUNTRY: USA
14 / ZIP: 94080
15 /
16 / COMPUTER READABLE FORM:
17 / MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
18 / COMPUTER: IBM PC compatible
19 / OPERATING SYSTEM: PC-DOS/MS-DOS
20 / SOFTWARE: patin (Genentech)
21 /
22 / CURRENT APPLICATION DATA:
23 / APPLICATION NUMBER: PCT/US93/07832
24 / FILING DATE: 19930820
25 /
26 / CLASSIFICATION:
27 / PRIOR APPLICATION DATA:
28 / APPLICATION NUMBER: 07/115272
29 / FILING DATE: 14-JUN-1991
30 /
31 / PRIOR APPLICATION DATA:
32 / APPLICATION NUMBER: PCT/US92/05126
33 / FILING DATE: 15-JUN-1992
34 /
35 / PRIOR APPLICATION DATA:

```



APPLICATION NUMBER: 07/934373  
FILING DATE: 21-AUG-1992  
ATTORNEY/AGENT INFORMATION:  
NAME:  
REGISTRATION NUMBER:  
REFERENCE/DOCKET NUMBER: 709P2PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE:  
TELEFAX: 415/952-9881  
TELEX: 910/371-7168  
INFORMATION FOR SEQ ID NO: 22:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 454 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
PCT-US93-07832-22

Query Match	53.8%	Score 1274.5	DB 5	Length 454
Best Local Similarity	59.9%	Pred. No. 2.1e-95		
Matches 275	Conservative 24	Mismatches 87	Indels 73	Gaps 11

Qy	30	LGKGDVIELCTISAKOKKSIF--HKMKSNOI KILGNGSFLTK-GPSKLNDRADSRSL	86
Db	11	LVKDGASVKISCTKSGYTFEYETWMMQSHGSKSLEWIGFNFPKNKGSSHHQRFMIDKATL	70
Qy	87	---WDQGNFLIITKNIKLI ESDPTI CEVEDOKEEVOLLVFGLTANSDFHLIQ--GQSILT	141
Db	71	AVDSTSTAVYVELLSLTS EDSGLIYCC-----ARMGILANGFDVRFYFDWGAGTTV	120
Qy	142	TLESPPGSPSPVQCRSPRGKNIQGG-----KTLSSVS-----QLE	175
Db	121	TVSSASTKGSFVFPFLAPSSKSTSGGTALGCLVKDYFPEEPYTVSNGSALTSCHTTPAV	180
Qy	176	LQDSGG-----TWCTVLQNKKEFEKIDIVPCAPSPKSCDKTHTC-	216
Db	181	LQSGSLVSLSSVTVPSSSLGTQYICNV--NHKSNFKVD---KKYEPKSCDKTHTCR	234
Qy	217	----PELLGGSVFLFPKPCKOTLMI STPEYTCYVDVSHEDPEVKRNMVYDGYEVANA	272
Db	235	PCPAPELLGGGSVFLFPKPCKDTLMI STPEYTCYVDVSHEDPEVKRNMVYDGYEVANA	294
Qy	273	KTGRREOYNSTYRVSVLTVLHODMLNGKEYKCKVSNKALPAPLEKTIISAKQGPREFQ	332
Db	295	KTGRREOYNSTYRVSVLTVLHODMLNGKEYKCKVSNKALPAPLEKTIISAKQGPREFQ	354
Qy	333	VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSDGSFFLY	392
Db	355	VYTLPPSRHEMTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSDGSFFLY	414
Qy	393	SKLTVDKSRMQQGNVFCSCVNHAEALHNHYTQKSLSLSPG	431
Db	415	SKLTVDKSRMQQGNVFCSCVNHAEALHNHYTQKSLSLSPG	453

RESULT 28  
 US-09-049-672A-4  
 Sequence 4, Application US/09049672A  
 Patent No. 613541  
 GENERAL INFORMATION:  
 APPLICANT: Hillman, Jennifer L.  
 APPLICANT: Lal, Preeti  
 APPLICANT: Tang, Y. Tom  
 APPLICANT: Yue, Henry  
 APPLICANT: Au-Yang, Janice  
 APPLICANT: Corley, Neil C.  
 APPLICANT: Guegler, Karl J.  
 APPLICANT: Baughn, Mariah R.  
 TITLE OF INVENTION: HUMAN IMMUNE SYSTEM ASSOCIATED PROTEINS  
 NUMBER OF SEQUENCES: 28  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Incyte Pharmaceuticals, Inc.  
 STREET: 3174 Porter Drive  
 CITY: Palo Alto

```

1 STATE: CA
2 COUNTRY: USA
3 ZIP: 94304
4 COMPUTER READABLE FORM:
5 MEDIUM TYPE: Diskette
6 COMPUTER: IBM Compatible
7 OPERATING SYSTEM: DOS
8 SOFTWARE: FastSeq for Windows Version 2.0
9 CURRENT APPLICATION DATA:
10 APPLICATION NUMBER: US/09/049,672A
11 FILING DATE: HEREMITH
12 CLASSIFICATION: 536
13 PRIOR APPLICATION DATA:
14 APPLICATION NUMBER:

```

REGISTRATION NUMBER: 39,132  
REFERENCE/DOCKET NUMBER: PF-0497 US  
TELECOMMUNICATION INFORMATION:

LIBRARY: PANCYTUT01  
CLONE: 1513264  
US-09-049-672A-4

Query Match	52.8%	Score 1274.5	DB 3	Length 473
Best Local Similarity	57.2%	Pred. No. 2.2e-95		
Matches 278; Conservative	29;	Mismatches 102;	Indels 77;	Gaps 11;

Qy	8	RHLILVLOQLLPP-----AATQNKVVLGKGGTYELCTAS--QKKSIOFHKNNOI	59
Db	2	KHLMFLLVLAARWVLQYQLOQESGGLVKPSETSLTCAVSGSITSGGYWMSIRQP	61
Qy	60	KILGNQ--GSFLTIGFSKLANDRADSRSL--WDQGNFLLIKNLKIEDSDTYICEVEDQ	114
Db	62	PGKGLEWIGTYIYSGSTLYNPSLKSRYTISVDRSKNQFSLKISSVTADRAVYVCARD	120
Qy	115	KEEVQLLVFELTANSDTHLQOGLTLETSPRESSPSVQCRSPRKNIGOG-----	166
Db	121	-----VLRGNGTGMVGGOGTLVTYVSSASTKGPVSFPLPSSKSTSGGTRALGCLV	172
Qy	167	-----KTLVS-----QELQDSG-----TWTCVVLQNO	190
Db	173	KDYFPEPVTVSMNSGALTSGVHTFPAVLQSSGGLYSLSVTVTPSSLSGTQTYICNV--NH	230
Qy	191	KXVEFKIDIVPCARPEKSCDKTHTC-----PELGGSPVFLPPRKDKDLMISRPEVT	245
Db	231	KPSNTKID---KRVEPKSCDKTHTCPCPAPELGGSPVFLPPRKDKDLMISRPEVT	286
Qy	246	CVVAVDVSHEDPEVKFMYVYDVGVEVHNAKTKPREEOYVSTRVVSVLTVLHQDMLNGKEYK	305
Db	287	CVVAVDVSHEDPEVKFMYVYDVGVEVHNAKTKPREEOYVSTRVVSVLTVLHQDMLNGKEYK	346
Qy	306	CKVSNKALPAPIEKTISKAKGQREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIABE	365
Db	347	CKVSNKALPAPIEKTISKAKGQREPOVYTLPPSRREMTNQOVSLTCLVKGFPSPDIABE	406
Qy	366	WESNGQPENNYKTTTPVLDSGDSFFLYSKTLTVDKSRMQOQNVSPCSVMHEALNNHYTQKS	425
Db	407	WESNGQPENNYKTTTPVLDSGDSFFLYSKTLTVDKSRMQOQNVSPCSVMHEALNNHYTQKS	466
Qy	426	LSTLSPG 431	
Db	467	LSTLSPG 472	

```

RESULT 29
US-09-740-002-27
; Sequence 27, Application US/09740002
; Patent No. 6537809
; GENERAL INFORMATION:
; APPLICANT: BRAMS, PETER
; APPLICANT: MORROW, PHILLIP
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR
; FILE REFERENCE: 037003-0275759
; CURRENT APPLICATION NUMBER: US/09/740,002
; PRIOR FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 09/335,697
; PRIOR FILING DATE: 1999-06-18
; PRIOR APPLICATION NUMBER: 08/488,376
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 475
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-740-002-27

Query Match      52.8%; Score 1273.5; DB 4; Length 475;
Best Local Similarity 57.1%; Pred. No. 2.7e-95;
Matches 276; Conservative 29; Mismatches 99; Indels 79; Gaps 11;

QY 10 LLLVLLPATOQNKVVLGKGDVLELTCTAS-----QKSIQFHMKNISQIKL--- 62
DB 10 LVAVATRVLSQVQLQESGALVKPTQTLTLCTFGFSLSTGMSVMNIROPGALML 69
QY 63 ---GNQGSFELTKG-PSKINDRADSRRLMDQGNPPLIKIKIEDSPYICEVEDQKE 117
DB 70 ARIDMDDDTFYASLKTSLISKDTSKN-----QVLRMTNVDPVDTATYFCARASLYDS 124
QY 118 VQLLVFGLTNSDTHLQGSLLTLLESPPSSPSVQCRSPRGKNIQGG----- 166
DB 125 DSFYLF-----YHAYWQGTIVVSSASTKGPSVFLPPLAPSSKSTSGTALAGCLVXDY 177
QY 167 --KTLVS-----OLELDQSG-----TWCTVLQONOKV 193
DB 178 FEEPTLVSNAGSLTSGVHTFPVAVIQSSGLVSLSSVTVWSSSLGTQYICNV--NHKPS 235
QY 194 EKKIDIVCPAPPEPKSCDKTHTC-----PELLGSPSVFLPFPKPKDTLMISRTPEVTCV 248
DB 236 NTKVD---KKAEPKSCDKTHTCPCPAPPELLGSPSVFLPFPKPKDTLMISRTPEVTCV 291
QY 249 VVSHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKV 308
DB 292 VVSHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKV 351
QY 309 SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 368
DB 352 SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 411
QY 369 NCQOPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSL 428
DB 412 NCQOPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSL 471
QY 429 SPG 431
DB 472 SPG 474

```

```

; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 497
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-6

Query Match      52.8%; Score 1273.5; DB 4; Length 497;
Best Local Similarity 57.5%; Pred. No. 2.9e-95;
Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;

QY 15 QLLPAPATQGNKVVVLGKGDVLELTCTASQKSIQFHM-KNSNQIK---ILNQGSFL 69
DB 45 KLHAVPAA-----KTVKFCPSSTGTPPFLRLMLKNGKEFPDRHIGGYKRVYA 92
QY 70 TKG-----PSKINDRADSRRLMDQGNPPLIKIKIEDSPYICEVEDQKEVQLLV 122
DB 93 TWSIIMDSVPS-----DKGNYTCIYENEGYSINHTYQLDIVERSPHRPILQ 139
QY 123 FGLTNSDTHLQGSLLTLLESPP-----GSS-----PSVQCRSPRGKNI 163
DB 140 AGLPANKTVALLGSLVNEVMCKVYSDPQHICMLKHEIVNGSKIGPDNLPYQILKTAGVNT 199
QY 164 --QGKTLVSQLELDQSGTWTCT-----TVLQONKVEFKIDIVPCP--- 203
DB 200 TDKMEVFLHARNVFEEDAGEYTCLAGNSIGLSHSAWLTYLE---ALBERAVMTSPLYL 256
QY 204 -----APEPKSCDKTHTC-----PELLGSPSVFLPFPKPKDTLMISRTPEVTCVYVDV 251
DB 257 EGSGSPGLQEPKSCDKTHTCPCPAPPELLGSPSVFLPFPKPKDTLMISRTPEVTCVYVDV 316
QY 252 SHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNK 311
DB 317 SHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNK 376
QY 312 ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
DB 377 ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 436
QY 372 PENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSLSPG 431
DB 437 PENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSLSPG 496

RESULT 31
US-09-499-846-4
; Sequence 4, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 525
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-4

Query Match      52.8%; Score 1273.5; DB 4; Length 525;
Best Local Similarity 57.5%; Pred. No. 3.1e-95;
Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;

```

```
QY 15 QALALPAATQGNKVLGKGGDTVELTCTASQKKSIOFHW-KNSNOJK-----ILGNQSF 69
   ||:|||||
Db 73 KLAIVPAA-----KTVKFKCPSSGTPPTLRMLKNGKEFKPRDHRIIGYKRYA 120
QY 70 TKG-----PSKLNBRADSRRLMDQGNFLLIKNLKIEDSDTYICEVEDQKEEVLV 122
   ||:|||||
Db 121 TWGIIIMDSVPS-----DKGNVTCIYENEGSINHTYQOLDVVERSPHPILO 167
QY 123 FGLTANSDTHTLLOGQSITLTLESPP-----GSS-----PSVQCRSPKKN 163
   ||:|||||
Db 168 AGIPAKRTVALAGSNVEFMCKVYSDPQPHIOMLKIEVNGSKIGPDMLPYQILKTAGVNT 227
QY 164 --QGKTLISVSOLELDSDGTWC-----TLQONQKVEFKIDVPCP----- 203
   ||:|||||
Db 228 TDKMEVLIHRNVSFEDEAGETCTLAGNSIGLSHHSAMLVLE--ALIEEPRAVMTSPLY 284
QY 204 -----APEPKSCDKTHTC-----PELLGSPSVFLFPPKCDTLMISRPEVTCVVVDY 251
   ||:|||||
Db 285 EGGSGPGLQEPKSCDKTHTCPCPAPPELLGSPSVFLFPPKCDTLMISRPEVTCVVVDY 344
QY 252 SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLIHQMNGKEYKCKVSNK 311
   ||:|||||
Db 345 SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLIHQMNGKEYKCKVSNK 404
QY 312 ALPAPLEKTSKAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAEMESNQ 371
   ||:|||||
Db 405 ALPAPLEKTSKAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAEMESNQ 464
QY 372 PENNYKTTTPVLDSDSFFLYSKLTVDKSRMQGNVSCSVMEALHNHYTQKSLSLSPG 431
   ||:|||||
Db 465 PENNYKTTTPVLDSDSFFLYSKLTVDKSRMQGNVSCSVMEALHNHYTQKSLSLSPG 524

RESULT 32
US-09-499-846-2
; Sequence 2, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 622
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-2

Query Match 52.8%; Score 1273.5; DB 4; Length 622;
Best Local Similarity 57.0%; Pred. No. 3.9e-95;
Matches 276; Conservative 31; Mismatches 86; Indels 91; Gaps 12;
```

```
QY 198 DIVP-----CPA-PEPKSCDKTHTC-----PELLGSPSVFLFPPKCDTLMISRPEVTCV 247
   ||:|||||
Db 378 GLVPRGSGSPGLQEPKSCDKTHTCPCPAPPELLGSPSVFLFPPKCDTLMISRPEVTCV 437
QY 248 VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLIHQMNGKEYKCK 307
   ||:|||||
Db 438 VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLIHQMNGKEYKCK 497
QY 308 VSNKALPAPIEKTISAKKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAEMES 367
   ||:|||||
Db 498 VSNKALPAPIEKTISAKKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAEMES 557
QY 368 SNGQPENNYKTTTPVLDSDSFFLYSKLTVDKSRMQGNVSCSVMEALHNHYTQKSLS 427
   ||:|||||
Db 558 SNGQPENNYKTTTPVLDSDSFFLYSKLTVDKSRMQGNVSCSVMEALHNHYTQKSLS 617
QY 428 LSPG 431
   ||:|||||
Db 618 LSPG 621
```

```
RESULT 33
US-09-301-593-18
; Sequence 18, Application US/09301593A
; Patent No. 6455677
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saldanha, Jose W.
; APPLICANT: Rettig, Wolfgang J.
; TITLE OF INVENTION: FAP-specific Antibody with Improved Producibility
; FILE REFERENCE: 0652.1890001
; CURRENT APPLICATION NUMBER: US/09/301,593A
; EARLIER FILING DATE: 1999-04-29
; EARLIER APPLICATION NUMBER: EP 98107925.4
; EARLIER FILING DATE: 1998-04-30
; EARLIER APPLICATION NUMBER: US 60/086,049
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 18
; LENGTH: 453
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-301-593-18

Query Match 52.7%; Score 1271.5; DB 4; Length 453;
Best Local Similarity 59.0%; Pred. No. 3.7e-95;
Matches 271; Conservative 31; Mismatches 84; Indels 73; Gaps 12;
```

```

|||||
Db 294 KTKPREEOYNSTRYRVSVLTVLHQPDLNGKEYCKCVSNKALPAPIEKTISKAKGPREPQ 353
333 VTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPPVLDSDGSFPLY 392
Db 354 VTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPPVLDSDGSFPLY 413
Qy 393 SKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db 414 SKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 452

RESULT 34
US-08-487-550-12
; Sequence 12, Application US/08487550
; Patent No. 6113898
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,550
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-6620
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-487-550-12

Query Match 52.7%; Score 1271; DB 3; Length 476;
Best Local Similarity 59.8%; Pred. No. 4.3e-95;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;

Qy 30 LGKGDVVELTCTAGS---KKSIOFHWNKSNQIKILGNQSF--TKGSKLNDRADRSRS 85
Db 30 LVKPSFTLSLTCAVSGSGISGGYGWGIROPKPKGLEWISGFYSSSGNTYINPSLKSQVT 89
Qy 86 L---MDQGNFPLIIRKLKIEDSDTYICEVEDQKEEVLVFGLTANSDTHLLQGSLLT 142
Db 90 ISTDTSKNGFSLKLSMTADTAAYYC-VRDRLFSVGVGNV-----NMWFDWGGPGVLVT 143
Qy 143 LESPPGSSSVQCRSGRKNIGG-----KTLVS-----QLEL 176
Db 144 VSSASTKGPVFPPLAPSSKSTSGGTALGCLVKDYFPEPVTVSNMNSGALTSQVHTFPVL 203
Qy 177 QDSG-----TWTCYVLQNKQKVEFKIDIVYCPARPESDKTHTC-- 216
Db 204 QSSGLYSLSVVTVDPSSSLGTQTYICNV--NHKPSNTKVD---KKAEPKSCDKTHTCPP 257

```

```

Qy 217 ---BELIGSSEVFLPPPKDITLMIKRTPEYTCVVVDVSHEDPEVKENMYVDGVEVNAK 273
Db 258 CPAPELLIGSPVFLPPPKDITLMIKRTPEYTCVVVDVSHEDPEVKENMYVDGVEVNAK 317
Qy 274 TKPREEOYNSTRYRVSVLTVLHQPDLNGKEYCKCVSNKALPAPIEKTISKAKGPREPQV 333
Db 318 TKPREEOYNSTRYRVSVLTVLHQPDLNGKEYCKCVSNKALPAPIEKTISKAKGPREPQV 377
Qy 334 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPPVLDSDGSFPLY 393
Db 378 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPPVLDSDGSFPLY 437
Qy 394 KLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db 438 KLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 475

```

```

RESULT 35
US-09-526-098-12
; Sequence 12, Application US/09526098
; Patent No. 6492134
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/526,098
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/383,916
; FILING DATE:
; APPLICATION NUMBER: US 08/487,550
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-6620
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-526-098-12

```

```

Query Match 52.7%; Score 1271; DB 4; Length 476;
Best Local Similarity 59.8%; Pred. No. 4.3e-95;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;

Qy 30 LGKGDVVELTCTAGS---KKSIOFHWNKSNQIKILGNQSF--TKGSKLNDRADRSRS 85
Db 30 LVKPSFTLSLTCAVSGSGISGGYGWGIROPKPKGLEWISGFYSSSGNTYINPSLKSQVT 89

```

```

OY      86 L---WDOGFPILITIKUKIEDSPYICEVDOCKEEYVLFGULANSDFHLQOQSILTT 142
Db      90 ISTDTSKNOFSLKUNSMTADTAIVYIC-VRDRLFSVGMVY-----NNMFVGMGPGLVLT 143
OY      143 IESPSSSPSPVOCRSBPKNIICG-----KTVSVS-----OLEL 176
Db      144 VSSASTKGPVSFPLAPSSKSTSGCTAALGCLVDPFEPEPTVSMNSGALTSYHTFPAYL 203
OY      177 QDSG-----TWCTVLONQKVEFKIDIVCPAPEPKSCDKTHTC- 216
Db      204 QSSGLYSLSSVTVPPSSSLGTQYICNV--NHKPSNTKVB-----KKAEPKSCDKTHTCPP 257
OY      217 ---PELLGSPVFLPPPKDTLMSIRTEPVTCVVVDVSHEDPEVKNNWYVDGEVYNNAK 273
Db      258 CPAPELLGSPVFLPPPKDPTLMSIRTEPVTCVVVDVSHEDPEVKNNWYVDGEVYNNAK 317
OY      274 TKPREEQNVSTYRVVSVLTVLHODMNLNGEKYKCKVSKNALPAPEKTIISAKGQPREPOV 333
Db      318 TKPREEQNVSTYRVVSVLTVLHODMNLNGEKYKCKVSKNALPAPEKTIISAKGQPREPOV 377
OY      334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTPRPVLDSDGSFPLYS 393
Db      378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTPRPVLDSDGSFPLYS 437
OY      394 KLTIVDKSRWQOQGVFSCSVNHEALHNHYTQKSISLSPG 431
Db      438 KLTIVDKSRWQOQGVFSCSVNHEALHNHYTQKSISLSPG 475

```

```

RESULT 36
US-09-485-737B-67
: Sequence 67, Application US/09485737B
: Patent No. 6350860
: GENERAL INFORMATION:
: APPLICANT: Buysse, Marie-Ange
: APPLICANT: Sablon, Erwin
: TITLE OF INVENTION: INTERFERON-gamma-BINDING MOLECULES FOR TREATING SEPTIC SHOCK
: FILE REFERENCE: INNS:015
: CURRENT APPLICATION NUMBER: US/09/485,737B
: CURRENT FILING DATE: 2000-02-14
: PRIOR APPLICATION NUMBER: PCT/EP 98/05165
: PRIOR FILING DATE: 1998-08-14
: PRIOR APPLICATION NUMBER: EPO 98870139.7
: PRIOR FILING DATE: 1998-06-18
: PRIOR APPLICATION NUMBER: EPO 97870122.5
: PRIOR FILING DATE: 1997-08-18
: NUMBER OF SEQ ID NOS: 104
: SOFTWARE: Patencin version 3.0
: SEQ ID NO 67
: LENGTH: 468
: TYPE: PRT
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: SYNTHETIC
US-09-485-737B-67

```

```

Query Match 52.4%; Score 1265.5; DB 4; Length 468;
Best Local Similarity 57.2%; Pred. No. 1.2e-94;
Matches 277; Conservative 31; Mismatches 79; Indels 97; Gaps 13;

Qy 11 LVLQALPAATQGNKVLGKKGDPVELCTASOKSIQFMKNSNQIKILGNQGSFLT 70
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
Db 17 VLSQVQLVQSSE-----LKKRGAIVKISCKAS-----GYFTDYGMMWVQAPOG---L 65

Qy 71 KGPSKLNDRADSRSLMD--QGNFP-----LIINKLTEDSDTYICEVEDQKEV 118
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
Db 66 KMMGMINTYGSESTVDDPKGRFVSLDTSVSAAYLIQISLKABDPTATYC----- 116

Qy 119 QLVVGLTNSDTHLQ--QGSITLTLESPPSSSPVQCSPPGKNIQGG----- 166
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
Db 117 -----ARRGFYADWVGQGTIVVSSASTGQSPFPLAPSPSKSTSGGTAALGLVKD 168
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::

```

```

QY      167  ---KITSLS-----QLBLDPSG-----TWTCTYLONQK 192
           : : :
Db      169  YPEPEPTVSNNGALTSVGHTEPPAVLQSSGLSLSSVTVBSSSLGTQYI CNT -MHP 226

QY      193  VEPKRIIVPCPAPPEPKSCDKHTC-----PELLGGPSVFLPPEPKDTLMISRPETVCV 247
           : : |
Db      227  SNTKVD---KVEPKSCDKHTCCPPCPAPELGGSPSVFLPPEPKDTLMISRPETVCV 288

QY      248  VDVSHEDPEVKFNWVVDGVEVHNAAKTRPEQYNSTYRVSVYLTVLHODWLNGKEYCK 307
Db      283  VDVSHEDPEVKFNWVVDGVEVHNAAKTRPEQYNSTYRVSVYLTVLHODWLNGKEYCK 342

QY      308  VSNKALPAPIEKTSIAKQGPPEPVYTLTPSGDELITNQVSLTCLVKGFPSPDAIEME 367
Db      343  VSNKALPASIEKTSIAKQGPPEPVYTLTPSREBMTNQVSLTCLVKGFPSPDAIEME 402

QY      368  SNOQPENNYKTPPVLDSDGSFFLYSKLTVDKSRHQQGNVSCSVMEHALHNHTQKSL 422
Db      403  SNOQPENNYKTPPVLDSDGSFFLYSKLTVDKSRHQQGNVSCSVMEHALHNHTQKSL 462

QY      428  LSPG 431
           |||
Db      463  LSPG 466

```

RESULT 37  
 US-09-485-737B-90  
 ; Sequence 90, Application US/09485737B  
 ; Patent No. 6350860  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Buysse, Marie-Ange  
 ; APPLICANT: Sablon, Erwin  
 ; TITLE OF INVENTION: INTERFERON-gamma-BINDING MOLECULES FOR TREATING SEPTIC SHOCK  
 ; TITLE OF INVENTION: CACHEXIA, IMMUNE DISEASES AND SKIN DISORDERS  
 ; FILE REFERENCE: INNS:015  
 ; CURRENT APPLICATION NUMBER: US/09/485,737B  
 ; CURRENT FILING DATE: 2000-02-14  
 ; PRIOR APPLICATION NUMBER: PCT/EP 98/05165  
 ; PRIOR FILING DATE: 1998-08-14  
 ; PRIOR APPLICATION NUMBER: EPO 98870139..7  
 ; PRIOR FILING DATE: 1998-06-18  
 ; PRIOR APPLICATION NUMBER: EPO 97870122..5  
 ; PRIOR FILING DATE: 1997-08-18  
 ; NUMBER OF SEQ ID NOS: 104  
 ; SOFTWARE: Patentin version 3.0  
 ; SEQ ID NO 90  
 ; LENGTH: 711  
 ; TYPE: prt  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: SYNTHETIC  
 US-09-485-737B-90

	Query Match	52.4%;	Score 1265.5;	DB 4;	Length 711;
	Best Local Similarity	57.2%;	Pred 2.1e-94;	Mismatches 99;	Indels 97; Gaps 133
	Matches	277;	Conservative	31;	
Qy	11 LVLQLALLPAATQGNKVYLGGKGDVLTCTASQKSIDPHMNKNQIKILGNGSFLT	70			
Db	17 VILSYQVLVGSSSE-----LKKPGASVKISCAAS---GYPTFDYGMNVMWKAQAPQG---L	65			
Qy	71 KGSSTKINDPADSRRLMD-QGNFP-----LIINKLIKIDSOTIYICEVDOKEEV	118			
Db	66 KMWGINTVTGSTYYVDPEKGFVSFLDTSVAAYLQISLKADADTAIFC-----	116			
Qy	119 QLIVFGILTANSDTHLLQ--GQSITLTLESPPGSSPSVOCSPRKKNIQG----	166			
Db	117 -----ARRGVAMDYWGCGTITYTVSSAATKGSVFPLAPSRSKSGGTALMGCLVKD	168			
Qy	167 ---KTLSVS-----OLELDNSG-----TWCTYLNQRK	192			
	169 YFEPEPTAVMNSGALTSGVTFEPATLGSSGLYSLSVTVPSSIGTQTYICNV--NHKP	226			

QY 193 VEFKIDIVPCAPPEKSCDKHTC-----PELLGSPVFLFPKPKDTLMTSRTEVTCV 247  
| : : : : :  
DB 227 SNTKVD---KRVPEKSCDKHTCPCPAPPELLGSPVFLFPKPKDTLMTSRTEVTCV 282  
QY 248 VVDVSHEDPEVKFNMYVDGVEVHNNAKTKREKQYNSTRVSVLTVLHODMLNGEYCK 307  
| : : : : :  
DB 283 VVDVSHEDPEVKFNMYVDGVEVHNNAKTKREKQYNSTRVSVLTVLHODMLNGEYCK 342  
QY 308 VSNKALPAPIEKTIKAKAQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWE 367  
| : : : : :  
DB 343 VSNKALPAPIEKTIKAKAQPREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWE 402  
QY 368 SNGQENNYKTPPYLSDSGSFLLYSKLTVDKSRMQGNVFSCSYMHEALHNHYTQKSL 427  
| : : : : :  
DB 403 SNGQENNYKTPPYLSDSGSFLLYSKLTVDKSRMQGNVFSCSYMHEALHNHYTQKSL 462  
QY 428 LSPG 431  
| : : : : :  
DB 463 LSPG 466

RESULT 38  
US-08-458-516-13  
; Sequence 13, Application US/08458516  
; Patent No. 5777085  
; GENERAL INFORMATION:  
; APPLICANT: CO, Man Sung  
; APPLICANT: Teo, J. Yun  
; TITLE OF INVENTION: Humanized Antibodies Reactive with  
; TITLE OF INVENTION: GP11B/IIIA  
; NUMBER OF SEQUENCES: 23  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: William M. Smith  
; STREET: One Market Plaza, Steuart Tower, Suite 2000  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: IBM PC compatible  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/458,516  
; FILING DATE:  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/059,159  
; FILING DATE: 03-MAY-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Smith, William M.  
; REGISTRATION NUMBER: 30,223  
; REFERENCE/DOCKET NUMBER: 11823-37-3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 415-326-2400  
; TELEFAX: 415-326-2422  
; INFORMATION FOR SEQ ID NO: 13:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 449 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-458-516-13

Query Match 52.4%; Score 1265; DB 1; Length 449;  
Best Local Similarity 58.7%; Pred. No. 1.2e-94;  
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGADVVELCTASOKKSIOF--HWKNSNOIKILNGO-----SLTLGSPSKLNDRAISR 83  
| : : : : :  
DB 13 KRGSSVAVSKASGYAFTNYLIEW-----VRQAPQGLGEMIGVIVPGSGTNYNEKFKGR 67

QY 84 RSLW---DQGNFPLIIRKLKIEDSDTYICEVEDQKEEVOLVFGLTANSDTHLQOGSLT 140  
| : : : : :  
DB 68 VTLTVDSSTNAYWELSLNSSEDYAVVFCARRD-----GNYGFAFYWGQTL 114  
QY 141 LTLSPGSSPSVOCRRPRGNIOG-----KTLVS-----QL 174  
| : : : : :  
DB 115 VTVSSASTKGPSVPLPAPSSKSTSGTALACLVDYFPEBEVTVSMNGALTSVHTPPA 174  
QY 175 ELQDSG-----TWTCYLNQNKVEPKIDIVPCAPPEKSCDKHTC 216  
| : : : : :  
DB 175 VLQSSGLYSSVTVTPSSSLGTOTYICNV--NKPSTNKVD---KRVPEKSCDKHTC 228  
QY 217 -----PELLGSPVFLFPKPKDTLMTSRTEVTCVVDVSHEDPEVKFNMYVDGVEVHN 271  
| : : : : :  
DB 229 PRCAPPELLGSPVFLFPKPKDTLMTSRTEVTCVVDVSHEDPEVKFNMYVDGVEVHN 288  
QY 272 AKTKPREKQYNSTRVSVLTVLHODMLNGEYCKVSNKALPAPIEKTISKAKQPREP 331  
| : : : : :  
DB 289 AKTKPREKQYNSTRVSVLTVLHODMLNGEYCKVSNKALPAPIEKTISKAKQPREP 348  
QY 332 QVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWSNGQENNYKTPPYLSDSGSFL 391  
| : : : : :  
DB 349 QVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWSNGQENNYKTPPYLSDSGSFL 408  
QY 392 YSKLTVDKSRMQGNVFSCSYMHEALHNHYTQKSLSLSPG 431  
| : : : : :  
DB 409 YSKLTVDKSRMQGNVFSCSYMHEALHNHYTQKSLSLSPG 448

RESULT 39  
US-09-247-352-3  
; Sequence 3, Application US/09247352  
; Patent No. 6312693  
; GENERAL INFORMATION:  
; APPLICANT: Aruffo, Alejandro A.  
; APPLICANT: Sladak, Anthony W.  
; APPLICANT: Berry, Karen K.  
; APPLICANT: Harris, Linda  
; APPLICANT: Thorne, Barbara A.  
; APPLICANT: Bajorath, Jurgen  
; APPLICANT: Huse, William D.  
; APPLICANT: Wu, Heiren  
; APPLICANT: Watkins, Jeffrey D.  
; TITLE OF INVENTION: ANTIBODIES AGAINST HUMAN CD40  
; FILE REFERENCE: DB2a SEQUENCE  
; CURRENT APPLICATION NUMBER: US/09/247,352  
; EARLIER FILING DATE: 1998-02-10  
; EARLIER APPLICATION NUMBER: 09/026,291  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: Patentin Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 451  
; TYPE: PRT  
; ORGANISM: Human and Mouse  
; US-09-247-352-3

Query Match 52.4%; Score 1264; DB 4; Length 451;  
Best Local Similarity 59.6%; Pred. No. 1.5e-94;  
Matches 276; Conservative 23; Mismatches 80; Indels 84; Gaps 13;

QY 30 LGGKGVVELCTASOKKSIOFHWKNSNOIKILNGO-----SLTLGSPSKLNDRAISRSLWD- 88  
| : : : : :  
DB 11 LKKPGETVIRISCKAS---GVAFTTGGQWVOEMGKG---LKMIGWINTHSGVRYVDF 64  
QY 89 QGNFP-----LIIRKLKIEDSDTYICEVEDQKEEVOLVFGLTANSDTHLQOG 137  
| : : : : :  
DB 65 KGRAFAFLETSANTAYVQISLKNEDTATYFC--VRSGNGVNDLAYFA-----YWGQ 114  
QY 138 SLTLSPGSSPSVOCRRPRGNIOG-----KTLVS----- 172  
| : : : : :  
DB 115 GLTVVSAASTKGPSVPLPAPSSKSTSGTALACLVDYFPEBEVTVSMNGALTSVHT 174

```
QY 173 -QLELDGSG-----TWTCVLQNGKKVEFIDIVPCAPAPKSCDXT 213
      |||||
      175 FPAVLSSGLYSLSSVVTWSSSLGTOTTCNV--NHKPSNTKVD---KKEVPKSCDXT 228
QY 214 HTC-----PELLGSPVFLFPPPKDITMISRTPEYTCVVVDVSHEDPEVKFMWYDGYE 268
      |||||
      229 HTCPGPAPAPELLGSPVFLFPPPKDITL-ISRTPEYTCVVVDVSHEDPEVKFMWYDGYE 287
QY 269 VHNAKTKPREEOYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPLEKITSKAKGP 328
      |||||
      288 VHNAKTKPREEOYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPLEKITSKAKGP 347
QY 329 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSGS 388
      |||||
      348 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSGS 407
QY 389 FFLYSKLTVDKSRMOQGNVFSQVMEHALNHYTKSLSLSPG 431
      |||||
      408 FFLYSKLTVDKSRMOQGNVFSQVMEHALNHYTKSLSLSPG 450
Db
```

```
RESULT 40
US-09-466-635-3
; Sequence 3, Application US/0946635
; Patent No. 6413514
; GENERAL INFORMATION:
; APPLICANT: Arutic, Alejandro A.
; APPLICANT: Sladak, Anthony W.
; APPLICANT: Berry, Karen K.
; APPLICANT: Harris, Linda
; APPLICANT: Thorne, Barbara A.
; APPLICANT: Bajorech, Jurgen
; TITLE OF INVENTION: ANTIBODIES AGAINST HUMAN CD40
; FILE REFERENCE: DB2 SEQUENCE
; CURRENT APPLICATION NUMBER: US/09/466,635
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Human and Mouse
US-09-466-635-3
```

```
Query Match 52.4%; Score 1264; DB 4; Length 451;
Best Local Similarity 59.6%; Pred. No. 1.5e-94;
Matches 276; Conservative 23; Mismatches 80; Indels 84; Gaps 13;

QY 30 LGKKGDVETLTASQKSIQFHWKNSNOIKILGNQSGFLTKGPKSLNDRADRSRLMP- 88
      |||||
      11 LKPGESTVRISKAS--GYAFTTGMQVQEMPGRG---LKWIGINHTSGVPRYEDF 64
QY 89 OGNFP-----LIINKLIEDSDTYICEVEDQKEVQLVFGLTANSPTHLQCG 137
      |||||
      65 KGFAPASLETSANTALQISNLKNEIDTATYFC-VRSNGNGYDLATYA-----YMGQ 114
Db
QY 138 SLTLTLESPGSSPVQCSPPKGNIOG-----KTLVS----- 172
      |||||
      115 GLTVTSAASTKQPSVFLAPSSKSTSGTALGCLVKDYFPEPVTVSNMGSALTSVHT 174
Db
QY 173 -QLELDGSG-----TWTCVLQNGKKVEFIDIVPCAPAPKSCDXT 213
      |||||
      175 FPAVLSSGLYSLSSVVTWSSSLGTOTTCNV--NHKPSNTKVD---KKEVPKSCDXT 228
QY 214 HTC-----PELLGSPVFLFPPPKDITMISRTPEYTCVVVDVSHEDPEVKFMWYDGYE 268
      |||||
      229 HTCPGPAPAPELLGSPVFLFPPPKDITL-ISRTPEYTCVVVDVSHEDPEVKFMWYDGYE 287
Db
QY 269 VHNAKTKPREEOYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPLEKITSKAKGP 328
      |||||
      288 VHNAKTKPREEOYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPLEKITSKAKGP 347
Db
```

```
QY 329 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSGS 388
      |||||
      348 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSGS 407
Db
QY 389 FFLYSKLTVDKSRMOQGNVFSQVMEHALNHYTKSLSLSPG 431
      |||||
      408 FFLYSKLTVDKSRMOQGNVFSQVMEHALNHYTKSLSLSPG 450
Db
```

```
RESULT 41
US-09-027-449-71
; Sequence 71, Application US/09027449
; Patent No. 6025158
; GENERAL INFORMATION:
; APPLICANT: Gonzalez, Tania R.
; APPLICANT: Leong, Steven R.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Antibody Fragment-Polymer Conjugates and
; TITLE OF INVENTION: Humanized Anti-IL-8 Monoclonal Antibodies
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/027,449
; FILING DATE: 20-Feb-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/074,330
; FILING DATE: 22-Jan-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/038,664
; FILING DATE: 21-Feb-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Love, Richard B.
; REGISTRATION NUMBER: 34,659
; REFERENCE/DOCKET NUMBER: P1085R3-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-5530
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 452 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-09-027-449-71
```

```
Query Match 52.3%; Score 1263.5; DB 3; Length 452;
Best Local Similarity 59.6%; Pred. No. 1.6e-94;
Matches 273; Conservative 26; Mismatches 86; Indels 73; Gaps 11;

QY 30 LGKKGDVETLTAS--QKSIQFHWKNSNOIKILGNQSGF-LTKGPKSLNDRADRSRL 86
      |||||
      11 LVQPGSLKLSASAGYSSSHYHWRQAPKGLWVGYYIDPSNGETTYNQKFGKRF 70
QY 87 W---DOGNFPLIKLIEDSDTYICEVEDQKEVQLVFGLTANSPTHL-LQGSLTLT 142
      |||||
      71 SMDNKNATYALQMSLRLABDFAVYYCARGDYR-----YMGDAFPDVGGLT 119
Db
QY 143 LESPPGSSPVQCSPPKGNIOG-----KTLVS-----QLEL 176
      |||||
      120 VSSASTKQPSVFLAPSSKSTSGTALGCLVKDYFPEPVTVSNMGSALTSVHTFPAVL 179
QY 177 QDSG-----TWTCVLQNGKKVEFIDIVPCAPAPKSCDXTHTC-- 216
```

```
Db      180 QSSGLYSLSSVTVTPSSSLGTQTYICNV--NHRKSNTKVD---KKVEPKSCDKTHCP 233
Qy      217 ---PELLGGPSVFLPPEPKDTLMISRTPEVTCVAVDSHEDPEVKFMNYVDGEVHNAAK 273
Db      234 CPAPELLGGPSVFLPPEPKDTLMISRTPEVTCVAVDSHEDPEVKFMNYVDGEVHNAAK 293
Qy      274 TKPREQYNSTYRVSVLVTLVHODMNGKEYCKVSNKALPAPIEKTISKAKGQPREPOV 333
Db      294 TKPREQYNSTYRVSVLVTLVHODMNGKEYCKVSNKALPAPIEKTISKAKGQPREPOV 353
Qy      334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 393
Db      354 YTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 413
Qy      394 KLTVDKSRMOQGNVFCSCVMHEALNHYTOKSLSLSPG 431
Db      414 KLTVDKSRMOQGNVFCSCVMHEALNHYTOKSLSLSPG 451
```

## RESULT 42

```
US-09-026-985-71
; Sequence 71, Application US/09026985
; Patent No. 6133426
; GENERAL INFORMATION:
; APPLICANT: Gonzalez, Tania R.
; APPLICANT: Leong, Steven R.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Antibody Fragment-Polymer Conjugates and
; TITLE OF INVENTION: Humanized Anti-IL-8 Monoclonal Antibodies
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/026,985
; FILING DATE: 20-Feb-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Love, Richard B.
; REGISTRATION NUMBER: 34,659
; REFERENCE/DOCKET NUMBER: P1085R3-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-5530
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 452 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-09-026-985-71
```

```
Query Match      52.3%; Score 1263.5; DB 3; Length 452;
Best Local Similarity 59.6%; Pred. No. 1.6e-94;
Matches 273; Conservative 26; Mismatches 86; Indels 73; Gaps 11;
```

```
Qy      30 LKKKEDTVLLTCTAS--QKKSIOFWKSNNOIKIIGNQSFLTGGPSKANDRADRSRL 86
Db      11 LVQPGSGLSLSCAASGSPSSHYMHWVROAPKGLIEWGYIDPSNGETTYNQKFGKRFLL 70
Qy      87 W---DOGNPPLIKLIKIDSDTYICEVDKEEVQLLVFGLTASDTHL--LQGQSLRLT 142
Db      71 SRDNKNTAYLQWNSLRADETAVYTCARGDYR-----YNGDFPVDWGQGLTAVT 119
```

```
Qy      143 LESPPGSSPSVQCSRPGRKNIQGG-----KTLSSV-----QLEL 176
Db      120 VSSASTKGPSTVFPLAPSKSTSGGTALGCLVKDYFPEPTVTSWNSGALTSGVHPFPAVL 179
Qy      177 QDSG-----TWTCVLOKQKVEKIDIVCPAPAEPPSCDKTHC-- 216
Db      180 QSSGLYSLSSVTVTPSSSLGTQTYICNV--NHRKSNTKVD---KKVEPKSCDKTHCP 233
Qy      217 ---PELLGGPSVFLPPEPKDTLMISRTPEVTCVAVDSHEDPEVKFMNYVDGEVHNAAK 273
Db      234 CPAPELLGGPSVFLPPEPKDTLMISRTPEVTCVAVDSHEDPEVKFMNYVDGEVHNAAK 293
Qy      274 TKPREQYNSTYRVSVLVTLVHODMNGKEYCKVSNKALPAPIEKTISKAKGQPREPOV 333
Db      294 TKPREQYNSTYRVSVLVTLVHODMNGKEYCKVSNKALPAPIEKTISKAKGQPREPOV 353
Qy      334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 393
Db      354 YTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 413
Qy      394 KLTVDKSRMOQGNVFCSCVMHEALNHYTOKSLSLSPG 431
Db      414 KLTVDKSRMOQGNVFCSCVMHEALNHYTOKSLSLSPG 451
```

## RESULT 43

```
US-09-121-952A-71
; Sequence 71, Application US/09121952A
; Patent No. 6458355
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc., Hsai, Vanessa
; APPLICANT: Koumenis, Iphigenia
; APPLICANT: Leong, Steven R.
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shahrokh, Zahra
; APPLICANT: Zapata, Gerardo A.
; TITLE OF INVENTION: METHODS OF TREATING INFLAMMATORY DISEASES
; TITLE OF INVENTION: WITH ANTI-IL-8 ANTIBODY FRAGMENT-POLYMER CONJUGATES
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/121,952A
; FILING DATE: 24-Jul-1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/074330
; FILING DATE: 22-JAN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/075467
; FILING DATE: 20-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Love, Richard B.
; REGISTRATION NUMBER: 34,659
; REFERENCE/DOCKET NUMBER: P1085R4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-5530
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 452 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
```





```

: EARLIER FILING DATE: 1998-05-18
: NUMBER OF SEQ ID NOS: 108
: SOFTWARE: PatentIn Ver. 2.0
: SEQ ID NO 30
: LENGTH: 472
: TYPE: prt
: ORGANISM: Homo sapiens
US-09-301-553-30

```

Query Match	52.3%;	Score 1263;	DB 4;	Length 472;
Best Local Similarity	59.0%;	Pred. No. 1.9e-94;		
Matches 271;	Conservative 31;	Mismatches 83;	Indels 74;	Gaps 13;

Qy	30	LGKKGDVTELTCTSOXKSIOF--HMKNNOIKILGNOSF--LTGSPKLNDRADRSRL	86
Db	30	LVRGASVKNMSCKTSRYTFEETVLIHMVAQSHKSLFEMJGGINPNNGIDINYNOKFEGRATL	89
Qy	87	W---DQGNFPLIKNLKIEDSDTYICEVEDOKEVOQLVFGELTANSDFHLLD--GQSILTL	141
Db	90	TVGKSSSTAVYMELSLSTBEDSAVYFC-----ARRIAAYG---DEGHANDYWGQGTSV	139
Qy	142	TLSEPPGSSPVGQCRSPRGKNIQGG-----KTLSSVS-----GLE	175
Db	140	TVSSST--KGPSVFPPLAPSSKTSIGSTALDGLCYKDYFPEEPYVSNNSGALISGVHTPPAV	198
Qy	176	LQDSG-----TWTCVLONOKKVEFKIDIVCPAPEPKSCDKTHTC-	216
Db	199	LQSGLYSLSSVTVPSSSLSGTQYICNV--NHKDSNTKVD---KAYEPKSCDKTHTCP	252
Qy	217	----PELLGGSSVLPFPKPKDITLISRTPEYTCVYDVSHDEPEVKNNYVDYGEVYNA	272
Db	253	PCPAPELLGGSSVFLFPPKPKDITLISRTPEYTCVYDVSHDEPVKNNYVDYGEVYNA	312
Qy	273	KTKREBEQYNSTYRVSVLTVLHQMNLNGKEVCKVSNKALPAPLEKTIISRAQGPREFQ	332
Db	313	KTKREBEQYNSTYRVSVLTVLHQMNLNGKEVCKVSNKALPAPLEKTIISRAQGPREFQ	372
Qy	333	VYTLRPSHDELTKQVSLTCLVKGFPEDIAVEMESNQEPENNYKTPPVLDSDSFPLY	392
Db	373	VYTLRPSSEEMTKQVSLTCLVKGFPEDIAVEMESNQEPENNYKTPPVLDSDSFPLY	432
Qy	393	SKLTVDKSRMOQGNVFCSSVNHAEALHNHYTKSLSLSFG	431
Db	433	SKLTVDKSRMOQGNVFCSSVNHAEALHNHYTKSLSLSFG	471

RESULT 46  
US-08-887-352B-18

GENERAL INFORMATION:  
APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardiou, John Lowe  
TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of  
TITLE OF INVENTION: Improving Polypeptides  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Genentech, Inc.  
STREET: 1 DNA Way  
CITY: South San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94080  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Winpatin (Genentech)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/887,352B  
FILING DATE: 03-Jul-1997  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Svoboda, Craig G.

```

?      REGISTRATION NUMBER: 39,044
?      REFERENCE/DOCKET NUMBER: P1222
?      TELECOMMUNICATION INFORMATION:
?      TELEPHONE: 650/225-1489
?      TELEFAX: 650/952-9881
?      INFORMATION FOR SEQ ID NO: 18:
?      SEQUENCE CHARACTERISTICS:
?      LENGTH: 451 amino acids
?      TYPE: Amino Acid
?      TOPOLOGY: Linear
US-08-887-352B-18

```

Query Match	52.3%;	Score 1262;	DB 2;	Length 451;
Best Local Similarity	58.6%;	Pred. NO. 2.2e-94;		
Matches 273; Conservative	25;	Mismatches 78;	Indels 90;	Gaps 12

```

Oy 30 IKGKGGTVELTCTAASO-----KKSIOGHMNSNOIKILNGOQSLFLTKGSKXN----- 77
Db 11 LVOPGSLSLKSAVSGYSTSGTSGYSMNMIRQAPGKGLEWVASIKXSGETKXNPSYKGRITI 70
Oy 78 DRADSRSLMDQGNFPLIILKNLIKIEDSDTYICEVEDOKEVOLLVFLGTANSDTH--LL 134
Db 71 SRDSSKNTFYLNQNN-----SLRADETVAUYVCARGSH-----YFG-----HMHFAV 110
Oy 135 OQGSLLTLTLSPFGSSPSVQCSRPGKXIOGG-----KTLVS----- 172
Db 111 WGGGTLVTYSSASTGKPSVFLPAPSKSGTGTALGCLVKDYFPPEVTVSNMNGALTSG 170
Oy 173 ----OLELDSG-----TWCTVLONOKRYEFKIDIVCPAPPEKSC 210
Db 171 VHTFPALVQSGSLSYLSSVYTPSSSLGTQYICNV--NHKPSMTYD-----KKVEPKSC 224
Oy 211 DKHTTC-----PELLAGPSVFLFPKPKOTLMISTREPVTCVVVDVSHEDPEVKFMYTYD 255
Db 225 DKHTHTPCPCAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMYTYD 284
Oy 266 GVEVHNAKTRPREEOYNSYTRYVSVLYTLVHODMYLNGEYKCKSVNKLPAPIEKTISKAK 325
Db 285 GVEVHNAKTRPREEOYNSYTRYVSVLYTLVHODMYLNGEYKCKSVNKLPAPIEKTISKAK 344
Oy 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQRENNYKTTTPRYLDS 365
Db 345 GQPREPOVYTLPPSRREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQRENNYKTTTPRYLDS 404
Oy 386 DGSFPLYSKLTVDKSRWQQGNVFGSVMHEDLNHHNYTKSLSPG 431
Db 405 DGSFPLYSKLTVDKSRWQQGNVFGSVMHEDLNHHNYTKSLSPG 450

```

RESULT 47  
US-09-109-207C-18  
; Sequence 18, Application US/09109207C  
; Patent No. 6172213

```

:
:
:
:
: TITLE/CAMT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
:
: TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides
:
: FILE REFERENCE: P1123x1
:
: CURRENT APPLICATION NUMBER: US/09/109,207C
:
: CURRENT FILING DATE: 1998-06-30
:
: PRIOR APPLICATION NUMBER: US 60/051,554
:
: PRIOR FILING DATE: 1997-07-03
:
: NUMBER OF SEQ ID NOS: 44
:
: SEQ ID NO 18
:
: LENGTH: 451
:
: TYPE: PRT
:
: ORGANISM: Artificial
:
: FEATURE:
:
: NAME/KEY: Artificial
:
: LOCATION: 1-451
:
: OTHER INFORMATION: Heavy chain sequence derived from MAE11
:
: US-09-109-207C-18

```

Query Match 52.3%; Score 1262; DB 3; Length 451;

Best Local Similarity 58.6%; Pred. No. 2.2e-94;  
Matches 273; Conservative 25; Mismatches 78; Indels 90; Gaps 12;

QY 30 LGGKGDVVELTCTASQ---KKSIQFMKNSNQIKILNGQSEFLTKPGSKN----- 77

Db 11 LVQGGSLRLSSCAVSGYSTSGYSNMWIRIADPGKLEWVAISKYSGEKKTPSVKGRIT 70

QY 78 DRADSRSLMDQGNFPLIIKMLKIEDSDPYICEVEDEQKEEVQLLVFGLTANSDTH---L13 134

Db 71 SRDSSKNTPFLQNMN-----SLRABEDTAYYYCARSH-----YFG-----HMHFAV 11.0

QY 135 QGGSLLTITLESPPGSSPSVQCNSPPRKNIIQG-----KTLSSVS----- 172

Db 111 WGGGTLVATVSSASTKGPSPVPLAPSSKSTSGGTALGCLVNDYPPPEPVTVSMNSGALTSG 170

QY 173 ----OLELQSG-----TWCTVLQNMOKKVEPKDITVCPAPEKSC 21.0

Db 171 VHTFPRAVLQSSGLYSLSSVYVTPSSSLGTYITICV---NHKPSNTKD---KKVEKSC 224

QY 211 DKTHTC-----PELLGSPSVFLPPPKPKDTLMSRTPEVTCVVDVSHEDBEVKFNMYD 265

Db 225 DKTHTCPPCAPPELLGSPSVFLPPPKPKDTLMSRTPEVTCVVDVSHEDBEVKFNMYD 284

QY 266 GVEVHNAKTPREEOVNSTYRVVSUTVLHQMNLNGKEYCKVSNKALPAIETKTSKAK 325

Db 285 GVEVHNAKTPREEOVNSTYRVVSUTVLHQMNLNGKEYCKVSNKALPAIETKTSKAK 344

QY 326 GQREPEPVYTLPPSRDELTKNQVSLTCLVKGCFPSDIAVEMESNQPENNYKTTPPVLDS 365

Db 345 GQREPEPVYTLPPSRDEMTKNQVSLTCLVKGCFPSDIAVEMESNQPENNYKTTPPVLDS 404

QY 386 DGSFPLYSKLTVDKSRMOQGNVPSGCVHAEALHNNHYTKSLSLSPG 431

Db 405 DGSFPLYSKLTVDKSRMOQGNVPSGCVHAEALHNNHYTKSLSLSPG 450

RESULT 48  
US-09-282-505-2

```

; Sequence 2, Application US/09282505A
; Patent No. 6194551
GENERAL INFORMATION:
APPLICANT: Esche Ekstrandee Idunogle et al.
TITLE OF INVENTION: Polypeptide Variants
FILE REFERENCE: P1266R1
CURRENT APPLICATION NUMBER: US/09/282,505A
CURRENT FILING DATE: 1999-03-31
NUMBER OF SEQ ID NOS: 2
SEQ ID NO 2
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: Artificial Sequence
LOCATION: 1-451
OTHER INFORMATION: Sequence is completely synthesized
; Patent No. 6194551
US-09-282-505-2

52.3%; Score 1262; DB 3; Length 451;
Best Local Similarity 58.6%; Pred. No. 2,2e-94;
Matches 273; Conservative 25; Mismatches 78; Indels 90; Gaps 12.;

QY 30 LGKGGDYVELTCTASQ--KKSIOFHWKNSOIKLGNQGSFLTTPGSKLN----- 77
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 11 LVPGGGSIRLSCAVSGYSITSGYSKWNMTRQAPKGLEWVASIKYSGETKYNPSYKGRITI 70
QY 78 DRASRRRLMQGNEPLTIKKUKIEDSDTYICEVEDQKEEVQLLVFGLTANDTH--LL 134
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 71 SRDSKNTFYQMN-----SLRAEDTAVYYCARQSH-----YFG-----HMPRAV 110
QY 135 QGGSLLTLLESPPGSSPSVQCRSPGKNIQGS-----KTLVS----- 172
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 111 WGGSTLVVSSASTSGPVPFLAPSSKSTSGTALGCLVDYFPEPVTVMNSGALTSG 170

```

OY	175	----	QLELDSDS-----	-----	-TMTCVLONOKKVEFKDIYPCAPAEKSC	210
Dd	171	VHTEPAVLSSGLYSLSVTVTPSSSLGTQTICNV--	NHPSRSTKVDD---	KVYEKSC	224	
OY	211	DKTHTC-----	PBLGSPVFLPPPKXDTLMISTRPEVTCVVVDVSHEDEVKNMYD	265		
Dd	225	DKTHTCPCPAPELLGGSPVFLLFPKPXDITLMISRTPEVTCVVVDVSHEDEVKNMYD	284			
OY	266	GVEVNAKKTKPREEQNSTFRVSVLTYLHODMLNGEKYCKVKSNKLPAIETISKAK	322			
Dd	285	GVEVNAKKTKPREEQNSTFRVSVLTYLHODMLNGEKYCKVKSNKLPAIETISKAK	344			
OY	326	GOEPREPOVYTLPPSRDELTKNOVSLTCLVKGFPESDIAVEMESNGOPENNKTTLPVULDS	385			
		:   :	:   :	:   :	:   :	
Dd	345	GOEPREPOVYTLPPSRDEMTKNOVSLTCLVKGFPESDIAVEMESNGOPENNKTTLPVULDS	400			
OY	386	DGSFPLYSKULTYDKSKMOOGANFSCSWMEALAHNHYTKSLSLSPG	431			
Dd	405	DGSFPLYSKULTYDKSKMOOGANFSCSWMEALAHNHYTKSLSLSPG	450			

```

RESULT 49
US-09-054-255-2
; Sequence 2, Application US/09054255
; Patent No. 6242195
; GENERAL INFORMATION:
; APPLICANT: Esche Kinaduese Idueogie et al.
; TITLE OF INVENTION: Polypeptide Variants
; FILE REFERENCE: P1266
; CURRENT APPLICATION NUMBER: US/09/054,255
; CURRENT FILING DATE: 1998-04-02
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: E27 anti-IGb antibody heavy chain
US-09-054-255-2

```

Query Match	52.3%	Score 1262;	DB 3;	Length 451;
Best Local Similarity	58.6%	Pred. No. 2.2e+4;		
Matches 273;	Conservative 25;	Mismatch 78;	Indels 90;	Gaps 12.
QY	30	LGKKDVLVELCTASQ---	KKSIQFHWKNSNQIKILGQSGFLTKGPSKLN-----	77
DB	11	LVQGGSLRLSCANVSGITS	SGYMNWIRQAPGKGLEWVASIKXSGEIKNVPYKGRITTI	70
QY	78	DRADSRSLMDQGNPPLII	KNKLIEDSDTYICEVEDQKEVOLLVFGILTANSDTH--	134
DB	71	SRDSKNTFYIQNM-----	SLRAEDPAVYYCARGSH-----YFG-----	110
QY	135	QGQSLTLTLSPSSPSSPQ	CRSGRKNIGQ-----KTLTSS-----	172
DB	111	WGQGLTVVSSASTKGPS	VFPPLAPSXSSTSGTALGCLVKDYRPEPELYTWSNGALTSG	170
QY	173	-----QLEIODSG-----	TWCTVLONOKKEVEFKIDIVPCAPRPSKC	210
DB	171	VHTEPAVLQSSGLVSLSS	VTVTPSSISLOTQIYICNV--NHKPSMTKVD---KKVEPRKSC	224
QY	211	DKHTTC-----	PALLGSPVFLFPFKPKDTLMIRTEBTVCVVVDVSHEDPEYKFNMYVD	265
DB	225	DKHTTCPCCAPELLGGPS	VFLFPFKPKDITLMISRTBEVTVCVVDVSHEDPEYKFNMYVD	284
QY	266	GVEVHNAAKTRREEQYN	STYRVVSVLVTLHODMVLNGREYCKYCNKALPAIEIKTISAK	325
DB	285	GVEVHNAAKTRREEQYN	STYRVVSVLVTLHODMVLNGREYCKYCNKALPAIEIKTISAK	344
QY	326	QGPPEPOVYTLPSRDEL	TKNQVSLTCLVKGFPSDIAVEMESNGOPENNYKTTTPVLVS	385
DB	345	QGPPEPOVYTLPSREEM	TKNQVSLTCLVKGFPSDIAVEMESNGOPENNYKTTTPVLVS	404

```
QY      386 DGSFFLYSKLTVDKSRWQGQNVFSCSVMHREALHNHYTQKSLSLSPG 431
         ||| | | | | | | | | | | | | | | | | | | | | | | | | |
Db       405 DGSSFLYSKLTVDKSRWQGQNVFSCSVMHREALHNHYTQKSLSLSPG 450
```

```

RESULT 50
US-09-296-005-18
: Sequence 18, Application US/09296005
: Patent No. 6290957
: GENERAL INFORMATION:
: APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardiou, John Lowe
: TITLE OF INVENTION: Improved Anti-19e Antibodies and Method of Improving Polypeptides
: FILE REFERENCE: P1123C1r
: CURRENT APPLICATION NUMBER: US/09/296,005
: CURRENT FILING DATE: 1999-04-21
: EARLIER APPLICATION NUMBER: US 08/887,352
: EARLIER FILING DATE: 1997-07-02
: NUMBER OF SEQ ID NOS: 26
: SEQ ID NO 18
: LENGTH: 451
: TYPE: PRT
: ORGANISM: Artificial Sequence
: FEATURE:
: NAME/KEY: Artificial
: LOCATION: 1-451
: OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-296-005-18

```

Query Match	52.3%;	Score 1262;	DB 3;	Length 451;
Best Local Similarity	58.6%;	Pred. No. 2.2e-94;		
Matches 273; Conservative	25;	Mismatches 78;	Indels 90;	Gaps 12

Qy	30	LGKKGGDVELVETJASQ----	KKSIQFHMKNKNOIKILKNGSFLTGPFKLN-----	77
Db	11	LVPGSGSLRLSCAVSGCYSTISG	SNMMIMQAGKGLFWALSLKYSGETKKNPSVKGRITL	70
Qy	78	DRADSRSLMDQGNFPLIKNLK	IEDSDTYICEVEDQKEVOLVFGLTANSDTH---LL	134
Db	71	SRDSSKNTFYLNQNF-----	SLRAEDTAYVYCARGSH-----YFG-----	HMHFAY 110
Qy	135	QGOSLTLTESPPGSSPSVOCSP	RKKNIGG-----KLTLSV-----	172
Db	111	WGQGLTVATYSSASTKGP	SVPLPASPSSKSTSGGTAALGCLVKDYPEPELTVSWMNGALTSG	170
Qy	173	-----OLELQDSG-----	-----TWCTVLQNOKKVEEKIDIVCPAPBEPKSC	210
Db	171	VHMFPAVLQSSGLYLSLSV	TVPSSSLGTYITICNV---NHKPSNPKVD---KKEVEKSC	224
Qy	211	DKTHTC-----	PELGGPSYFLFPFKPKOTLMI	SRTPEVTCVVDVSHEDPEVKFNNYVD 265
Db	225	DKTHTCPPCPAPILG	SPSVFLFPFKPKDTLMI	ISTRPEVTCVVDVSHEDPEVKFNNYVD 284
Qy	266	GVEVHNAKTPREEOVNSTY	RVVSVYLTVAHQMLNGKEYCKVCVSKALPA	IEKTSIKAK 325
Db	285	GVEVHNAKTPREEOVNSTY	RVVSVYLTVAHQMLNGKEYCKVCVSKALPA	IEKTSIKAK 344
Qy	326	GQPRAPQVYTLPPSRDEL	TKNOVSLTCLVKGFP	PSDIAVEMESNQPENNYKTPPYLDS 385
Db	345	GQPREPQVYTLPPSRDEMT	KNOVSLTCLVKGFP	PSDIAVEMESNQPENNYKTPPYLDS 404
Qy	386	DGSEFLYSKLTIVDKSR	MOQGNVFGSCVHMEALAHNYTQKSL	LSLSPG 431
Db	405	DGSEFLYSKLTIVDKSR	MOQGNVFGSCVHMEALAHNYTQKSL	LSLSPG 450

RESULT 51  
US-09-283-846-2  
: Sequence 2, Application US/09282846  
: Patent No. 6528624  
: GENERAL INFORMATION:  
: APPLICANT: Esche Ekinaadese Idusogie et al  
: TITLE OF INVENTION: Polypeptide Variants  
: FILE REFERENCE: P126CR2

```

; CURRENT APPLICATION NUMBER: US/09/282,846
; CURRENT FILING DATE: 1999-03-31
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2

```

Query Match	52.3%	Score 1262	DB 4	Length 451
Best Local Similarity	58.6%	Pred. No. 2.2e-94		
Matches 273	Conservative 25	Mismatches 78	Indels 90	Gaps 12

QY	30	LGKGGVTLCTGAQ----	KSIQCHMNKSNQIKILGQSGFLLTKGSKLNL-----	77		
Db	11	LVPGSGSLCAVSGYSTISGYSNMWLRQAPKGQLEVVASIKXSGETKYNPVSXGRITI		70		
QY	78	DRADSRSLMDQGNFPLIKIKLKIEDSDTYICEVEDQKEVQLLVFGLTANSDTH---	LL	134		
Db	71	SRDGSKNTEFYLMNN-----	SLRADDTAVVYCCARGSH-----	YFG-----	HMHFAV	110
QY	135	QCGSLTLTLESPGSGSPSQCSRPGKNIQGG-----	KTLSVS-----	172		
Db	111	WGGGTLVTVSSASTGQSPVFPLAPBSKSTSGGTALGLVKDYRPEPEPTVSNMSGALTSG		170		
QY	173	----QLELQDSG-----	TWCTVLQONQKVEFKIDVPCPAPEKSC	210		
Db	171	VHTFPAVLQSGSLYSLSVTVPBSSSLGTQTYICNV--	NHKPSNTKD----	KKVEPKSC	224	
QY	211	DKHTHC-----	PELLGGPSVFLFPKPKQDTLMISTRTPTCVVVDVSHEDPEYKFNMYVD	265		
Db	225	DKHTHTPCCPAPELLGGPSVFLFPKPKQDTLMISTRTPTCVVVDVSHEDPEYKFNMYVD		284		
QY	266	GVEVHNAKTPREBEQYNSTYRVASVLTVLHODMYLNGKCYKCSVSNKALPAPIEKTISKAK		325		
Db	285	GVEVHNAKTPREBEQYNSTYRVASVLTVLHODMYLNGEKYKCSVSNKALPAPIEKTISKAK		344		
QY	326	GQPREQVYTLTPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNGQRENNYKTTTPVYLD		385		
Db	345	GQPREQVYTLTPPSREEMTKQVSLTCLVKGFYPSDIAVEMESNGQRENNYKTTTPVYLD		404		
QY	386	DGSEFLYSLKLTVDKSRMOQGNFSCSVNHGALHNHYOKSLSPG		431		
Db	405	DGSEFLYSLKLTVDKSRMOQGNFSCSVNHGALHNHYOKSLSPG		450		

```

RESULT 52
: US-09-680-145-2
: Sequence 2, Application US/09680145
: Patent No. 6538124
: GENERAL INFORMATION:
:   APPLICANT: Esocle Ekinaduse Idusogie et al.
:   TITLE OF INVENTION: Polypeptide Variants
:   FILE REFERENCE: P126CR1
:   CURRENT APPLICATION NUMBER: US/09/680,145
:   CURRENT FILING DATE: 2000-10-03
:   PRIOR APPLICATION NUMBER: 09/282,505
:   PRIOR FILING DATE: 1999-03-13
:   NUMBER OF SEQ ID NOS: 2
:   SEQ ID NO 2
:   LENGTH: 451
:   TYPE: PRT
:   ORGANISM: Artificial Sequence
:   FEATURE:
:   NAME/KEY: Artificial Sequence
:   LOCATION: 1-451
:   OTHER INFORMATION: Sequence is completely synthesized
:   Patent No. 6538124

```

US-09-680-145-2

Query Match	52.3%	Score 1262;	DB 4;	Length 451;
Best Local Similarity	58.6%	Pred. No. 2.2e-94;		
Matches 273; Conservative	25;	Mismatches 78;	Indels 90;	Gaps 12

QY	30	LGKGGTVELTCTAASQ----	KSIHFPMKNSQIKILGNQSGFLTGPKIKL-----	77
Db	11	LVPGGSLRASCASVSGSYITSGSNMIIQAQBGKLEWVAISIKTSGEIKTPSVKGRIT	70	
QY	78	DRADSRSLWDQGNFPLIIKNIKIEDSDTYICEVEDQKEEVLAVFGLTANSDTH---	LL 134	
Db	71	SRDQSKATFYLOKN-----	SLRAEDTAVYYCARGSH-----YFG-----HMFPAV 110	
QY	135	QGQSLTLTLESPPGSSSPVQCSPKRNKIQG-----	KLTSVS-----172	
Db	111	WGCGTLVATYSSASTKGPSPVPLAPSSKSTSGGTALGCLVDDYPEEPVATWSNGALTSG	170	
QY	173	-----OLELDSG-----	---TWCTVLONOKKVEBEKIDIVCPAPEKSC 210	
Db	171	VHMFPAVLQSSGGLYSLSVYTVPSSSLGTYIICNV--	NHKPSNPKVD----KKEVEKSC 224	
QY	211	DKTHTC-----	PELLCGPSVFLPPEPKQDTLMISTRPEVTCVVDVSHEDVEKFNKYVD 265	
Db	225	DKHTHCPCPCAPPELLCGPSVFLPPEPKQDTLMISTRPEVTCVVDVSHEDVEKFNKYVD	284	
QY	266	GVEVHNAKTKPREEOYSTYRYVSVYTLVHDOMLNGEKYCKVCSKALPAIETIKSAK	325	
Db	285	GVEVHNAKTKPREEOYSTYRYVSVYTLVHDOMLNGEKYCKVCSKALPAIETIKSAK	344	
QY	326	GQREPOVYTLPEPSRDELTKNOVSLTCLVKGFPYSDIAVEWESNQPENNKTTTPVPLDS	365	
Db	345	GQREPOVYTLPEPSRDEMTKNQSLTCLVKGYPSDIAVEWESNQPENNKTTTPVPLDS	404	
QY	386	DGSEFLYSKLTVDKSRMOQGNVPCSGVHMEALAHNYTKSLSLSPG 431		
Db	405	DGSEFLYSKLTVDKSRMOQGNVPCSGVHMEALAHNYTKSLSLSPG 450		

```

US RESULT 53
US-09-920-171-18
; Sequence 18, Application US/09920171
; Patent No. 6682735
; GENERAL INFORMATION:
; APPLICANT: Lowman, Henry B.
; APPLICANT: Presta, Leonard G.
; APPLICANT: Jarden, Paula M.
; APPLICANT: Lowe, John
; TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)
; FILE REFERENCE: P1123C/US
; CURRENT APPLICATION NUMBER: US/09/920,171
; CURRENT FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: US 08/887,352
; PRIOR FILING DATE: 1997-07-02
; PRIOR APPLICATION NUMBER: US 09/296,005
; PRIOR FILING DATE: 1999-04-21
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 18
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-920-171-18

```

	Query March	52.3%	Score 1262;	DB 4	Length 451;
	Best Local Similarity	58.6%	Pred. No. 2e-94;		
	Matches 273;	Conservative	25;	Mismatches 78;	Indels 90; Gaps 12
Oy	30 LGKKGDIYELTCTASQ---	KSIQFHMKNSNOIKLGNQSFLLTPKSKLN-----	77		
	:::::	:::::			
Db	11 LVPGSGSRRLSCAVSGYISITGSYSNWRARAPGKLEWVASISKVSGEETKYNSSVGKRITI	70			

```

QY 78 DRDSSRSIMDQCNFPLIKLKNKIEDSPYICEVEDQEEVQLLVFGLTANSQTH---TL 134
Db 71 SRDSSKATFYLOQNN-----SLRAETAVNYICARSH-----YFC-----HMHFAV 110
QY 135 QGQSLTLTLTSPGSSPSVQCRSPGKNIQCG-----KTLVS----- 172
Db 111 MGQGLTVYVSSAATKPSVFLAPASKSISGSTALLGLVDYDFPEPYVSNMGALTS 170
QY 173 ----QELQDSG-----TWTCVLONOKKVEFKDIYCPAPEKSC 210
Db 171 VHTFPAYLOSSGGLYSLSVTVTPSSSLGTYICNV--NHKPSNTKYD---KAYEKKSC 224
QY 211 DKXHTC-----PELGGSPVFLFPBKPDOTLISRTEPVTCVVYVDSHEDPEVKFNNYVD 265
Db 225 DKXHTCPCPAPFLPLGGSPVFLFPBKPDOTLISRTEPVTCVVYVDSHEDPEVKFNNYVD 284
QY 266 GVEVHNAKTKPREEQYNSYTRVVSVLYLVHODMLNGKCYKCKVSNKLLPAPIEKTISKAK 359
Db 285 GVEVHNAKTKPREEQYNSYTRVVSVLYLVHODMLNGKCYKCKVSNKLLPAPIEKTISKAK 344
QY 326 GQREPEQVYTLPPSRBELTKNOVSLTCLYKGFPSDIAVENESNGQPENNYKTPPVLDS 385
Db 345 GQREPEQVYTLPPSRBEEMTKNOVSLTCLYKGFPSDIAVENESNGQPENNYKTPPVLDS 404
QY 386 DGSFPLYSKLTVDKSRMOQGNFSCSWHBAHLNNHYTKSLSLSPG 431
Db 405 DGSFPLYSKLTVDKSRMOQGNFSCSWHBAHLNNHYTKSLSLSPG 450

```

RESULT 54  
 US-09-049-672A-8  
 ; Sequence 8, Application on US/09049672A  
 ; Patent No. 6155941  
 GENERAL INFORMATION:  
 APPLICANT: Hallman, Jennifer L.  
 APPLICANT: Lal, Preeti  
 APPLICANT: Tang, Y. Tom  
 APPLICANT: Yue, Henry  
 APPLICANT: Au-Young, Janice  
 APPLICANT: Corley, Neil C.  
 APPLICANT: Guegler, Karl J.  
 TITLE OF INVENTION: HUMAN IMMUNE SYSTEM ASS  
 NUMBER OF SEQUENCES: 28  
 CORRESPONDENCE ADDRESSES:  
 ADDRESSEE: Incyte Pharmaceuticals, Inc.  
 STREET: 3174 Porter Drive  
 CITY: Palo Alto  
 STATE: CA  
 COUNTRY: USA  
 ZIP: 94304  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM compatible  
 OPERATING SYSTEM: DOS  
 SOFTWARE: FASTSEQ for Windows Version 2.0.C  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/049,672A  
 FILING DATE: HEREWTH  
 CLASSIFICATION: 536  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER:  
 FILING DATE:  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Ceirone, Michael C  
 REGISTRATION NUMBER: 39,132  
 REFERENCE/DOCKET NUMBER: PF-0497 US  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650-855-0555  
 TELEFAX: 650-845-4166  
 TELEX:  
 INFORMATION FOR SEQ ID NO: 8:  
 SEQUENCE CHARACTERISTICS:

```

; LENGTH: 467 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: LUNGTUT11
; CLONE: 2747531
US-09-049-672A-8

```

```

Query Match      52.3%; Score 1261.5; DB 3; Length 467;
Best Local Similarity 55.6%; Pred. No. 2.5e-94;
Matches 278; Conservative 24; Mismatches 73; Indels 125; Gaps 14;

```

```

QY 16 LALLPAAATQGNKVV-----LGKKGDTVELTCTAS--QKSKIQFHW-----53
DB 8 LFLVAATHTHAQVQLVGSAGAVKKFGASVQVSTVSGFTLSLDSLVHWVRAQPGGLEWM 67
QY 54 ----KNSNQI---KILNGQSFLLTKGPKLNDRADSRSLWDQGNFPLIINKLIEDSD 105
DB 68 GGLABENGSAVVAQKFLGR-----LTLSEDTSDTA-----YMFLLNLGSEDSA 111
QY 106 TYICEVEDQKEVQLVRLTANSQTHL-----LQGSILTLLESPPGSSPSVQCRSPRG 160
DB 112 IYYC-----ARQHYDFFDFWQGTMTVVSASATKGPSPVFLAPSS 152
QY 161 KNIQGG-----KTLVS-----QLFLQDSG-----180
DB 153 KSTSGTALAGCLVADYFPEPVTVSMNSGALTSQVHTPAVLAQSSGLYSLSLSTVTPSSS 212
QY 181 ----TWCTVLONQKVEPKIDIVPCPAPRPKSCDKTHTC-----PELLGSPVFLPPK 231
DB 213 LGTYIYICNV--NHRPSNTKVD---KVEPKSCDKTHTCPCPAPPELLGSPVFLPPK 266
QY 232 PKDTLMISTPREVTCVVDVSHEDPEVKRWVVDGVEVHNATKREQYNSTYVSVL 291
DB 267 PKDTLMISTPREVTCVVDVSHEDPEVKRWVVDGVEVHNATKREQYNSTYVSVL 326
QY 292 TVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQPREPVYTLPPSRDELTKNQVSLT 351
DB 327 TVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQPREPVYTLPPSRDELTKNQVSLT 386
QY 352 CLVKGFPYPSDIAVEMESNGQFPENNYKTPPVLDSDGSPFLYSKLTVDKSRMOQGNVFS 411
DB 387 CLVKGFPYPSDIAVEMESNGQFPENNYKTPPVLDSDGSPFLYSKLTVDKSRMOQGNVFS 446
QY 412 VMHEALHNHYTKQSLSPG 431
DB 447 VMHEALHNHYTKQSLSPG 466

```

```

RESULT 55
US-09-499-846-12
; Sequence 12, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FaastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 488
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-12

```

```

Query Match      52.2%; Score 1261; DB 4; Length 488;
Best Local Similarity 57.9%; Pred. No. 2.9e-94;
Matches 272; Conservative 30; Mismatches 88; Indels 80; Gaps 11;

```

```

QY 15 QLALLPAAATQGNKVVLGKKGDTVELTCTASQKSKIQFHW--KNSNQIKILNGQSFLLTKGP 73
DB 45 KLHAVPAA-----KTVFKCPSSGTPPTLRMLKNGKEFPDRHRIGYKV---89
QY 74 SKLNDRADSRRLW-----DQGNFPLIINKLIEDSDTYICEVEDQKEVQLLVF 123
DB 90 -----RYATWSIIMDSVSPDKGNVTCIYENEGYSINHVTQLDIVERSPHRLIQA 140
QY 124 GLTANSPTHLQGSLSLTLLESPP-----GSS-----PSVQCRSPRKNL-163
DB 141 GLPANKTVLAGSNVNEFMCKVSDPQPHIQMLKHIENVGSKI GPNNLPYQQLTKAGVNTT 200
QY 164 -QGKTLVSQLELQDSGTWTC-----TVLONQKVEFKIDIVCPA--PE 206
DB 201 DKEMEVHLNRVSEDADEYTCLAGNSIGLSHSAMLTVE---ALBERPAVMTSPYLE 257
QY 207 PKSCDKTHTC-----PELLGSPVFLPPPKDTLMSRPEVTCVVDVSHEDPEVKFN 261
DB 258 PKSCDKTHTCPCPAPRLGSPSVFLPPPKDTLMSRPEVTCVVDVSHEDPEVKFN 317
QY 262 MYVDGVEVHNAKTPREEQYNSTYRVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKT 321
DB 318 MYVDGVEVHNAKTPREEQYNSTYRVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKT 377
QY 322 SKAGQPREPVYTLPPSRDELTKNQVSLTCLVKGFPYPSDIAVEMESNGQFPENNYKTPP 381
DB 378 SKAGQPREPVYTLPPSRDELTKNQVSLTCLVKGFPYPSDIAVEMESNGQFPENNYKTPP 437
QY 382 VLSDGSPFLYSKLTVDKSRMOQGNVFSVMHEALHNHYTKQSLSPG 431
DB 438 VLSDGSPFLYSKLTVDKSRMOQGNVFSVMHEALHNHYTKQSLSPG 487

```

```

RESULT 56
US-08-466-151-8
; Sequence 8, Application US/08466151
; Patent No. 6037453
; GENERAL INFORMATION:
; APPLICANT: Jardeu, Paula M.
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,151
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/466163
; FILING DATE: 06-Jun-1995
; APPLICATION NUMBER: 08/405617
; FILING DATE: 15-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/185899
; FILING DATE: 26-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/879495
; FILING DATE: 07-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/744768
; FILING DATE: 14-AUG-1991
; ATTORNEY/AGENT INFORMATION:

```

```

; NAME: Svoboda, Craig G.
; REGISTRATION NUMBER: 39,044
; REFERENCE/DOCKET NUMBER: P0718P2C1D1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1489
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 453 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
;
US-08-466-151-8

Query Match      52.2%; Score 1259; DB 3; Length 453;
Best Local Similarity 58.9%; Pred. No. 3.8e-94;
Matches 271; Conservative 26; Mismatches 87; Indels 76; Gaps 11;

QY 30 LGKKGDVVELTCTASQ---KKSIOFHWKNSNOIKILGNQGSFLTQGPSKLNDRADSRSL 86
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 11 LVQPGSLRLSCAVSGYSITSGYSNMWIRQAPGKGLFWASITYDGSITVADSVKGRFTI 70
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 87 W---DQGNFPLIITKMLKIEDSDTYICEVEDQKEEVQLVFGLTANSDFHLL---QGQSILT 140
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 71 SRDSSKNTFYLGKNSIRAEEDTAVYYCARGSH-----YFG-----HMHFAVWGQSTLVY 118
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 141 LTLESPPGSSPSVQCRSPRGKNIQGS-----KTLSSVS-----QL 174
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 119 VSSASTKKGKSPVFLPPLAPBSKSTSGGTALGCLVNDYFPEPVTVMNSGALTSVHTFPA 178
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 175 ELQDSG-----TWCTVLQNKKEFKIDIVPCPAPBPKSCDKTHTC 216
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 179 VLQSSGLVSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKVEPKSCDKTHTC 232
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 217 -----PELLGGPSVFLPPEPKDITMISRTPEVTCVVDVSHEDPEVKFNWYDGYEVHN 271
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 233 PCPAPBELLGGPSVFLPPEPKDITMISRTPEVTCVVDVSHEDPEVKFNWYDGYEVHN 292
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 272 AKTKREBOYNSTYRVSVTLVTHQDMLNGKCYKCVSNKALPAPLEKTIISAKGQPRP 331
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 293 AKTKREBOYNSTYRVSVTLVTHQDMLNGKCYKCVSNKALPAPLEKTIISAKGQPRP 352
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPL 391
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 353 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPL 412
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 392 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 413 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 452
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |

RESULT 57
US-08-466-163B-8
; Sequence 8, Application US/08466163B
; Patent No. 6329509
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; FILE REFERENCE: P0718P2C1D1
; CURRENT APPLICATION NUMBER: US/08/466,163B
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 8
; LENGTH: 453
; TYPE: PRT
```

```

; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: humanized mae11, version 1 heavy chain
US-08-466-163B-8

Query Match      52.2%; Score 1259; DB 4; Length 453;
Best Local Similarity 58.9%; Pred. No. 3.8e-94;
Matches 271; Conservative 26; Mismatches 87; Indels 76; Gaps 11;

QY 30 LGKKGDVVELTCTASQ---KKSIOFHWKNSNOIKILGNQGSFLTQGPSKLNDRADSRSL 86
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 11 LVQPGSLRLSCAVSGYSITSGYSNMWIRQAPGKGLFWASITYDGSITVADSVKGRFTI 70
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 87 W---DQGNFPLIITKMLKIEDSDTYICEVEDQKEEVQLVFGLTANSDFHLL---QGQSILT 140
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 71 SRDSSKNTFYLGKNSIRAEEDTAVYYCARGSH-----YFG-----HMHFAVWGQSTLVY 118
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 141 LTLESPPGSSPSVQCRSPRGKNIQGS-----KTLSSVS-----QL 174
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 119 VSSASTKKGKSPVFLPPLAPBSKSTSGGTALGCLVNDYFPEPVTVMNSGALTSVHTFPA 178
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 175 ELQDSG-----TWCTVLQNKKEFKIDIVPCPAPBPKSCDKTHTC 216
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 179 VLQSSGLVSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKVEPKSCDKTHTC 232
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 217 -----PELLGGPSVFLPPEPKDITMISRTPEVTCVVDVSHEDPEVKFNWYDGYEVHN 271
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 233 PCPAPBELLGGPSVFLPPEPKDITMISRTPEVTCVVDVSHEDPEVKFNWYDGYEVHN 292
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 272 AKTKREBOYNSTYRVSVTLVTHQDMLNGKCYKCVSNKALPAPLEKTIISAKGQPRP 331
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 293 AKTKREBOYNSTYRVSVTLVTHQDMLNGKCYKCVSNKALPAPLEKTIISAKGQPRP 352
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPL 391
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 353 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPL 412
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
QY 392 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |
DB 413 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 452
   | : : : | : : : | : : : | : : : | : : : | : : : | : : : | : : : |

RESULT 58
US-09-802-096-8
; Sequence 8, Application US/09802096
; Patent No. 6685939
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Method of Preventing the Onset of Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C3US
; CURRENT APPLICATION NUMBER: US/09/802,096
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 8
; LENGTH: 453
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: humanized mae11, version 1 heavy chain
US-09-802-096-8

Query Match      52.2%; Score 1259; DB 4; Length 453;
```





```

; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 478 amino acids
;   TYPE: amino acid
;   TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-487-550-8
```

```

Query Match      52.2%; Score 1259; DB 3; Length 478;
Best Local Similarity 66.9%; Pred. No. 4.1e-94;
Matches 259; Conservative 12; Mismatches 56; Indels 60; Gaps 7;
```

```

QY 94 LIINKKIEDSDPTIYCEVEDQKEEVQLVFGLTANS DTHLLOGSILTLTLESPGSSPSV 153
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 102 LQMSLKIETDVAIVYCTTSYISH-----CRGVCYGGEFEGQALVTVSSASTKGPSV 156
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 154 QCRSPKNGIKGG-----KTVSVS-----QLRLDSG-----180
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 157 FLAPBSKSTSGTALGLVDYFPEPVTVSNAGALTSVHTPPAVLQSSGLYSLSV 216
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 181 -----TWCTVLQNKVEFKIDIVCPAPEPKSCDTHTC-----PELLGGS 224
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 217 VTFVSSSLGTQYICNV--NHKPSNTKVD---KKAEPKSCDTHTCPPCPAPPELLGGS 270
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 225 VFLEPPPKPDITMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNT 284
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 271 VFLEPPPKPDITMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNT 330
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 285 YRVVSVLTVLHODMNGEKYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELT 344
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 331 YRVVSVLTVLHODMNGEKYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELT 390
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 345 KQVSLTCLVKGYPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQ 404
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 391 KQVSLTCLVKGYPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQ 450
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 405 GNVFSCSVMEALHNHYTOKSLSPG 431
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 451 GNVFSCSVMEALHNHYTOKSLSPG 477
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
```

```

RESULT 61
US-09-526-098-8
; Sequence 8, Application US/09526098
; Patent No. 6492134
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATED FORMS THEREOF
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/526,098
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/383,916
; FILING DATE:
; APPLICATION NUMBER: US 08/487,550
; FILING DATE: 07-JUN-1995
```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-2021
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 478 amino acids
;   TYPE: amino acid
;   TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-526-098-8
```

```

Query Match      52.2%; Score 1259; DB 4; Length 478;
Best Local Similarity 66.9%; Pred. No. 4.1e-94;
Matches 259; Conservative 12; Mismatches 56; Indels 60; Gaps 7;
```

```

QY 94 LIINKKIEDSDPTIYCEVEDQKEEVQLVFGLTANS DTHLLOGSILTLTLESPGSSPSV 153
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 102 LQMSLKIETDVAIVYCTTSYISH-----CRGVCYGGEFEGQALVTVSSASTKGPSV 156
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 154 QCRSPKNGIKGG-----KTVSVS-----QLRLDSG-----180
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 157 FLAPBSKSTSGTALGLVDYFPEPVTVSNAGALTSVHTPPAVLQSSGLYSLSV 216
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 181 -----TWCTVLQNKVEFKIDIVCPAPEPKSCDTHTC-----PELLGGS 224
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 217 VTFVSSSLGTQYICNV--NHKPSNTKVD---KKAEPKSCDTHTCPPCPAPPELLGGS 270
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 225 VFLEPPPKPDITMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNT 284
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 271 VFLEPPPKPDITMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNT 330
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 285 YRVVSVLTVLHODMNGEKYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELT 344
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 331 YRVVSVLTVLHODMNGEKYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELT 390
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 345 KQVSLTCLVKGYPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQ 404
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 391 KQVSLTCLVKGYPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQ 450
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
QY 405 GNVFSCSVMEALHNHYTOKSLSPG 431
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
DB 451 GNVFSCSVMEALHNHYTOKSLSPG 477
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
```

```

RESULT 62
US-09-499-846-10
; Sequence 10, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 497
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-10
```

```

Query Match      52.1%; Score 1258.5; DB 4; Length 497;
Best Local Similarity 57.1%; Pred. No. 4.8e-94;
Matches 274; Conservative 30; Mismatches 85; Indels 91; Gaps 12;

QY 15 QIALPPAATGKNKIVLGGKGDVLELTCTASQKSIQFHW-KNSNQIK-----ILNGQGSFL 69
   | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
```

45 KLIHAVPA-----KTVKFCPSSTGTPNFTLRMLKXGKFKDPDRIGYKAVYA 92  
QY 70 TKG-----PSKLNDRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDOKEEVOLLV 122  
DB 93 TWSIIMDSVPS-----DKGNYTCIVENEGSINHITQDLVDERSPIRPILQ 139  
QY 123 FGLTNSDTHLLQGGSLTTLTLESP-----GSS-----PSVQCRSPRGNI 163  
DB 140 AGLPANKYVALGSNVEFMCKVYSDPQPHIQMLKIEVNGSKIGPNDLPVQILKTAGVNT 199  
QY 164 --QGKTLTSLVSOLELDQSGTWTCT-----TVLONQKVEFKDIDVPC--- 203  
DB 200 TDKEMEVLHLRNVSFEEDAGEYTCLAGNSIGLSHSAAMLTVLE--ALBERPAVMTSPILYL 256  
QY 204 -----APEPKSCDKTHTC-----PELLGSPVLFPPPKPDITMISRTPEVTCVAVDV 251  
DB 257 EGSSGSGLOEPKSCDKTHTCPCPAPALEGGSVLFPPKPDITMISRTPEVTCVAVDV 316  
QY 252 SHEDPEVKFNMYVDGVEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNGEKYKCVSNK 311  
DB 317 SHEDPEVKFNMYVDGVEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNGEKYKCVSNK 376  
QY 312 ALPAPIEKTISKAKQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371  
DB 377 ALPAPIEKTISKAKQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 436  
QY 372 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMOQGNVSCSVMHBALNHNHTQKSLSPG 431  
DB 437 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMOQGNVSCSVMHBALNHNHTQKSLSPG 496

RESULT 63  
US-09-499-846-8  
Sequence 8, Application US/09499846

Patent No. 6566728  
GENERAL INFORMATION:  
APPLICANT: Kavanaugh et al.  
TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR  
TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION  
FILE REFERENCE: 035784/195012 (5784-  
CURRENT APPLICATION NUMBER: US/09/499, 846  
CURRENT FILING DATE: 2000-02-07  
NUMBER OF SEQ ID NOS: 12  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 8  
LENGTH: 525  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-499-846-8

Query Match 52.1%; Score 1258.5; DB 4; Length 525;  
Best Local Similarity 57.1%; Pred. No. 5.1e-94;  
Matches 274; Conservative 30; Mismatches 85; Indels 91; Gaps 12;

QY 15 QALLPAPATQGNKVVLGKKGDVVELTCTASQKKSIOFHM-KNSNQIK---ILGNQGSFL 69  
DB 73 KLIHAVPA-----KTVKFCPSSTGTPNFTLRMLKXGKFKDPDRIGYKAVYA 120  
QY 70 TKG-----PSKLNDRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDOKEEVOLLV 122  
DB 121 TWSIIMDSVPS-----DKGNYTCIVENEGSINHITQDLVDERSPIRPILQ 167  
QY 123 FGLTNSDTHLLQGGSLTTLTLESP-----GSS-----PSVQCRSPRGNI 163  
DB 168 AGLPANKYVALGSNVEFMCKVYSDPQPHIQMLKIEVNGSKIGPNDLPVQILKTAGVNT 227  
QY 164 --QGKTLTSLVSOLELDQSGTWTCT-----TVLONQKVEFKDIDVPC--- 203  
DB 228 TDKEMEVLHLRNVSFEEDAGEYTCLAGNSIGLSHSAAMLTVLE--ALBERPAVMTSPILYL 284  
QY 204 -----APEPKSCDKTHTC-----PELLGSPVLFPPKPDITMISRTPEVTCVAVDV 251  
DB 285 EGSSGSGLOEPKSCDKTHTCPCPAPALEGGSVLFPPKPDITMISRTPEVTCVAVDV 344

QY 252 SHEDPEVKFNMYVDGVEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNGEKYKCVSNK 311  
DB 345 SHEDPEVKFNMYVDGVEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNGEKYKCVSNK 404  
QY 312 ALPAPIEKTISKAKQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371  
DB 405 ALPAPIEKTISKAKQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 464  
QY 372 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMOQGNVSCSVMHBALNHNHTQKSLSPG 431  
DB 465 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMOQGNVSCSVMHBALNHNHTQKSLSPG 524

RESULT 64  
US-08-887-352B-14  
Sequence 14, Application US/08887352B

Patent No. 5994511  
GENERAL INFORMATION:  
APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe  
TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of  
TITLE OF INVENTION: Improving Polypeptides  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESS: Genentech, Inc.  
STREET: 1 DNA Way  
CITY: South San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94080  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Winpacin (Genentech)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/887,352B  
FILING DATE: 03-Jul-1997  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: Svoboda, Craig G.  
REGISTRATION NUMBER: 39,044  
REFERENCE/DOCKET NUMBER: P1123  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650/952-9881  
FAX: 650/952-9881  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 451 amino acids  
TYPE: Amino Acid  
TOPOLOGY: Linear  
US-08-887-352B-14

Query Match 52.1%; Score 1257; DB 2; Length 451;  
Best Local Similarity 58.4%; Pred. No. 5.5e-94;  
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKGDVVELTCTASQ---KKSIOFHMKNNSQIKILGNQGSFLTKGSKLN----- 77  
DB 11 LVQPGSLRLRISCAVSGVSTSGYSWMNIRQAPGKGLMVASITYDGSNTNPSYKGRITI 70  
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDOKEEVOLLVFLTANSDTH---LL 134  
DB 71 SRDSSKNTFYIQNM-----SLRREDPAVYYCARGSH-----HMHFAV 110  
QY 135 QGGSLLTLESPPGSSPSVQCRSPRGNIQGG-----KTLVS----- 172  
DB 111 WGCGTLVTVSSASTKGSVPFLAPSSKSTSGTALGLVDYFPEPVTVMNSGALTSG 170  
QY 173 ---QLBLQSG-----TWCTTVLONQKVEFKDIDVPCPAPEPKSC 210  
DB 171 VHPFPAVLQSSGLYSLSSVTVTPSSSLGTGTQYICNV--NHPKSNPKVD---KVEPKSC 224

QY	211	DKHTC-----PELLGGSPVFLPPEKPDLTMTSRPEVTCVVVDVSHDEPKFMMVVD	265
DB	225	DKHTCPGPCAPBELLGGSVFLFPPEKPDLTMTSRPEVTCVVVDVSHDEPKFMMVVD	284
QY	266	GVEVHNATKTKREEQNVSTYRVVSVLTVLTHQDWLNGEKYCKVSNALPAPIEKTISKAK	325
DB	285	GVEVHNATKTKREEQNVSTYRVVSVLTVLTHQDWLNGEKYCKVSNALPAPIEKTISKAK	344
QY	326	GQPREPOVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPEVLDS	385
DB	345	GQPREPOVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPEVLDS	404
QY	386	DGSFELYSKLTVDKSRWQQGVFSCSMYHALLHNHYTKSLSPG	431
DB	405	DGSFELYSKLTVDKSRWQQGVFSCSMYHALLHNHYTKSLSPG	450
RESULT 65			
US-08-887-352B-16			
/ Sequence 16, Application US/0887352B			
/ Patent No. 5994511			
/ GENERAL INFORMATION:			
/ APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe			
/ TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of			
/ TITLE OF INVENTION: Improving Polypeptides			
/ NUMBER OF SEQUENCES: 26			
/ CORRESPONDENCE ADDRESS:			
/ ADDRESSEE: Genentech, Inc.			
/ STREET: 1 DNA Way			
/ CITY: South San Francisco			
/ STATE: California			
/ COUNTRY: USA			
/ ZIP: 94080			
/ COMPUTER READABLE FORM:			
/ MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk			
/ COMPUTER: IBM PC compatible			
/ OPERATING SYSTEM: PC-DOS/MS-DOS			
/ SOFTWARE: Winpatin (Genentech)			
/ CURRENT APPLICATION DATA:			
/ APPLICATION NUMBER: US/08/887,352B			
/ FILING DATE: 03-Jul-1997			
/ CLASSIFICATION: 530			
/ ATTORNEY/AGENT INFORMATION:			
/ NAME: Svoboda, Craig G.			
/ REGISTRATION NUMBER: 39,044			
/ REFERENCE/DOCKET NUMBER: P1123			
/ TELECOMMUNICATION INFORMATION:			
/ TELEPHONE: 650/225-1489			
/ TELEFAX: 650/952-9881			
/ INFORMATION FOR SEQ ID NO: 16:			
/ SEQUENCE CHARACTERISTICS:			
/ LENGTH: 451 amino acids			
/ TYPE: Amino Acid			
/ TOPOLOGY: Linear			
US-08-887-352B-16			
QY	52.1%	Score 1257; DB 2; Length 451;	
DB	58.4%	Pred. No. 5.5e-94;	
QY	272;	Conervative	25; Mismatches 79; Indels 90; Gaps 12;
DB	272;	Conervative	25; Mismatches 79; Indels 90; Gaps 12;
QY	30	LGGKGDVTELTCTASQ--KKSIOFHWNKSNQIKILIGNGSFLTKPSPKLN-----	77
DB	11	LVQGGGILRLSCAVSGSITGSYMNIRQAPKGLEWVASITVDGSTVNVSPVKRITV	70
QY	78	DRASRSRLMDGGFPLIKNLKTEDSDTYICEVEQKEVQLLVGLTANSTH---LL	134
DB	71	SRDSKNTFTYQNM-----SLREDYAVVYCARGSH-----YFG-----HWHPAV	110
QY	135	QGOSLITLTLESPSSSPVOCSPRGKNIQGG-----RTLSVS-----	172
DB	111	WGQGTIVTVSSASRTKGSVFPFLPAASSKSTGCGTALALGVKQVFPPEPVYVSNMNGALTS	170
QY	173	-----QLEIQDSG-----TWCTVLQNGKVEFKIDIVCPAPPEKSC	210

Db	171	VHFFPAVLQSSGLYSLSSVYVPPSSLSLGTQYICNV--NHKFSNTKYD----	KYVEKSC	224
Qy	211	DKHTTC-----PELLGGSEVLFPPPKPDYTLMTSTPEVTCVVDVSHEDPEVKFNYYD		265
Db	225	DKHTTCPCCPAPLGGSPVFLPPPKPDYTLMTSTPEVTCVVDVSHEDPEVKFNYYD		284
Qy	266	GVEVHNAKTPREEOYNSTYRVVSVLYVLHDQWLNKGEYKCKVSNKALPAIEKTIISKAK		325
Db	285	GVEVHNAKTPREEOYNSTYRVVSVLYVLHDQWLNKGEYKCKVSNKALPAIEKTIISKAK		344
Qy	326	GOEPEPOVYTLPPSRDELTKNOVSLTCLYKGVSPSDIIVEMESNGOPENNYKTPPVLDS		385
Db	345	GQREPEQVYTLPPSRREMTKNOVSLTCLYKGVSPSDIIVEMESNGOPENNYKTPPVLDS		405
Qy	386	DGSFPLYSKULTYDKSKWQOGNPFSSVHMEALAHNYTKSLSLSPG	431	
Db	405	DGSFPLYSKULTYDKSKWQOGNPFSSVHMEALAHNYTKSLSLSPG	450	

```

1      RESULT 66
2      US-08-466-151-65
3      : Sequence 65, Application US/08466151
4      : Patent No. 6037453
5      : GENERAL INFORMATION:
6      : APPLICANT: Jardieu, Paula M.
7      : APPLICANT: Prestea, Leonard G.
8      : TITLE OF INVENTION: Immunoglobulin Variants
9      : NUMBER OF SEQUENCES: 65
10     : CORRESPONDENCE ADDRESS:
11     : ADDRESSEE: Genentech, Inc.
12     : STREET: 1 DNA Way
13     : CITY: South San Francisco
14     : STATE: California
15     : COUNTRY: USA
16     : ZIP: 94080
17     : COMPUTER READABLE FORM:
18     : MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
19     : COMPUTER: IBM PC compatible
20     : OPERATING SYSTEM: PC-DOS/MS-DOS
21     : SOFTWARE: Winpatlin (Genentech)
22     : CURRENT APPLICATION DATA:
23     : APPLICATION NUMBER: US/08/466,151
24     : FILING DATE:
25     : CLASSIFICATION:
26     : PRIOR APPLICATION DATA:
27     : APPLICATION NUMBER: 08/466163
28     : FILING DATE: 06-Jun-1995
29     : APPLICATION NUMBER: 08/405617
30     : FILING DATE: 15-MAR-1995
31     : PRIOR APPLICATION DATA:
32     : APPLICATION NUMBER: 08/185899
33     : FILING DATE: 26-JAN-1994
34     : PRIOR APPLICATION DATA:
35     : APPLICATION NUMBER: 07/879495
36     : FILING DATE: 07-MAY-1992
37     : PRIOR APPLICATION DATA:
38     : APPLICATION NUMBER: 07/744768
39     : FILING DATE: 14-AUG-1991
40     : ATTORNEY/AGENT INFORMATION:
41     : NAME: Svoboda, Craig G.
42     : REGISTRATION NUMBER: 39,044
43     : REFERENCE/DOCKET NUMBER: P0718P2C1D1
44     : TELECOMMUNICATION INFORMATION:
45     : TELEPHONE: 650/225-1489
46     : TELEFAX: 650/952-9881
47     : INFORMATION FOR SEQ ID NO: 65:
48     : SEQUENCE CHARACTERISTICS:
49     : LENGTH: 451 amino acids
50     : TYPE: Amino Acid
51     : TOPOLOGY: Linear
52     : US-08-466-151-65

```

```

Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKDVTVELTCTAAG--KKSIOFHMKNSNQIKILGNQGSFLTGPCKLN----- 77
DB 11 LVQPGSLRLSCAVGSYTSISGYSMWIRQAPGKGLWVASITYDGSITNPNVSVKGRITTI 70
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLVFGTLANSDDTH---LL 134
DB 71 SRDSDSKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGQSLTTLTLESPPGSSPSVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGQTLVTWVSASATKGPVSFPLAPSSKSTSGTALGCLVDYPPPEVTVSNNGALTSG 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVPCPAPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KVEPSPSC 224
QY 211 DKTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKTHTCPCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETKISAK 325
DB 285 GVEVHNAAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETKISAK 344
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEESNQGPENNYKTTTPVLD 385
DB 345 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEESNQGPENNYKTTTPVLD 404
QY 386 DGSFFLYSKLTVDKSRMQQGNVFSCSVMHREALHNYTQKSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMQQGNVFSCSVMHREALHNYTQKSLSPG 450

RESULT 67
US-09-109-207C-14
; Sequence 14, Application US/09109207C
; Patent No. 6172213
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-1gE Antibodies and Method of Improving Polypeptide
; FILE REFERENCE: P1123R1
; CURRENT APPLICATION NUMBER: US/09/109,207C
; CURRENT FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/051,554
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 14
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-109-207C-14

Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKDVTVELTCTAAG--KKSIOFHMKNSNQIKILGNQGSFLTGPCKLN----- 77
DB 11 LVQPGSLRLSCAVGSYTSISGYSMWIRQAPGKGLWVASITYDGSITNPNVSVKGRITTI 70
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLVFGTLANSDDTH---LL 134
DB 71 SRDSDSKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGQSLTTLTLESPPGSSPSVQCRSPRGKNIQGG-----KTLSSVS----- 172

```

```

DB 111 WGGQTLVTWVSASATKGPVSFPLAPSSKSTSGTALGCLVDYPPPEVTVSNNGALTSG 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVPCPAPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KVEPSPSC 224
QY 211 DKTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKTHTCPCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETKISAK 325
DB 285 GVEVHNAAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETKISAK 344
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEESNQGPENNYKTTTPVLD 385
DB 345 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEESNQGPENNYKTTTPVLD 404
QY 386 DGSFFLYSKLTVDKSRMQQGNVFSCSVMHREALHNYTQKSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMQQGNVFSCSVMHREALHNYTQKSLSPG 450

RESULT 68
US-09-109-207C-16
; Sequence 16, Application US/09109207C
; Patent No. 6172213
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-1gE Antibodies and Method of Improving Polypeptide
; FILE REFERENCE: P1123R1
; CURRENT APPLICATION NUMBER: US/09/109,207C
; CURRENT FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/051,554
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 16
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-109-207C-16

Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKDVTVELTCTAAG--KKSIOFHMKNSNQIKILGNQGSFLTGPCKLN----- 77
DB 11 LVQPGSLRLSCAVGSYTSISGYSMWIRQAPGKGLWVASITYDGSITNPNVSVKGRITTI 70
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLVFGTLANSDDTH---LL 134
DB 71 SRDSDSKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGQSLTTLTLESPPGSSPSVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGQTLVTWVSASATKGPVSFPLAPSSKSTSGTALGCLVDYPPPEVTVSNNGALTSG 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVPCPAPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KVEPSPSC 224
QY 211 DKTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKTHTCPCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETKISAK 325

```

Db 285 GVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344  
QY 326 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGPENNYKTTTPVLDS 385  
Db 345 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGPENNYKTTTPVLDS 404  
QY 386 DGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431  
Db 405 DGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 450

RESULT 69  
US-09-296-005-14  
; Sequence 14, Application US/09296005  
; Patent No. 6290957  
; GENERAL INFORMATION:  
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardiou, John Lowe  
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides  
; FILE REFERENCE: P1123C1T  
; CURRENT APPLICATION NUMBER: US/09/296,005  
; EARLIER FILING DATE: 1999-04-21  
; EARLIER APPLICATION NUMBER: US 08/887,352  
; EARLIER FILING DATE: 1997-07-02  
; NUMBER OF SEQ ID NOS: 26  
; SEQ ID NO 14  
; LENGTH: 451  
; TYPE: PRT  
; ORGANISM: Artificial  
; NAME/KEY: Artificial  
; LOCATION: 1-451  
; OTHER INFORMATION: Heavy chain sequence derived from MAE11  
US-09-296-005-14

Query Match 52.1%; Score 1257; DB 3; Length 451;  
Best Local Similarity 58.4%; Pred. No. 5,5e-94;  
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKGGDTVELTCTASQ---KKSIOFHMKNSNQIKILNGSGFLTKGPSKLN----- 77  
Db 11 LVQPGSLRLSCAVSGYSTSGYSNMWIRQAPGKLEWVASITTDSTYNPSVKGRIIT 70  
QY 78 DRADSRSLMDQGNFPLIINKLIEDSDTYICEVEDQKEVQLVFGTLANSPTDTH---LL 134  
Db 71 SRDSDKNTFYLGDM-----SLRAEDTAVYYCARSGH-----YFG-----HMHFAY 110  
QY 135 OGQSLTLTLESPPGSSPSVQCRSPRGKNIQGS-----KTLSSVS----- 172  
Db 111 WQGGTLVTVSSASTKGSFVFLPAPSSKSTSGGTALGCLVKDYFPEPTVSNMNSGALTSG 170  
QY 173 ---QLELDQSG-----TWTCYVLONQKVEFKIDIVPCPAPKSC 210  
Db 171 VHTFPAVLQSSGLYSLSVTVPPSSLTGTQTYICNV--NHKPSNTKVD---KQVEPKSC 224  
QY 211 DKTHTC-----PELLGSPVFLFPKPKDITLMISRTPEVTCVYVDVSHEDPEVKFNWYVD 265  
Db 225 DKTHTCPCPAPAPPELLGSPVFLFPKPKDITLMISRTPEVTCVYVDVSHEDPEVKFNWYVD 284  
QY 266 GVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 325  
Db 285 GVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344  
QY 326 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGPENNYKTTTPVLDS 385  
Db 345 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGPENNYKTTTPVLDS 404  
QY 386 DGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431  
Db 405 DGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 450

RESULT 70  
US-09-296-005-16

; Sequence 16, Application US/09296005  
; Patent No. 6290957  
; GENERAL INFORMATION:  
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardiou, John Lowe  
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides  
; FILE REFERENCE: P1123C1T  
; CURRENT APPLICATION NUMBER: US/09/296,005  
; EARLIER FILING DATE: 1999-04-21  
; EARLIER APPLICATION NUMBER: US 08/887,352  
; EARLIER FILING DATE: 1997-07-02  
; NUMBER OF SEQ ID NOS: 26  
; SEQ ID NO 16  
; LENGTH: 451  
; TYPE: PRT  
; ORGANISM: Artificial  
; NAME/KEY: Artificial  
; LOCATION: 1-451  
; OTHER INFORMATION: Heavy chain sequence derived from MAE11  
US-09-296-005-16

Query Match 52.1%; Score 1257; DB 3; Length 451;  
Best Local Similarity 58.4%; Pred. No. 5,5e-94;  
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKGGDTVELTCTASQ---KKSIOFHMKNSNQIKILNGSGFLTKGPSKLN----- 77  
Db 11 LVQPGSLRLSCAVSGYSTSGYSNMWIRQAPGKLEWVASITTDSTYNPSVKGRIIT 70  
QY 78 DRADSRSLMDQGNFPLIINKLIEDSDTYICEVEDQKEVQLVFGTLANSPTDTH---LL 134  
Db 71 SRDSDKNTFYLGDM-----SLRAEDTAVYYCARSGH-----YFG-----HMHFAY 110  
QY 135 OGQSLTLTLESPPGSSPSVQCRSPRGKNIQGS-----KTLSSVS----- 172  
Db 111 WQGGTLVTVSSASTKGSFVFLPAPSSKSTSGGTALGCLVKDYFPEPTVSNMNSGALTSG 170  
QY 173 ---QLELDQSG-----TWTCYVLONQKVEFKIDIVPCPAPKSC 210  
Db 171 VHTFPAVLQSSGLYSLSVTVPPSSLTGTQTYICNV--NHKPSNTKVD---KQVEPKSC 224  
QY 211 DKTHTC-----PELLGSPVFLFPKPKDITLMISRTPEVTCVYVDVSHEDPEVKFNWYVD 265  
Db 225 DKTHTCPCPAPAPPELLGSPVFLFPKPKDITLMISRTPEVTCVYVDVSHEDPEVKFNWYVD 284  
QY 266 GVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 325  
Db 285 GVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344  
QY 326 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGPENNYKTTTPVLDS 385  
Db 345 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGPENNYKTTTPVLDS 404  
QY 386 DGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431  
Db 405 DGSFPLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 450

RESULT 71  
US-09-920-171-14  
; Sequence 14, Application US/09920171  
; Patent No. 6682735  
; GENERAL INFORMATION:  
; APPLICANT: Lowman, Henry B.  
; APPLICANT: Presta, Leonard G.  
; APPLICANT: Jardiou, Paula M.  
; APPLICANT: Lowe, John  
; TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)  
; FILE REFERENCE: P1123C2US  
; CURRENT APPLICATION NUMBER: US/09/920,171  
; EARLIER FILING DATE: 2001-08-01  
; PRIOR APPLICATION NUMBER: US 08/887,352  
; EARLIER FILING DATE: 1997-07-02

PRIOR APPLICATION NUMBER: US 09/296,005  
PRIOR FILING DATE: 1999-04-21  
NUMBER OF SEQ ID NOS: 44  
SEQ ID NO 14  
LENGTH: 451  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Heavy chain sequence derived from MAE11  
US-09-920-171-14

Query Match 52.1%; Score 1257; DB 4; Length 451;  
Best Local Similarity 58.4%; Pred. No. 5,5e-94;  
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LKKKGDVTELCTASQ---KKSIOFHMKNSQIKILNGSFLTKGSPKLN----- 77  
DB 11 LVQPGGSLRLSCAVSGYTSYGSMMWIRQAPGKLEWVASITVDGSTNYPVSKGRITTI 70  
QY 78 DRADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSDTH---LL 134  
DB 71 SRDSDKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110  
QY 135 QGQSLTTLSPSPSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172  
DB 111 WGGGLTVTVSASASTKGPVFPPLAPSSKSTSGTAAAGCLVVDYFPEPVTVSNWNGALTSG 170  
QY 173 ---QLELDSDG-----TWTCYVLOQKVEFKIDIVPCPAPEPKSC 210  
DB 171 VHTFPAYVLOSGSLYSLSVTVFPSSSLGTQYICNV--NHKPSNTKYD---KKEVPKSC 224  
QY 211 DKHTTC-----PELLGSPVFLFPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 265  
DB 225 DKHTTCPPCPAPELLGGSPVFLFPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 284  
QY 266 GVEVHNAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 325  
DB 285 GVEVHNAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344  
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPVLD 385  
DB 345 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPVLD 404  
QY 386 DGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 431  
DB 405 DGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 450

## RESULT 72

US-09-920-171-16  
Sequence 16, Application US/09920171  
Patent No. 6682735  
GENERAL INFORMATION:  
APPLICANT: Lowman, Henry B.  
APPLICANT: Prestea, Leonard G.  
APPLICANT: Jarden, Paula M.  
APPLICANT: Lowe, John  
TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)  
FILE REFERENCE: P1123C2US  
CURRENT APPLICATION NUMBER: US/09/920,171  
CURRENT FILING DATE: 2001-08-01  
PRIOR APPLICATION NUMBER: US 08/887,352  
PRIOR FILING DATE: 1997-07-02  
PRIOR APPLICATION NUMBER: US 09/296,005  
PRIOR FILING DATE: 1999-04-21  
NUMBER OF SEQ ID NOS: 44  
SEQ ID NO 16  
LENGTH: 451  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Heavy chain sequence derived from MAE11  
US-09-920-171-16

Query Match 52.1%; Score 1257; DB 4; Length 451;  
Best Local Similarity 58.4%; Pred. No. 5,5e-94;  
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LKKKGDVTELCTASQ---KKSIOFHMKNSQIKILNGSFLTKGSPKLN----- 77  
DB 11 LVQPGGSLRLSCAVSGYTSYGSMMWIRQAPGKLEWVASITVDGSTNYPVSKGRITTI 70  
QY 78 DRADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSDTH---LL 134  
DB 71 SRDSDKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110  
QY 135 QGQSLTTLSPSPSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172  
DB 111 WGGGLTVTVSASASTKGPVFPPLAPSSKSTSGTAAAGCLVVDYFPEPVTVSNWNGALTSG 170  
QY 173 ---QLELDSDG-----TWTCYVLOQKVEFKIDIVPCPAPEPKSC 210  
DB 171 VHTFPAYVLOSGSLYSLSVTVFPSSSLGTQYICNV--NHKPSNTKYD---KKEVPKSC 224  
QY 211 DKHTTC-----PELLGSPVFLFPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 265  
DB 225 DKHTTCPPCPAPELLGGSPVFLFPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 284  
QY 266 GVEVHNAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 325  
DB 285 GVEVHNAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344  
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPVLD 385  
DB 345 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPVLD 404  
QY 386 DGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 431  
DB 405 DGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 450

## RESULT 73

US-08-793-450-8  
Sequence 8, Application US/08793450  
Patent No. 6312690  
GENERAL INFORMATION:  
APPLICANT: EDELMAN, LENA  
APPLICANT: MARGARITTE, CHRISTEL  
APPLICANT: KACZOREK, MICHEL  
APPLICANT: CHABIRI, HASSAN  
TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: OBION, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,  
STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400  
CITY: ARLINGTON  
STATE: VA  
COUNTRY: USA  
ZIP: 22202  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/793,450  
FILING DATE: 03-MAR-1997  
CLASSIFICATION: 536  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: FR 94/10566  
FILING DATE: 02-SEP-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: OBION, NORMAN F.  
REGISTRATION NUMBER: 24,618

```
REFERENCE/DOCKET NUMBER: 660-118-0 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 472 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-793-450-8

Query Match      52.1%; Score 1257; DB 4; Length 472;
Best Local Similarity 59.0%; Pred. No. 5.9e-94;
Matches 268; Conservative 25; Mismatches 93; Indels 68; Gaps 9;

QY 32 KKGDIVELTCTASQKKSIOFHMKNSQIKILGNQ--GSFLTKGPSKLNDRADSRSL---86
DB 32 KPSETLSTCTVYGSGFSGYWMINQPPGKGLEWIGEINHSGSTVYNPSLKSRTVITSDV 91
QY 87 WDQGNPLIIKULKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLQGSILTLTLESP 146
DB 92 TSKNQSLKLNSTYADTAVYCARAPE-----YKMKYHGMDFDPMGQGTTVVSSA 143
QY 147 PGSSPVCGRSPRGKNIQGG-----KTLVS-----QLELDGSG 180
DB 144 STKGPSVFLPAPSSKSTSGGTALGCLVMDYFPEPVTVSNAGALTSGVHTFPVAVLQSSG 203
QY 181 -----TWCTVLQNOKKVEFKIDIVCPAPEPKSCDKTHC-----P 217
DB 204 LVSLSSVTVTPSSSLGTFYICNV--NHKPSNTKVD---KKAEPKSCDKTQCPCPCAP 257
QY 218 ELLGGSVFLFPKPKDPTLMISTPEVTCVVDVSHEDPEVKKNVYDGVENATKTR 277
DB 258 ELLGGSVFLFPKPKDPTLMISTPEVTCVVDVSHEDPEVKKNVYDGVENATKTR 317
QY 278 EEOYNSTYRVSILTVLHODMLNGKEYCKVSNKALPAPEKTIISAKGQPREPOVYTL 337
DB 318 EEOYNSTYRVSILTVLHODMLNGKEYCKVSNKALPAPEKTIISAKGQPREPOVYTL 377
QY 338 PSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQCPERNNYKTPPVLDSDGSFPLYSLTV 397
DB 378 PSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQCPERNNYKTPPVLDSDGSFPLYSLTV 437
QY 398 DKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 431
DB 438 DKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 471

RESULT 74
US-09-301-593-43
Sequence 43, Application US/09301593A
Patent No. 6455677
GENERAL INFORMATION:
APPLICANT: Park, John E.
APPLICANT: Gartin-Cheea, Pilar
APPLICANT: Bamberger, Uwe
APPLICANT: Leger, Olivier
APPLICANT: Saldanha, Jose W.
APPLICANT: Rettig, Wolfgang J.
TITLE OF INVENTION: PAP-specific Antibody with Improved Productibility
FILE REFERENCE: 0652.1890001
CURRENT APPLICATION NUMBER: US/09/301,593A
EARLIER FILING DATE: 1999-04-29
EARLIER APPLICATION NUMBER: EP 98107925.4
EARLIER FILING DATE: 1998-04-30
EARLIER APPLICATION NUMBER: US 60/086,049
EARLIER FILING DATE: 1998-05-18
NUMBER OF SEQ ID NOS: 108
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 43
LENGTH: 472
TYPE: PRT
```

```
ORGANISM: Homo sapiens
US-09-301-593-43

Query Match      52.1%; Score 1256.5; DB 4; Length 472;
Best Local Similarity 56.9%; Pred. No. 6.5e-94;
Matches 273; Conservative 38; Mismatches 86; Indels 83; Gaps 15;

QY 16 LALLPAAIQGNKV-----LGKKSDIVELTCTASQKKSIOF--HMKN---SNQIKILGNQ 65
DB 11 LAVAPGASQVQLVSGAEVKRPGASVKSCTSRFTETVTHHWRAQGRLEWIG--68
QY 66 GSFLTKGPSKLNDRADSRSLW---DQGNFPLIILKIEDSDTYICEVEDQKEEVQLLV 122
DB 69 GINPNNGIPNNYQKRGKRAITLVGKSASATYMWELSLRSREDTAVYTC-----ARRRA 121
QY 123 FGLTANSDTHLIQ--GQSILTLTLESPGSSPSVQCRSPRGKNIQGG-----K 167
DB 122 YGY---DEGHADWDYGGQGLTVVSSST--KGPSVFLPAPSSKSTSGGTALGCLVMDYFPE 177
QY 168 TLSVS-----QLELDGSG-----TWCTVLQNOKKVEPK 196
DB 178 PVTVMNSGALTSGVHTFPVAVLQSSGLVSLSSVTVTPSSSLGTFYICNV--NHKPSNTK 235
QY 197 IDIVCPAPEPKSCDKTHC-----PELLGGSVFLFPKPKDPTLMISTPEVTCVVDV 251
DB 236 VD---KKAEPKSCDKTHCPCPCAPPELLGGSVFLFPKPKDPTLMISTPEVTCVVDV 291
QY 252 SHEDPEVKKNVYDGVENATKPREEQYNSTYRVSILTVLHODMLNGKEYCKVSNK 311
DB 292 SHEDPEVKKNVYDGVENATKPREEQYNSTYRVSILTVLHODMLNGKEYCKVSNK 351
QY 312 ALPAPEKTIISAKGQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
DB 352 ALPAPEKTIISAKGQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 411
QY 372 PENNYKTPPVLDSDGSFPLYSLTVDKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 431
DB 412 PENNYKTPPVLDSDGSFPLYSLTVDKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 471

RESULT 75
US-09-289-942A-7
Sequence 7, Application US/09289942A
Patent No. 6482928
GENERAL INFORMATION:
APPLICANT: Pai, Emil F.
APPLICANT: Klein, Michel H.
APPLICANT: Chong, Pele
APPLICANT: Podyczak, Arthur
TITLE OF INVENTION: Fab'-EPTIOPRE COMPLEX FROM THE HIV-1 CROSS-NEUTRALIZING
FILE REFERENCE: MONOCLONAL ANTIBODY 2P5
CURRENT APPLICATION NUMBER: US/09/289,942A
CURRENT FILING DATE: 1999-04-13
NUMBER OF SEQ ID NOS: 9
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 7
LENGTH: 462
TYPE: PRT
ORGANISM: Human immunodeficiency virus type 1
US-09-289-942A-7

Query Match      52.0%; Score 1255; DB 4; Length 462;
Best Local Similarity 66.2%; Pred. No. 8.3e-94;
Matches 258; Conservative 18; Mismatches 52; Indels 62; Gaps 9;

QY 94 LIKKULKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLIQ--GQSILTLTLESPGSS 150
DB 82 LVMTKTVSPVDIATYFC---AHRGPTTLFGVPIARGPVNADWDYGGQITVTSASTKG 137
QY 151 PSVQCRSPRGKNIQGG-----KTLVS-----QLELDGSG----- 180
DB 138 PSVFPPLAPSSKSTSGGTALGCLVMDYFPEPVTVSNAGALTSGVHTFPVAVLQSSGLVSL 197
```

```

QY 181 -----TWCTVLONOKKVEFKIDIVPCPAPEPKSCDKTHTC-----PELLG 221
DB 198 SSVTVTPSSSLGTOTYICNV--NHKPSNTKYD-----KKVEPKSCDKTHTCPCPAPPELLG 251
QY 222 GSVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNMYDGVVHNNAKTKRREOY 281
DB 252 GSVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNMYDGVVHNNAKTKRREOY 311
QY 282 NSTYVAVSLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRD 341
DB 312 NSTYVAVSLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRD 371
QY 342 ELTKNOVSLTCLVKGFPSPDIIVAVESNQGPNENNYKTPPVLDSDGSPFLYSKLTVDKSR 401
DB 372 ELTKNOVSLTCLVKGFPSPDIIVAVESNQGPNENNYKTPPVLDSDGSPFLYSKLTVDKSR 431
QY 402 WQGNVFGSCVMHEALHNHYTOKSLSLSPG 431
DB 432 WQGNVFGSCVMHEALHNHYTOKSLSLSPG 461

```

## RESULT 76

```

US-09-679-397-2
; Sequence 2, Application US/09679397
; Patent No. 6339142
; GENERAL INFORMATION:
; APPLICANT: BASEY, CAROL D.
; TITLE OF INVENTION: PROTEIN PURIFICATION
; FILE REFERENCE: P1241R1D2
; CURRENT APPLICATION NUMBER: US/09/679,397
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: US 60/084,459
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: US 09/304,465
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 449
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
US-09-679-397-2

```

Query Match 52.0%; Score 1254.5; DB 4; Length 449;

Best Local Similarity 57.8%; Pred. No. 8.8e-94; Matches 268; Conservative 30; Mismatches 79; Indels 87; Gaps 12;

```

QY 30 LGKKGDVTELTCTAS--QKKSIOFHWKNSNQIKILGNQ-----SFLTKGSKLNDPAD 81
DB 11 LVQPGSLRLSCAASGFNPKDTYTHM-----VRQAPGKLEWVARIPTNGTYRADS 65
QY 82 SRSRL--WDQGNFLLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSOTHLQ--G 136
DB 66 GRFTISADTSKNTAYLQNNLSRAEDTAVYVC-----SRMGDGFYAMDYG 111
QY 137 QSLTILTESPPGSSPVQCSPPRGKNIQG-----KTLNYS----- 172
DB 112 QGLTVTVSSASTKGPSVFPLAAPSSTSGGTALGCLVKDYRPEPEVTVSNMNGALTSGVH 171
QY 173 --QLELSDSG-----TWCTVLONOKKVEFKIDIVPCPAPEPKSCDK 212
DB 172 TTPAVLQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHKPSNTKYD-----KKVEPKSCDK 225
QY 213 THTC-----PELLGSPVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 267
DB 226 THTCPCPAPPELLGSPVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 285
QY 268 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQ 327
DB 266 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQ 345
QY 286 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQ 345

```

```

QY 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIIVAVESNQGPNENNYKTPPVLDSDG 387
DB 346 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIIVAVESNQGPNENNYKTPPVLDSDG 405
QY 388 SFPLYSKLTVDKSRWQGNVFGSCVMHEALHNHYTOKSLSLSPG 431
DB 406 SFPLYSKLTVDKSRWQGNVFGSCVMHEALHNHYTOKSLSLSPG 449

```

## RESULT 77

```

US-09-680-148-2
; Sequence 2, Application US/09680148
; Patent No. 6417335
; GENERAL INFORMATION:
; APPLICANT: BASEY, CAROL D.
; TITLE OF INVENTION: PROTEIN PURIFICATION
; FILE REFERENCE: P1241R1D1
; CURRENT APPLICATION NUMBER: US/09/680,148
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: US 60/084,459
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: US 09/304,465
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 449
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
US-09-680-148-2

```

Query Match 52.0%; Score 1254.5; DB 4; Length 449;

Best Local Similarity 57.8%; Pred. No. 8.8e-94; Matches 268; Conservative 30; Mismatches 79; Indels 87; Gaps 12;

```

QY 30 LGKKGDVTELTCTAS--QKKSIOFHWKNSNQIKILGNQ-----SFLTKGSKLNDPAD 81
DB 11 LVQPGSLRLSCAASGFNPKDTYTHM-----VRQAPGKLEWVARIPTNGTYRADS 65
QY 82 SRSRL--WDQGNFLLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSOTHLQ--G 136
DB 66 GRFTISADTSKNTAYLQNNLSRAEDTAVYVC-----SRMGDGFYAMDYG 111
QY 137 QSLTILTESPPGSSPVQCSPPRGKNIQG-----KTLNYS----- 172
DB 112 QGLTVTVSSASTKGPSVFPLAAPSSTSGGTALGCLVKDYRPEPEVTVSNMNGALTSGVH 171
QY 173 --QLELSDSG-----TWCTVLONOKKVEFKIDIVPCPAPEPKSCDK 212
DB 172 TTPAVLQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHKPSNTKYD-----KKVEPKSCDK 225
QY 213 THTC-----PELLGSPVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 267
DB 226 THTCPCPAPPELLGSPVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 285
QY 268 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQ 327
DB 266 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQ 345
QY 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIIVAVESNQGPNENNYKTPPVLDSDG 387
DB 346 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIIVAVESNQGPNENNYKTPPVLDSDG 405
QY 388 SFPLYSKLTVDKSRWQGNVFGSCVMHEALHNHYTOKSLSLSPG 431
DB 406 SFPLYSKLTVDKSRWQGNVFGSCVMHEALHNHYTOKSLSLSPG 449

```

## RESULT 78



```
US-09-304-465A-2
; Sequence 2, Application US/09304465A
; Patent No. 6489447
; GENERAL INFORMATION:
; APPLICANT: BASEY, CAROL D.
; APPLICANT: BLANK, GREG S.
; TITLE OF INVENTION: PROTEIN PURIFICATION
; FILE REFERENCE: P1241R1
; CURRENT APPLICATION NUMBER: US/09/304,465A
; PRIOR FILING DATE: 1999-05-03
; PRIOR FILING DATE: 1998-05-06
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 449
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
; Patent No. 6489447
US-09-304-465A-2

Query Match          52.0%; Score 1254.5; DB 4; Length 449;
Best Local Similarity 57.8%; Pred. No. 8.8e-94;
Matches 268; Conservative 30; Mismatches 79; Indels 87; Gaps 12;

QY 30 LGKGGDTVELTCTAS--QKSIQPHWKNNOIKILNQG-----SFLTKGSPKLNDRAD 81
DB 11 LVPGGSLRLSCAAGSFGNIIDTYIHW-----VRQAPKGLKLEWVARLYPTGTGYRADSVK 65
QY 82 SRRL--WDQGFPLIILKLIKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHLQ--G 136
DB 66 GRITISADTSKNTAVYLAQMSLRAEDTAVYIC-----SRMGDGGFYAMDYMG 111
QY 137 QSILTLFLESPGSSPSVQCSPPGKNIQGG-----KTLVS----- 172
DB 112 QGLTVVSSASTKGPVSFPLAPPSKSTSGGTALGLVKDYFPEPTVSNNSGALTSGVH 171
QY 173 --GLEIODSG-----TWCTVLOQKKEVERKIDIVPCPAPBPSCDK 212
DB 172 TEPAVLQSSGLSLSSVTVVSSSLGTQTYICNV--NHKPSNTKVD---KKVEPKSCDK 225
QY 213 THTC-----PELIGSPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDG 267
DB 226 THTCPCPCPABELGSGSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDG 285
QY 268 EVHNAKTPREEOYNSTYRVVSVLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKGQ 327
DB 286 EVHNAKTPREEOYNSTYRVVSVLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKGQ 345
QY 328 PREPOVYTLPPSDELTKNOVSLTCLVKGFPSPSDIAVWESNQPENNTKTPPVLDSDG 387
DB 346 PREPOVYTLPPSDEETKNOVSLTCLVKGFPSPSDIAVWESNQPENNTKTPPVLDSDG 405
QY 388 SFLYSLKLTVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 431
DB 406 SFLYSLKLTVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 449

RESULT 79
US-08-487-550-4
; Sequence 4, Application US/08487550
; Patent No. 6113898
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF.
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS".
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
```

```

; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,550
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Teakin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-2021
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-487-550-4

Query Match          51.7%; Score 1248; DB 3; Length 476;
Best Local Similarity 59.2%; Pred. No. 3.2e-93;
Matches 270; Conservative 26; Mismatches 86; Indels 74; Gaps 13;

QY 35 DVELTCTASQCK-SIQFHWKNSNOI-----KILNQGSFLTKGSPKLNDRADSR 84
DB 35 ETLSRCTVSGSGISGYWTWIRQTPRGLEWIGHIYGN-GATTNVPSS-LKSRVLTISK 92
QY 85 SLWDQGNPFLIKKLIKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHLQGSILTLTE 144
DB 93 DT-SKQPFLLNLSVTDADTAVYIC-ARGPRDCTTTCYGVWD---VMGRGLVTVS 145
QY 145 SPPGSSPSVQCSPPGKNIQGG-----KTLVS-----OLEIOD 178
DB 146 SASTGSPSVFPLAPPSKSTSGGTALGLVKDYFPEPTVSNNSGALTSGVHTFPAVLQS 205
QY 179 SG-----TWCTVLOQKKEVERKIDIVPCPAPBPSCDKTHTC---- 216
DB 206 SGLYSLSSVTVVSSSLGTQTYICNV--NHKPSNTKVD---KKAEPKSCDKTHTCPCP 259
QY 217 -PELIGSPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGEVHNAKTK 275
DB 260 APELLGSPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGEVHNAKTK 319
QY 276 PREEOYNSTYRVVSVLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKQPREPOVYT 335
DB 320 PREEOYNSTYRVVSVLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKQPREPOVYT 379
QY 336 LPPSRDELTKNOVSLTCLVKGFPSPSDIAVWESNQPENNTKTPPVLDSDGSFLYSLK 395
DB 380 LPPSRDELTKNOVSLTCLVKGFPSPSDIAVWESNQPENNTKTPPVLDSDGSFLYSLK 439
QY 396 TVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 431
DB 440 TVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 475

RESULT 80
US-09-526-098-4
; Sequence 4, Application US/09526098
; Patent No. 6492134
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
```

```
/ TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
/ NUMBER OF INVENTION: IMMUNOSUPPRESSANTS"
/ NUMBER OF SEQUENCES: 12
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: BURNS, DOANE, SWECKER & MATTHIS
/ STREET: 699 Prince Street
/ CITY: Alexandria
/ STATE: VA
/ COUNTRY: USA
/ ZIP: 22314
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/526,098
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/383,916
/ FILING DATE:
/ APPLICATION NUMBER: US 08/487,550
/ FILING DATE: 07-JUN-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Teskin, Robin L.
/ REGISTRATION NUMBER: 35,030
/ REFERENCE/DOCKET NUMBER: 012712-131
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-836-6620
/ TELEFAX: 703-836-2021
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 476 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ US-09-526-098-4

Query Match      51.7%; Score 1248; DB 4; Length 476;
Best Local Similarity 59.2%; Pred. No. 3,2e-93;
Matches 270; Conservative 26; Mismatches 86; Indels 74; Gaps 13;

QY 35 DTVELTCTASQOK-SIOFHMKNSNOI-----KILNQGSPFTKPSKLNDRADSR 84
DB 35 ETLSTRTCVSGSGSIGYYTWIRQTPRGLEWIGHIYGN-GATTNYPNS-LKSAVTTSK 92
QY 85 SLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVOLLVFGLTANSDTLLQGSILTLLE 144
DB 93 DT-SKQGFPLNLSVTDADTAAYYC-ARGPRDCTTICVGMWD-----VMQPGDLTVTS 145
QY 145 SPFGSSPSVQCSPPKKNIOGG-----KILSVS-----OLEIOD 178
DB 146 SASSTGKPSVFLPAPSSKSTSGTAAIGCLVKDYFPPEPVTVSWNSGALTSVHTPPAVLIQS 205
QY 179 SG-----TWTCVLOQKQKVEFKIDIVPCAPAPKSCDKTHTC----- 216
DB 206 SGLYSLSSVTVYVSSSLGTQYICNV--NHKPSNKTVD---KKAPRSCDKTHTCPPCP 259
QY 217 -PELLGSPSVFLPPEPKDITLMISRTPEVTCVAVDVSHEDPEVKFNWYVDGEVANAATK 275
DB 260 APELLGSPSVFLPPEPKDITLMISRTPEVTCVAVDVSHEDPEVKFNWYVDGEVANAATK 319
QY 276 PREEQVNSTYRVAVSVLTVHODMLNGKEYCKKCVSNKALPAPIEKTISAKAGPREPOVYT 335
DB 320 PREEQVNSTYRVAVSVLTVHODMLNGKEYCKKCVSNKALPAPIEKTISAKAGPREPOVYT 379
QY 336 LPPSDELTKNQVSLTCLVKGFPSPDIAMVESNQGPENNYKTTTPVLDSDGSFLYSKL 395
DB 380 LPPSDELTKNQVSLTCLVKGFPSPDIAMVESNQGPENNYKTTTPVLDSDGSFLYSKL 439
QY 396 TVDKSRMOQGNVFCSSVMHEALHNHYTKSLSLSPG 431
```

```
DB 440 TVDKSRMOQGNVFCSSVMHEALHNHYTKSLSLSPG 475

RESULT 81
US-09-313-942-9
/ Sequence 9, Application US/09313942
/ Patent No. 6472179
/ GENERAL INFORMATION:
/ APPLICANT: REGENERON PHARMACEUTICALS, INC.
/ TITLE OF INVENTION: RECEPTOR BASED ANTAGONISTS, AND METHODS OF MAKING
/ TITLE OF INVENTION: AND USING
/ FILE REFERENCE: RBG 203-A
/ CURRENT APPLICATION NUMBER: US/09/313,942
/ CURRENT FILING DATE: 1999-05-19
/ PRIOR APPLICATION NUMBER: 09/313,942
/ PRIOR FILING DATE: 1999-05-19
/ PRIOR APPLICATION NUMBER: 60/101,858
/ PRIOR FILING DATE: 1998-09-25
/ NUMBER OF SEQ ID NOS: 32
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 9
/ LENGTH: 951
/ TYPE: PRT
/ ORGANISM: Homo sapiens
/ US-09-313-942-9

Query Match      51.4%; Score 1240.5; DB 4; Length 951;
Best Local Similarity 60.4%; Pred. No. 3.4e-92;
Matches 265; Conservative 23; Mismatches 66; Indels 85; Gaps 11;

QY 70 TKGPSKLNDRADSRSL--MDQGNFPLIKNLKIEDSDTYICEVEDQKEVO----- 119
DB 520 SKGPTVTRTKYKGNKRAVLENDQ--LPVDQNGFIRNTIIFRTIIGMETANVDSSTREY 577
QY 120 -----LIVFGLTANSDTLLQGSILTL-----ESPSS--PSVQCRSPRK 161
DB 578 TLSSLTSDTLTYVMMAVTDGKGDEFTFTTPKFAQGEIESGASTKGPSVFLAPSSK 637
QY 162 NIQGG-----KILSVS-----OLEIODSG----- 180
DB 638 STSGTAAIGCLVKDYFPPEPVTVSWNSGALTSVHTPPAVLIQSGLSLSSVTVPPSSSL 697
QY 181 ---TWTCVLOQKQKVEFKIDIVPCAPAPKSCDKTHTC-----PELLGSPSVFLPPEKP 232
DB 698 GTQYVICNV--NHKPSNKTVD---KKAPRSCDKTHTCPPCAPPELLGSPSVFLPPEKP 751
QY 233 KOTLMISTPEVTCVAVDVSHEDPEVKFNWYVDGEVANAATKPKREBOYNSTYRVAVSVLT 292
DB 752 KOTLMISTPEVTCVAVDVSHEDPEVKFNWYVDGEVANAATKPKREBOYNSTYRVAVSVLT 811
QY 293 VLHODMLNGKEYCKKCVSNKALPAPIEKTISAKAGPREPOVYTLPPSRDELTKNQVSLTC 352
DB 812 VLHODMLNGKEYCKKCVSNKALPAPIEKTISAKAGPREPOVYTLPPSRDELTKNQVSLTC 871
QY 353 LVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSDGSFLYSKLTVDKSRMOQGNVFCSSV 412
DB 872 LVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSDGSFLYSKLTVDKSRMOQGNVFCSSV 931
QY 413 MHEALHNHYTKSLSLSPG 431
DB 932 MHEALHNHYTKSLSLSPG 950

RESULT 82
US-08-472-888A-7
/ Sequence 7, Application US/08472888A
/ Patent No. 6613746
/ GENERAL INFORMATION:
/ APPLICANT: Seed, Brian
/ TITLE OF INVENTION: AGP-ANTIBODY FUSION PROTEINS
/ TITLE OF INVENTION: AND RELATED MOLECULES AND METHODS
/ NUMBER OF SEQUENCES: 9
```

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Clark & Ebling LLP
STREET: 176 Federal Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02110
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,888A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 07/618,314
FILING DATE: 23-NOV-1990
ATTORNEY/AGENT INFORMATION:
NAME: Eibling, Karen L
REGISTRATION NUMBER: 35,238
REFERENCE/DOCKET NUMBER: 00786/258001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-428-0200
TELEFAX: 617-428-7045
TELEX:
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 442 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-472-888A-7

```

Query Match	51.3%	Score 1238	DB 4	Length 442
Best Local Similarity	74.1%	Pred. No. 1.9e-92		
Matches 246	Conservative 12	Mismatches 26	Indels 48	Gaps 5

```

Oy      136 GCGSLTLLTESPPGSSSSVOCRRPRGNIOG-----KTLSS----- 172
Db      122 GCGTLVTVSSASTKCGSVFPLPSSSTSGGTAALCGLKVDYFPEPVTVSWSNGALTSGV 181
Oy      173 ---QELQDSGTMTCTVL-----ONOKYEFKIDIVCPAPBEKSCDKTHTC-----PEL 219
Db      182 HTFPAVLQSSGLYSLSSVTVTPSSSDKV-----EKSQDKNHTCPCPAPEL 229
Oy      220 LGGESVFLFPKPKPKOTLMSRTPEVTCVVDVDSHEPVEKFNMYVGVGVHNAKTPREE 279
Db      230 LGGPSVFLFPKPKPKOTLMSRTPEVTCVVDVDSHEPVEKFNMYVGVGVHNAKTPREE 289
Oy      280 QYNSTRVAVSVTLVTHQDMLNGKEYCKYCNKALPAPIEKTISKAKGAPREPQVTLTPS 339
Db      290 QYNSTRVAVSVTLVTHQDMLNGKEYCKYCNKALPAPIEKTISKAKGAPREPQVTLTPS 349
Oy      340 RDELTKNOVSLTCLYKGFPSDIAVEMESNGOPENNYKTPPYLDSGSEFELYSLTVDK 399
Db      350 RDELTKNOVSLTCLYKGFPSDIAVEMESNGOPENNYKTPPYLDSGSEFELYSLTVDK 409
Oy      400 SRMOGQNVFSCVMHEALHNHTYQKSLSPG 431
Db      410 SRMOGQNVFSCVMHEALHNHTYQKSLSPG 441

RESULT 83
PCT-US96-10043-9
; Sequence 9, Application PC/TUS9610043
; GENERAL INFORMATION:
; APPLICANT: The General Hospital Corporation
; TITLE OF INVENTION: P-SELECTIN LIGANDS AND RELATED MOLECULES
; TITLE OF INVENTION: P-SELECTIN LIGANDS AND RELATED MOLECULES
; NUMBER OF SEQUENCES: 14

```

CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: USA  
ZIP: 02210-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/10043  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/000,213  
FILING DATE: 14-JUN-1995  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Lech, Karen F.  
REGISTRATION NUMBER:  
REFERENCE/DOCKET NUMBER: 00786/284001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617/542-5070  
TELEFAX: 617/542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 442 amino acids  
TYPE: amino acid  
STRANDEDNESS: not relevant  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
PCT-US96-10043-9

Query Match	51.3%	Score 1238	DB 5	Length 442
Best Local Similarity	74.1%	Pred. No. 1.9e-92		
Matches 246; Conservative	12	Mismatches 26	Indels 48	Gaps 5

```

QY      136  GGGTLITLESPPSSSSVQCRRSPKRNIGG-----KITLSV-----172
Db      122  GGGTLITVSSASTKGPVSFPLPSKSKTSIGGTAALGCLVQDFPEBPVTVSNNGALTSV 181
QY      173  ---QLELOBSGTMTCVL-----NQKKYKFEKIDIVCPAPRPSCKTKHTC-----PEL 219
Db      182  HTFPAAVQSSGLSYLSVTVTPSSSDKTV-----EPKSCKTKHCPCPAPEL 229
QY      220  LGSPSVFLPPPKKOTLMISRTPEYTCVVDVSHDEPEVENMAYVDGEVYNAKTKREE 279
Db      230  LGSPSVFLPPPKKOTLMISRTPEYTCVVDVSHDEPEVKNMAYVDGEVYNAKTKREE 289
QY      280  QYNSTYRVVSVLTVLHQMNLNGEKYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPS 339
Db      290  QYNSTYRVVSVLTVLHQMNLNGEKYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPS 349
QY      340  RDELTKQVSLTCLVKGFPDIAVEMSNNGQPENNYKTPPVLDGSGFFLSKLTVDK 399
Db      350  RDELTKQVSLTCLVKGFPDIAVEMSNNGQPENNYKTPPVLDGSGFFLSKLTVDK 409
QY      400  SRMQGQNVFSCVYMEHALNHHTQKSLSPG 431
Db      410  SRMQGQNVFSCVYMEHALNHHTQKSLSPG 441

```

```
/ APPLICANT: Xu, Wenfeng
/ APPLICANT: Madden, Karen L.
/ APPLICANT: Kelly, James D.
/ APPLICANT: Sprecher, Cindy A.
/ APPLICANT: Blumberg, Hal
/ APPLICANT: Eagan, Maribeth A.
/ APPLICANT: Jasper, Stephen R.
/ APPLICANT: Chandrasekhar, Yashin A.
/ APPLICANT: No. 6610286ak, Julia E.
/ TITLE OF INVENTION: Method for Treating Inflammation
/ FILE REFERENCE: 99-108
/ CURRENT APPLICATION NUMBER: US/09/746,359A
/ PRIOR FILING DATE: 2001-05-21
/ PRIOR APPLICATION NUMBER: 60/171,969
/ PRIOR FILING DATE: 1999-12-23
/ PRIOR APPLICATION NUMBER: 60/213,341
/ NUMBER OF SEQ ID NOS: 72
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 54
/ LENGTH: 547
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-746-359A-54

Query Match          51.3%; Score 1238; DB 4; Length 547;
Best Local Similarity 58.8%; Pred. No. 2.5e-92;
Matches 276; Conservative 23; Mismatches 72; Indels 98; Gaps 15;

QY 27 KVLGKGGDVELCTASOKKSIQFHWK-NSNOIKILGNQ-GSFLTGPSKLNDRADSR 84
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 112 EVALTTDEKSI SVLTAPK-----WKRPEDLPVSMQIYSNLKYNVSVLNTKSN--- 162

QY 85 SLMDQ--GNFPLIKNLKIEDSDTYICEVD-----QKEVQLVFGLTANS DTHL 133
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 163 RTWSQCVTNHTLVLTWL--EPNTLYCVHVESFVGPBRAPRQPSKQ----- 207

QY 134 LOGSLTLTLESPPGSS--PSVQCRSPRGKNIQGG-----KTLSVS----- 172
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 208 ----ARTLKQSSASSTKGPSVFLPAPLAPSSKSTSGTALGCLVKDYFPEPVTVSNAGAL 263

QY 173 -----QLELDQSG-----TWCTVLONQKVEFKIDIVPCAPAP 207
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 264 TSGVHTPAVLQSSGLYSLSSVTVPSSSLGTQTYICNV--NHKPSNTKVD---KVEP 317

QY 208 KSCDKHTHC-----PELLGGSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 318 KSCDKHTHCPCPAPABELLGGPSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 377

QY 263 YVDGEVHNAAKTKRREQYNSTRYVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTIS 322
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 378 YVDGEVHNAAKTKRREQYNSTRYVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTIS 437

QY 333 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 382
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 438 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 497

QY 383 LDDSGSFFLYSLKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPG 431
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 498 LDDSGSFFLYSLKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPG 546

RESULT 85
US-09-746-359A-53
/ Sequence 53, Application US/09746359A
/ Patent No. 6610286
/ GENERAL INFORMATION:
/ APPLICANT: Thompson, Penny
/ APPLICANT: Foster, Donald C.
/ APPLICANT: Xu, Wenfeng
/ APPLICANT: Madden, Karen L.
/ APPLICANT: Kelly, James D.
/ APPLICANT: Sprecher, Cindy A.
```

```
/ APPLICANT: Blumberg, Hal
/ APPLICANT: Eagan, Maribeth A.
/ APPLICANT: Jasper, Stephen R.
/ APPLICANT: Chandrasekhar, Yashin A.
/ APPLICANT: No. 6610286ak, Julia E.
/ TITLE OF INVENTION: Method for Treating Inflammation
/ FILE REFERENCE: 99-108
/ CURRENT APPLICATION NUMBER: US/09/746,359A
/ PRIOR FILING DATE: 2001-05-21
/ PRIOR APPLICATION NUMBER: 60/171,969
/ PRIOR FILING DATE: 1999-12-23
/ PRIOR APPLICATION NUMBER: 60/213,341
/ NUMBER OF SEQ ID NOS: 72
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 53
/ LENGTH: 571
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-746-359A-53

Query Match          51.3%; Score 1238; DB 4; Length 571;
Best Local Similarity 58.8%; Pred. No. 2.7e-92;
Matches 276; Conservative 23; Mismatches 72; Indels 98; Gaps 15;

QY 27 KVLGKGGDVELCTASOKKSIQFHWK-NSNOIKILGNQ-GSFLTGPSKLNDRADSR 84
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 136 EVALTTDEKSI SVLTAPK-----WKRPEDLPVSMQIYSNLKYNVSVLNTKSN--- 186

QY 85 SLMDQ--GNFPLIKNLKIEDSDTYICEVD-----QKEVQLVFGLTANS DTHL 133
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 187 RTWSQCVTNHTLVLTWL--EPNTLYCVHVESFVGPBRAPRQPSKQ----- 231

QY 134 LOGSLTLTLESPPGSS--PSVQCRSPRGKNIQGG-----KTLSVS----- 172
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 232 ----ARTLKQSSASSTKGPSVFLPAPLAPSSKSTSGTALGCLVKDYFPEPVTVSNAGAL 287

QY 173 -----QLELDQSG-----TWCTVLONQKVEFKIDIVPCAPAP 207
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 288 TSGVHTPAVLQSSGLYSLSSVTVPSSSLGTQTYICNV--NHKPSNTKVD---KVEP 341

QY 208 KSCDKHTHC-----PELLGGSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 342 KSCDKHTHCPCPAPABELLGGPSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 401

QY 263 YVDGEVHNAAKTKRREQYNSTRYVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTIS 322
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 402 YVDGEVHNAAKTKRREQYNSTRYVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTIS 461

QY 323 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 382
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 462 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPV 521

QY 383 LDDSGSFFLYSLKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPG 431
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 522 LDDSGSFFLYSLKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPG 570

RESULT 86
US-08-236-311-7
/ Sequence 7, Application US/08236311
/ Patent No. 5565335
/ GENERAL INFORMATION:
/ APPLICANT: Capon, Daniel J.
/ APPLICANT: Gregory, Timothy J.
/ TITLE OF INVENTION: Adhesion Variants
/ NUMBER OF SEQUENCES: 25
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Genentech, Inc.
/ STREET: 460 Point San Bruno Blvd
/ CITY: South San Francisco
/ STATE: California
/ COUNTRY: USA
```



Db 326 GSFFLYSKLTVDKSRWQGNVFSVWHEALHNHYTKSLSPG 370

## RESULT 88

US-09-157-452B-12  
; Sequence 12, Application US/09157452B  
; Patent No. 6482409  
; GENERAL INFORMATION:  
; APPLICANT: Lobb, Roy R.  
; APPLICANT: Burkly, Linda C.  
; TITLE OF INVENTION: TREATMENT FOR INFLAMMATORY BOWEL DISEASE  
; FILE REFERENCE: 10274-004003  
; CURRENT APPLICATION NUMBER: US/09/157,452B  
; PRIOR FILING DATE: 1998-09-21  
; PRIOR APPLICATION NUMBER: US 08/950,660  
; PRIOR FILING DATE: 1997-10-15  
; PRIOR APPLICATION NUMBER: US 08/373,857  
; PRIOR FILING DATE: 1995-01-18  
; PRIOR APPLICATION NUMBER: US 08/284,603  
; PRIOR FILING DATE: 1994-08-11  
; PRIOR APPLICATION NUMBER: PCT/US93/00924  
; PRIOR FILING DATE: 1993-02-02  
; PRIOR APPLICATION NUMBER: US 07/835,139  
; NUMBER OF SEQ ID NOS: 16  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 12  
; LENGTH: 446  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-157-452B-12

Query Match 51.1%; Score 1234.5; DB 4; Length 446;  
Best Local Similarity 57.3%; Pred. No. 3.6e-92;  
Matches 270; Conservative 36; Mismatches 70; Indels 95; Gaps 15;

QY 16 LALLPAATQGNKV-----VLGKRDVTELTCTASQKKSIOFHMKNSNQIKILG---NQ 65  
DB 15 LWMFAAQAQAFKLETTPEBRYLAQGDVSLTCTGCGESPFSRRTQIDSLANKVNE 74  
QY 66 G-SFLTGPSKLANDRADSRSLMDQGNPLTIKNLKIEDSPTYCEV--EDQKEE--VQ 119  
DB 75 GTTSTLTWNP-----VSFGNEHSYLTCTATCESRKLKGIQ 109  
QY 120 LVLFLTANSOTHLQGSULTLESPP---GSSPSVQCRSP-----RGKNI 163  
DB 110 VEIYFPPKDPETHL-----SGPLEAKPITVCSVADVPPRRLIEDLKGHL 158  
QY 164 QGG-----KTLVSQLE-----LDSSGTWCTVVLQNOQKVEF-KIDIVPC--DAP 205  
DB 159 MNSQFLEADADKSLKSLTSLVETFPVIEDIG---KVLVCARKHIDEMDSVPVRQAV 214  
QY 206 EPKSCDKTHTC-----PELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEYKF 260  
DB 215 KELQVDTKHTCPCPAPBELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEYKF 274  
QY 261 NMYVGVVHNKAKTPEBQVNSTRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 320  
DB 275 NMYVGVVHNKAKTPEBQVNSTRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 334  
QY 321 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIJAVWESNGOPENNYKTTTP 380  
DB 335 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIJAVWESNGOPENNYKTTTP 394  
QY 361 PVLDSGSEFFLYSKLTVDKSRWQGNVFSVWHEALHNHYTKSLSPG 431  
DB 395 PVLDSGSEFFLYSKLTVDKSRWQGNVFSVWHEALHNHYTKSLSPG 445

RESULT 89  
US-09-590-656-2  
; Sequence 2, Application US/09590656

; Patent No. 6413932  
; GENERAL INFORMATION:  
; APPLICANT: Cerretti, Douglas P.  
; APPLICANT: Borges, Luis G.  
; APPLICANT: Fanslow, IIT, William C.  
; TITLE OF INVENTION: TEK ANTAGONISTS  
; FILE REFERENCE: 2900-A  
; CURRENT APPLICATION NUMBER: US/09/590,656  
; PRIOR FILING DATE: 2000-06-07  
; PRIOR APPLICATION NUMBER: 60/137,889  
; PRIOR FILING DATE: 1999-06-07  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 704  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-590-656-2

Query Match 51.0%; Score 1232; DB 4; Length 704;  
Best Local Similarity 82.5%; Pred. No. 1.1e-91;  
Matches 236; Conservative 4; Mismatches 14; Indels 32; Gaps 3;

QY 178 DSGTWTCTVLQNOQKVE--FKIDIVPCPAP-----EPKSC 210  
DB 418 DSGVWCVSVNTVAGMVEKPFNISVYKVLPKPLNAPNVIDTGHNFVAVINISSEPPYGEPPKSC 477  
QY 211 DKHTTC-----PELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEYKFNMYVD 265  
DB 478 DKHTCPCPAPBELLGSPSVFLPFPKPKDTLMTSRPEVTCVVVDVSHEDPEYKFNMYVD 537  
QY 266 GVEVHNKAKTPEBQVNSTRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 325  
DB 538 GVEVHNKAKTPEBQVNSTRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 597  
QY 326 GQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIJAVWESNGOPENNYKTTTPVLDS 385  
DB 598 GQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIJAVWESNGOPENNYKTTTPVLDS 657  
QY 386 DGSFELYSKLTVDKSRWQGNVFSVWHEALHNHYTKSLSPG 431  
DB 658 DGSFELYSKLTVDKSRWQGNVFSVWHEALHNHYTKSLSPG 703

## RESULT 90

US-09-733-764-2  
; Sequence 2, Application US/09733764  
; Patent No. 6521424  
; GENERAL INFORMATION:  
; APPLICANT: Cerretti, Douglas P.  
; APPLICANT: Borges, Luis G.  
; APPLICANT: Fanslow, IIT, William C.  
; TITLE OF INVENTION: TEK ANTAGONISTS  
; FILE REFERENCE: 2900-A  
; CURRENT APPLICATION NUMBER: US/09/733,764  
; PRIOR FILING DATE: 2000-12-07  
; PRIOR APPLICATION NUMBER: 09/590,656  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 704  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-733-764-2

Query Match 51.0%; Score 1232; DB 4; Length 704;  
Best Local Similarity 82.5%; Pred. No. 1.1e-91;  
Matches 236; Conservative 4; Mismatches 14; Indels 32; Gaps 3;

QY 178 DSGTWTCTVLQNOQKVE--FKIDIVPCPAP-----EPKSC 210  
DB 418 DSGVWCVSVNTVAGMVEKPFNISVYKVLPKPLNAPNVIDTGHNFVAVINISSEPPYGEPPKSC 477

Qy	211	DKNHTC-----PELLGGBSVFLPRPPKDTLMIISTPBTCCVVDVSHDEPEKFNMYVD	265
Db	478	DKNHTCPCPAPFLGGSVFLPRPPKDTLMIISTPBTCCVVDVSHDEPEKFNMYVD	537
Qy	266	GVEVHNAKTPREEQNSTYTRYVSVYTLVHDOMLNGEKYKCKVSNKALPAIEKTIKAK	325
Db	538	GVEVHNAKTPREEQNSTYTRYVSVYTLVHDOMLNGEKYKCKVSNKALPAIEKTIKAK	597
Qy	326	GQPREQVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNGQPENNYKTPPVLD	385
Db	598	GQPREQVYTLPPSRDEMTKNQVSLTCLVKGFPSDIAVEMESNGQPENNYKTPPVLD	657
Qy	386	DGSFPLYSKULTVDKSNMOQGNFSCGWHAEALAHNHYTKSLSLSPG	431
Db	658	DGSFPLYSKULTVDKSNMOQGNFSCGWHAEALAHNHYTKSLSLSPG	703

RESULT 91  
US-08-461-968A-5  
; Sequence 5, Application US/08461968A

```

1 Patent No. 5801044
2 GENERAL INFORMATION:
3 APPLICANT: Seed et al., Brian
4 TITLE OF INVENTION: INHIBITION OF CELL ADHESION
5 TITLE OF INVENTION: PROTEIN-CARBOHYDRATE INTERACTIONS
6 NUMBER OF SEQUENCES: 5
7 CORRESPONDENCE ADDRESSES:
8 ADDRESSEE: Fish & Richardson P.C.
9 STREET: 225 Franklin Street
10 CITY: Boston
11 STATE: MA
12 COUNTRY: USA
13 ZIP: 0210-2804
14 COMPUTER READABLE FORM:
15 MEDIUM TYPE: Floppy disk
16 COMPUTER: IBM PC compatible
17 OPERATING SYSTEM: PC-DOS/MS-DOS
18 SOFTWARE: Patentin Release #1.0, Version #1.30
19 CURRENT APPLICATION DATA:
20 APPLICATION NUMBER: US/08/461,968A
21 FILING DATE: 05-JUN-1995
22 CLASSIFICATION: 536
23 PRIOR APPLICATION DATA:
24 APPLICATION NUMBER: US 07/618,314
25 FILING DATE: 23-NOV-1990
26 ATTORNEY/AGENT INFORMATION:
27 NAME: Lech, Karen P.
28 REGISTRATION NUMBER: 35,238
29 REFERENCE/DOCKET NUMBER: 00786/067003
30 TELECOMMUNICATION INFORMATION:
31 TELEPHONE: 617/542-5070
32 TELEFAX: 617/542-8906
33 TELEX: 200154
34 INFORMATION FOR SEQ ID NO: 5:
35 SEQUENCE CHARACTERISTICS:
36 LENGTH: 442 amino acids
37 TYPE: amino acid
38 STRANDEDNESS: not relevant
39 TOPOLOGY: linear
40 MOLECULE TYPE: protein
41 US-08-461-968A-5
42
43 Query Match 50.8%; Score 1226; DB 1; Length 442;
44 Best Local Similarity 73.5%; Pred. No. 1,8e-91;
45 Matches 244; Conservative 12; Mismatches 28; Indels 48; Gaps 5
46
47 QY 136 GQSILTTLESPPSSPVOCRSRPGKNIQGG-----KTLVS----- 172
48 || :||: ||| ||| :||: ||| :||: ||| :||: ||| :||: |||
49 Db 122 GCGTIVTVSSAKTSKGSVFPPLAPSSKSTSGCGAALGCLVKDYPPEPTVYSNGLATSGV 181
50 || :||: ||| ||| :||: ||| :||: ||| :||: ||| :||: |||
51 QY 173 ---QLSLDSSGTTCTIVL-----QNKQKVEFKIDIVPCPADPSPSCDKTHTC-----PEL 219
52 || :||: ||| ||| :||: ||| :||: ||| :||: ||| :||: |||

```

Db	182	HFEPALQSSGLYLSLSSVTVPSSSSDKV-----EPKSCDKHTCPCPAPEL	229
Qy	220	LGSPSVFLFPYPKOTLMISRTPEVTCVVVDVSHEDPEVKNNYVDGVEYHNAKTRRE	279
Db	230	LGSPSVFLFPYPKOTLMISRTPEVTCVVVDVSHEDPEVKNNYVDGVEYHNAKTRREE	289
Qy	280	QVNSTRVAVSVLTVLHDMVLNGKEYKCVSKALPAPEKTIISKAKQPREPOVYTLPPS	339
Db	290	QVNSTRVAVSVLTVLHDMVLNGKEYKCVSKALPAPEKTIISKAKQPREPOVYTLPPS	349
Qy	340	RDELTKQVSLTCLVKGFYPSDIAEWESNGCPENNNYKTPRPVLDSGSPFLYSKLTVDK	399
Db	350	RDELTKQVSLTCLVKGFYPSDIAEWESNGCPENNNYKTPRPVLDSGSPFLYSKLTVDK	409
Qy	400	SRWQGNVPSGVMEHALHNHTQKSLSLSPG	431
Db	410	SRWQGNVPSGVMEHALHNHTQKSLSLSPG	441

RESULT 92  
US-08-462-571-5  
; Sequence 5, Application US/08462571

```

Db      182 HTFPAVLSSGLYSLSVTVPSSDCKV-----EPKSCDTHTCPCPAPBL 229
Qy      220 LGSPSVFLPPPKXDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVYDGVENNAKTKPREB 279
Db      230 LGSPSVFLPPPKXDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVYDGVENNAKTKPREB 289
Qy      280 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPS 339
Db      290 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPS 349
Qy      340 RDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPVLDSGSEFLYSKLTVDKSR 399
Db      350 RDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPVLDSGSEFLYSKLTVDKSR 409
Qy      400 SRMOQGNVFCSCVMHEALHNHTYOKSLSLSPG 431
Db      410 SRMOQGNVFCSCVMHEALHNHTYOKSLSLSPG 441

```

## RESULT 93

PCT-US96-10043-11

Sequence 11, Application PC/TUS9610043

```

; GENERAL INFORMATION:
; APPLICANT: The General Hospital Corporation
; TITLE OF INVENTION: P-SELECTIN LIGANDS AND RELATED MOLECULES
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02210-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10043
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/000,213
; FILING DATE: 14-JUN-1995
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lech, Karen F.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 00786/284001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 437 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; PCT-US96-10043-11

```

Query Match 50.7%; Score 1224; DB 5; Length 437;

Best Local Similarity 72.3%; Pred. No. 2.5e-91;

Matches 250; Conservative 16; Mismatches 38; Indels 42; Gaps 8;

```

Qy      99 LKIDSDTYIC--EVEDQKEEVQLVFGLTANSDTHLLOGSLTLTLSPGSSPSVOC- 155
Db      120 LILRLTKTYMLAFDVNDEN-----WGLSVYADRPETTKEDLGEFYF-----ALDCL 166

```

```

Qy      156 RSPRGKNIQGGKTLVSQLELDGSGTWCTVLQNO-----KQVEFKIDIVPCPAPEPKSC 210
Db      167 RLPK-----SDVYTTDWKDKCEPLEKQHEKERKQEGESD-----PEGEPSK 210
Qy      211 DKHTC-----PELLGSPVFLPPPKXDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVD 265
Db      211 DKHTCPCPAPBLGSPVFLPPPKXDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVD 270
Qy      266 GVEVHNAKTKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 325
Db      271 GVEVHNAKTKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 330
Qy      326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPVLDS 385
Db      331 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPVLDS 390
Qy      386 DGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHTYOKSLSLSPG 431
Db      391 DGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHTYOKSLSLSPG 436

```

## RESULT 94

US-09-301-593-22

Sequence 22, Application US/09301593A

```

; Patent No. 645677
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saldana, Jose W.
; TITLE OF INVENTION: FAP-specific Antibody with Improved Productibility
; FILE REFERENCE: 0652.1890001
; CURRENT APPLICATION NUMBER: US/09/301,593A
; EARLIER FILING DATE: 1998-04-29
; EARLIER APPLICATION NUMBER: EP 98107925.4
; EARLIER FILING DATE: 1998-04-30
; EARLIER APPLICATION NUMBER: US 60/086,049
; EARLIER FILING DATE: 1998-05-16
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 22
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-301-593-22

```

Query Match 50.6%; Score 1221.5; DB 4; Length 330;

Best Local Similarity 73.9%; Pred. No. 2.7e-91;

Matches 244; Conservative 9; Mismatches 22; Indels 55; Gaps 6;

```

Qy      151 PSVOCRSRGNKIQG-----KTLVS-----QLELDGSG----- 180
Db      6 PSVPLABSSKSTSGGTAALGCLVKDYFPEVYISNNISGALTSGVTHFPPAVLQSSGLYS 65
Qy      181 -----TWCTVLQNOQKVEFKIDIVPCPAPEPKSCDKHTTC-----PELLG 221
Db      66 SSVTVTPSSSLGTQTYICNV--NHKPSNTKYD-----KKVEPKSCDKHTTCPCPAPBLG 119
Qy      222 GPSVFLPPPKXDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVYDGVENNAKTKPREQY 281
Db      120 GPSVFLPPPKXDTLMSRTPEVTCVVVDVSHEDPEVKFNNYVYDGVENNAKTKPREQY 179
Qy      282 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRD 341
Db      180 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRD 239
Qy      342 ELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPVLDSGSEFLYSKLTVDKSR 401
Db      240 EMTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPVLDSGSEFLYSKLTVDKSR 299
Qy      402 WQGNVFCSCVMHEALHNHTYOKSLSLSPG 431

```



Db 300 MOGNVFCSCVMHEALHNHYTKSLSPG 329

## RESULT 95

US-09-313-942-8  
Sequence 8, Application US/09313942  
Patent No. 6472179  
GENERAL INFORMATION:  
APPLICANT: REGENERON PHARMACEUTICALS, INC.  
TITLE OF INVENTION: RECEPTOR BASED ANTAGONISTS, AND METHODS OF MAKING  
FILE REFERENCE: REG 203-A  
CURRENT APPLICATION NUMBER: US/09/313,942  
PRIOR FILING DATE: 1999-05-19  
PRIOR APPLICATION NUMBER: 60/101,858  
PRIOR FILING DATE: 1998-09-25  
NUMBER OF SEQ ID NOS: 32  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 8  
LENGTH: 592  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-313-942-8

## Query Match

Best Local Similarity 50.6%; Score 1221; DB 4; Length 592;  
Matches 236; Conservative 10; Mismatches 22; Indels 25; Gaps 3;

QY 150 SPVOCSPRGKNIQGGKTLVS-----QLELDGSGTWTCTVLOQKVEFKIDVPCP 203  
DB 313 TPTWTERSPPAENWSTPMQALTTNKDDNLTFRDSANATSLPVD----- 358  
QY 204 AEPKSCDKTHTC-----PELLGSPVFLFPKPKOTLMIISRTPEVTCVVVDVSHEDPEV 258  
DB 359 AEPKSCDKTHTCPPCPAPBELLGSPVFLFPKPKOTLMIISRTPEVTCVVVDVSHEDPEV 418  
QY 259 KRNWYDGVENAKTKPREEOYNSTYRVVSVLTVLHQMUNGKEYCKCVSNKALPAPIE 318  
DB 419 KRNWYDGVENAKTKPREEOYNSTYRVVSVLTVLHQMUNGKEYCKCVSNKALPAPIE 478  
QY 319 KTISSAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAWESNGQPENNYKT 378  
DB 479 KTISSAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAWESNGQPENNYKT 538  
QY 379 TPVLDSDGSFLLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 431  
DB 539 TPVLDSDGSFLLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 591

## RESULT 96

PCT-US95-03866-12  
Sequence 12, Application PC/TUS9503866  
GENERAL INFORMATION:  
APPLICANT: Cytomed, Inc. (all states except US)  
APPLICANT: Nocka, Karl (US only)  
APPLICANT: Lobell, Robert B (US only)  
TITLE OF INVENTION: STABILIZED DIMER OF KIT LIGAND AND  
TITLE OF INVENTION: FLT-3/FLK-2 LIGAND  
NUMBER OF SEQUENCES: 36  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10020  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US95/03866  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/220,379  
FILING DATE: 28-MAR-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Haley Jr, James F  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: Cytomed/2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-596-9000  
TELEFAX: 212-596-9090  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 424 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
PCT-US95-03866-12

Query Match 50.5%; Score 1219; DB 5; Length 424;  
Best Local Similarity 66.8%; Pred. No. 6.2e-91;  
Matches 253; Conservative 18; Mismatches 48; Indels 60; Gaps 9;

QY 80 ADSRSLMDQ-----GNPFLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSOT 131  
DB 78 SDLTDLDDKFSNISEGLSNYSIIDLVNIYD-DLVECVKENSXDLK----- 124  
QY 132 HLLQGSULTLTIESPPGSPSVQCRSPR-----GKNIQGGKTLVSQLELDGSGTWTCT 185  
DB 125 -----KSFKSPERLFTPEEFRIENRSIDAFDQFVA-----SETSDCV 164  
QY 186 V-----LONQKVEFKID-----IYCPA-PEPKSCDKTHTC-----PELLGSPVFLFPKPK 232  
DB 165 VSTISPEKDSVSTYKPFMLPVAADBPKSCDKTHTCPPCPAPBELLGSPVFLFPKPK 224  
QY 233 KOTLMIISRTPEVTCVVVDVSHEDPEVKFNWYDGVENAKTKPREEOYNSTYRVVSVLT 292  
DB 225 KOTLMIISRTPEVTCVVVDVSHEDPEVKFNWYDGVENAKTKPREEOYNSTYRVVSVLT 284  
QY 293 VLHQMUNGKEYCKCVSNKALPAPIEKTISAKGQPREPOVYTLPPSRDELTKNOVSLTC 352  
DB 285 VLHQMUNGKEYCKCVSNKALPAPIEKTISAKGQPREPOVYTLPPSRDELTKNOVSLTC 344  
QY 353 LVKGFYPSDIAWESNGQPENNYKTTPVLDSDGSFLLYSKLTVDKSRMOQGNVFCSCV 412  
DB 345 LVKGFYPSDIAWESNGQPENNYKTTPVLDSDGSFLLYSKLTVDKSRMOQGNVFCSCV 404  
QY 413 MHEALHNHYTKSLSPG 431  
DB 405 MHEALHNHYTKSLSPG 423

## RESULT 97

PCT-US95-03866-14  
Sequence 14, Application PC/TUS9503866  
GENERAL INFORMATION:  
APPLICANT: Cytomed, Inc. (all states except US)  
APPLICANT: Nocka, Karl (US only)  
APPLICANT: Lobell, Robert B (US only)  
TITLE OF INVENTION: STABILIZED DIMER OF KIT LIGAND AND  
TITLE OF INVENTION: FLT-3/FLK-2 LIGAND  
NUMBER OF SEQUENCES: 36  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10020



Tue Aug 3 13:58:17 2004

Ov 419 NHYTKSLSPG 431  
Db 363 NHYTKSLSPG 375

```
RESULT 100
US-09-333-593A-8
; Sequence 8, Application US/09333593A
; Patent No. 6313269
; GENERAL INFORMATION:
; APPLICANT: DEEN, KEITH C.
; APPLICANT: YOUNG, PETER R.
; APPLICANT: MARSHALL, LISA A.
; APPLICANT: ROSHAK, AMY K.
; APPLICANT: TAN, KONG B.
; APPLICANT: TRUNEH, ALEMESEGED
; TITLE OF INVENTION: TUMOR NECROSIS FACTOR RELATED RECEPTOR,
; TITLE OF INVENTION: TR6
; FILE REFERENCE: GH-50008-2
; CURRENT APPLICATION NUMBER: US/09/333,593A
; PRIOR FILING DATE: 1999-06-15
; PRIOR APPLICATION NUMBER: 08/916,625
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 08/853,684
; PRIOR FILING DATE: 1997-05-09
; PRIOR APPLICATION NUMBER: 60/041,230
; PRIOR FILING DATE: 1997-03-14
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 424
; TYPE: PRN
; ORGANISM: HOMO SAPIENS
US-09-333-593A-8
```

```
Query Match 50.3%; Score 1215; DB 4; Length 424;
Best Local Similarity 74.6%; Pred. No. 1,3e-90;
Matches 241; Conservative 14; Mismatches 38; Indels 30; Gaps 5;

Ov 117 EVQLVIGLTVNSDTHLQGS/LT/LLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLEL 176
Db 123 EVELSPCTTRNT---VQCEEGTFREEDSPEMCRKCRGTCPRG-----MVKV 167

Ov 177 QDSGT---CTVLQNKQKFEFKIDIVPCAPAPKSCDKTHTC-----PELLGSPVFLF 228
Db 168 GDCTPMSDIECVKESGRSIEGR-----GTEPKSADKTHTCPCPAPPELLGSPVFLF 220

Ov 229 PPKKDTLMISRTPEVTCVVDVSHEDPEVKFMVYDGVVHNAKTKPREBOYNSTRYRV 288
Db 221 PPKKDTLMISRTPEVTCVVDVSHEDPEVKFMVYDGVVHNAKTKPREBOYNSTRYRV 280

Ov 289 SVLTVLHODWLNKKEYKCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKQV 348
Db 281 SVLTVLHODWLNKKEYKCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKQV 340

Ov 349 SLTCLVKGFPSPDIAYEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGNVF 408
Db 341 SLTCLVKGFPSPDIAYEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQGNVF 400

Ov 409 SCSVMHEALHNHYTKSLSPG 431
Db 401 SCSVMHEALHNHYTKSLSPG 423
```

Search completed: August 3, 2004, 13:16:54  
Job time : 20.3604 secs

THIS PAGE BLANK (USPTO)